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Background: Rheumatoid arthritis (RA), the most common autoimmune disease in the UK, is a chronic
systemic inflammatory arthritis that affects 0.8% of the UK population.
Objectives: To determine whether or not an alternative class of biologic disease-modifying antirheumatic
drugs (bDMARDs) are comparable to rituximab in terms of efficacy and safety outcomes in patients with
RA in whom initial tumour necrosis factor inhibitor (TNFi) bDMARD and methotrexate (MTX) therapy failed
because of inefficacy.
Design: Multicentre, Phase III, open-label, parallel-group, three-arm, non-inferiority randomised controlled
trial comparing the clinical and cost-effectiveness of alternative TNFi and abatacept with that of rituximab
(and background MTX therapy). Eligible consenting patients were randomised in a 1 : 1 : 1 ratio using
minimisation incorporating a random element. Minimisation factors were centre, disease duration,
non-response category and seropositive/seronegative status.
Setting: UK outpatient rheumatology departments.
Participants: Patients aged ≥ 18 years who were diagnosed with RA and were receiving MTX, but had
not responded to two or more conventional synthetic disease-modifying antirheumatic drug therapies and
had shown an inadequate treatment response to a first TNFi.
Interventions: Alternative TNFi, abatacept or rituximab (and continued background MTX).
Main outcome measures: The primary outcome was absolute reduction in the Disease Activity Score of
28 joints (DAS28) at 24 weeks post randomisation. Secondary outcome measures over 48 weeks were
additional measures of disease activity, quality of life, cost-effectiveness, radiographic measures, safety
and toxicity.
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Limitations: Owing to third-party contractual issues, commissioning challenges delaying centre set-up and
thus slower than expected recruitment, the funders terminated the trial early.
Results: Between July 2012 and December 2014, 149 patients in 35 centres were registered, of whom 122
were randomised to treatment (alternative TNFi, n = 41; abatacept, n = 41; rituximab, n = 40). The numbers,
as specified, were analysed in each group [in line with the intention-to-treat (ITT) principle]. Comparing
alternative TNFi with rituximab, the difference in mean reduction in DAS28 at 24 weeks post randomisation
was 0.3 [95% confidence interval (CI) –0.45 to 1.05] in the ITT patient population and –0.58 (95% CI
–1.72 to 0.55) in the per protocol (PP) population. Corresponding results for the abatacept and rituximab
comparison were 0.04 (95% CI –0.72 to 0.79) in the ITT population and –0.15 (95% CI –1.27 to 0.98) in the
PP population. General improvement in the Health Assessment Questionnaire Disability Index, Rheumatoid
Arthritis Quality of Life and the patients’ general health was apparent over time, with no notable differences
between treatment groups. There was a marked initial improvement in the patients’ global assessment
of pain and arthritis at 12 weeks across all three treatment groups. Switching to alternative TNFi may be
cost-effective compared with rituximab [incremental cost-effectiveness ratio (ICER) £5332.02 per quality-
adjusted life-year gained]; however, switching to abatacept compared with switching to alternative TNFi is
unlikely to be cost-effective (ICER £253,967.96), but there was substantial uncertainty in the decisions. The
value of information analysis indicated that further research would be highly valuable to the NHS. Ten serious
adverse events in nine patients were reported; none were suspected unexpected serious adverse reactions.
Two patients died and 10 experienced toxicity.
Future work: The results will add to the randomised evidence base and could be included in future
meta-analyses.
Conclusions: How to manage first-line TNFi treatment failures remains unresolved. Had the trial recruited
to target, more credible evidence on whether or not either of the interventions were non-inferior to
rituximab may have been provided, although this remains speculative.
Trial registration: Current Controlled Trials ISRCTN89222125 and ClinicalTrials.gov NCT01295151.
Funding: This project was funded by the National Institute for Health Research (NIHR) Health Technology
Assessment programme and will be published in full in Health Technology Assessment; Vol. 22, No. 34.
See the NIHR Journals Library website for further project information.
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Plain English summary
Rheumatoid arthritis (RA) is a long-term problem that causes pain and swelling (inflammation) in thejoints. Many patients need treatment with drugs known as biologics, usually starting with a group
known as TNFi. If patients do not respond to a TNFi, the National Institute for Health and Care Excellence
currently recommends another biologic, rituximab, but again not all will respond.
The aim of the SWITCH trial was to find out whether or not two alternative biologics (alternative TNFi
or abatacept) were as good as rituximab at improving disease activity, quality of life, safety and
cost-effectiveness in patients who did not respond to their initial TNFi treatment.
Between July 2012 and December 2014, 122 patients from 35 hospitals were recruited into the trial and
randomly put into three treatment groups (1) rituximab, (2) alternative TNFi or (3) abatacept. We planned
to recruit 477 patients into the SWITCH trial. The trial was stopped early because of slow recruitment
(largely attributable to operational challenges throughout the study period), achieving only 122 patients
enrolled, and as a result was too small to test if either drug works as well as rituximab in reducing disease
activity. A similar general improvement in patients’ physical functioning, quality of life relating to their RA,
general health and safety over the 12-month period was apparent for all three treatments.
Switching to alternative TNFi may be cost-effective compared with the current treatment; however, the use
of abatacept is unlikely to be cost-effective.
Alternative options to rituximab may work in patients who do not respond to their first biologic therapy,
but uncertainty remains about which treatments to choose following an initial TNFi treatment failure.
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Scientific summary
Background
Rheumatoid arthritis (RA) is a chronic systemic inflammatory arthritis that affects 0.8% of the UK population.
RA has a considerable impact on health and socioeconomics as a result of of hospitalisation and loss of
employment, with over 50% of patients work-disabled within 10 years of diagnosis. The National Institute
for Health and Care Excellence (NICE)’s guidance recommends commencement of conventional synthetic
disease-modifying antirheumatic drugs (csDMARDs) on diagnosis, usually methotrexate (MTX) and/or
additional csDMARDs. If patients fail to respond to these and demonstrate high disease activity [i.e. Disease
Activity Score of 28 joints (DAS28) of > 5.1], NICE recommends the use of biologic disease-modifying
antirheumatic drugs (bDMARDs). Four different classes of bDMARD are available. Tumour necrosis factor
inhibitor (TNFi) (of which there are five different drugs) is the most commonly used. However, up to 30–40%
of patients fail to respond or lose an initial response to this bDMARD. In this setting, of the other three
classes of bDMARD available, NICE recommends use of only rituximab, which not all patients respond to.
This guidance thus limits the use of other potentially effective treatments (alternative TNFi, abatacept and
tocilizumab) and is in the absence of any direct trial comparisons.
The ambition of the SWITCH randomised trial was to deliver a definitive trial that would be a paradigm shift in
the RA community, delivering the largest RA pragmatic trial undertaken in the UK and thus also establishing
a UK-wide research network on which to build future studies. The specific aim of the SWITCH trial was to
provide clear guidance on successive bDMARD use to clinicians by assessing whether or not alternative class
bDMARDs were comparable in efficacy and safety outcomes with rituximab, the NICE-preferred second-line
option. The results of this study were expected to contribute to the development of a treatment algorithm for
clinically effective and cost-effective management, in particular to inform individualised treatment regimens as
opposed to a blanket switching of all patients to a single (and potentially unsuccessful and toxic) therapy.
Objectives
The primary objective was to determine whether or not an alternative-mechanism TNFi or abatacept
(Orencia®; Bristol-Myers Squibb, New York City, NY, USA) was non-inferior to rituximab (MabThera; Roche,
Basel, Switzerland) in disease response at 24 weeks post randomisation in patients with RA who had failed
to respond to an initial TNFi and concomitant MTX (because of inefficacy).
The secondary objectives were to compare alternative TNFi and abatacept with rituximab with respect to
disease response, quality of life, toxicity and safety over 48 weeks; to undertake an evaluation of the
cost-effectiveness of switching patients to alternative TNFi (abatacept or rituximab); and, finally, to
compare structural and bone density outcomes for abatacept and alternative TNFi to rituximab over
48 weeks using plain radiography and bone densitometry score.
Exploratory objectives were to determine the optimal sequence of treatments by assessing whether or not
the response to the second treatment in patients with RA is affected by which of the initial TNFi groups
the patients failed, to evaluate if the response to the second treatment is affected by whether or not the
patient was a primary or secondary response failure to their initial TNFi therapy and, finally, to ascertain
whether or not seropositive [to either or both of rheumatoid factor (RF) and anti-citrullinated peptide
antibody (ACPA)] and seronegative (RF and ACPA negative) RA patients behave differently in their
response and disease outcome measures in the three treatment arms. These exploratory objectives
represented more unique aspects of the trial that held particular clinical relevance.
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Methods
Design
The SWITCH study was a multicentre, Phase III, open-label, non-inferiority, three-arm randomised
controlled trial comparing the clinical effectiveness and cost-effectiveness of alternative TNFi and abatacept
with that of rituximab in patients with RA who have failed to respond to an initial TNFi drug (with
concomitant MTX).
Patients were randomised (1 : 1 : 1) to receive alternative TNFi [etanercept (if initial treatment with a
monoclonal antibody failed) or a monoclonal antibody of the clinician’s choice (if initial treatment with
etanercept failed)], abatacept or rituximab (and concomitant MTX), via a minimisation programme
incorporating a random element, with minimisation factors centre, disease duration, non-response
category seropositive/negative status. Patients received randomised treatment during the interventional
phase to a maximum of 48 weeks and were then subsequently followed up to a maximum of 96 weeks
in the observational phase.
Setting
The study took place in outpatient rheumatology departments in 35 hospitals throughout the UK.
Participants
Patients diagnosed with RA who were receiving MTX, had not responded to at least two csDMARD
therapies, including MTX, and had experienced inadequate response to treatment with one TNFi; these
eligibility criteria were based on the NICE and British Society of Rheumatology (BSR)’s guidelines on the use
of first-line TNFi.
Interventions
Rituximab (control) is a genetically engineered chimeric (human–murine) monoclonal antibody against the
B-cell protein marker CD20.
Abatacept is a selective T-cell co-stimulation blocking agent that is a fusion protein composed of the Fc
region of the immunoglobulin G1 (IgG1) fused to the extracellular domain of cytotoxic T-lymphocyte-
associated protein 4 (CTLA-4).
Alternative TNFi was etanercept (Enbrel®; Pfizer, New York City, NY, USA) [a human TNF receptor–p75Fc
fusion protein produced by recombinant deoxyribonucleic acid (rDNA) technology] or a TNF monoclonal
antibody. The specific monoclonal antibodies used were at the discretion of the treating clinician but
they were restricted to one of adalimumab (HUMIRA®; Abbott, now AbbVie, North Chicago, IL, USA)
(a recombinant fully human IgG1 monoclonal antibody specific for TNF), certolizumab pegol (CIMZIA®; UCB,
Brussels, Belgium) [a recombinant (Fc-free) humanised antibody Fab’ fragment against TNF and conjugated
to polyethylene glycol], infliximab (REMICADE®; Janssen Pharmaceutical, Beerse, Belgium) (a chimeric
human–murine IgG1 monoclonal antibody produced by rDNA technology) or golimumab (SIMPONI®;
Janssen Pharmaceutical) (a fully human IgG1 monoclonal antibody to TNF).
Outcome measures
The primary outcome measure was the absolute reduction in DAS28 at 24 weeks post randomisation.
DAS28 is a composite score calculated as a function of the number of tender and swollen joints, the
erythrocyte sedimentation rate and the patient’s global assessment of their arthritis.
Secondary outcome measures over 48 weeks were additional measures of disease activity [a reduction in
DAS28 of ≥ 1.2, low disease activity rate and remission rate, European League Against Rheumatism
(EULAR) and American College of Rheumatology (ACR) response, ACR/EULAR Boolean remission, Clinical
Disease Activity Index and Simplified Disease Activity Index] and patient-reported outcome measures
[Rheumatoid Arthritis Quality of Life (RAQoL), Hospital Anxiety and Depression Scale (HADS), Health
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Assessment Questionnaire Disability Index (HAQ-DI) and global assessment of pain, arthritis and general
health using visual analogue scales]. The outcomes required for the cost-effectiveness analysis were the
EuroQol 5 Dimensions, 3 levels (EQ-5D-3L), and health- and social-care resource use attributable to RA.
In addition, radiographic outcome measure and bone densitometry T-scores of the neck of femur and
lumbar spine were included. Further outcomes related to safety (adverse events and reactions) and toxicity
(requiring cessation of treatment) were reported throughout the trial treatment.
Sample size
A total of 477 patients was required for the sample to have 80% power for demonstrating non-inferiority,
at 95% confidence, of either abatacept or alternative TNFi to rituximab in the mean reduction in DAS28
at 24 weeks post randomisation, assuming a non-inferiority limit of –0.6 units, no difference between
treatment groups, a between-patient standard deviation (SD) of 1.8 units and loss to follow-up of 10%.
Analysis
An analysis of the primary outcome measure was completed for the intention-to-treat (ITT), per protocol
(PP) and complete-case populations. Non-inferiority was defined as the lower limit of the 95% confidence
interval (CI) lying above –0.6 units in both the ITT and PP populations. An analysis of secondary outcome
measures was undertaken on the ITT and complete-case populations as appropriate. Safety data are
summarised on the safety population.
Multiple imputation by chained equations was used to impute missing values at the component level for
the DAS28 and American College of Rheumatology 20 (ACR20), under the assumption that the data were
‘missing at random’. Parameter estimates across each of the fully imputed data sets were combined using
Rubin’s rules.
A mixed-effects linear regression model was fitted to the primary outcome measure with covariates
corresponding to the minimisation factors and treatment group. Centre was fitted as a random effect.
Covariance pattern models were fitted to the DAS28 and the binary marker (logit link) of a reduction in
DAS28 of ≥ 1.2 units over time with covariates entered for the minimisation factors (excluding centre),
baseline DAS28, treatment group, time and time-by-treatment interaction. A logistic regression model
was fitted to the ACR20 at 24 weeks post randomisation, with covariates entered for the minimisation
factors (excluding centre) and treatment group. All additional secondary outcome measures, including
further measures of disease activity and quality of life, the exploratory subgroup analyses to evaluate the
treatment modification effect of RF/ACPA status, non-response category and initial TNFi group failed on
and DAS28 at 24 weeks, are summarised by treatment group and compared informally using descriptive
statistics. In addition, treatment compliance, toxicity and safety were summarised.
For the primary cost-effectiveness analysis, total cost and quality-adjusted life-years (QALYs) over the
48-week time horizon and corresponding incremental cost-effectiveness ratios (ICERs) were calculated for
each treatment group. For the secondary analysis, a wider cost perspective was adopted to include the
total costs incurred by patients.
Results
Between July 2012 and December 2014, when the trial was stopped, 149 patients in 35 centres were
registered in the trial, of whom 122 were randomised to treatment.
Comparing alternative TNFi with rituximab, the difference in mean reduction in DAS28 at 24 weeks post
randomisation was 0.3 (95% CI –0.45 to 1.05) in the ITT population and –0.58 (95% CI –1.72 to 0.55) in
the PP population.
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The corresponding results for the comparison of abatacept and rituximab were 0.04 (95% CI –0.72 to
0.79) in the ITT population and –0.15 (95% CI –1.27 to 0.98) in the PP population.
There was evidence of a statistically significant difference in DAS28 at week 36 (p = 0.022) between
alternative TNFi and rituximab, with a lower DAS28 in the TNFi arm, but this difference was not
maintained at week 48. There was no evidence of a clinically or statistically significant difference in DAS28
for abatacept compared with rituximab at any time point. There was no statistically significant difference in
the odds of achieving a DAS28 response (i.e. reduction of ≥ 1.2) for either intervention compared with
rituximab at any of the time points. Moreover, there was no evidence of a difference in the odds of
achieving an ACR20 response at 24 weeks post randomisation for either intervention relative to rituximab.
Overall, a general improvement in HAQ-DI, RAQoL and the patients’ general health was apparent over
time, with no notable differences between treatment groups. There was a marked initial improvement in
the average global assessment of pain and arthritis at 12 weeks for all three treatment groups. Small
improvements in the HADS scores sustained over the 48-week period were observed for alternative TNFi
and abatacept, whereas no notable improvement was apparent for rituximab.
Ten serious adverse events (SAEs) were reported in nine patients, of which three events in three patients
were considered to be related to trial medications. No suspected unexpected serious adverse reactions
were reported. Two patients died, both following the development of a SAE (rituximab, abatacept), one of
which was a suspected serious adverse reaction (abatacept). Ten patients experienced toxicity resulting
in a permanent cessation of treatment (four patients on alternative TNFi, two on abatacept and four
on rituximab).
The health economic analysis suggested that switching to alternative TNFi may be cost-effective compared
with rituximab [mean cost alternative TNFi, £9680.23 (SD £1263.71); mean cost rituximab, £9367.27
(SD £3215.13); mean QALY alternative TNFi, 0.52 (SD 0.14); mean QALY rituximab, 0.46 (SD 0.18); ICER,
£5332.02 per QALY gained]; however, switching to abatacept compared with switching to alternative TNFi
is unlikely to be cost-effective [mean cost abatacept, £13,475.09 (SD £4173.22); mean QALY abatacept,
0.53 (SD 0.17); ICER, £253,367.96] when considered against the NICE cost/QALY acceptance threshold of
£20,000. The value of information analysis indicated that it would be highly valuable to the NHS to reduce
the current uncertainty regarding the effectiveness of alternative TNFi compared with rituximab in the
management of RA.
Conclusions
Implications for health care
The clinical question of whether or not alternative bDMARDs and rituximab are comparable in efficacy and
safety outcomes in patients with RA who had not responded adequately to an initial TNFi bDMARD and
MTX remains unresolved. The lack of evidence, which is based on a single treatment (rituximab) being
appropriate for all patients, limits guidance options.
Had the study been extended to enable recruitment to target, definitive evidence on whether or not either
of the interventions were non-inferior to rituximab may have been provided, which may have opened up
further treatment options for patients.
Trial registration
This trial is registered as ISRCTN89222125 and NCT01295151.
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Chapter 1 Introduction
Background
Rheumatoid arthritis (RA), the most common autoimmune disease in the Western world,1 is a chronic and
systemic inflammatory arthritis that affects 0.8% of the UK population.2 RA is the largest cause of treatable
disability in the Western world.3,4 Patients with RA suffer considerable pain, stiffness and swelling and, if not
adequately controlled, sustain various degrees of joint destruction, deformity and significant functional
decline. RA has a considerable health and socioeconomic impact, as a result of both hospitalisation and loss
of employment, with over 50% of patients work-disabled within 10 years of diagnosis.5–7
Rheumatoid arthritis is associated with significant comorbidity and increased mortality compared with the
general population,8 largely because the prevalence of premature cardiovascular disease9 is as high as that
seen in patients with other major cardiovascular disease risk factors, such as type 2 diabetes,10 and, in fact,
is the cause of death of 48% of patients with RA. RA-related inflammation and disease activity over time
are associated with increased cardiovascular disease risk in patients with RA,11–14 which further emphasises
the importance of ensuring optimal and effective disease control.
As compared with other chronic diseases, such as hypertension and type 2 diabetes, treatment of RA
previously employed a gradual ‘step-up’ strategy with the use of conventional synthetic disease-modifying
antirheumatic drugs (csDMARDs).15 The concept of the ability to modify disease course started to be
realised in the 1990s,16 with key studies demonstrating the importance of early diagnosis and expedient
implementation of csDMARD therapy,17–19 which remain the cornerstones of management of RA. These
paradigms have been consolidated by strategy trials and meta-analysis on the radiographic benefit.20–24
The National Institute for Health and Care Excellence’s rheumatoid
arthritis management guidance
The National Institute for Health and Care Excellence (NICE)’s clinical guidance for the management of
RA25 recommends, in people with newly diagnosed active RA, a combination of csDMARDs [including
methotrexate (MTX) and at least one other csDMARD, plus short-term glucocorticoids] as first-line
treatment as soon as possible, ideally within 3 months of the onset of persistent symptoms (and within
6 weeks of diagnosis by a rheumatologist).
Methotrexate is thus recommended as the optimal first-line treatment strategy25,26 either as monotherapy
or in combination. Nevertheless, it had become clear that poor response (even if initially effective)
remained a feature with most csDMARDs over time, with progression of joint damage and functional
decline. In addition, a high incidence of toxicity has been observed with these drugs.27 Such obstacles to
therapy, combined with data suggesting limited alteration in long-term outcome, even in those patients
showing a response, are an argument for more effective therapy.28
Biological therapies
This unmet clinical need fuelled continued research into our understanding of RA, which led to significant
advances by the 1990s. Inflammation was recognised to be a result of imbalance between pro-inflammatory
cytokines such as tumour necrosis factor (TNF) alpha [as well as interleukin 1(IL-1), IL-6 and others] and
anti-inflammatory cytokines such as IL-4 and IL-10. In RA, an excess of pro-inflammatory cytokines, in particular
TNF and IL-1, has been shown to be responsible for disrupting this balance towards continued inflammation
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and cartilage and bone damage, and thus critical in driving RA pathogenesis.29 This understanding was
complemented with significant advances in biotechnology. Following in vitro and in vivo work, the most
compelling evidence for a key role for TNF stemmed from studies in which marked clinical benefit was
observed in patients with RA treated with a chimeric anti-TNF monoclonal antibody.30 The subsequent
introduction of several costly, but highly effective, tumour necrosis factor inhibitor (TNFi) therapies marked the
start of a new era in biologic disease-modifying antirheumatic drug (bDMARD) development for RA.31–33
Tumour necrosis factor inhibitors
Tumour necrosis factor inhibitor drugs [etanercept (Enbrel®; Pfizer, New York City, NT, USA), infliximab
(REMICADE®, Janssen Pharmaceutical, Beerse, Belgium), adalimumab (HUMIRA®; Abbott, now AbbVie,
North Chicago, IL, USA), certolizumab pegol (CZP) (CIMZIA®; UCB, Brussels, Belgium) and golimumab
(Simponi®; Janssen Pharmaceutical)] in combination with MTX produce better outcomes in RA than in
placebo or treatment with MTX alone.31–37 TNFi drugs, however, differ in several respects:
i. molecule type [chimeric (mouse–human) monoclonal antibody (infliximab), fully human monoclonal
antibody (adalimumab, golimumab), pegylated Fab fragment of a humanised monoclonal antibody
(CZP) and a TNF receptor fusion protein (etanercept)]38
ii. target (etanercept binds both TNF and another cytokine, lymphotoxin alpha)39
iii. binding affinity to TNF
iv. mechanism of drug action40–42
v. clinical administration (intravenous vs. subcutaneous).
Non-tumour necrosis factor inhibitors
Following the development of TNFis, recognition of other key cytokines and immune cells in RA
pathogenesis43 led to the development of additional bDMARDs: rituximab (MabThera; Roche, Basel,
Switzerland), a chimeric anti-CD20-depleting monoclonal antibody,44 tocilizumab (Actemra®; Roche), an
IL-6 receptor monoclonal antibody45 and abatacept (Orencia®; Bristol-Myers Squibb, New York City, NY,
USA), a recombinant fusion protein T-cell co-stimulation blocking agent.46 All of these bDMARDs
demonstrated significant benefits compared with placebo and MTX in MTX-inadequate response44,47,48
and TNFi-inadequate response49–51 groups, respectively.
The clinical unmet need
Tumour necrosis factor inhibitor is the most frequently used first-line bDMARD. Despite the extensive
benefits of TNF-directed bDMARDs, a significant proportion, 20–40%, of patients with RA who have
MTX-inadequate response and treated with TNFi52 fail to achieve sufficient response (primary non-response)
or lose responsiveness over time (secondary non-response).36,52
Thus, following initial TNFi-inadequate response, two broad approaches could theoretically be employed to
manage patients: switching to alternative TNFi therapy or switching to a bDMARD with another mode
of action.26
The National Institute for Health and Care Excellence’s technology
appraisal for biologic disease-modifying antirheumatic drugs
At the time of the SWITCH study, a NICE technology appraisal recommended TNFi use if disease is severe,
that is, a Disease Activity Score of 28 joints (DAS28) of > 5.1 units and disease has not responded to
at least two conventional disease-modifying antirheumatic drugs (DMARDs), including MTX. Initially,
adalimumab, etanercept and infliximab53 (and later on CZP54 and golimumab55) were recommended by
NICE as first-line bDMARD therapy for the treatment of patients with RA who had failed to respond to, or
had been intolerant of, at least two csDMARDs including MTX.56
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The current NICE technology appraisal 37556 has updated possible first-line bDMARD options and now
recommends use not only of one of the five TNFi, but also of tocilizumab57 and abatacept,58 which are also
approved by NICE for first-line bDMARD therapy following MTX-inadequate response.58 Nevertheless, TNFi
remains the most frequently used first-line bDMARD (both in the UK and worldwide).
Non-response to tumour necrosis factor inhibitor
In the context of first-line bDMARD TNFi failure, NICE guidance recommends using rituximab as second-line
bDMARD.59 Switching to alternative TNFi, abatacept or tocilizumab, is permitted only if patients have had an
inadequate response to rituximab57 or are intolerant of rituximab57,59 or if rituximab is contraindicated.57,59
This is in the absence of any trial data demonstrating that rituximab is more appropriate than the alternative
bDMARDs. Of note is the fact that this technology appraisal guidance applies to bDMARD use with
background MTX. For individuals who are unable to take MTX, TNFi switching is permitted. This guidance has
not been comprehensively updated following approval of tocilizumab and abatacept as first-line bDMARDs.
It is the absence of robust trial data to support NICE’s guidance regarding the process to follow in the
event of failure of initial TNFi treatment (discussed below), effectively limiting the treatment choice to
rituximab, which we recognise is not effective for all individuals, that is the basis for the SWITCH study.
Switching between tumour necrosis factor inhibitors
Observational studies
Several early-phase uncontrolled studies and an initial small randomised study suggested benefit in
switching between TNFi agents.60–70 A report of extremely high responses on alternative TNFi agent in
specific subgroups of patients62 also indicated the potential value and the need to explore this approach
further. A literature review71 documented 29 reports on switching from one TNFi to another in RA, with
the data largely indicating benefit of switching from a first TNFi to a second, with switching for secondary
non-response likely to be more effective. A systematic review reported similar findings.72
Randomised controlled trials
No randomised controlled trials (RCTs) of switching between adalimumab, etanercept and infliximab have
been conducted in patients in whom these three established TNFi have failed. The rationale and argument
for switching between different TNFi drugs, however, were further strengthened by a large, international,
multicentre, randomised, Phase II study73 that investigated 461 patients who had previously received and
either failed or were intolerant of one or more TNFis. Patients were randomised to either golimumab (50 mg
or 100mg every 4 weeks) or placebo. American College of Rheumatology 20 (ACR20) response rates at
week 14 were significantly higher in the golimumab groups than in the placebo group (35% and 38% vs.
18%, respectively). More recently, two RCT studies,74,75 one with open-label evaluation,74 have demonstrated
significant efficacy of CZP in prior TNFi treatment failures. In a small but first prospective RCT,74 patients in
whom an initial TNFi was stopped because of secondary non-response (i.e. the initial response to the TNFi
was lost) were randomised to 12 weeks of either CZP (n = 27) or placebo (n = 10), followed by an open-label
CZP 12-week period. The primary end point was the proportion of patients reaching an ACR20 response by
week 12, observed in 61.5% of patients in the CZP group, compared with 0% of patients in the placebo
group. Placebo patients who were switched blindly to CZP attained similar results seen with CZP in weeks
0–12. As this result was highly significant, study inclusion was terminated after entry of 33.6% of the
originally planned 102 patients. The REALISTIC study, a 28-week Phase IIIb study, assessed safety and
maintenance of response to CZP in a diverse population of RA patients, stratified by prior TNFi exposure,
concomitant MTX use and disease duration.
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Switching to non-tumour necrosis factor inhibitor biologic
disease-modifying antirheumatic drug therapies
Randomised controlled trials
Randomised controlled trials49–51 and their long-term extension studies (LTEs)76–78 have demonstrated the
benefits of non-TNFi bDMARDs over placebo/MTX following TNFi-inadequate response.
The randomised evaluation of long-term efficacy of rituximab in RA (REFLEX) study evaluated the efficacy of
rituximab versus placebo in patients receiving MTX who had failed at least one TNFi.49 Significantly more
rituximab-treated patients than placebo-treated patients achieved ACR20, American College of Rheumatology
50 (ACR50), American College of Rheumatology 70 (ACR70) and moderate to good European League
Against Rheumatism (EULAR) responses at week 24. Of note, despite a significant reduction in Disease Activity
Score in the rituximab group, the mean DAS28 at week 24 was still high, at 5.1 units (a reduction of 1.83
from 6.9 at baseline).49 In the LTE study (and thus a selected subgroup), rituximab showed sustained effects
on joint damage progression.76 The ATTAIN (A Therapeutic Trial of Afatinib In the Neoadjuvant Setting)
study51 compared the efficacy of abatacept and placebo/MTX in patients with TNFi-inadequate response and
found that significantly more patients in the abatacept group achieved ACR20, ACR50 and ACR70 responses,
impressive quality-of-life results and improvement in DAS28 (a reduction in Disease Activity Score of > 1.2 in
70% in the abatacept group vs. 18.2% in the placebo group)51 and patients continued to maintain these
improvements throughout the 2-year LTE study.77 The RA study in anti-TNF failures (RADIATE) study compared
the efficacy of tocilizumab (8 mg/kg or 4 mg/kg) plus MTX to placebo plus MTX in patients with one or more
TNFi-inadequate responses.50 At week 24, more patients in the tocilizumab groups than in the placebo group
achieved ACR20, ACR50 and ACR70 responses and good or moderate EULAR responses.50 The efficacy of
tocilizumab was maintained for up to 4.2 years during the LTE study.78
Switching to a second tumour necrosis factor inhibitor or alternative
class biologic disease-modifying antirheumatic drug
Observational studies
A number of observational studies have compared clinical response after switching to either rituximab or
alternative TNFi in patients who failed initial TNFi treatment.79–82 As summarised below, most have suggested
better efficacy on switching to rituximab, although there are also reports of equivalent clinical responses
in patients who switched to either alternative TNFi or rituximab following failure of one or more TNFi
therapies.83,84 These observational studies, however, had several design limitations, such as small sample
sizes,79 selection bias,79–82 pooling all causes of TNFi failure81 and missing data,79–82 although they tried to
address these issues by calculating propensity scores and using multivariable analysis techniques.79–82
Analysis of patients with RA in the Swiss Clinical Quality Management in Rheumatic Diseases RA registry
(SCQM-RA),79,80 who had treatment failure with at least one TNFi and were switched either to alternative
TNFi or to one cycle of rituximab, showed that switching to rituximab may be more effective than switching
to another TNFi. Furthermore, when the motive for switching was ineffectiveness of the TNFi, patients who
received rituximab achieved a significantly better improvement in DAS28 at 6 months than patients who
received alternative TNFi.80 However, when the reason for switching was other causes, the improvement in
DAS28 was similar in the two groups.80 The same registry also reported that rituximab was as effective as
alternative TNFi in preventing joint erosions in patients who had previous treatment failure with a TNFi.83 A
study of 1300 patients with RA on the British Society of Rheumatology (BSR)’s Biologics Register who had a
failed response to their first TNFi treatment and were switched to a single cycle of either rituximab or
alternative TNFi found that patients who switched to rituximab had better EULAR responses and were more
likely to achieve improvement in their Health Assessment Questionnaire (HAQ) scores.81 More recently, a
global observational real-life study (SWITCH-RA)82 also showed that among patients with RA who failed to
respond to, or were intolerant of, a single previous TNFi, those who were switched to rituximab achieved
significantly better clinical responses at 6 months than those patients who were switched to a second TNFi.
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However, further subgroup analysis showed that these differences were observed only in seropositive
[to either or both of rheumatoid factor (RF) and anti-citrullinated peptide antibody (ACPA)] patients who
switched because of lack of efficacy of the first TNFi.82
An observational study from the US Consortium of Rheumatology Researchers of North America (CORRONA)
cohort85 reported clinical effectiveness of abatacept versus subsequent TNFi in patients with RA following one
or more TNFi drug failures, using propensity scoring to reduce bias attributable to systematic prescribing
practices. Six- and/or 12-month response outcomes with change in disease activity, remission rates based
on the Clinical Disease Activity Index (CDAI) and modified DAS28 (mDAS28) and American College of
Rheumatology (ACR) response rates were evaluated. The main analysis included all patients regardless of the
reason for switching in the main analysis, with inadequate response to prior TNFi addressed in a sensitivity
analysis. For the primary outcome (minimum clinically important difference in the change in CDAI score of
4.3) and the secondary outcomes, no differences between the two treatments were recorded.
Head-to-head comparisons
Gottenberg et al.86 reported a 52-week pragmatic open-label RCT that randomised 300 patients who did
not respond to a first TNFi to receive either alternative TNFi or an alternative-mechanism bDMARD
(abatacept, rituximab or tocilizumab). This was a superiority trial, with the primary outcome of a good or
moderate EULAR response at 6 months. Primary outcome was achieved in a significantly greater proportion
of patients in the non-TNFi group, with 70% achieving a good or moderate EULAR response, compared
with 52% in the second TNFi group. Similar differences were observed from week 12 and persisted at
week 52, with, in addition, significantly better low disease activity and remission rates. Although an
instructive and randomised study, the multiple treatment options included within the non-TNFi group limit
the extent to which these data can inform on which specific targeted agent should be considered.
In contrast, a recent preliminary report from a Dutch randomised trial of 144 patients with RA who had failed
a first TNFi and were randomised (1 : 1 : 1) to receive alternative TNFi, abatacept or rituximab, showed that
there was comparable improvement in the DAS28, HAQ scores and Short Form questionnaire-36 items
(SF-36) outcome measures over a 12-month period.87 Rituximab therapy was the most cost-effective of the
three (although this finding may not be true in other countries with different health-care provision and
pricing structures).87 Further studies with larger sample sizes and inclusion of tocilizumab in the treatment
options are needed to confirm these results.
Serology and response
Compared with rituximab, and potentially the other two non-TNFi bDMARDs, a key benefit of the TNFi
appears to be its suitability in both seropositive (either or both of RF and ACPA positive) and particularly
seronegative disease.82 Seronegative antibody status (seen in up to 25–30% of patients with RA) is associated
with a poorer response to rituximab84,88,89 and better response rates have been demonstrated in antibody-
positive patients treated with rituximab, which was most evident in the TNFi failure group;84 perhaps intuitive
in the light of its target and rationale for use. Recent studies have also demonstrated that abatacept may be
more effective in seropositive (ACPA-positive) patients.90–93 Furthermore, a Japanese study of 58 patients
with RA treated with tocilizumab (including 22 patients who previously received a TNFi) reported that a
high titre of immunoglobulin M RFs at baseline was the only variable to be associated with CDAI remission
at 24 weeks.94 However, a larger French cohort study95 of 208 patients with RA did not find an association
between seropositivity at baseline and a EULAR response after 24 weeks of tocilizumab therapy.
Additional clinical factors for consideration
Apart from antibody status, certain patients will not be appropriate for rituximab therapy, and coexisting
pathologies, such as inflammatory bowel disease and psoriasis, that are also treated with TNFi may make
DOI: 10.3310/hta22340 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 34
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Brown et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
5
other agents less appropriate. Rituximab, for example, has been associated with the development of
psoriasis in patients with no previous history of the disease,96 although it is recognised that bDMARDs,
including TNFi therapy, can induce paradoxical clinical manifestations such as pustular psoriasis.97,98
Summary comments
Despite the benefits of recent advances in the management of RA, no universally effective treatment exists.
It remains unclear how best to utilise the alternative bDMARDs following an initial TNFi-inadequate
response. Although large observational studies have been performed, the need for more direct
comparisons to provide sufficiently robust evidence to inform clinicians is necessary. Results from recent
trials are emerging. Nevertheless, data suggesting that subgroups are more responsive to a particular
targeted therapy (seronegativity and TNFi99) highlight the importance of including such factors in study
design to avoid prematurely discounting alternative TNFi drug as an effective therapeutic option,
particularly in the context of resistant and aggressive disease cohorts. In addition, optimal bDMARD choice
based on the nature of prior inefficacy (primary or secondary) has not been addressed to date. Despite
several treatment options now available, no large-scale head-to-head comparisons investigating the
efficacy of sequential biologic treatments have been conducted to date.
The SWITCH trial100 was a well-designed randomised trial in this therapeutic area, which also aimed to
explore the more refined clinical questions that would thus provide clear guidance to clinicians. This study
aimed to evaluate whether or not alternative class bDMARDs compared with rituximab (the NICE-preferred
second-line option) were comparable in efficacy and safety outcomes. The results of this study were
expected to contribute to the development of a rational treatment algorithm and more judicious and
cost-effective management, in particular to allow individualised treatment regimens rather than switching
all patients to a single (and potentially unsuccessful and toxic) therapy. The trial was stopped early by the
funding committee because of unforeseen interruptions and lengthy site set-up, which, thus, impacted on
the inability to recruit to target on time. Although the results presented in this report are not sufficiently
powerful to address these aims, we expect that the controlled data will inform the emerging evidence base
and can be included in meta-analyses.
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Chapter 2 Clinical trial methods
Objectives
In patients with RA who had failed treatment to an initial TNFi (according to NICE guidance), the objectives
of this study were as follows.
Primary objective
The primary objective was to determine whether or not an alternative-mechanism TNFi or abatacept is
non-inferior to rituximab in disease response at 24 weeks post randomisation.
Secondary objectives
The secondary objectives were:
l to compare alternative TNFis and abatacept with rituximab for disease response, quality of life, toxicity
and safety over 48 weeks
l to undertake an evaluation of the cost-effectiveness of switching patients to alternative TNFi, abatacept
or rituximab
l to compare structural and bone density outcomes for abatacept and alternative TNFis with those for
rituximab over 48 weeks using plain radiography and bone densitometry score.
Exploratory objectives
The exploratory objectives were:
l to determine the optimal sequence of treatments by assessing whether or not the response to the
second treatment in patients with RA is affected by which initial TNFi the patients failed treatment on
(TNFi monoclonal or TNFi receptor fusion protein)
l to evaluate whether or not the response to the second treatment (alternative TNFi, abatacept or
rituximab) is affected by whether or not the patient was a primary (no initial response) or secondary
(loss of an initial response) response failure to their initial TNFi therapy
l to ascertain whether or not seropositive (to either or both of RF and ACPA) and seronegative patients
with RA behave differently in their response and disease outcome measures across the three treatment
arms, particularly with respect to rituximab.
Design
The study was a multicentre, Phase III, open-label, non-inferiority, parallel-group, three-arm RCT comparing
the clinical effectiveness and cost-effectiveness of alternative TNFi and abatacept (separately) with that of
rituximab in patients with RA who have failed an initial TNFi treatment.
Patients were randomised on a 1 : 1 : 1 basis to receive one of the following:
1. alternative TNFi:
i. etanercept if patient had initial failure of a monoclonal antibody: infliximab, adalimumab, certolizumab
or golimumab
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OR
ii. monoclonal antibody: infliximab, adalimumab, certolizumab or golimumab if patient had initial
failure of etanercept (choice of monoclonal TNFi at investigator’s discretion)
2. abatacept
3. rituximab.
Patients received randomised treatment during the interventional phase to a maximum of 48 weeks and
were subsequently followed up to a maximum of 96 weeks in the observational phase.
The study was reviewed and approved by the National Research Ethics Service, Research Ethics Committee
Leeds (West) (reference number 11/H1307/6) and was registered as an International Standard Randomised
Controlled Trial number 89222125 and with ClinicalTrials.gov identifier NCT01295151. The trial protocol100
can be accessed at http://bmcmusculoskeletdisord.biomedcentral.com/articles/10.1186/1471-2474-15-452.
Patient and public involvement
Ailsa Bosworth, Chief Executive and Founder of the National Rheumatoid Arthritis Society, was the patient
and public involvement (PPI) member on the Trial Management Group and provided valuable PPI input to
the development of the SWITCH trial proposal and on key decisions throughout the trial.
There was also involvement from a PPI representative on the Trial Steering Committee, Sandra Purdy, who
provided input into the patient information sheet and other trial documentation intended for use by
patients. Through membership of the Trial Steering Committee, the PPI representative also provided input
into the design and conduct of the trial through annual meetings.
Participants
Patients attending hospital-based rheumatology outpatient departments throughout the UK, who had
been diagnosed with RA, were receiving MTX, had not responded to (at least two) csDMARD therapy
(including MTX) and had experienced an inadequate response to treatment with one TNFi were invited to
be screened for eligibility in the trial if they:
l were male or female and aged ≥ 18 years
l had a diagnosis of RA as per the ACR/EULAR 2010 classification criteria confirmed at least 24 weeks
prior to the screening visit
l failed csDMARD therapy according to NICE/BSR guidelines,101 that is failure of at least two csDMARDs
including MTX
l had persistent RA disease activity despite having been treated with a current initial TNFi agent for at
least 12 weeks. Active RA was defined as:
¢ primary non-response defined as failing to improve DAS28 by > 1.2 units or failing to achieve a DAS28
of ≤ 3.2 units within the first 12–24 weeks of starting the initial TNFi treatment (this may include
patients who have shown a reduction in DAS28 of > 1.2 units but still demonstrate an unacceptably
high disease activity in the physician’s judgement with evidence of an overall DAS28 of ≥ 3.2 units)
OR
¢ secondary non-response defined as lack of efficacy of the first TNFi treatment (having
demonstrated prior satisfactory response) as per clinician judgement, with the reason for cessation
of the first TNFi treatment other than intolerance
CLINICAL TRIAL METHODS
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l were MTX dose stable for 4 weeks prior to the screening visit and to be continued for the duration of
the study
l were on non-steroidal anti-inflammatory drugs (NSAIDs) and/or corticosteroids (oral prednisolone not
exceeding 10 mg daily), on an unchanged regimen for at least 4 weeks prior to the screening visit
and were expected to remain on a stable dose until the baseline assessments have been completed
l provided written informed consent prior to any trial-specific procedures.
Patients were excluded if they met any one of the following criteria.
l They had had major surgery (including joint surgery) within 8 weeks prior to the screening visit or
planned major surgery within 52 weeks following randomisation.
l They had inflammatory joint disease of different origin, mixed connective tissue disease, Reiter’s
syndrome, psoriatic arthritis, systemic lupus erythematosus, or any arthritis with onset prior to 16 years
of age.
l They had received doses of prednisolone of > 10 mg/day within the 4 weeks prior to the screening visit.
l They had received intra-articular or intramuscular steroid injections within 4 weeks prior to the
screening visit.
l They had previously received more than one TNFi drug OR any other bDMARD for the treatment of RA.
l They were unable or unwilling to stop treatment with a prohibited DMARD (i.e. synthetic DMARD aside
from MTX, e.g. oral or injectable gold, chloroquine, hydroxychloroquine, ciclosporin, azathioprine,
leflunomide, sulfasalazine) prior to the start of protocol treatment.
l They had been treated with any investigational drug in the last 12 weeks prior to the start of
protocol treatment.
l They had other comorbidities including acute, severe infections, uncontrolled diabetes, uncontrolled
hypertension, unstable ischaemic heart disease, moderate/severe heart failure (class III/IV of the New
York Heart Association functional classification system102), active bowel disease, active peptic ulcer
disease, recent stroke (within 12 weeks before the screening visit), or any other condition which, in the
opinion of the investigator, would put them at risk if they participated in the study or would make
implementation of the protocol difficult.
l They had experienced any major episode of infection requiring hospitalisation or treatment with
intravenous antibiotics within 12 weeks of start of the treatment protocol or oral antibiotics within
4 weeks of start of the protocol treatment.
l They were at significant risk of infection that, in the opinion of the investigator, would put them at risk
if they participated in the study [e.g. leg ulceration, indwelling urinary catheter, septic joint within
52 weeks (or ever if a prosthetic joint is still in situ)].
l They had known active current or a history of recurrent bacterial, viral, fungal, mycobacterial or other
infections including herpes zoster [for tuberculosis (TB) and hepatitis B and C, see below], but excluding
fungal infections of nail beds as per clinical judgement.
l They had untreated active current or latent TB. Patients should have been screened for latent TB (as per
BSR’s guidelines) within 24 weeks prior to the screening visit and, if positive, treated following local
practice guidelines prior to the start of protocol treatment.
l They had active current hepatitis B and/or C infection. Patients should have been screened for hepatitis B
and C within 24 weeks prior to the screening visit and, if positive, excluded from the study.
l The had primary or secondary immunodeficiency (history of or currently active) unless related to primary
disease under investigation.
l In the case of women, they were pregnant or lactating or were women of child-bearing potential
(WCBP) who were unwilling to use an effective birth control measure while receiving treatment and
after the last dose of protocol treatment, as indicated in the relevant summary of product
characteristics (SmPC) or investigator’s brochure (IB).
l In the case of men, their partners were WCPB who were unwilling to use an effective birth control
measure while receiving treatment and after the last dose of protocol treatment as indicated in the
relevant SmPC/IB.
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l They were known to have significantly impaired bone marrow function as a result of, for example,
significant anaemia, leucopenia, neutropenia or thrombocytopenia, defined by the following laboratory
values at the time of the screening visit:
¢ haemoglobin level of < 8.5 g/dl
¢ platelet count of < 100 × 109/l
¢ white blood cell count of < 2.0 × 109/l
¢ neutrophil count of < 1 × 109/l
l They were known to have severe hypoproteinaemia at the time of the screening visit as a result of,
for example, nephrotic syndrome or impaired renal function, defined by:
¢ a serum creatinine concentration of > 150 µmol/l.
The eligibility criteria were based on BSR’s guidelines on the use of TNFi.101 Important exclusion criteria that
are adhered to in clinical practice were applied in this study.
Recruitment
Patients were approached during standard clinic visits for the management of their RA, or were identified
by waiting lists, registries or reviews of case records, and sent a personalised letter inviting them to
participate. Patients were provided with verbal and written details about the trial and had as long as they
required to consider participation. Assenting patients provided written consent before being registered into
the trial and formally assessed for eligibility. Patients at Chapel Allerton Hospital also had the option of
giving informed consent for blood and tissue samples to be taken for the SWITCH trial biobank for future
scientific research. The participant information sheet and consent forms are provided in Appendix 1.
Interventions
Abatacept
Abatacept is a selective T-cell co-stimulation blocking agent that is a fusion protein composed of the Fc
region of the immunoglobulin G1 (IgG1) fused to the extracellular domain of cytotoxic T-lymphocyte-
associated protein 4 (CTLA-4).
Alternative tumour necrosis factor inhibitors
Etanercept
Etanercept is a human TNF receptor p75Fc fusion protein produced by recombinant deoxyribonucleic acid
(rDNA) technology. Patients randomised to receive alternative TNFis whose initial TNFi was a monoclonal
antibody received etanercept as their intervention.
Monoclonal antibodies
For patients randomised to receive alternative TNFi whose initial TNFi was etanercept, the allocation was to
one of four anti-TNF monoclonal antibodies. Within this group of interventions, allocation was at the
discretion of the treating clinician.
l Adalimumab: a recombinant fully human IgG1 monoclonal antibody specific for TNF produced in a
mammalian cell expression system.
l CZP: a recombinant (Fc-free) humanised antibody Fab fragment against TNF and conjugated to
polyethylene glycol.
l Infliximab: a chimeric (human–murine) IgG1 monoclonal antibody produced by rDNA technology.
l Golimumab: a fully human IgG1 monoclonal antibody to TNF.
CLINICAL TRIAL METHODS
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Rituximab (control)
A genetically engineered chimeric (human–murine) monoclonal antibody against the B-cell protein marker
CD20 (clusters of differentiation 20).
Efficacy of rituximab to placebo was established in a similar patient population in the REFLEX study.49
Table 1 illustrates the treatment regimen including mode of administration and dose, for each of the three
treatment arms. The intervention period was 48 weeks, achieved via treatment regimens administered for
a minimum of 24 weeks.
Study procedures
Screening and baseline assessments
Following written informed consent and prior to any trial-related procedures, patients were registered into
the study. All patients had a screening assessment within 4 weeks prior to the baseline assessment (and,
when applicable, the assessment was repeated at the baseline assessment) to establish eligibility. The
clinical assessment included a medical history, a physical examination, which included measurements of
height, weight and vital signs, electrocardiography (ECG), chest radiography and a screen for TB (if not
performed within specified time window prior to the screening visit). In addition, a 28 swollen joint count
(SJC) and tender joint count (TJC) were performed (Figure 1), and blood and urine tests [haematology,
blood chemistry, C-reactive protein (CRP) level test, erythrocyte sedimentation rate (ESR), serological tests,
hepatitis B and C screen, a pregnancy test and urinalysis] were undertaken. At the baseline assessment,
a further blood test was undertaken to assess glucose levels and lipid profiles.
TABLE 1 Trial treatment regimen by treatment arm
Treatment arm Treatment description
Rituximab A single dose of 1 g as an intravenous infusion administered at days 0 (week 0) and
15 (week 2). In line with standard practice, a patient who lost an initial 6-month (week 24)
response, as per NICE’s guidance, could receive a further cycle of rituximab after a minimum
of 6 months following the first dose. The second cycle of rituximab was, again, given at a
dose of 1 g; two intravenous infusions administered at a 2-week interval, for example week
24 and 26. Prior to receiving rituximab, 100mg of intravenous methylprednisolone was given
as a premedication
Abatacept Solution for subcutaneous injection: 125 mg per syringe (125mg/ml). Administered at a dose
of 125 mg at week 0 and once weekly thereafter for a minimum of 24 weeks
Alternative TNFi
Etanercept A single dose of 50 mg by subcutaneous injection weekly for a minimum of 24 weeks (unless
not tolerated)
Adalimumab A single dose of 40 mg by subcutaneous injection every 2 weeks for a minimum of 24 weeks
(unless not tolerated)
Infliximab A dose of 3 mg/kg per intravenous infusion, administered on a day-case unit or equivalent at
weeks 0, 2 and 6 and then every 8 weeks thereafter for a minimum of 24 weeks
CZP Single dose of 400 mg by subcutaneous injection at weeks 0, 2 and 4 and then at a dose of
200 mg every 2 weeks thereafter for a minimum of 24 weeks
Golimumab Dose of 50 mg by subcutaneous injection every 4 weeks for a minimum of 24 weeks.
Available as IMP within the SWITCH trial following approval in November 2013
IMP, investigational medicinal product.
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At screening and baseline assessments, patients completed a Global Assessment of Arthritis using a visual
analogue scale (VAS) and reported the extent of their early-morning stiffness. The clinician assessed the
Global Disease Activity using a VAS. At the baseline assessment, patients completed a Global Assessment
of Pain VAS and an assessment of their general health using a VAS.
Intervention and observational phase assessments
Randomised patients attended clinic assessment visits at weeks 12, 24, 36 and 48 in the interventional
phase and at weeks 60, 72, 84 and 96 in the observational phase. Patients allocated to the subcutaneous
TNFi or abatacept therapies had additional standard assessment for safety purposes (usually week 4) in line
with local practice. At the Leeds Chapel Allerton Hospital site, biological samples from patients consenting
to the SWITCH trial biobank substudy were collected prior to commencement of the trial treatment and at
weeks 2, 4, 12, 24 and 48 or at the time of early discontinuation, and stored for future research. See
Appendix 5, Tables 33–35, for the schedule of events for rituximab, infliximab and subcutaneous bDMARDs.
Outcome measures
Primary outcome measure
The primary outcome measure was the absolute reduction from baseline in DAS28 at 24 weeks post
randomisation. DAS28 is a measure of disease activity in RA.103,104 The composite score is calculated as a
function of the number of tender and swollen joints (total 28 joints), the ESR and the patient’s global
assessment of their arthritis measured using a VAS (see Appendix 6, Box 1).
Secondary outcome measures
The following outcomes were measured over 48 weeks (at each of the visit time points).
Clinical measures
l DAS28.
l Reduction in DAS28 of ≥ 1.2 units.
l Low disease activity rate and remission rate: low disease activity is defined as 2.6 < DAS28 ≤ 3.2 units
and remission as DAS28 of ≤ 2.6 units (see Appendix 6, Table 36).
l EULAR response scores: EULAR response criteria are applied to the DAS28 and classify patients as
good, moderate or non-responders using the DAS28 and the absolute reduction in the DAS28 from
baseline (see Appendix 6, Table 37).
FIGURE 1 Manikin showing joints to be included in the SJC and TJC. MCPJ, metacarpophalangeal joint;
PIPJ, proximal interphalangeal joint.
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l ACR20, ACR50 and ACR70:105 composite measures developed for RA. These are defined as a relative
improvement (reduction) from baseline of at least 20% (or 50% or 70% for ACR50 and ACR70,
respectively) in TJCs and SJCs and a relative 20% (or 50% or 70% for ACR50 and ACR70, respectively)
improvement in three out of the five following criteria:
¢ Patient Global Assessment of Arthritis (VAS)
¢ Physician Global Assessment of Disease Activity (VAS)
¢ Patient Global Assessment of Pain (VAS)
¢ Patient assessment of physical function as measured by the Health Assessment Questionnaire
Disability Index (HAQ-DI) questionnaire
¢ Results of laboratory test for inflammatory markers (either ESR or CRP level).
l CDAI:104,106 a composite outcome measure consisting of the number of tender joints (i.e. 28-joint
count), the number of swollen joints (i.e. 28-joint count), a patient global assessment of disease activity
(measured via a 100-mm VAS) and Physician Global Assessment of Disease Activity (measured via a
100-mm VAS). Appendix 6,Table 38, provides the response categories for CDAI.
l Simplified Disease Activity Index (SDAI):104,107 a composite outcome measure consisting of the number
of tender joints (28-joint count), the number of swollen joints (28-joint count), the Patient Global
Assessment of Disease Activity (measured via a 100-mm VAS), the Physician Global Assessment of
Disease Activity (measured via a 100-mm VAS) and CRP level (mg/dl). Appendix 6,Table 39 provides the
response categories for SDAI.
l In-remission rates according to the ACR/EULAR Boolean criteria: this is defined as SJC, TJC, patient
global assessment and CRP level scores all ≤ 1.108
The use of 28-joint count-based outcome measures is well accepted and established in RA trials. This is
based on prior evaluation of the performance between 28- and 66-joint count assessments.109–111 However,
we acknowledge on an individual patient level, RA activity outside the 28 joints may be missed and thus
influence individual disease activity and response assessments.
Quality of life
l The Health Assessment Questionnaire Disability Index112 includes 20 questions across eight domains
relating to physical function and the need for any help or aids to undertake daily activities. The extent
of disability is scored on a scale from 0 (no disability) to 3 (severe disability) for each item relating to
rising, dressing, walking and other activities; patients are then asked to list any aids or devices required
to undertake such activities. The use of help or aids increases the category score from 0 or 1 to 2 if it
has been indicated that aids/help are required in that category. If the category score is already a 2 or 3,
no adjustment is made. The total score is derived by taking the maximum score across all domains
(0–24) and dividing by 8 to provide an average score (0–3), with higher scores representing
greater disability.
l The Hospital Anxiety and Depression Scale (HADS)113 describes the degree to which patients feel
anxious and/or depressed. It comprises 14 questions for each symptom, and each question has four
possible responses, ranging from 0, representing no anxiety/depression, to 3, representing high anxiety/
depression. Responses are totalled to provide two scales, one for each domain, with a measurement
range from 0 to 21.
l The Rheumatoid Arthritis Quality of Life (RAQoL)114 questionnaire is a specific disease activity measure
for RA. It is a 30-item questionnaire, the response to each item being yes (score as 1) or no (score as 0),
that ascertains the extent of RA symptoms experienced. The maximum RAQoL score is 30.
Safety
Toxicity is defined as any symptom or event requiring permanent cessation of treatment.
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Imaging
Plain radiographs of hands and feet were requested (for later scoring to calculate the modified Genant
score) and bone densitometry scans for T-scores of unilateral neck of femur and lumbar spine were
obtained at baseline and week 48 in a subgroup of patients recruited at centres with the facilities to do
the imaging. Note that the plain radiographs were not scored because of the inability to secure additional
resource centrally to conduct the analysis (compounded by the early termination/underpowered study).
Safety monitoring
Adverse events (AEs) and adverse reactions (ARs) were monitored throughout the trial and recorded at
each treatment visit. An AE was defined as any untoward medical occurrence in a trial patient that does
not necessarily have a causal relationship with the treatment. An AR was defined as any untoward and
unexpected responses to an investigational medicinal product (IMP) related to any dose administered.
A serious adverse event (SAE) or a suspected serious adverse reaction (SSAR) was defined as any untoward
medical occurrence or effect that resulted in death, persistent or significant disability or incapacity or a
congenital anomaly or birth defect, or was life-threatening, or required inpatient hospitalisation or
prolongation of existing hospitalisation or may have jeopardised the patient necessitating medical or
surgical intervention to prevent one of the outcomes stated in Outcome measures.
Expected common SAEs related to RA were the development of major extra-articular manifestations of
disease, for example vasculitis, and blood dyscrasia associated with disease activity. Expected serious ARs
common to all treatments were allergic reactions, injection site/infusion reaction, blood dyscrasias, serious
infections, diarrhoea, new infections, toxic epidermal necrolysis, Stevens–Johnson syndrome or severe rash,
pulmonary fibrosis, renal failure, neurological impairment, new autoimmunity and cardiovascular abnormalities.
All SAEs, regardless of the suspected relationship to the trial treatment, were reported to the Clinical Trials
Research Unit within 24 hours of the research staff becoming aware of the event. SAEs were followed up
until the event had resolved or a trial outcome had been reached. All AEs/ARs and SAEs were monitored
from randomisation until a maximum of 30 days (later revised to 32 days) after the last dose of
randomised treatment during the interventional phase (week 48 maximum). Beyond this, only SAEs
considered to be related to the randomised treatment administered during the interventional phase
were reported.
Patient withdrawal
Patients could withdraw from the trial at any time without explanation, and continue to receive treatment
as per standard clinical practice. Patient withdrawal was categorised as withdrawal of consent for: further
trial treatment only, further trial treatment and visits but willing to have follow-up data collected or further
trial treatment and follow-up information.
Sample size and power calculation
A total of 429 evaluable patients were required to have 80% power to demonstrate non-inferiority of either
abatacept or alternative TNFi to rituximab at the 5% significance level. A total of 143 evaluable patients in
each treatment group provided 80% power for the lower limit of the two-sided 95% confidence interval
(CI) for the true difference in the reduction in the DAS28 (abatacept/alternative TNFi – rituximab) to lay
above –0.6 units, assuming no difference between treatment groups and a standard deviation (SD) between
patients of 1.8 units (the REFLEX study49). Allowing for a loss to follow-up of 10%, a total of 477 patients
CLINICAL TRIAL METHODS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
14
were to be recruited. No adjustment for multiplicity of the comparisons of each treatment group to
rituximab was made.115,116
The proposed non-inferiority margin of –0.6 units in the reduction in the DAS28 at 24 weeks post
randomisation corresponds to the maximum difference in a reduction in the DAS28 that is considered to
be of no clinical relevance and is the threshold for the clinical distinction of ‘inferiority’ (corresponds to the
maximum change in the DAS28 within patients with a low or moderate disease activity that is classified as
‘no response’ by the EULAR criteria). A DAS28 of 0.6 units is also the reported measurement error.117
For the analysis of the secondary outcome measures to compare quality of life, toxicity and safety at
24 weeks between treatment arms the sample size of 143 evaluable patients per group would detect a
standardised effect size of 0.33 (small to medium by the definition of Cohen118), with 80% power and
two-sided 5% significance level.
After opening, the trial underwent a major redesign. The original target sample size was 870, based on 80%
power to determine whether or not abatacept or alternative TNFi are non-inferior to rituximab at 24 weeks
post randomisation in the proportion of patients achieving a DAS28 reduction of ≥ 1.2 units without toxicity.
The corresponding non-inferiority margin was set at 12% (as an absolute difference) and assumed a response
rate of 65% in the rituximab arm. The original trial design was also powered for a definitive subgroup analysis
to determine if there was a differential treatment response between seropositive and seronegative patients.
Owing to the challenges in trial setup and associated poor initial patient recruitment, and reassessment of
important end points, the primary outcome measure was changed from a binary to a continuous outcome
that (following consensus discussion with the principal investigators) was still considered clinically relevant.
This allowed a reduction in sample size to 477 patients while still ensuring a trial of clinical relevance. The
previous planned definitive subgroup analysis was relegated to an exploratory analysis. The trial redesign was
unanimously supported by the Data Monitoring and Ethics Committee and the Trial Steering Committee, was
approved by the funder and received ethics approval.
Randomisation
Randomisation took place once eligibility was confirmed and baseline assessments and questionnaires
were complete. Patients were randomised in a 1 : 1 : 1 allocation ratio to receive alternative TNFi,
abatacept or rituximab. Treatment group allocation used a computer-generated minimisation program
incorporating a random element of 0.8, to ensure that treatment groups were well balanced for the
following minimisation factors: centre, disease duration (< 5 years or ≥ 5 years), non-response (primary or
secondary) and RF/ACPA status (either of RF or ACPA positive, or both RF and ACPA negative).
Both registration and randomisation were performed centrally using an automated 24-hour telephone
system based at the Clinical Trials Research Unit. Centres completed a log of all patients aged > 18 years
with RA whose treatment had failed for an initial TNFi agent and were considered for the trial but who were
not registered for screening or randomised, either because of ineligibility or because of refusal to participate.
Blinding
Blinding of patients and the treating clinicians to treatment allocation was not possible in the trial because
of the nature and mode of administration of the different treatment regimens.
Analysis
Formal analyses were conducted using a two-sided 5% level of significance, with exception of the primary
analysis, which used a one-sided 2.5% level of significance. All analyses were performed using SAS version
9.4 (SAS Institute Inc., Cary, NC, USA). The statistical analysis plan is provided in Appendix 7.
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The trial planned for one interim analysis to allow for early stopping of either abatacept or alternative TNFi
if inferiority compared with rituximab was demonstrated. This analysis would have taken place once 50%
of patients (i.e. 239) had reached 24 weeks of follow-up. Following the early termination of the trial, there
was no basis for an interim analysis.
Patient populations
All patients recruited into the trial were included in the analysis using ‘intention to treat’ (ITT) and analysed
according to the randomised allocation.
A per protocol (PP) population analysis was also undertaken; patients who deviated from the protocol or
failed to comply with the required treatment regimen were excluded (see Appendix 7 for further details of
exclusions). For the analysis of the primary outcome measure, non-inferiority needed to be demonstrated in
both the ITT and PP populations in order to infer non-inferiority.
The complete-case population included all patients with complete data for the relevant outcome
measure summarised.
The safety population included all patients who received at least one dose of treatment and is summarised
by treatment received.
Missing data
Multiple imputation by chained equations was used to impute missing values at the component level for
the DAS28 and ACR20,119 under the assumption that the data were ‘missing at random’. The minimisation
factors of disease duration, RF/ACPA status and non-response category and the values of the component
end points at all visits from baseline to week 48 (for DAS28 components) and to week 24 (for ACR
components) were included in the imputation models. Centre was not included because of the small
number of patients recruited in each centre.
Imputations were performed separately for each of the three treatment groups; 27 imputed data sets were
created for each treatment group for the primary end point DAS28 and 22 for the secondary end-point
ACR20, corresponding to the maximum percentage of missing data across all end points and time points.
Predictive mean matching was used to select a value to impute from the three observed values closest to
the fitted value in each imputation.120 The composite end points were then derived in each of the fully
imputed data sets (see Appendix 7 for further detail).
Primary outcome measure
A mixed-effects linear regression model was fitted to the primary end point, absolute reduction in the
DAS28 at 24 weeks, with covariates corresponding to the minimisation factors and treatment group;
centre was fitted as a random effect.
Algebraic representation for the mixed-effects linear regression model is:
DAS28i = α1 + α2disease duration + α3RF&ACPA status + α4non-responder status + α5treatAltTNFi
+ α6treatABAT + (α7 + α7i)centre + εi.
(1)
Parameter estimates from the mixed-effects models across each of the fully imputed data sets were
combined using Rubin’s rules.119,121 Estimates of each treatment effect and corresponding 95% CIs and
p-values were reported in relation to the predefined non-inferiority margin of –0.6 units on the reduction
in the DAS28 at 24 weeks post randomisation.
The primary analysis model was fitted to the ITT, PP and complete-case populations. Non-inferiority in both
the ITT and PP patient populations was required in order to conclude non-inferiority. A sensitivity analysis
CLINICAL TRIAL METHODS
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was completed on the ITT population with an additional covariate, baseline DAS28, fitted to the primary
analysis model.
Key secondary outcome measures
Disease Activity Score of 28-joint scores over 48 weeks
Initially a random coefficient linear regression model was fitted to the DAS28 over time, with covariates
entered for the minimisation factors, baseline DAS28, treatment group, time and time-by-treatment
interaction; centre, patient and patient-by-time interaction random effects were fitted. However, as there
was evidence of non-constant residual error variance, a multivariable covariance pattern model was
fitted to the scores over time (at weeks 12, 24, 36 and 48), with the same covariates entered for the
minimisation factors (excluding centre), baseline DAS28, treatment group, time and time-by-treatment
interaction, and an unstructured covariance pattern was specified. Centre was not fitted as a random
effect, as there was no centre component of variation in 24 of the 27 imputed data sets.
Algebraic representation for the random coefficient linear regression model is:
DAS28ij = (α1 + α1i) + (α2 + α2i)time + (α3 + α3i)centre + α4baseline DAS28 + α5disease duration
+ α6RF&ACPA status + α7non-responder status + α8treatAltTNFi + α9treatABAT
+ α10(timej × treatAltTNFi) + α11(timej × treatABAT) + εij.
(2)
Algebraic representation for the covariance pattern model is:
DAS28ij = α1 + α2BaselineDAS28 + α3disease duration + α4RF&ACPA status
+ α5non-responder status + α6treatAltTNFi + α7treatABAT + α8visit j=Week 24
+ α9visit j=Week 36 + α10visit j=Week 48 + α11(treatAltTNFi × visit j=Week 24)
+ α12(treatABAT × visit j=Week 24) + α13(treatAltTNFi × visit j=Week 36)
+ α14(treatABAT × visit j=Week 36) + α15(treatAltTNFi × visit j=Week 48)
+ α16(treatABAT × visit j=Week 48) + εij; corr(εi, j=m, εi, j=n) = ρmn for m≠n,
(3)
where m and n denote two (arbitrary) different visit time points.
Disease Activity Score of 28 joints response over 48 weeks (reduction in Disease Activity
Score of 28 joints of ≥ 1.2)
A multivariable covariance pattern logistic model was fitted to the response variable, achieving a reduction
in the DAS28 of ≥ 1.2 units over time (at weeks 12, 24, 36 and 48), with covariates entered for the
minimisation factors (excluding centre), baseline DAS28, treatment group, time and time-by-treatment
interaction. An unstructured covariance pattern was specified. Centre was not fitted as a random effect
because the model failed to converge.
logit½pr(Reduction in DAS28i j≥1:2 since baseline) = α1 + α2BaselineDAS28
+ α3disease duration + α4RF&ACPA status + α5non-responder status
+ α6treatAltTNFi + α7treatABAT + α8visit j=Week 24 + α9visit j=Week 36 + α10visit j=Week 48
+ α11(treatAltTNFi × visit j=Week 24) + α12(treatABAT × visit j=Week 24) + α13(treatAltTNFi × visit j=Week 36)
+ α14(treatABAT × visit j=Week 36) + α15(treatAltTNFi × visit j=Week 48) + α16(treatABAT × visit j=Week 48)
+ εij; corr(εi, j=m, εi, j=n) = ρmn for m≠n,
(4)
where m and n denote two (arbitrary) different visit time points.
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American College of Rheumatology 20 at week 24
A multivariable logistic regression model was fitted to ACR20 at 24 weeks post randomisation, with
covariates entered for the minimisation factors (excluding centre) and treatment group. Centre was not
fitted as a random effect, as there was no centre component of variation.
Algebraic representation of the analysis model:
logit½pr(ACR20 response at week 24) = α1 + α2disease duration + α3RF&ACPA status
+ α4non-responder status + α5treatAltTNFi + α6treatABAT + εij.
(5)
In all analyses estimation of the treatment effects was of primary interest, but hypothesis testing was also
performed. Treatment group effects were tested and the significance level is presented based on the Wald
test (because of limitations of the likelihood ratio test for imputed data sets119). Model fit was assessed
informally by examination of standardised residuals.
Additional secondary outcome measures
All additional secondary outcome measures, including further measures of disease activity and quality of
life were summarised by treatment group and compared informally using descriptive statistics. The
predefined subgroup analyses to evaluate the treatment modification effect of RF/ACPA status, initial TNFi
group failed on and non-response category on the DAS28 were summarised by treatment group. In
addition, treatment compliance, toxicity and safety were summarised.
Summary of protocol amendments
Appendix 8 provides a summary of the key protocol amendments throughout the trial.
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Chapter 3 Clinical trial results
Patient recruitment
Between July 2012 and December 2014, 678 patients were screened for the trial across 35 centres. A total
of 529 patients were excluded at screening (pre-registration), 417 of whom failed to meet the eligibility
criteria. The main reasons for failing to meet the eligibility criteria were that they had not failed an initial
TNFi agent (n = 95), were not on a stable dose of MTX over the previous 28 days (n = 92) and had
received more than one TNFi drug or other biological agent (n = 72). A total of 149 patients gave written
informed consent and were registered onto the trial.
Twenty-seven patients were excluded post registration, of whom 19 did not meet the eligibility criteria, two
withdrew consent and six were excluded for other reasons (rescreening required, previous hepatitis infection,
raised alkaline phosphatase levels, awaiting cancer diagnosis/treatment, patient not contactable, unknown
reason). The remaining 122 patients were randomised to treatment. Following early trial termination because
of the withdrawal of funding, the last patient was randomised on 18 December 2014.
A summary of the number of patients considered, registered and randomised by centre is provided in
Appendix 9,Table 40. The flow of patients from initial assessment through to the end of follow-up is
shown in Figure 2 (Consolidated Standards of Reporting Trials diagram). Full reasons for ineligibility and
non-consent are provided in Appendix 9, Tables 41–43.
Recruitment target
Figure 3 displays the projected recruitment against the actual recruitment across all centres during the trial
recruitment period. Although the target for recruitment of 16 centres was reached by September 2013, the
number of eligible patients identified by centres was much lower than expected (see Appendix 9, Table 40).
Barriers to reaching the target included a 9-month halt to recruitment because of unforeseen contractual
issues with a home health-care company, longer times for centre set-up, primarily because of the
commissioning environment with significant geographical variability in receptiveness of Clinical Commissioning
Groups (CCGs) to approve RCTs that included non-NICE-approved therapies and delays to approval.
Although the patient recruitment rate improved as new centres were initiated, overturning the deficit
accrued from the above delays was not feasible within the planned recruitment period. Based on the
number of centres opened and observed recruitment rates, recruitment to November 2017 would have
been required to reach the target of 477 patients, at an additional cost of £450,000. Consequently, the
Health Technology Assessment (HTA) programme monitoring panel withdrew funding in November 2014;
the trial closed to recruitment in December 2014.
The study closure patient information sheet and article for the National Rheumatoid Arthritis Society web
page (and other relevant electronic forums) are in Appendices 3 and 4, respectively.
Randomisation
The overall mean randomisation rate was 0.26 patients per month, that is, 3.12 patients per centre per
year, across 35 centres. Twenty-eight centres randomised at least one patient and only seven centres
randomised more than five patients, with the co-ordinating hospital (Chapel Allerton) providing 32 (26%)
of all the randomised patients.
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Of the 122 patients randomised to the treatment group, 41 were allocated to alternative TNFi, 41 were
allocated to abatacept and 40 were allocated to rituximab.
The median time from the centre opening to randomisation of the first patient was 3.8 months (95% CI
2.5 to 7 months). Two centres did not randomise their first patient until more than 12 months after
opening, and two further centres recruited no patients despite being open for more than 12 months.
Assessed for eligibility 
(n = 678)
Allocated to abatacept
(n = 41)
Excluded pre registration 
(n = 529)
• Not meeting eligibility criteria, n = 417
• Declined to participate, n = 90
• Other reasons, n = 22
Excluded post registration 
(n = 27)
• Not meeting eligibility criteria, n = 19
• Withdrew consent, n = 2
• Other reasons, n = 6
Randomised
(n = 122)
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Consented, registered 
and screened
(n = 149)
Allocated to rituximab
(n = 40)
Allocated to alternative TNFi
(n = 41)
• Received allocated 
   intervention, n = 40
• Received etanercept, 
   n = 25
• Received monoclonal 
   antibody, n = 15
• Received nothing, n = 1
Lost to follow-up
(n = 7)
• Withdrawn, n = 4
• Lost to follow-up, n = 2
• Death, n = 1
Lost to follow-up
(n = 9)
• Withdrawn, n = 7
• Lost to follow-up, n = 1
• Death, n = 1
Lost to follow-up
(n = 10)
• Withdrawn, n = 8
• Lost to follow-up, n = 2
• Analysed in ITT-abatacept 
   population, n = 41
• Analysed in PP population,
   n = 14
• PP population exclusions, 
   n = 27
• Analysed in ITT-rituximab 
   population, n = 40
• Analysed in PP population,
   n = 14
• PP population exclusions,
   n = 26
• Analysed in ITT-TNFi 
   population, n = 41
• Analysed in PP population,
   n = 13
• PP population exclusions,
   n = 28
• Received allocated
   intervention, n = 41
• Received nothing, n = 0
• Received allocated 
   intervention, n = 40
• Received nothing, n = 0
FIGURE 2 The flow of patients through the SWITCH trial (Consolidated Standards of Reporting Trials diagram).
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(1) Projection (to HTA programme 
in December 2013)
(2) Projection with expected rates 
based on June–August 2014
FIGURE 3 Graph showing actual recruitment and projected recruitment when the trial was terminated. Projection 1 assumes 35 centres opened. Projection 2 assumes 31
centres opened. (XX), number of centres open.
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Generalisability of the patient population randomised
Summaries of the clinical and demographic variables collected on the non-registration logs for patients
considered for enrolment, registered but not randomised, and for patients randomised are provided in
Appendix 9, Table 44. Age distribution and sex of registered, consented and non-randomised patients
were similar. The proportion of patients who were RF seropositive or ACPA positive was also similar
between patients registered but not randomised and those patients who were randomised; however, there
was a large proportion of patients for whom RF and ACPA status was unknown among non-registered
patients, making an assessment of generalisability on RF/ACPA status difficult.
Withdrawals
A summary of follow-up attendance up to the end of the 48-week intervention phase is provided in
Figure 4.
Six patients withdrew consent to continue with randomised treatment and follow-up, two patients on
alternative TNFi, one on abatacept and three on rituximab. Two further patients, one on alternative
TNFi and one on abatacept, withdrew from follow-up during the observational period after week 48.
An additional patient (2.4%) on abatacept withdrew from treatment but continued to have follow-up
assessments and a further patient, also on abatacept (2.4%), was withdrawn from the study because of an
AE (chest infection).
Appendix 9, Table 45 provides a full list of the reasons for withdrawal.
Two patients on alternative TNFi were lost to follow-up by 48 weeks: one patient (2.4%) on abatacept and
one on rituximab.
Protocol deviations
Two patients were eligibility violations, one randomised to alternative TNFi and one to rituximab, both of
whom continued to receive their allocated treatment and were followed up. One patient had juvenile-onset
RA and one received sulfasalazine and hydroxychloroquine prior to the start of protocol treatment, had not
received MTX and had started taking NSAIDs (naproxen) within 4 weeks prior to the screening visit.
A further patient randomised to alternative TNFi had a susceptibility to myeloma if given a monoclonal
antibody and a clinical judgement was made to withdraw this patient before the allocated treatment and
follow-up.
Eighty-one patients (66.4%) deviated from the protocol in some way, which resulted in exclusion from the
PP population, corresponding to 28 (68.3%) patients on alternative TNFi, 27 (65.9%) on abatacept and
26 (65.0%) on rituximab. The most common protocol deviation was receiving steroid treatment within
6 weeks of an end-point assessment (35 patients; 28.7%), followed by not being compliant with treatment
up to week 24 (based on information obtained via direct questioning) (27 patients; 22.1%), and receiving
additional contraindicated treatment (23 patients; 18.9%). Appendix 10, Table 46, provides a further
summary of reasons for protocol deviations resulting in exclusion from the PP population.
Treatment compliance
All except one patient received their allocated treatment. One patient was randomised to receive
alternative TNFi (monoclonal antibody) but before treatment commenced the treating clinician withdrew
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Randomised
(n = 122)
Follow-up
Abatacept
(n = 41)
Baseline assessment
Week 12 assessment
• Attended, n = 39
• Did not attend, n = 2
   • DNA, n = 1
   • Withdrawn by PI due to AE, n = 1
   • Lost to follow-up, n = 0
Week 24 assessment
• Attended, n = 38
• Did not attend, n = 3
   • Already lost, n = 1
   • DNA, n = 2
   • Withdrawn, n = 0
   • Lost to follow-up, n = 0
Week 36 assessment
• Attended, n = 34
• Did not attend, n = 7
   • Already lost, n = 1
   • DNA, n = 4
   • Trial termination, n = 1
   • Death, n = 1
   • Lost to follow-up, n = 0
Week 48 assessment
• Attended, n = 34
• Did not attend, n = 7
   • Already lost, n = 3
   • Withdrawn, n = 1
   • Trial termination, n = 2
   • Lost to follow-up, n = 1
Alternative TNFi
(n = 41)
Baseline assessment
Week 12 assessment
Week 24 assessment
Week 36 assessment
• Attended, n = 34
• Did not attend, n = 7
   • Already lost, n = 4
   • DNA, n = 1
   • Trial termination, n = 1
   • Lost to follow-up, n = 1
Week 48 assessment
• Attended, n = 31
• Did not attend, n = 10
   • Already lost, n = 6
   • Trial termination, n = 3
   • Lost to follow-up, n = 1
Rituximab
(n = 40)
Baseline assessment
Week 12 assessment
Week 24 assessment
Week 36 assessment
• Attended, n = 35
• Did not attend, n = 5
   • Already lost, n = 0
   • DNA, n = 2
   • Withdrawn, n = 2
   • Death, n = 1
   • Lost to follow-up, n = 0
Week 48 assessment
• Attended, n = 31
• Did not attend, n = 9
   • Already lost, n = 3
   • Withdrawn, n = 1
   • Trial termination, n = 4
   • Lost to follow-up, n = 1
• Attended, n = 38
• Did not attend, n = 3
   • DNA, n = 0
   • Withdrawn, n = 3
      • Suboptimal response, n = 1
      • Eligibility violation, n = 1
      • Patient decision, n = 1
   • Lost to follow-up, n = 0
• Attended, n = 37
• Did not attend, n = 4
   • Already lost, n = 3
   • DNA, n = 0
   • Withdrawn, n = 1
      • Patient decision, n = 1
   • Lost to follow-up, n = 0
• Attended, n = 41 • Attended, n = 41 • Attended, n = 40
• Attended, n = 40
• Did not attend, n = 0
• Attended, n = 40
• Did not attend, n = 0
FIGURE 4 Summary of follow-up attendance up to the end of the 48-week intervention phase. DNA, did
not attend.
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the patient because of the presence of a comorbidity that precluded treatment with a monoclonal
antibody TNFi.
Rituximab
All 40 patients randomised to rituximab received at least one infusion of rituximab. By week 12, all
infusions had been given in line with the protocol, although infusions for four patients had been delayed
(because of patient choice, clinician examination delaying first dose, AE and out-of-range pre-treatment
tests). A total of 35 (87.5%) patients were known to be at least 80% compliant with treatment up to
week 24.
Abatacept
All 41 patients randomised to receive abatacept received at least one injection of abatacept. A total of 29
patients (70.7%) were known to be at least 80% compliant with treatment up to week 24.
Alternative tumour necrosis factor inhibitor
Forty out of 41 patients (97.6%) randomised to the alternative TNFi treatment arm received their allocated
treatment. A total of 31 patients (75.6%) were known to be at least 80% compliant with their
randomised treatment up to week 24.
Etanercept
Twenty-five patients were assigned to receive etanercept as a result of being randomised to alternative
TNFi. All 25 received at least one injection of etanercept.
Monoclonal antibody
The remaining 16 patients randomised to an TNFi were assigned to receive a monoclonal antibody,
the choice of which was at the clinician’s discretion.
Adalimumab
Ten patients received adalimumab as a result of allocation to a monoclonal antibody and all 10 received at
least one injection.
Certolizumab pegol
Only one patient received CZP as a result of allocation to a monoclonal antibody. With the exception of
one missed injection between baseline and week 12, this patient received all injections in line with the
protocol up to week 36.
Golimumab
Three patients received golimumab as a result of allocation to a monoclonal antibody. All three patients
received all injections to at least week 24.
Infliximab
One patient received infliximab as a result of allocation to alternative TNFi. Up to week 24, infusions were
delivered in line with the protocol.
Baseline characteristics
Baseline characteristics are presented in Tables 2–6. The mean age was 56.7 years (SD 12.2 years; range
24–81 years). A total of 102 patients (83.6%) were female.
Minimisation factors
The median disease duration was 6.7 years (range 0.4–43.5 years) (see Table 2). Seventy-seven patients
(63.1%) were secondary non-responders and 100 patients (82.0%) were RF seropositive or ACPA positive.
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TABLE 2 Summary of minimisation factors at baseline: ITT patient population
Minimisation factor
Treatment arm
Total (n= 122)
Alternative
TNFi (n= 41)
Abatacept
(n= 41)
Rituximab
(n= 40)
Disease duration category, n (%)
< 5 years 16 (39.0) 15 (36.6) 14 (35.0) 45 (36.9)
≥ 5 years 25 (61.0) 26 (63.4) 26 (65.0) 77 (63.1)
Disease duration (years)
Median (IQR) 5.9 (3.9–12.3) 6.9 (4.0–15.4) 7.0 (3.9–15.6) 6.7 (3.9–14.2)
Range 0.4–35.2 0.6–43.5 1.3–33.7 0.4–43.5
Missing 0 1 0 1
RA/ACPA seropositivity, n (%)
RF seropositive or ACPA positive 36 (87.8) 31 (75.6) 33 (82.5) 100 (82.0)
Both RF seronegative and ACPA
negative
5 (12.2) 10 (24.4) 7 (17.5) 22 (18.0)
Non-response category, n (%)
Primary 15 (36.6) 15 (36.6) 15 (37.5) 45 (36.9)
Secondary 26 (63.4) 26 (63.4) 25 (62.5) 77 (63.1)
TABLE 3 Summaries of patient characteristics at baseline: ITT patient population
Patient characteristic
Treatment arm
Total (n= 122)
Alternative
TNFi (n= 41)
Abatacept
(n= 41)
Rituximab
(n= 40)
Sex, n (%)
Male 8 (19.5) 2 (4.9) 10 (25.0) 20 (16.4)
Female 33 (80.5) 39 (95.1) 30 (75.0) 102 (83.6)
Patient age (years)
Mean (SD) 54.2 (9.98) 58.1 (13.89) 57.8 (12.37) 56.7 (12.21)
Median (IQR) 56.9 (45.5–59.8) 60.5 (45.2–66.9) 57.0 (52.4–67.4) 57.3 (46.7–65.4)
Range 34.2–73.6 28.8–81.7 24.5–81.1 24.5–81.7
Body mass index (kg/m2)
Mean (SD) 30.1 (7.25) 29.2 (5.74) 30.4 (6.80) 29.9 (6.60)
Median (IQR) 28.7 (25.0–34.0) 28.4 (24.3–34.5) 29.0 (25.4–33.5) 29.0 (24.9–34.1)
Missing 1 2 2 5
Smoking status, n (%)
Non-smoking (never smoked) 12 (29.3) 17 (41.5) 21 (52.5) 50 (41.0)
Past smoker 18 (43.9) 13 (31.7) 11 (27.5) 42 (34.4)
Current smoker 11 (26.8) 11 (26.8) 8 (20.0) 30 (24.6)
continued
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TABLE 3 Summaries of patient characteristics at baseline: ITT patient population (continued )
Patient characteristic
Treatment arm
Total (n= 122)
Alternative
TNFi (n= 41)
Abatacept
(n= 41)
Rituximab
(n= 40)
Prior comorbidities, n (%)
Hypertension 15 (36.6) 13 (31.7) 14 (35.0) 42 (34.4)
Osteoarthritis 11 (26.8) 14 (34.1) 8 (20.0) 33 (27.0)
Hyperchloesterolaemia 7 (17.1) 8 (19.5) 10 (25.0) 25 (20.5)
Depression 7 (17.1) 7 (17.1) 4 (10.0) 18 (14.8)
Thyroid dysfunction 8 (19.5) 5 (12.2) 2 (5.0) 15 (12.3)
Asthma 6 (14.6) 3 (7.3) 4 (10.0) 13 (10.7)
Diabetes 4 (9.8) 1 (2.4) 5 (12.5) 10 (8.2)
Cancer 3 (7.3) 1 (2.4) 1 (2.5) 5 (4.1)
Bowel disease – 2 (4.9) 1 (2.5) 3 (2.5)
Ischaemic heart disease 1 (2.4) – 2 (5.0) 3 (2.5)
Emphysema/chronic bronchitis 1 (2.4) 1 (2.4) – 2 (1.6)
Myocardial infarction – – 2 (5.0) 2 (1.6)
Peptic ulcer disease – 1 (2.4) 1 (2.5) 2 (1.6)
Stroke – 1 (2.4) 1 (2.5) 2 (1.6)
Chronic liver disease 1 (2.4) – – 1 (0.8)
Epilepsy 1 (2.4) – – 1 (0.8)
Peripheral vascular disease – – 1 (2.5) 1 (0.8)
Renal disease – 1 (2.4) – 1 (0.8)
IQR, interquartile range.
TABLE 4 Summary of treatment histories at baseline: ITT patient population
Treatment history
Treatment arm, n (%)
Total (n= 122),
n (%)
Alternative
TNFi (n= 41)
Abatacept
(n= 41)
Rituximab
(n= 40)
Type of initial TNFi that failed
Monoclonal antibody 25 (61.0) 23 (56.1) 22 (55.0) 70 (57.4)
Etanercept 16 (39.0) 18 (43.9) 18 (45.0) 52 (42.6)
Previous TNFi agent
Adalimumab 10 (24.4) 10 (24.4) 8 (20.0) 28 (23.0)
CZP 11 (26.8) 9 (22.0) 5 (12.5) 25 (20.5)
Etanercept 16 (39.0) 18 (43.9) 18 (45.0) 52 (42.6)
Golimumab 2 (4.9) – 4 (10.0) 6 (4.9)
Infliximab 2 (4.9) 4 (9.8) 5 (12.5) 11 (9.0)
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Demographics
Ninety patients (73.8%) had a current comorbidity, with the most frequently reported being hypertension
(42 patients; 34.4%), osteoarthritis (33 patients; 27.0%) and hypercholesterolaemia (25 patients; 20.5%)
(see Table 3).
Treatment history
Seventy patients (57.4%) had previously failed to respond to a monoclonal antibody TNFi agent. The most
common first TNFi agent used was etanercept (52 patients; 42.6%), followed by adalimumab (28 patients;
23.0%) and then CZP (25 patients; 20.5%) (see Table 4).
TABLE 5 Summary of baseline disease activity: ITT patient population
Measure of disease
activity
Treatment arm
Total (n= 122)
Alternative TNFi
(n= 41)
Abatacept
(n= 41)
Rituximab
(n= 40)
Experience early-morning stiffness?, n (%)
Yes 39 (95.1) 39 (95.1) 40 (100.0) 118 (96.7)
No 2 (4.9) 2 (4.9) – 4 (3.3)
TJC
Mean (SD) 15.3 (6.40) 15.1 (7.39) 17.4 (8.13) 15.9 (7.33)
Missing 0 0 1 1
SJC
Mean (SD) 9.9 (6.43) 8.8 (5.54) 10.0 (6.64) 9.5 (6.19)
Missing 0 0 1 1
ESR (mm/hour)
Median (IQR) 19.0 (8.0–27.0) 34.0 (17.0–54.0) 27.0 (9.0–44.0) 26.0 (11.0–43.0)
Missing 0 2 2 4
CRP level (mg/l)
Median (IQR) 5.0 (4.0–15.5) 9.0 (5.0–27.0) 6.0 (5.0–15.0) 6.0 (5.0–18.0)
Missing 1 2 1 4
DAS28
Mean (SD) 5.9 (1.05) 6.2 (1.08) 6.2 (1.28) 6.1 (1.13)
Missing 1 3 5 9
CDAI score
Mean (SD) 38.6 (13.12) 36.6 (13.34) 39.6 (13.68) 38.3 (13.31)
Missing 1 3 4 8
SDAI score
Mean (SD) 39.8 (13.98) 38.8 (13.87) 41.9 (14.49) 40.2 (14.04)
Missing 2 5 5 12
Physician Global Assessment of Disease Activity VAS (mm)
Median (IQR) 67.0 (56.0–75.0) 66.0 (58.0–84.0) 65.0 (53.0–84.2) 66.0 (57.0–79.0)
Missing 0 2 1 3
IQR, interquartile range.
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A total of 24 patients (19.7%) had received some form of steroid or corticosteroid within 4 weeks of
screening, with oral prednisolone the most frequently reported (22 patients;18.0%). Sixty patients (49.2%)
reported receiving NSAIDs within 4 weeks of screening, with naproxen, diclofenac and ibuprofen most
frequently reported. The most common non-bDMARDs used prior to participating were sulfasalazine
(91 patients; 74.6%), hydroxychloroquine (84 patients; 68.9%) and leflunomide (26 patient;, 21.3%)
(see Appendix 11).
Baseline disease activity and individual component measures
The mean number of TJCs and SJCs at baseline was 15.9 (SD 7.3) and 9.5 (SD 6.2), respectively. The
median ESR was 26.0 mm/hour (quartiles 11.0 mm/hour and 43.0 mm/hour) and the median CRP level was
6.0 mg/l (quartiles 5.0 mg/l and 18.0 mg/l) (see Table 5).
The mean DAS28 at baseline was 6.1 units (SD 1.1 units), with 76.2% patients having high disease activity
(see Table 5 and Appendix 12, Table 59). The mean CDAI score was 38.3 (SD 13.3), with 82.0% patients
categorised as having high disease activity (see Table 5 and Appendix 12, Table 63). Furthermore, the
mean SDAI score was 40.2 (SD 14.0) and 77.9% patients were categorised as having high disease activity
(see Table 5 and Appendix 12, Table 65).
The median Physician Global Assessment Disease Activity score was 66.0 (quartiles 57.0 and 79.0).
TABLE 6 Summaries of variables used as patient-reported outcomes measured at baseline: ITT patient population
Patient-reported outcome
measure
Treatment arm
Total (n= 122)
Alternative TNFi
(n= 41)
Abatacept
(n= 41)
Rituximab
(n= 40)
Patient Global Assessment of Arthritis VAS (mm)
Median (IQR) 70.5 (62.0–83.0) 67.5 (52.0–79.5) 74.0 (53.0–85.0) 71.0 (56.0–83.0)
Missing 1 1 3 5
Patient Assessment of General Health VAS (mm)
Median (IQR) 56.5 (45.5–72.0) 62.0 (47.8–68.5) 61.0 (46.0–74.0) 59.0 (47.0–70.0)
Missing 1 1 3 5
Patient Global Assessment of Pain VAS (mm)
Median (IQR) 70.5 (59.0–82.5) 69.5 (57.5–79.0) 77.0 (55.0–85.0) 71.0 (58.0–81.0)
Missing 1 1 3 5
HAQ-DI score
Median (IQR) 1.9 (1.4–2.1) 1.9 (1.6–2.3) 1.9 (1.4–2.3) 1.9 (1.5–2.1)
Missing 1 1 1 3
RAQoL score
Median (IQR) 21.6 (15.0–24.5) 22.0 (14.0–25.5) 22.0 (15.0–25.0) 22.0 (15.0–25.0)
Missing 1 1 2 4
HADS score
Median (IQR) 13.5 (8.0–20.0) 17.0 (10.0–22.0) 14.0 (11.0–19.0) 15.0 (10.0–21.0)
Missing 1 1 3 5
IQR, interquartile range.
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Baseline patient-reported outcomes
The median global assessment of arthritis, general health and pain scores, as rated by the patient, were
71.0 (quartiles 56.0 and 83.0), 59.0 (quartiles 47.0 and 70.0) and 71.0 (quartiles 58.0 and 81.0),
respectively (see Table 6). The median HAQ-DI score was 1.9 (quartiles 1.5 and 2.1), the median RAQoL
score was 22.0 (quartiles 15.0 and 25.0) and the median HADS score was 15.0 (quartiles 10.0 and 21.0)
(see Table 6).
Comparability of baseline characteristics between groups
The baseline characteristics were balanced across the three treatment groups, with the following notable
exceptions. A higher percentage of females were randomised to abatacept (95.1%, compared with
80.5% and 75.0% randomised to alternative TNFi and rituximab, respectively). A greater proportion of
patients in the alternative TNFi or abatacept arms were current or past smokers (70.7% and 68.5%,
respectively) than in the rituximab arm (47.5%). A higher proportion of patients on abatacept had
osteoarthritis, whereas more patients on rituximab had a history of hypercholesterolaemia. A greater
proportion of patients on alternative TNFi and abatacept had a history of depression and also a history
of thyroid dysfunction. Furthermore, a slightly greater proportion of patients on the alternative TNFi or
rituximab had a history of diabetes (see Table 3). A slight imbalance in the RF/ACPA status was apparent,
whereby a greater proportion of patients on alternative TNFi were seropositive than those taking abatacept
and rituximab (see Table 2). The slight imbalances observed are consistent with the random allocation to
the treatment group and result from the small sample size.
Tables 47–51 in Appendix 10 summarise the baseline characteristics for the PP population.
Primary and secondary outcomes
Although the results are presented in accordance with the planned analysis, the trial is underpowered for
our planned objectives relating to the primary and secondary outcome measures.
Primary outcome
Intention-to-treat patient population
Tables 7 and 8 and Figure 5 present the results of the primary end-point analysis for the ITT
patient population.
TABLE 7 Primary end-point analysis: multivariable linear regression analysis for a reduction in the DAS28 at
24 weeks post randomisation – ITT patient population
Effect Estimate 95% CI p-value
Intercept 1.50 0.72 to 2.28 < 0.001
Randomised treatment: alternative TNFi vs. rituximab 0.30 –0.45 to 1.05 0.436
Randomised treatment: abatacept vs. rituximab 0.04 –0.72 to 0.79 0.927
RF/anti-CCP seropositivity: both seronegative vs. either seropositive –0.17 –1.00 to 0.66 0.690
Disease duration: ≥ 5 years vs. < 5 years –0.05 –0.70 to 0.60 0.883
Non-responder type: secondary vs. primary –0.45 –1.11 to 0.21 0.181
CCP, cyclic citrullinated peptide.
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For the comparison between alternative TNFi and rituximab, the lower limit of the 95% CI for the difference
in the mean reduction in the DAS28 lies above the predefined, non-inferiority limit of –0.6 units; the
difference in the mean reduction in DAS28 (alternative TNFi – rituximab) at 24 weeks post randomisation
was 0.3 units (95% CI –0.45 to 1.05 units). Therefore, alternative TNFi was non-inferior to rituximab in the
ITT patient population.
For the comparison between abatacept and rituximab, the lower limit of the 95% CI lay just below the
predefined non-inferiority limit; the difference in mean reduction in the DAS28 at 24 weeks (abatacept –
rituximab) was 0.04 units (95% CI –0.72 to 0.79 units). Therefore, abatacept was not shown to be
non-inferior to rituximab in the ITT patient population.
Summaries of the missing values for the component end points of the DAS28 by treatment group are
presented in Appendix 13, Tables 69 and 70.
Sensitivity analysis
Table 9 and Figure 6 present results of the sensitivity analysis on the primary end point for the ITT patient
population, adjusting for the baseline DAS28.
TABLE 8 Adjusted mean reduction in the DAS28 and the corresponding difference between alternative TNFi,
abatacept and rituximab at 24 weeks post randomisation – ITT patient population
Treatment arm
Adjusted mean
DAS28 reduction at
week 24 (95% CI) Treatment comparison
Difference in
mean DAS28
reductions
(experimental –
rituximab 95% CI)
Probabilitya
(δ> –0.6)
Rituximab (n= 40) 1.17 (0.56 to 1.77) – – –
Alternative TNFi (n= 41) 1.47 (0.85 to 2.08) Alternative TNFi vs. rituximab 0.30 (–0.45 to 1.05) 0.0094
Abatacept (n = 41) 1.20 (0.62 to 1.78) Abatacept vs. rituximab 0.04 (–0.72 to 0.79) 0.0493
a One-sided p-value corresponding to the one-sided 97.5% test for non-inferiority of alternative TNFi/abatacept
compared with rituximab using the lower margin of –0.6 units; the one-sided p-value needs to be < 0.025 to conclude
non-inferiority with rituximab.
Alternative TNFi
Abatacept
–2.4 –1.8 –1.2 –0.6 0.0
Difference in DAS28 reductions at week 24 (experimental – rituximab)
0.6 1.2 1.8 2.4
Favours rituximab Favours experimental
FIGURE 5 Primary end-point analysis: difference in mean reduction in the DAS28 at 24 weeks post randomisation
between alternative TNFi, abatacept and rituximab – ITT population analysis. The dotted line at zero is the null
difference value and the thick dashed line denotes the non-inferiority margin.
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For the comparison between alternative TNFi and rituximab, the lower limit of the 95% CI for the difference
in the mean reduction in the DAS28 lies above the predefined non-inferiority limit of –0.6 units; the
difference in mean reduction in the DAS28 (alternative TNFi – rituximab) at 24 weeks post randomisation
was 0.54 units (95% CI –0.12 to 1.20 units). Therefore, again alternative TNFi was non-inferior to rituximab
in the ITT patient population.
For the comparison between abatacept and rituximab, the lower limit of the 95% CI lay just below the
predefined non-inferiority limit; the difference in the mean reduction in the DAS28 at 24 weeks
(abatacept – rituximab) was 0.05 units (95% CI –0.61 to 0.70 units). Therefore, there was only marginal
evidence that abatacept was non-inferior to rituximab in the ITT patient population.
Per protocol population
A total of 41 patients were included in the PP population with 13 (31.7%), 14 (34.1%) and 14 (35.0%) in
alternative TNFi, abatacept and rituximab treatment groups, respectively. Owing to the small number of
patients in the PP population, only the primary outcome has been analysed.
Tables 10 and 11 and Figure 7 provide the results of the primary end-point analysis for the PP population.
TABLE 9 Sensitivity analysis: adjusted mean reduction in DAS28 and corresponding difference between alternative
TNFi, abatacept and rituximab at 24 weeks post randomisation – ITT patient population
Treatment arm
Adjusted mean
DAS28 reduction at
week 24 (95% CI) Treatment comparison
Baseline-adjusted
difference in mean
DAS28 reductions
(experimental –
rituximab 95% CI)
Probabilitya
(δ> 0.6)
Rituximab (n= 40) 1.07 (0.53 to 1.60) – – –
Alternative TNFi (n= 41) 1.60 (1.05 to 2.15) Alternative TNFi vs. rituximab 0.54 (–0.12 to 1.20) < 0.001
Abatacept (n= 41) 1.11 (0.60 to 1.62) Abatacept vs. rituximab 0.05 (–0.61 to 0.70) 0.026
a One sided p-value corresponding to one-sided 97.5% test for non-inferiority of alternative TNFi/abatacept compared
with rituximab using the lower margin of –0.6 units; the one sided p-value needs to be < 0.025 to conclude
non-inferiority with rituximab.
Alternative TNFi
Abatacept
–2.4 –1.8 –1.2 –0.6 0.0
Baseline-adjusted difference in DAS28 reductions (in units) at week 24 (experimental – rituximab)
0.6 1.2 1.8 2.4
Favours rituximab Favours experimental
FIGURE 6 Sensitivity analysis on the primary end point: difference in the mean reduction in the DAS28 at 24 weeks
post randomisation between alternative TNFi, abatacept and rituximab.
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TABLE 10 Primary end-point analysis: multivariable linear regression analysis for a reduction in the DAS28 at
24 weeks post randomisation – PP population
Effect Estimate 95% CI p-value
Intercept 2.07 0.91 to 3.23 0.001
Randomised treatment: alternative TNFi vs. rituximab –0.58 –1.72 to 0.55 0.312
Randomised treatment: abatacept vs. rituximab –0.15 –1.27 to 0.98 0.796
RF/anti-CCP seropositivity: both seronegative vs. either seropositive –0.73 –1.96 to 0.50 0.245
Disease duration: ≤ 5 years vs. > 5 years –0.05 –1.10 to 1.01 0.930
Non-responder type: secondary vs. primary –0.05 –0.99 to 0.88 0.908
CCP, cyclic citrullinated peptide.
TABLE 11 Adjusted mean reduction in the DAS28 and corresponding difference between alternative TNFi,
abatacept and rituximab at 24 weeks post randomisation – PP population
Treatment group
Adjusted mean
DAS28 reduction at
week 24 (95% CI) Treatment comparison
Difference in mean
DAS28 reductions
(experimental –
rituximab 95% CI)
Probabilitya
(δ> –0.6)
Rituximab (n= 14) 1.66 (0.77 to 2.55) – – –
Alternative TNFi (n= 13) 1.07 (0.11 to 2.03) Alternative TNFi vs. rituximab –0.58 (–1.72 to 0.55) 0.489
Abatacept (n = 14) 1.51 (0.70 to 2.31) Abatacept vs. rituximab –0.15 (–1.27 to 0.98) 0.216
a One-sided p-value corresponding to the one-sided 97.5% test for non-inferiority of alternative TNFi/abatacept compared
with rituximab using the lower margin of –0.6 units; the one-sided p-value needs to be < 0.025 to conclude
non-inferiority with rituximab.
Alternative TNFi
Abatacept
–2.4 –1.8 –1.2 –0.6 0.0
Difference in DAS28 reductions (in units) at week 24 (experimental – rituximab)
0.6 1.2 1.8 2.4
Favours rituximab Favours experimental
FIGURE 7 Primary end-point analysis: difference in the mean reduction in the DAS28 at 24 weeks post
randomisation between alternative TNFi, abatacept and rituximab – PP population.
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For the comparison of alternative TNFi versus rituximab, the lower limit of the 95% CI for the difference in
the mean reduction in the DAS28 was below the predefined non-inferiority limit of –0.6 units; the difference
in the mean reduction in the DAS28 at 24 weeks post randomisation (alternative TNFi – rituximab) was
–0.58 units (95% CI –1.72 to 0.55 units). Therefore, non-inferiority of alternative TNFi to rituximab was not
demonstrated in the PP population and so we cannot conclude that alternative TNFi is non-inferior to rituximab.
Similarly, for the comparison of abatacept versus rituximab, the lower limit of the 95% CI for the difference
in the mean reduction in the DAS28 was below –0.6 units; the difference in the mean reduction in the
DAS28 at 24 weeks post randomisation (abatacept – rituximab) was –0.15 units (95% CI –1.27 to 0.98
units). Therefore, non-inferiority of abatacept to rituximab was not demonstrated in the PP population.
Hence, a conclusion of non-inferiority of abatacept to rituximab was not reached in both analyses (although
in an underpowered cohort).
Complete-case analysis population
The primary end-point analysis was also conducted on the population of all patients with complete data at
both baseline and week 24. Table 12 and Figure 8 provide the results of the primary end-point analysis in
the complete-case analysis population.
For both alternative TNFi and abatacept, the lower limit of the 95% CI for the true difference in the mean
reduction in the DAS28 lay just below the predefined non-inferiority limit of –0.6 units. The difference
in the mean reduction in the DAS28 at 24 weeks post randomisation for alternative TNFi compared
with rituximab was 0.10 units (95% CI –0.71 to 0.91 units) and for abatacept relative to rituximab was
–0.04 units (95% CI –0.86 to 0.79 units). Therefore, non-inferiority of alternative TNFi and abatacept to
rituximab was not demonstrated in the complete-case analysis population.
Summary statistics for the DAS28 at baseline, week 24 and the corresponding reduction for the
complete-case population is summarised in Appendix 12, Table 58.
Exploratory subgroup analysis
Table 13 presents the least squares means and corresponding 95% CIs of the reduction in the DAS28 at
week 24 by RF/ACPA seropositivity status, initial TNFi type and non-responder status to an initial bDMARD
for the ITT population; corresponding summary statistics for the complete-case population are provided in
Appendix 12, Table 53. The results of the subgroup analysis are not sufficiently precise to draw definitive
conclusions and, therefore, only informal comparisons between treatment groups were made. All results
should be interpreted cautiously.
TABLE 12 Adjusted mean reduction in the DAS28 and corresponding difference between alternative TNFi,
abatacept and rituximab at 24 weeks post randomisation – complete-case population
Treatment group
Adjusted mean
DAS28 reduction at
week 24 (95% CI) Treatment comparison
Difference in
mean DAS28
reductions
(experimental –
rituximab 95% CI)
Probabilitya
(δ> –0.6)
Rituximab (n= 32) 1.14 (0.44 to 1.85) – – –
Alternative TNFi (n= 36) 1.24 (0.57 to 1.91) Alternative TNFi vs. rituximab 0.10 (–0.71 to 0.91) 0.044
Abatacept (n= 34) 1.10 (0.47 to 1.74) Abatacept vs. rituximab –0.04 (–0.86 to 0.79) 0.090
a One-sided p-value corresponding to the one-sided 97.5% test for non-inferiority of alternative TNFi/abatacept
compared with rituximab using the lower margin of –0.6 units; the one-sided p-value needs to be < 0.025 to conclude
non-inferiority with rituximab.
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Rheumatoid factor/anti-citrullinated peptide antibody seropositivity effect on
treatment response
It was hypothesised that patients who were RF/ACPA seronegative would have a greater response to
alternative TNFi or abatacept than to rituximab.
The DAS28 improvements at week 24 among patients who were RF or ACPA seropositive appeared to be
similar in the alternative TNFi and rituximab groups, although a small improvement was observed in the
abatacept group. However, among patients who were seronegative, no improvement in the rituximab
group was apparent, with a greater improvement observed in the alternative TNFi and abatacept groups.
However, as only approximately 18% of patients were seronegative, the conclusions that could be drawn
are limited.
Alternative TNFi
Abatacept
–2.4 –1.8 –1.2 –0.6 0.0
Difference in DAS28 reductions (in units) at week 24 (experimental – rituximab)
0.6 1.2 1.8 2.4
Favours rituximab Favours experimental
FIGURE 8 Primary end-point analysis: difference in the mean reduction in the DAS28 at 24 weeks post
randomisation between alternative TNFi, abatacept and rituximab – complete-case population.
TABLE 13 Least squares means (95% CIs) of the DAS28 reduction at week 24 in each subgroup by treatment arm –
ITT patient population
Subgroup
Treatment arm, mean (95% CI)
Alternative TNFi Abatacept Rituximab
RF/ACPA seropositivity status
Both RF seronegative and ACPA seronegative 1.76 (0.23 to 3.29) 1.64 (0.57 to 2.70) 0.09 (–1.20 to 1.39)
RF seropositive and/or ACPA seropositive 1.50 (0.93 to 2.07) 1.13 (0.50 to 1.75) 1.47 (0.87 to 2.06)
Non-response category
Primary 1.15 (0.25 to 2.05) 1.84 (0.97 to 2.71) 1.45 (0.56 to 2.35)
Secondary 1.48 (0.72 to 2.24) 0.68 (–0.07 to 1.44) 0.84 (0.09 to 1.58)
Type of TNFi failed
Etanercept 1.64 (0.71 to 2.56) 1.50 (0.64 to 2.36) 1.38 (0.50 to 2.26)
Monoclonal antibody 1.38 (0.64 to 2.12) 0.99 (0.25 to 1.73) 1.02 (0.26 to 1.78)
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Primary or secondary non-responder status (on an initial tumour necrosis
factor inhibitor) on treatment response
Primary non-responders appeared to show greater improvement, on average, on abatacept and rituximab
than on alternative TNFi, although the reverse was observed for secondary non-response patients.
Initial alternative tumour necrosis factor inhibitor failed on treatment response
In the case of patients who previously did not respond to etanercept, similar improvements in the DAS28
at week 24 were observed across all treatment groups, although, among those who previously failed to
respond to a monoclonal antibody, alternative TNFi (fusion protein, etanercept) appeared to confer a
greater improvement than abatacept or rituximab.
Secondary outcomes
Disease Activity Score of 28 joints over time
Table 14 provides the parameter estimates for the model for the DAS28 up to week 48. Table 15 presents
the adjusted DAS28 and corresponding difference from rituximab at each time point up to week 48.
Figure 9 provides a graphical representation of the adjusted means and corresponding 95% CIs from the
model. The covariance matrix is provided in Appendix 12, Table 55.
TABLE 14 Estimated coefficients from a multivariable covariance pattern model for the DAS28 over 48 weeks post
randomisation – ITT patient population
Effect Parameter estimate 95% CI p-value
Intercept (rituximab at week 12) 2.72 1.48 to 3.96 < 0.0001
Baseline DAS28 0.38 0.21 to 0.55 < 0.0001
Randomised treatment
Alternative TNFi vs. rituximab –0.18 –0.72 to 0.35 0.503
Abatacept vs. rituximab –0.04 –0.57 to 0.48 0.870
RF/ACPA status: both seronegative vs. either RF/ACPA seropositive 0.19 –0.32 to 0.69 0.475
Years since diagnosis: ≥ 5 years vs. 0–4 years –0.16 –0.57 to 0.25 0.440
Non-response type: secondary vs. primary 0.13 –0.27 to 0.53 0.524
Visit
24 weeks –0.09 –0.54 to 0.36 0.701
36 weeks –0.14 –0.52 to 0.24 0.477
48 weeks –0.29 –0.75 to 0.17 0.218
Interaction effect for
Alternative TNFi
At 24 weeks –0.32 –0.96 to 0.33 0.338
At 36 weeks –0.53 –1.11 to 0.05 0.071
At 48 weeks –0.20 –0.88 to 0.47 0.552
Abatacept
At 24 weeks –0.01 –0.65 to 0.63 0.976
At 36 weeks 0.05 –0.51 to 0.60 0.871
At 48 weeks 0.10 –0.55 to 0.75 0.755
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TABLE 15 Adjusted mean (95% CI) DAS28 and comparisons of alternative TNFi and abatacept with rituximab by
assessment time point over 48 weeks
Treatment arm Adjusted mean (95% CI) Difference in adjusted means (95% CI) p-value
12 weeks
Rituximab 5.09 (4.69 to 5.48) – –
Abatacept 5.03 (4.63 to 5.43) –0.04 (–0.57 to 0.48) 0.870
Alternative TNFi 4.89 (4.47 to 5.32) –0.18 (–0.72 to 0.35) 0.503
24 weeks
Rituximab 4.99 (4.50 to 5.47) – –
Abatacept 4.93 (4.46 to 5.41) –0.05 (–0.71 to 0.60) 0.872
Alternative TNFi 4.49 (3.99 to 4.99) –0.50 (–1.16 to 0.16) 0.137
36 weeks
Rituximab 4.94 (4.49 to 5.39) – –
Abatacept 4.94 (4.49 to 5.39) 0.00 (–0.60 to 0.61) 0.995
Alternative TNFi 4.22 (3.75 to 4.70) –0.71 (–1.32 to 0.11) 0.022
48 weeks
Rituximab 4.79 (4.28 to 5.29) – –
Abatacept 4.84 (4.38 to 5.31) 0.06 (–0.59 to 0.71) 0.859
Alternative TNFi 4.40 (3.88 to 4.92) –0.39 (–1.04 to 0.27) 0.249
10
9
8
7
6
5
4
B
as
el
in
e-
ad
ju
st
ed
 D
A
S2
8
D
if
fe
re
n
ce
 in
 le
as
t 
sq
u
ar
es
 m
ea
n
s 
fo
r 
b
as
el
in
e-
ad
ju
st
ed
 D
A
S2
8
3
2
1
0 1.5
1.0
0.5
0.0
–0.5
–1.0
–1.5
0 12 24
Weeks
36
Favours rituximab
Treatment arm
Favours experimental
48
Alternative
TNFi
Abatacept
Rituximab
FIGURE 9 Adjusted mean DAS28 over the 48-week intervention period and the comparisons of alternative TNFi and
abatacept with rituximab over 48 weeks. Adjusted mean DAS28 over the 48-week intervention period (top, left
axis). Estimated differences between each intervention arm and rituximab at each time point (bottom, right axis).
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There was no evidence of a treatment effect for abatacept compared with rituximab at any of the time
points (see Table 15). This analysis showed significant evidence of a difference between alternative TNFi
and rituximab at week 36 (–0.71 units, 95% CI –1.32 to –0.11 units; p = 0.022), although this difference
was not maintained at week 48.
From 24 weeks post randomisation, the 95% CIs for the mean DAS28 in the alternative TNFi group
exclude values greater than 4.99, suggesting that the mean DAS28 for this group is lower than the DAS28
threshold for high disease activity (i.e. DAS28 > 5.1 units). For abatacept and rituximab the estimated
95% CIs for the mean DAS28 include values corresponding to high disease activity at all time points.
Reduction in the Disease Activity Score of 28 joints of ≥ 1.2 units over time
The frequency of patients achieving a DAS28 response over 48 weeks for the complete-case population is
provided in Appendix 12, Table 54.
Parameter estimates for the model are given in Table 16. Table 17 shows the odds of achieving DAS28
≥ 1.2 units in each group and the odds ratios relative to rituximab at each time point up to week 48.
Figure 10 provides a graphical representation of the fitted values from the model. The covariance matrix is
provided in Appendix 12, Table 56.
TABLE 16 Estimated coefficients for the multivariable covariance pattern model for the DAS28 response over
48 weeks post randomisation: ITT patient population
Effect Odds ratio (95% CI) p-value
Intercept < 0.001
Baseline DAS28 2.23 (1.65 to 3.02) < 0.001
Randomised treatment
Alternative TNFi vs. rituximab 1.07 (0.38 to 3.02) 0.904
Abatacept vs. rituximab 1.22 (0.44 to 3.39) 0.701
Seropositivity: RF/ACPA both seronegative vs. either RF/ACPA seropositive 0.74 (0.33 to 1.65) 0.464
Years since diagnosis: ≥ 5 years vs. 0–4 years 1.56 (0.82 to 2.97) 0.178
Non-response type: secondary vs. primary 0.96 (0.51 to 1.81) 0.888
Visit
24 weeks 0.98 (0.45 to 2.13) 0.963
36 weeks 1.17 (0.49 to 2.77) 0.726
48 weeks 1.77 (0.64 to 4.90) 0.269
Interaction effect for
Alternative TNFi
At 24 weeks 2.37 (0.81 to 6.94) 0.116
At 36 weeks 1.79 (0.56 to 5.72) 0.327
At 48 weeks 1.32 (0.33 to 5.33) 0.699
Abatacept
At 24 weeks 0.95 (0.33 to 2.76) 0.930
At 36 weeks 0.92 (0.28 to 2.98) 0.888
At 48 weeks 0.75 (0.19 to 2.93) 0.675
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TABLE 17 Adjusted odds of achieving a DAS28 response and the corresponding odds ratios over time
Treatment arm
Adjusted odds ratio
of response (95% CI)
Adjusted odds ratio of response
vs. rituximab (95% CI) p-value
12 weeks
Rituximab 0.65 (0.29 to 1.42) – –
Abatacept 0.79 (0.38 to 1.65) 1.22 (0.44 to 3.39) 0.701
Alternative TNFi 0.69 (0.32 to 1.50) 1.07 (0.38 to 3.02) 0.905
24 weeks
Rituximab 0.64 (0.29 to 1.39) – –
Abatacept 0.74 (0.35 to 1.55) 1.16 (0.42 to 3.24) 0.771
Alternative TNFi 1.61 (0.75 to 3.46) 2.53 (0.90 to 7.07) 0.077
36 weeks
Rituximab 0.76 (0.33 to 1.74) – –
Abatacept 0.85 (0.40 to 1.81) 1.12 (0.37 to 3.42) 0.839
Alternative TNFi 1.44 (0.66 to 3.12) 1.91 (0.65 to 5.60) 0.240
48 weeks
Rituximab 1.15 (0.49 to 2.71) – –
Abatacept 1.05 (0.50 to 2.19) 0.91 (0.30 to 2.73) 0.869
Alternative TNFi 1.61 (0.72 to 3.62) 1.40 (0.47 to 4.19) 0.543
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FIGURE 10 Adjusted odds of achieving a DAS28 response and odds ratios of a response over 48 weeks. Covariance
pattern model of a DAS28 response over time. Unstructured covariance pattern. Random centre effect excluded,
baseline score adjusted. Estimated odds of achieving a DAS28 response at follow-up (top, left axis). Odds ratios of
response of alternative TNFi and abatacept to rituximab at each time point (bottom, right axis).
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There was no evidence of a treatment effect for either alternative TNFi or abatacept compared with
rituximab after adjusting for the minimisation factors and baseline covariates, at any of the time points
(see Table 17).
American College of Rheumatology 20 response at week 24
Table 18 provides the parameter estimates for the model and Table 19 provides the adjusted odds ratios for
achieving ACR20 response at 24 weeks post randomisation. Figure 11 provides a graphical representation of
the fitted values from the model.
There was no evidence of a difference in the odds of achieving an ACR20 response at 24 weeks post
randomisation in either intervention compared with rituximab (OR 2.06, 95% CI 0.77 to 5.53 and OR
1.19, 95% CI 0.44 to 3.21 for alternative TNFi and abatacept, respectively).
Summaries of the missing values for the component end points of the ACR20 by treatment group are
presented in Appendix 13, Tables 69 and 70.
Additional secondary outcomes
Clinical assessment of disease activity over 48 weeks
Appendix 12, Tables 54 and 57–65, summarise measures of disease activity over 48 weeks by randomised
treatment group. Summary statistics for each of the secondary outcomes over the observational period
(weeks 60–96) are provided in Appendix 12, Tables 58–65. A brief description of the findings is given
below. There were too few patients to make firm inferences from any of these analyses.
TABLE 18 Multivariable logistic regression model for the ACR20 response at 24 weeks post randomisation: ITT
patient population
Parameter Odds ratio 95% CI p-value
Intercept 0.062
Randomised treatment
Alternative TNFi vs. rituximab 2.06 0.77 to 5.53 0.150
Abatacept vs. rituximab 1.19 0.44 to 3.21 0.736
RF/ACPA status: both seronegative vs. either seropositive 1.39 0.48 to 3.99 0.539
Disease duration: ≥ 5 years vs. < 5 years 1.73 0.73 to 4.12 0.216
Non-responder type: secondary vs. primary 0.55 0.24 to 1.26 0.161
TABLE 19 Adjusted odds of an ACR20 response at 24 weeks post randomisation: ITT patient population
Treatment group
Adjusted odds ratio
of response (95% CI)
Adjusted odds ratio of response
vs. rituximab (95% CI) p-value
Rituximab 0.43 (0.20 to 0.94)
Abatacept 0.51 (0.24 to 1.08) 1.19 (0.44 to 3.21) 0.736
Alternative TNFi 0.89 (0.41 to 1.96) 2.06 (0.77 to 5.53) 0.150
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American College of Rheumatology 20, American College of Rheumatology 50 and
American College of Rheumatology 70 response
The proportion of patients on alternative TNFi who achieved an ACR20 response appeared to increase over
time, reaching 54.8% by week 48, although, among patients on abatacept, the proportion decreased to
35.5% by week 48 and, among those on rituximab, it had increased by week 48 to 42.9% after an initial
reduction at week 24 (27.0%), potentially reflecting the need for a repeat cycle of rituximab in the second
6-month period. The proportion of patients achieving an ACR50 response generally increased over time on
alternative TNFi and rituximab and plateaued after week 24 for abatacept. The proportion of patients
achieving an ACR70 fluctuated over time across all three treatment groups; overall, only 11.8% achieved
an ACR70 by week 48 (see Appendix 12, Table 57).
Disease Activity Score of 28 joints and Disease Activity Score of 28 joints
response category
The mean reduction in the DAS28 over 48 weeks was greater among patients on alternative TNFi than
among those on rituximab, whereas a similar mean reduction in the DAS28 was apparent in the abatacept
and rituximab groups [alternative TNFi mean at 48 weeks, 1.6 units (SD 1.64 units); abatacept mean at
48 weeks, 1.4 units (SD 1.38 units); and rituximab mean at 48 weeks, 1.2 units (SD 1.49 units)] (see
Appendix 12, Table 58).
The proportion of patients who achieved DAS28 low disease activity or remission at 24 weeks was similar
in the alternative TNFi and rituximab groups, but lower in the abatacept group (19.5%, 20.0% and
14.6%, respectively). The proportion of patients achieving remission at week 24 showed a similar pattern
(alternative TNFi, 9.8%; rituximab, 10.0%; abatacept, 7.3%). Furthermore, in the alternative TNFi group,
this figure continued to increase, reaching 26.8% by week 48; in contrast, in the abatacept and rituximab
groups, it fell, to 7.3% and 7.5%, respectively (see Appendix 12, Table 59). The proportion of patients
reaching remission at week 48 showed a corresponding increase in the alternative TNFi group (12.2%),
but in the abatacept and rituximab groups, this fell to 4.9% and 5.0%, respectively.
European League Against Rheumatism response
The proportion of patients with a good EULAR response at 24 weeks was similar in the alternative TNFi
and rituximab groups, at 19.5% and 17.5%, respectively, but was lower in the abatacept group, at
12.2%. Furthermore, in the alternative TNFi group, the proportion of patients achieving a good response
generally increased over time, reaching 26.8% at week 48, whereas in the abatacept and rituximab
groups, a reduction to 4.9% and 5.0%, respectively, was observed (see Appendix 12, Table 60).
Alternative TNFi
Abatacept
0.125 0.250 0.500 1.000
Adjusted odds ratio (experimental vs. RTX) of ACR20 response at week 24
2.000 4.000 8.000
Favours rituximab Favours experimental
FIGURE 11 Odds ratios of an ACR20 response relative to rituximab at 24 weeks post randomisation: ITT
patient population.
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American College of Rheumatology/Boolean remission
A minority of patients achieved ACR/Boolean remission status over the 48 weeks. At 24 weeks, two
patients (4.9%) on alternative TNFi and one patient (2.4%) on abatacept reached ACR/Boolean remission,
compared with none on rituximab. By week 48 the frequency remained very low, with only one patient
(2.4%) on alternative TNFi and a further one patient (2.4%) on abatacept reaching this status (see
Appendix 12, Table 61).
Clinical Disease Activity Index
Similar improvements over 48 weeks were observed in CDAI in the alternative TNFi and rituximab groups,,
with a lower improvement observed in the abatacept group [median improvement of 19.3 (quartiles 5.7
and 28.8), 20.3 (quartiles 5.3 and 32.3) and 14.1 (quartiles 5.9 and 29.2) respectively] (see Appendix 12,
Table 62).
Simplified Disease Activity Index
Like the CDAI, improvement in the SDAI over 48 weeks was similar in the alternative TNFi and rituximab
groups, but lower in the abatacept group [median improvement of 20.1 (quartiles 7.9 and 27.2), 20.1
(quartiles 5.3 and 34.0) and 13.7 (quartiles 6.3 and 31.2) respectively] (see Appendix 12, Table 64).
Patient-reported outcomes over 48 weeks
Figures 12–15 summarise the patient-reported outcomes of the HAQ-DI, RAQoL and HADS and
Figures 16–18 summarise the Patient Global Assessment of Pain, Patient Global Assessment of Arthritis
and Patient Assessment of General Health VAS scores over 48 weeks by treatment group. Further
summaries over the 96 weeks are provided in Appendix 12, Tables 66 and 67.
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FIGURE 12 Box and whisker plot: HAQ-DI score over 48 weeks by treatment group. X inside the bars corresponds
to the mean value; X outside the bars corresponds to outlier values. B/L, baseline.
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FIGURE 13 Box and whisker plot: RAQoL over 48 weeks by treatment group. X inside the bars corresponds to the
mean value; X outside the bars corresponds to outlier values. B/L, baseline.
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FIGURE 14 Box and whisker plot: HADS anxiety scale over 48 weeks by treatment group. X inside the bars
corresponds to the mean value; X outside the bars corresponds to outlier values. B/L, baseline.
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FIGURE 15 Box and whisker plot: HADS depression scale over 48 weeks by treatment group. X inside the bars
corresponds to the mean value; X outside the bars corresponds to outlier values. B/L, baseline.
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FIGURE 16 Box and whisker plot: Patient Global Assessment of Pain over 48 weeks by treatment group. X inside
the bars corresponds to the mean value; X outside the bars corresponds to outlier values. B/L, baseline.
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FIGURE 18 Box and whisker plot: Patient Assessment of General Health over 48 weeks by treatment group.
X inside the bars corresponds to the mean value; X outside the bars corresponds to outlier values. B/L, baseline.
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FIGURE 17 Box and whisker plot: Patient Global Assessment of Arthritis over 48 weeks by treatment group.
X inside the bars corresponds to the mean value; X outside the bars corresponds to outlier values. B/L, baseline.
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Health Assessment Questionnaire Disability Index, Rheumatoid Arthritis Quality of Life
and Hospital Anxiety and Depression Scale
Overall, there was an improvement in the HAQ-DI over the 48-week period across all three treatment
groups. The median HAQ-DI score decreased to 1.5 (quartiles 1.1 and 1.9) in the alternative TNFi group,
to 1.6 (quartiles 1.0 and 2.1) in abatacept group and to 1.7 (quartiles 1.1 and 2.1) the rituximab group
(see Figure 12). Similarly, a general improvement in the RAQoL was observed over time, with no notable
differences between treatment groups [median score of 19.0 (quartiles 9.0 and 23.0) was reported at
48 weeks in the alternative TNFi group, 17.5 (quartiles 11.4 and 24.0) in the abatacept group and 19.5
(quartiles 12.0 and 25.0) in the rituximab group] (see Figure 13). Small improvements in the HADS scores
over the 48-week period were observed in the alternative TNFi and abatacept groups [median scores for
anxiety and depression of 6 (quartiles 3.0 and 11.0) and 4.5 (quartiles 2.0, 9.0), respectively, in the
alternative TNFi group and of 7.0 (quartiles 4.0 and 10.0) and 5.0 (quartiles 3.0 and 7.0), respectively, in
the abatacept group], whereas no notable improvement was apparent in the rituximab group [median
scores of 8.0 (quartiles 5.0 and 12.0) and 5.5 (quartiles 4.0 and 9.0), respectively] (see Figures 14 and 15).
Patients’ global assessment of pain, arthritis and general health
A marked improvement in the patients’ global assessments of pain was apparent in all three treatment
groups by 12 weeks post randomisation; thereafter small fluctuations in median pain scores over time
were observed (see Figure 16). The median pain VAS scores at 48 weeks were 49.0 (quartiles 22.0 and
66.0), 51.5 (quartiles 19.0 and 72.0) and 57.0 (quartiles 34.0 and 67.0) in the alternative TNFi, abatacept
and rituximab groups, respectively; the observed higher median score for rituximab may in part be
explained by the higher median score observed at baseline.
Similarly, an initial marked improvement in the patients’ global assessment of their arthritis by 12 weeks
post randomisation was apparent across all three treatment groups (see Figure 17). In the alternative TNFi
arm, this improvement continued to 36 weeks, followed by a slight deterioration by 48 weeks [median 47.0
(quartiles 22.0 and 69.0)]. In comparison, following the initial 12-week improvement, in the abatacept
and rituximab groups there was a slight deterioration in patients’ global assessment of their arthritis by
48 weeks [median 55.5 (quartiles 25.0 and 68.0) and 55.0 (quartiles 35.0 and 70.0), respectively].
Overall, an improvement in patients’ general health was observed over time, with no notable difference
between treatment groups; the median score at 48 weeks was 48.0 (quartiles 26.0 and 63.0), 49.0
(quartiles 27.0 and 67.0) and 52.0 (quartiles 31.0 and, 64.0) in the alternative TNFi, abatacept and
rituximab groups, respectively (see Figure 18).
Bone densitometry
A total of 33 (60.0%) patients in the centres that had the facilities underwent a bone densitometry scan
at their baseline assessment, with 14 (25.5%) patients undergoing scans at the week 48 assessment.
Appendix 12, Table 68, presents the densitometry scores at baseline and 48 weeks for the subgroup
of patients.
Safety
Serious adverse events
A full listing of the SAEs and SSARs is included in Appendix 14, Tables 71–74. Ten SAEs were reported in
nine patients. Of these, three events in three patients were considered to be related to trial medications
and classed as SSARs. There were no suspected unexpected serious adverse reactions (SUSARs).
One patient in the TNFi arm, receiving infliximab, had a SSAR of autoimmune hepatitis but recovered with
sequelae. Two patients who received abatacept experienced SSARs (one experienced angiooedema and
recovered and one contracted pneumonia and died) and a further two patients who received abatacept
experienced SAEs (one experienced chest pain/epigastric pain, which remained unresolved, and one
DOI: 10.3310/hta22340 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 34
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Brown et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
45
contracted a chest infection but recovered). Finally, three patients who received rituximab each experienced
a SAE: one patient developed malignant melanoma and subbsequently died; one suffered a broken coccyx
bone, attributable to collapsing, but recovered with sequelae, and a third experienced abdominal pain, but
later recovered. A further patient who was randomised to receive rituximab experienced two SAEs occurring
prior to first infusion: a flare of RA and left basal pneumonia, from both of which the patient recovered.
As summarised above, two patients died following the development of a SAE. One patient receiving
rituximab had developed malignant melanoma, while a second patient developed pneumonia, considered
by the treating physicians to be related to abatacept treatment, as well as another illness.
No pregnancies were reported in any of the trial patients or in any partners of the trial patients.
Adverse events
Overall, 243 non-SAEs were reported in 90 patients (Table 20). Twelve events resulted in a permanent
cessation of treatment. Table 20 summarises the number of non-SAEs reported by treatment received.
A listing of all AEs is provided in Appendix 14, Table 75.
A total of 10 patients experienced one or more AE or SAE that resulted in a permanent cessation of
treatment: four patients on alternative TNFi (9.8%), two on abatacept (4.9%) and four on rituximab (10.0%).
TABLE 20 Frequency of non-SAEs reported by treatment group
AEs
Treatment arm
TotalAlternative TNFi Abatacept Rituximab
Number of patients with one or more AE 28 31 31 90
Number of AEs reported 83 73 87 243
Number of AEs per patient
Mean (SD) 2.1 (2.27) 1.8 (1.68) 2.2 (2.17) 2.0 (2.04)
Median (IQR) 1.0 (0–3) 1.0 (1–3) 2.0 (1–3) 1.0 (0–3)
Range 0–8 0–6 0–8 0–8
IQR, interquartile range.
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Chapter 4 Health economic analysis
Introduction
As described in Chapter 1, DMARDs are used in the early stages of management of RA. However, even
when there is an initial positive response, treatment efficacy often reduces over time. bDMARDs are usually
given to patients experiencing insufficient response to conventional DMARDs, but at a markedly higher
cost of around £9500 per patient per year, compared with around £450 per year for conventional
therapy.122 During 2007–8, expenditure on bDMARDs for the treatment of RA alone ranged between
£0.8M and £3.5M per acute trust, with expenditure on bDMARDs accounting for the highest
pharmaceutical spend within some trusts.122
Tumour necrosis factor inhibitor drugs are a type of bDMARD that have been found to be costly but highly
effective.31–33 However, NICE currently approves only rituximab following TNFi non-response, with the
use of alternative TNFi being permitted only when rituximab (and/or MTX that is co-prescribed) is
contraindicated.
An economic evaluation was conducted to estimate the cost-effectiveness of alternative TNFi or abatacept
compared with the current practice of rituximab in patients with RA who have failed treatment with an
initial TNFi. The economic evaluation was conducted alongside the SWITCH clinical trial so that only the
data collected within the (reduced) trial were analysed. Originally, the health economic analysis included a
within-trial analysis and a decision analytical model. Given the early termination of the trial and the
consequent reduced period of follow-up, the health economic analysis was adapted to include a within-trial
cost-effectiveness analysis over 48 weeks and a value of information analysis to inform future research.
Methods
Aim and end points
The primary aim of this analysis was to assess the cost-effectiveness of the use of abatacept or alternative
TNFi compared with the current practice of rituximab in patients with RA who have failed treatment with an
initial TNFi. The primary end point was the cost per quality-adjusted life-year (QALY) gained. The methods
used for this within-trial analysis were guided by the recommendations from the NICE methods guide.123
Perspective and time frame
The study adopted a NHS and Public Social Services perspective for cost evaluation, but a broader societal
perspective was adopted for secondary analysis to incorporate costs to patients and productivity costs.
Costs and benefits for the base-case analysis were calculated for the study period of 48 weeks. As the time
frame of the trial was < 1 year, discounting of the costs and benefits was not required.
Measurement of effectiveness
This analysis used the QALY as the main outcome measure. QALYs are a generic measure of health state
that take account of both quality and length of life such that 1 QALY is equal to 1 year in full health.124
Health-related quality of life was measured using the EuroQol 5 Dimensions, 3 levels (EQ-5D-3L). The
EuroQol 5 Dimensions (EQ-5D) is a commonly used generic measure of health-related quality of life and is
NICE’s preferred outcome measure for cost-effectiveness analyses.123 The questionnaire comprises five
domains: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each domain consists
of three levels: no problems, some problems and severe problems.125
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The EQ-5D-3L was administered at baseline and at follow-up visits in weeks 12, 24, 36 and 48. Responses
were converted to health state utility values using the UK general population time trade-off tariff values.126
Measurement of costs
Health-care resource utilisation data were collected using patient self-reported questionnaires covering
primary care [e.g. general practitioner (GP) and nurse visits] and secondary care (e.g. hospital stays/visits)
resource use over the trial period (see Appendix 2). The questionnaires also captured personal costs to
patients related to RA (e.g. travel to/from hospital and cost of aids) and any impact the disease had on
their income over the trial period. The resource-use questionnaires were completed at weeks 12, 24, 36
and 48 by the research teams at the participating centres and were supplemented by case report forms
(CRFs) capturing data on hospital inpatient or outpatient visits. When there were discrepancies between
the CRFs and the patient-completed forms, the CRFs were given precedence. Unit costs for health service
staff and resources were obtained from the Personal Social Services Research Unit (PSSRU) report in 2015,
entitled Unit Costs of Health and Social Care 2015,127 and NHS Reference Costs 2014 to 2015.128 For
medications, a unit cost per treatment received was assigned. The Commercial Medicines Unit’s electronic
market Information Tool (eMit) was used to cost the drugs when possible.129 However, when drugs were
not listed on eMit, costs were taken from the British National Formulary (BNF).130 When unit costs were not
available, targeted literature searches were used to provide the relevant costs which were inflated to 2015
prices (pounds sterling) using an online inflator.131 Unit costs are presented in Appendix 15, Table 76.
Assumptions related to medication use
A number of assumptions were required in order to measure the costs related to the drugs used within
the trial:
l When the patient’s weight was needed to calculate the dose of trial medication, the baseline weight
was used. This applied to the one patient using infliximab and, in this case, the associated cost was not
affected if the patient’s weight at each clinical assessment had been used instead.
As no stop date was recorded for the trial drugs, the number of doses was deduced from the CRFs making
the following assumptions.
1. If the records showed that all infusions were received as per the protocol, the full protocol-defined
allocation for the relevant time period was allocated to that patient.
2. In patients who were reported to have received some randomised treatment but the infusions received
did not follow protocol because they were delayed, it was assumed that the patient received the full
allocation of trial medication.
3. In patients who were reported to have received some randomised treatment but for whom infusions
received did not follow protocol because treatment was stopped, it was assumed that the patient
received half the allocation of trial medication for that time period.
4. If it was indicated that some of the randomised treatment had been received but it was not reported
whether or not all the treatment had been received or whether or not there had been any
modifications to the treatment protocol, it was assumed that the full allocation of treatment for that
time period had been received.
5. For treatments administered by injection, if the number of missing injections was recorded, the number
of missing injections was taken from the full protocol-defined allocation for the relevant time period.
6. For treatments administered by injection, if some treatments were missed but the number of treatments
missed was not recorded, then it was assumed that half of the allocation for the relevant time period
was received.
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The following assumptions were applied in order to cost the concomitant drugs used within the trial period.
l When dose was not recorded, it was assumed that the standard dose was received.
l When it was indicated that it was an ongoing drug with no start or end date recorded, it was assumed
that it was taken for the full 48 weeks.
l For those patients who took MTX, it was assumed that it was taken orally at an average dose of 15 mg
per week based on the relevant literature and expert opinion.132
Missing data
The base-case analysis was conducted using only complete cases. That is, patients were included in the
analysis if they had no missing resource use data as well as no missing quality-of-life data. In the case of
resource use, no missing data were defined as a resource use form having been completed at all time points.
For the resource use questionnaires, if a patient recorded that they had used a form of health care (e.g. GP
visit) but did not record the number of visits, the mean number of visits was imputed. For quality of life,
complete data were defined as a completed quality-of-life questionnaire returned at each time point.
Sensitivity analyses were conducted using imputed data so that all patients were included in the analysis.
Two imputation methods were explored: mean imputation and multiple imputation. For the mean
imputation, when a QALY value for a given time point was missing, the mean of the non-missing QALYs
for the trial arm at that time point was imputed. The same approach was taken to impute missing cost
data for resource use. For the multiple imputation, costs for each follow-up and total QALYs were imputed
by chained equations using predictive mean matching.133 Forty-five data sets were imputed (reflecting the
percentage of incomplete cases), which were then combined using Rubin’s rules.119,134
Analysis
The primary analysis was a cost-effectiveness analysis of the three relevant treatment arms of the trial.
A complete-case analysis was the primary method for analysing the trial data and an ITT analysis was
undertaken as a sensitivity analysis.
Resource use and costs were quantified and analysed using analysis of variance and independent sample
t-tests. Owing to the small sample size and, subsequently, the potential violation of the underlying normality
assumption when using t-tests, the robustness of the results was checked using a non-parametric bootstrap.
Health-state utilities were used to calculate QALYs using an area under the curve approach:
QALY = f½(EQ-5DBaseline + EQ-5D12)/2 × 0:231g + f½(EQ-5D12 + EQ-5D24)/2 × 0:231g
+ f½(EQ-5D24 + EQ-5D36)/2 × 0:231g + f½(EQ-5D36 + EQ-5D48)/2 × 0:231g,
(6)
where EQ-5DBaseline, EQ-5D12, EQ-5D24, EQ-5D36 and EQ-5D48 are the EQ-5D scores at baseline, week 12,
week 24, week 36 and week 48, respectively; 0.230769 represents 12 weeks out of 52 for each time period:
t =
12
52
= 0:230769 (7)
Total costs and QALYs for each arm of the trial were calculated. For the secondary analysis, a wider cost
perspective was adopted to include the total costs incurred by the patients.
Incremental cost-effectiveness ratios (ICERs) were calculated.135 An ICER represents the additional cost per
QALY gained for each intervention compared with the next best alternative and is calculated as follows for
treatment A relative to treatment B:
ICER = (CostA − CostB)/(QALYA − QALYB), (8)
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where CostA and CostB are the mean costs and QALYA and QALYB are the mean QALYs for groups A and
B. An intervention was judged to be cost-effective using the lower limit of the NICE acceptance threshold
of £20,000 per incremental QALY (λ = £20,000) as the decision rule for the analysis.123
The level of sampling uncertainty around the ICER was determined using non-parametric bootstrapping
(with replacement) to generate 10,000 estimates of incremental costs and benefits. These were then
plotted on the cost-effectiveness plane to visualise the uncertainty around the mean incremental costs and
effects. The expected ICERs for the primary analysis were estimated from the means of bootstrapped cost
and outcome distributions.
Net monetary benefit (NMB) values were also calculated. Net benefit (NB) combines cost-effectiveness and
willingness to pay to give an explicit monetary valuation of the health outcome. It is calculated by rearranging
the ICER calculation and incorporating a proposed willingness-to-pay threshold value per QALY.135 The
expected value of the NMB was calculated for each treatment. Treatments with positive NMBs provide more
health benefit than is displaced by the associated opportunity costs and should be adopted. The treatment
with the highest positive NMB is the most cost-effective.135 The probability that the treatments were
cost-effective was evaluated by generating estimates of NMB for a range of cost-effectiveness thresholds (λ).
This analysis was presented as a cost-effectiveness acceptability curve.136,137 The cost-effectiveness acceptability
curve provides decision-makers with useful information regarding the risk of making a wrong decision;
however, the decision to fund or not fund a treatment should be made on the expected value of the NMB.
Net monetary benefit is derived for each patient as:
NMB = (λ × QALYs) − costs. (9)
Sensitivity analyses
The following scenario sensitivity analyses were conducted to test the robustness of the conclusions drawn
from the results.
1. Mean imputed data: an analysis was conducted using singly imputed data for missing QALYs and costs
to enable an assessment of cost-effectiveness using data from all patients.
2. Multiple imputation: an analysis was conducted using multiply imputed data for missing QALYs
and costs.
3. Adjust baseline: an analysis was conducted to evaluate the effect of adjusting for baseline differences in
EQ-5D score (using an ordinary least squares regression and adjustment: total QALYs over 48 weeks
were regressed on trial arm, EQ-5D score at baseline, age at baseline and sex).
4. Subcutaneous MTX: patients could have taken MTX orally or by subcutaneous injection but, as the
method was not recorded, at baseline an assumption was made that MTX was taken orally by all
patients. Therefore, sensitivity analysis was conducted that explored the alternative scenario that MTX
was instead taken via subcutaneous injection by all patients.
Secondary analysis assessed the effect of taking a broader, societal cost perspective. The analysis uses health
and social sector costs together with the addition of patient out-of-pocket costs plus values from the EQ-5D
to estimate QALYs (replicating the primary analysis). As in the primary analysis the base case used complete
cases. Sensitivity analyses using mean imputation and multiple imputation were undertaken.
Value of information analysis
Value of information analysis was conducted to estimate the potential gains from the elimination of
uncertainty as a result of conducting additional research. As decisions based on current information are
uncertain (because of imperfect information) there is a chance that the wrong decision will be made,
resulting in costs being incurred in the form of health benefit and cost of resources forgone. Given the
very small sample size, the decision uncertainty is large and, therefore, the value of information analysis is
HEALTH ECONOMIC ANALYSIS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
50
especially important. The expected value of perfect information (EVPI) is derived from the expected costs
associated with the uncertainty in decisions. The EVPI provides the maximum value that a health-care
system should be willing to pay for additional evidence to eliminate uncertainty in parameter estimates to
inform future decisions, and gives an upper bound for the value of additional research. As information is
valuable to all patients with a disease (not just one patient) EVPI can be expressed for the population of
patients who could benefit.138,139 The EVPI was calculated for the population of the UK who have RA
as follows:
EVPI = Eθmax jNB( j, θ) − max jEθNB( j, θ). (10)
The bootstrap simulation provides estimates of costs and benefits and, therefore, NB. Eθmaxj NB( j, θ) is the
expected NB with perfect information, which is the mean value of NMB in the set when the intervention
with the higher NMB is chosen for each simulation, and maxjEθNB(j, θ) is the expected NB with current
information, which is obtained when the intervention with the higher expected NB is chosen across
all simulations.140
All of the analyses were conducted in Stata® (version 14, StataCorp LP, College Station, TX, USA) and
Microsoft Excel® (2013, Microsoft Corporation, Redmond, WA, USA).
Results
Sample
Of the 122 patients recruited to the trial, 70 patients with complete resource use data and EQ-5D results
(25 rituximab, 24 abatacept and 21 alternative TNFi) were included in the base-case analysis.
Baseline characteristics of the 70 patients analysed in the complete case are presented in Table 21 (see
Table 3 for baseline characteristics of the ITT population). In all treatment arms more than two-thirds of the
patients were female. The average weight was slightly lower in the abatacept group than in the other
treatment groups. Fewer patients in the alternative TNFi arm were non-smokers and a higher percentage
were past smokers than in the other treatment arms. There was some variation between arms in baseline
EQ-5D scores, with the alternative TNFi group having the highest scores. However, the difference between
the scores was not statistically significant.
Resource use and costs
Table 22 shows the average resource use of patients with complete resource use data over the trial period
in each trial arm (rituximab, n = 29; abatacept, n = 26; and alternative TNFi, n = 25). Further breakdown
of resource use is provided in Appendix 15, Table 79. Average health-care costs over the trial period are
presented in Table 23. These are broken down further in Appendix 15, Table 80. The mean (SD) total costs
of community health and social services were £927.17 (£1238.60) for the rituximab group, £601.20
(£553.70) for the abatacept group and £557.80 (£513.42) for the alternative TNFi group. The mean (SD)
total costs for hospital and residential care services were £1112.71 (£1137.51) for the rituximab group,
£862.61 (£788.43) for the abatacept group and £957.78 (£678.42) for the alternative TNFi group. All
groups have large SDs for these costs, particularly rituximab, which are driven by the skewed distribution
of costs, floor effects (zero costs for each cost component were observed for a proportion of patients) and
by a number of high-cost outliers. This is shown in the box and whisker plots in Figure 19. It would be
wrong to overinterpret differences between the groups given the outliers, skewness and small sample.
Despite having the highest resource use cost, the rituximab treatment group incurred the lowest mean
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total NHS cost along the whole treatment pathway. The trial medication costs reported in Table 23 include
the cost of administering the drugs as well as the cost of the medication. The unit costs of the trial
medication are reported in Appendix 15, Table 77, and a breakdown of the cost of administering each of
the trial drugs is presented in Appendix 15, Table 78, for other relevant unit costs. As costs are assigned
per treatment received, we note that there may be cases in which retreatment occurs within the trial
period. In these cases, the costs for retreatment are included in the analysis but some of the benefits that
may extend beyond the end of the trial could be excluded. This may be particularly relevant for rituximab,
as 20 patients received re-infusion within the trial period.
Independent-sample t-tests were undertaken to explore differences in the mean total NHS costs associated
with treatment groups. However, the t-test is based on the assumption that the data are normally
distributed, which is violated, and asymptotic results surrounding normality of the mean costs are not
robust because of the small sample size. Consequently, a non-parametric bootstrap of the difference in
costs was conducted as a check on the robustness of the standard Student t-tests.124 Independent-sample
t-tests indicated that there was a significant difference in the mean total NHS costs associated with the
rituximab treatment group and the abatacept treatment group (p = 0.0003). There was also a significant
difference between the mean costs for the alternative TNFi group and the abatacept group (p = 0.0002),
but there was no statistically significant difference between the mean costs associated with the rituximab
group and the alternative TNFi group (p = 0.6772). The bootstrap confirmed the results of the t-test.
TABLE 21 Baseline characteristics of patients included in the complete-case analysis by treatment group
Patient characteristic
Treatment arm
Rituximab (n= 25) Abatacept (n= 24) Alternative TNFi (n= 21)
Age (years)
Mean (SD) 58.51 (11.55) 57.17 (13.90) 56.53 (9.31)
Sex, n (%)
Male 7 (28) 1 (4) 5 (24)
Female 18 (72) 23 (96) 16 (76)
Weight (kg)
Mean (SD) 85.26 (21.05) 75.86 (15.79) 81.91 (20.24)
Smoking status, n (%)
Non-smoking 10 (40) 9 (37.5) 5 (23.8)
Past smoker 10 (40) 9 (37.5) 10 (47.6)
Current smoker 5 (20) 6 (25) 6 (28.6)
EQ-5D score
Mean (SD) 0.31 (0.34) 0.39 (0.32) 0.46 (0.27)
DAS28
Mean (SD) 6.14 (1.34) 6.23 (0.97) 5.77 (0.78)
Missing 3 3 0
HAQ score
Mean (SD) 1.74 (0.84) 1.8 (0.59) 1.75 (0.5)
Missing 0 1 0
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TABLE 22 Average resource use per patient over the trial period in each treatment group (complete resource use data)a
Resource use
Treatment arm
Rituximab (n= 29) Abatacept (n= 26) TNFi (n= 25)
Mean (SD) Minimum Maximum Mean (SD) Minimum Maximum Mean (SD) Minimum Maximum
Community health and social services
GP surgery visit
Face to face 9.10 (10.88) 0 43 6.19 (4.84) 0 23 6.32 (4.91) 0 15
Telephone/e-mail 2.34 (4.15) 0 19 0.57 (1.79) 0 9 1.44 (2.48) 0 10
GP home visit
Face to face 0.24 (0.99) 0 5 0.07 (0.39) 0 2 0.04 (0.2) 0 1
District nurse
Face to face 0.72 (1.87) 0 9 0.81 (1.55) 0 6 1.28 (2.30) 0 7
Telephone/e-mail 0.34 (0.19) 0 1 0.27 (0.96) 0 4 0.08 (0.4) 0 2
Social worker
Face to face 0.10 (0.41) 0 2 0 0 0 0 (0) 0 0
Telephone/e-mail 0.07 (0.37) 0 1 0 0 0 0 (0) 0 0
Physiotherapist
Face to face 3.14 (7.00) 0 30 2.88 (8.12) 0 40 1.36 (3.38) 0 14
Telephone/e-mail 0.41 (1.88) 0 10 0.04 (0.20) 0 1 0 (0) 0 0
Occupational therapist
Face to face 0.41 (1.43) 0 6 0.54 (1.07) 0 4 0.32 (1.6) 0 8
Telephone/e-mail 0.07 (0.26) 0 2 0.04 (0.20) 0 1 0 (0) 0 0
Podiatrist
Face to face 2.24 (4.28) 0 18 2.12 (4.10) 0 14 1.96 (4.21) 0 14
Telephone/e-mail 0.28 (1.16) 0 6 0 (0) 0 0 0 (0) 0 0
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TABLE 22 Average resource use per patient over the trial period in each treatment group (complete resource use data)a (continued )
Resource use
Treatment arm
Rituximab (n= 29) Abatacept (n= 26) TNFi (n= 25)
Mean (SD) Minimum Maximum Mean (SD) Minimum Maximum Mean (SD) Minimum Maximum
Counsellor
Face to face 0.31 (1.67) 0 9 0 (0) 0 0 0.24 (0.88) 0 4
Telephone/e-mail 0 (0) 0 0 0 (0) 0 0 0.16 (0.8) 0 4
Psychologistb
Face to face 0.14 (0.74) 0 4 0 (0) 0 0 0 (0) 0 0
Home helpb
Face to face 3.72 (12.46) 0 48 0.46 (2.59) 0 12 0.48 (2.4) 0 12
Hospital or residential care services
Hospital inpatient stay 0.79 (2.27) 0 10 0 (0) 0 0 0.08 (0.28) 0 1
Hospital outpatient clinic 3.48 (2.94) 0 12 4.15 (2.60) 0 8 4.76 (3.38) 0 16
Hospital day centre 1.76 (2.41) 0 8 1.08 (2.59) 0 10 1.2 (2.40) 0 9
Hospital accident and emergency department 0.34 (0.94) 0 4 0.19 (0.98) 0 5 0.4 (0.28) 0 7
a The table reports only the use of main services, and because there were no nursing home or residential home visits these are excluded from the table.
b There were no reported household help or psychologist contacts by telephone or e-mail.
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TABLE 23 Mean health-care costs by trial arm (complete cost data)
Health-care cost (£)
Treatment arm
Rituximab (n= 29) Abatacept (n= 26) TNFi (n= 25)
Community health and social services
Mean (SD) 927.17 (1238.6) 601.2 (553.7) 557.8 (513.42)
Minimum 0 0 0
Maximum 5291.57 2388 1818.23
Hospital and residential care services
Mean (SD) 1112.71 (1137.51) 862.61 (788.43) 957.78 (678.42)
Minimum 0 0 224
Maximum 5039.21 3322 2523
Trial medicationa
Mean (SD) 6633.49 (3197.01) 11,584.52 (4733.65) 6939.19 (2679.69)
Minimum 2024.96 1407.6 902.28
Maximum 16,199.68 15,015.6 9353.64
MTX
Mean (SD) 32.36 (5.27) 30.92 (3.42) 35.14 (3.09)
Minimum 14.4 21.6 31.2
Maximum 38.4 33.6 45.6
Other concomitant medication
Mean (SD) 396.78 (1830.36) 519.51 (1168.58) 807.93 (1909.68)
Minimum 0 0 0
Maximum 9907.84 3590.59 7014.68
Total NHS
Mean (SD) 9102.51 (3375.77) 13,598.77 (4092.09) 9297.84 (2007.36)
Minimum 4716.78 2690.88 1462.19
Maximum 18,064.16 17,661.2 12,573.96
Patient costs
Mean (SD) 1081.66 (2020.47) 387.79 (655.19) 947.07 (2521.82)
Minimum 0 0 0
Maximum 9028.5 2552 12676
Total all
Mean (SD) 10,184.17 (3509.55) 13,986.55 (4382.28) 10,244.91 (3298.72)
Minimum 4874.25 2692.23 1462.19
Maximum 18,292.16 20,213.2 21,882.63
a Includes drug administration cost.
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Quality-of-life data
The mean (SD) EQ-5D scores for each trial arm, at each time point, are presented in Table 24. There was
an apparent increase in mean EQ-5D score from baseline to week 12 in all treatment groups. Although
there were small fluctuations in scores, this initial improvement was more or less maintained up to week
48 in all arms of the trial. All three treatment groups show an increase in EQ-5D score from baseline to
week 48. Despite the apparent slightly higher baseline EQ-5D score for the alternative TNFi group,
statistical tests indicated that there was no statistically significant difference in EQ-5D scores at baseline
(p = 0.2592). This was explored further in a sensitivity analysis adjusting for baseline differences in
EQ-5D score.
Table 25 shows the mean EQ-5D change scores between baseline and each of the follow-up time points.
Statistical analysis using analysis of variance indicated that the variation among groups in the changes in
EQ-5D scores was not statistically significant (p = 0.7071).
Missing data
Seventy-four patients had complete EQ-5D scores across all time points. The remaining 48 had EQ-5D
scores missing for at least one of the time periods. All 122 patients completed resource use questionnaires
in the first two time periods (12 and 24 weeks), but the response rate dropped in the following two time
periods to 98 forms returned (79%) at 36 weeks and 89 forms returned (71%) at 48 weeks.
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FIGURE 19 Box and whisker plots of the distributions of the resource use costs by treatment group. (a) Total
community health and social services cost and (b) total hospital and residential care services cost. X inside the bars
corresponds to the mean value; and X outside the bars corresponds to outlier values.
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TABLE 24 Mean (SD) EQ-5D scores by treatment group and time point (complete outcome data)
Time point
Treatment arm
Rituximab Abatacept Alternative TNFi
Baseline
Mean (SD) 0.36 (0.33) 0.34 (0.33) 0.42 (0.29)
n valid (missing) 37 (3) 36 (5) 40 (1)
Week 12
Mean (SD) 0.51 (0.25) 0.52 (0.29) 0.59 (0.23)
n valid (missing) 38 (2) 39 (2) 37 (4)
Week 24
Mean (SD) 0.48 (0.29) 0.55 (0.29) 0.57 (0.24)
n valid (missing) 36 (4) 37 (4) 33 (8)
Week 36
Mean (SD) 0.52 (0.23) 0.54 (0.32) 0.59 (0.29)
n valid (missing) 34 (6) 33 (8) 33 (8)
Week 48
Mean (SD) 0.51 (0.29) 0.50 (0.29) 0.55 (0.28)
n valid (missing) 30 (10) 33 (8) 29 (12)
TABLE 25 Mean EQ-5D change from baseline to each follow-up time point for each trial arm
Time point
Treatment arm
Rituximab Abatacept Alternative TNFi
Baseline to week 12
Mean (SD) 0.19 (0.33) 0.17 (0.32) 0.14 (0.25)
n 35 34 36
Baseline to week 24
Mean (SD) 0.13 (0.37) 0.22 (0.32) 0.11 (0.29)
n 34 33 32
Baseline to week 36
Mean (SD) 0.15 (0.35) 0.20 (0.39) 0.13 (0.37)
n 32 29 32
Baseline to week 48
Mean (SD) 0.18 (0.38) 0.12 (0.37) 0.10 (0.34)
n 28 29 28
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Cost-effectiveness results
The costs and outcomes from the observed data are presented in Table 26. As the sample size of the
observed data is small, the average costs and effects from the non-parametric bootstrap provide a more
accurate and robust estimate of the distribution of the population costs and effects. Table 27 shows the
costs and QALYs gained for each treatment arm, the incremental costs and QALYs of the relevant
comparisons and the resulting ICERs calculated from the bootstrap sample. The treatments are arranged in
order of increasing cost so that the incremental costs and QALYs refer to the comparison between the
neighbouring treatments in the table. The abatacept treatment group had the highest QALYs gained over
the trial period, although the rituximab group had the lowest. The mean total cost was highest for the
abatacept treatment group and lowest for the rituximab treatment group.
The results suggest that switching to alternative TNFi would be cost-effective compared with rituximab, as
QALY gains are higher and costs are only slightly higher, leading to an ICER value of £5332.02 per QALY
gained. This is well below the NICE acceptance threshold (λ = £20,000), which indicates that switching to
alternative TNFi would be a cost-effective treatment option. Conversely, the abatacept group has much
higher costs and only marginal gains in QALYs compared with the alternative TNFi treatment group.
This results in an ICER value of £253,967.96 per QALY gained, indicating that switching to abatacept
compared with switching to alternative TNFi drug would not be cost-effective, as this ICER value is well
above the NICE cost/QALY threshold. However, these results should be interpreted very cautiously given
the small number of cases and the substantial probability of a very small QALY difference, resulting in a
divisor close to zero. Moreover, the SD is likely to be underestimated.
Figure 20 shows the joint distribution of incremental costs and incremental effects in the cost-effectiveness
plane for alternative TNFi compared with rituximab and alternative TNFi compared with abatacept. The
wide spread of the ‘clouds’ shows the high degree of uncertainty around the central results. This is to be
expected given the small sample sizes.
TABLE 26 Total costs and QALYs for each treatment (complete-case data)
Treatment group Total cost (£), mean (SD) QALYs, mean (SD)
Rituximab (n= 25) 9367.27 (3215.13) 0.46 (0.18)
Alternative TNFi (n= 21) 9680.23 (1263.71) 0.52 (0.14)
Abatacept (n = 24) 13,475.09 (4173.22) 0.53 (0.17)
TABLE 27 Cost-effectiveness results (bootstrap of complete-case data)
Treatment group
Total cost (£),
mean (SD)
Incremental
cost (£)
QALYs,
mean (SD)
Incremental
QALYs
ICER
(£/QALY)
Rituximab 9367.80 (624.70) 0.46 (0.04)
Alternative TNFi compared
with rituximab
9673.77 (268.03) 305.96 0.52 (0.03) 0.06 5332.02
Abatacept compared with
alternative TNFi
13,441.77 (833.12) 3768.00 0.53 (0.03) 0.02 253,967.96
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FIGURE 20 Scatterplot on the cost-effectiveness plane: alternative TNFi vs. rituximab and abatacept vs. TNFi.
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Net benefit
The NMB for each treatment group is presented in Table 28. Given the decision rule, the NMB results
indicate that rituximab and abatacept are not cost-effective treatments, although alternative TNFi has a
positive NMB, indicating that it is cost-effective. These results suggest that switching to rituximab following
an initial TNFi failure, as recommended in the current NICE guidance, is not the most efficient use of NHS
resources. The probability that the treatments are cost-effective is presented in the cost-effectiveness
acceptability curve shown in Figure 21. This shows that rituximab has the highest probability of being
cost-effective for very low threshold values but that at threshold values > £6000 alternative TNFi has the
highest probability of being cost-effective. At a £20,000 threshold, there is a 74.5% probability that
alternative TNFi is cost-effective. Abatacept is never the most likely to be cost-effective and has a low
probability of cost-effectiveness even at high threshold values.
Sensitivity analysis
The costs and benefits from the observed data for each scenario explored in the sensitivity analyses are
presented in Table 29. For each scenario the observed data were used to conduct a non-parametric
bootstrap to provide the cost-effectiveness results, which are presented in Table 30.
Given that only complete cases were used for the base-case analysis, sensitivity analyses using mean
imputation and multiple imputation were conducted, so that all randomised patients could be included.
In each case, this does not alter the conclusion drawn from the base-case analysis, as alternative TNFi
dominates all other treatment arms and is the optimal treatment option. We note that in the case of the
mean imputation the increase in precision of these estimates is spurious, as the uncertainty attributable
to imputation of a single value is ignored. Moreover, the imputed value did not take the characteristics of
the missing cases into account; however, these are accounted for in the multiple imputation. Changing the
administration of MTX to subcutaneous injection and adjusting for baseline differences also supports the
results of the base-case analysis, with alternative TNFi remaining the most cost-effective treatment.
Variances of population distributions are known to be underestimated in small samples, which is
exacerbated by the high level of skewness in cost data, and we note that these sensitivity analyses have a
large effect on the SD of the estimates (i.e. standard error). Consequently, we should be cautious when
interpreting these results.
Secondary analyses
Secondary analyses incorporating costs using a wider social perspective were also conducted. As such,
the costs to the patient as well as health-care provider costs were included. Initially, this perspective was
explored using complete cases: those patients with complete health-care cost and quality-of-life data
(rituximab, n = 25; abatacept, n = 24; and alternative TNFi, n = 21). In the complete-case analysis, those
observations without complete cost and quality-of-life data were excluded. In addition, the wider social
cost perspective was explored using imputed health-care cost and quality-of-life data in a similar way to
the primary analysis. This enabled the inclusion of the whole sample in the analysis. The total costs and
QALYs for each analysis, obtained from the observed data, are presented in Table 31. The observed data
were used to conduct a non-parametric bootstrap to provide the cost-effectiveness results which are
presented in Table 32. Including societal costs does not alter the conclusions drawn from the primary
analyses, with alternative TNFi continuing to be the most cost-effective treatment.
TABLE 28 Net monetary benefit (= £20,000)
Treatment group Expected value NMB SD of the estimates 95% CI
Rituximab –160 1076 –2336 to 1877
Abatacept –2790 947 –4594 to –921
Alternative TNFi 681 659 –643 to 1943
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TABLE 29 Sensitivity analyses: total costs and QALYs for each treatment (observed data)
Treatment group Cost (£), mean (SD) QALYs, mean (SD)
Mean imputed data
Alternative TNFi (n = 41) 9011.85 (1874.19) 0.51 (0.14)
Rituximab (n = 40) 11,611.90 (15,601.15) 0.45 (0.15)
Abatacept (n= 41) 12,484.63 (3792.04) 0.48 (0.18)
Multiple imputation
Alternative TNFi (n = 41) 7313.11 (2641.83) 0.54 (0.11)
Rituximab (n = 40) 7563.66 (3466.92) 0.49 (0.15)
Abatacept (n= 41) 9757.76 (5469.32) 0.53 (0.13)
Adjust baseline
Rituximab (n = 25) 9367.27 (3215.13) 0.48 (0.03)
Alternative TNFi (n = 21) 9680.23 (1263.71) 0.51 (0.02)
Abatacept (n= 24) 13,475.09 (4173.22) 0.51 (0.01)
Subcutaneous MTX
Rituximab (n = 25) 10,126.88 (3168.76) 0.46 (0.18)
Alternative TNFi (n = 21) 10,519.07 (1281.09) 0.52 (0.14)
Abatacept (n= 24) 14,217.46 (4219.53) 0.53 (0.17)
TABLE 30 Sensitivity analyses: cost-effectiveness results (bootstrapped data)
Sensitivity analysis
Total cost (£),
mean (SD)
Incremental
cost (£)
QALY,
mean (SD)
Incremental
QALY ICER (£)
Mean imputed data
Alternative TNFi 9016.65 (283.76) 0.52 (0.02)
Rituximab compared with
alternative TNFi
11,675.67 (2428.85) 2659.01 0.45 (0.02) –0.07 Dominated
Abatacept compared with
alternative TNFi
12,489.87 (583.13) 3473.21 0.48 (0.03) –0.04 Dominated
Multiple imputation
Alternative TNFi 7311.22 (407.52) 0.54 (0.02)
Rituximab compared with
alternative TNFi
7577.46 (545.39) 266.24 0.49 (0.02) –0.05 Dominated
Abatacept compared with
alternative TNFi
9747.11 (847.59) 2435.89 0.53 (0.02) –0.01 Dominated
Adjust baseline
Rituximab 9358.71 (632.32) 0.48 (0.01)
Alternative TNFi compared with
rituximab
9681.06 (267.89) 322.35 0.51 (0.00) 0.03 10,948.76
Abatacept compared with
alternative TNFi
13,470.63 (830.90) 3789.57 0.51 (0.00) 0.00 Dominated
Subcutaneous MTX
Rituximab 10,123.97 (616.01) 0.46 (0.04)
Alternative TNFi compared with
rituximab
10,519.20 (273.74) 395.24 0.52 (0.03) 0.06 6863.26
Abatacept compared with
alternative TNFi
14,214.03 (840.88) 3694.83 0.53 (0.03) 0.02 237,955.53
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TABLE 31 Secondary analyses: total costs and QALYs for each treatment (observed data)
Treatment group Cost (£), mean (SD) QALYs, mean (SD)
Complete case
Rituximab (n= 25) 10,234.14 (3398.08) 0.46 (0.18)
Alternative TNFi (n = 21) 10,801.87 (2952.71) 0.52 (0.14)
Abatacept (n = 24) 13,786.91 (4365.49) 0.53 (0.17)
Mean imputed data
Alternative TNFi (n = 41) 10,543.76 (6729.35) 0.51 (0.14)
Rituximab (n= 40) 12,582.66 (15,489.78) 0.45 (0.15)
Abatacept (n = 41) 13,177.04 (4319.81) 0.48 (0.18)
Multiple imputation
Rituximab (n= 40) 8482.35 (3918.54) 0.49 (0.15)
Alternative TNFi (n = 41) 8855.76 (6511.18) 0.54 (0.11)
Abatacept (n = 41) 10,461.48 (5720.53) 0.53 (0.13)
TABLE 32 Secondary analyses: cost-effectiveness results (bootstrapped data)
Treatment group Cost (£), mean (SD)
Incremental
cost (£)
QALYs,
mean (SD)
Incremental
QALYs
ICER
(£/QALY)
Complete case
Rituximab 10,229.65 (660.23) 0.46 (0.04)
Alternative TNFi
compared with rituximab
10,811.13 (626.02) 581.48 0.52 (0.03) 0.06 10,145.42
Abatacept compared
with alternative TNFi
13,785.52 (872.09) 2974.39 0.53 (0.04) 0.02 188,842.00
Mean imputed data
Alternative TNFi 10,538.72 (1040.50) 0.51 (0.02)
Rituximab compared
with alternative TNFi
12,606.74 (2423.23) 2068.02 0.45 (0.02) –0.06 Dominated
Abatacept compared
with alternative TNFi
13,173.90 (673.21) 2635.17 0.48 (0.03) –0.04 Dominated
Multiple imputation
Alternative TNFi 8490.97 (599.60) 0.49 (0.02)
Rituximab compared
with alternative TNFi
8853.82 (997.76) 362.85 0.54 (0.02) 0.05 7647
Abatacept compared
with alternative TNFi
10,449.61 (883.59) 1595.79 0.53 (0.02) –0.01 Dominated
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Value of information analysis
There are 690,000 people with RA in the UK.3,141 The population EVPI, at the NICE cost-effectiveness threshold
value of lambda (λ= £20,000), is £129,227,589. The population EVPI for other values of lambda is plotted
in Figure 22. This indicates that it would be highly valuable to the NHS to reduce the current uncertainty
regarding the effectiveness of alternative TNFi compared with rituximab in the management of RA.
Conclusions
Owing to the sample size, the conclusions drawn from the cost-effectiveness analyses should be treated
with caution. The analysis shows that switching to alternative TNFi following an initial TNFi failure may
be a cost-effective option compared with rituximab, although switching to abatacept is unlikely to be
cost-effective. Although the conclusion was robust to several alternative sensitivity analyses and was also
corroborated when taking a broader societal perspective, which includes the costs incurred by patients
there are caveats given that the full sample size was not achieved within the study. The value of information
analysis indicates that it would be highly valuable to the NHS to reduce the current uncertainty regarding
the effectiveness of alternative TNFi compared with rituximab in the management of RA.
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Chapter 5 Discussion
Principal findings
Primary outcome
Owing to the early termination of the trial by the funders, the ‘SWITCH’ study was substantially
underpowered in its objective to demonstrate non-inferiority of either alternative TNFi or abatacept to
rituximab in terms of a reduction in the DAS28 at 24 weeks post randomisation. In the context of the low
number of patients, alternative TNFi was non-inferior to rituximab in the ITT patient population, in that the
estimate of the treatment effect excluded the non-inferiority margin of –0.6 units, but non-inferiority
was not demonstrated in the PP population, which was our prespecified requirement for demonstrating
non-inferiority overall. Non-inferiority of abatacept to rituximab was not demonstrated in either patient
population; the 95% CI did not exclude the non-inferiority margin of –0.6 units and is therefore a
plausible value.
As the trial was not permitted to recruit the target number of patients, the main interpretation of the
results is based on the estimated treatment effect and corresponding precision. In the ITT patient
population, the estimated mean difference in the reduction in the DAS28 after 24 weeks between
alternative TNFi and rituximab was 0.30 units (95% CI –0.45 to 1.05 units); the corresponding estimate for
the difference between abatacept and rituximab was 0.04 units (95% CI –0.72 to 0.79 units). Hence, the
treatment effect in the ITT patient population is estimated with a precision of ± 0.75 units (corresponding
to the half-width of the 95% CI).
Following exclusion of patients according to the prespecified criteria, the number of patients included in
the PP population resulted in the treatment effect for both interventions compared with rituximab being
estimated with very low precision. The estimated treatment effect for alternative TNFi compared with
rituximab was –0.58 units (95% CI –1.72 to 0.55 units) and for abatacept was –0.15 units (95% CI –1.27
to 0.98 units) for the DAS28 at 24 weeks. Therefore, the treatment effect was estimated with a precision
of ± 1.13 units, so there is large uncertainty in the estimate of the treatment effect in the PP population.
Exploratory subgroup analysis
Subgroup effect estimates in this underpowered study should be interpreted cautiously; however, this
component of the study was particularly novel and important clinically.
The suggestion of an association between negative serological status and poorer response to rituximab
was consistent with meta-analyses,3–84 a recent RCT of the first-line use of a bDMARD (as opposed to
following first TNFi failure as with the ‘SWITCH’ study) in which non-inferiority of rituximab compared with
a TNFi in seropositive patients142 was observed and observational registry data.82 The dependency of
individual CCG receptiveness to secure such agreements, however, increases the potential for regional
inconsistency in prescribing options and approach. Complete SWITCH data could have pushed for inclusion
in future technology appraisals.
Primary and secondary non-response to an initial TNFi is well recognised and an important marker of the
mechanisms for treatment failure, with secondary non-response suggesting a pharmacokinetic basis for
failure and primary non-response suggesting the wrong target.143 The results suggest that primary
non-response may benefit from a change in class of bDMARD, whereas secondary non-response can be
circumvented by use of alternative TNFi; these are consistent with other published literature, albeit from
uncontrolled cohort studies.
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Secondary outcomes
Rheumatoid arthritis is a chronic disease that in the main requires long-term DMARD therapy. RCTs usually
comprise a primary end point at week 24 (or earlier) that provides guidance only on short-term outcome
whereas, in practice, reassurance on the maintenance (durability) of response is equally relevant. The
secondary outcomes at weeks 36 and 48 go some way to providing this additional context. In the ‘SWITCH’
study, there was evidence of a greater improvement in disease activity (via the DAS28) at week 36 for
alternative TNFi than for rituximab, although this difference was not maintained at week 48. There was no
evidence of a difference in the DAS28 between abatacept and rituximab at any time point. However, when
assessing disease activity in terms of the odds of achieving a DAS28 response (≥ 1.2 units), there was no
evidence of a difference for either intervention compared with rituximab at any of the time points.
Moreover, there was no evidence of a difference in the odds of achieving an ACR20 response at 24 weeks
post randomisation for either intervention relative to rituximab.
In addition to demonstrating a reduction in the DAS28, the overall disease activity status and setting of a
target of at least low disease activity (if not remission) is now established as an important goal, which is
coined as part of a ‘treat to target’ management approach of RA.144 In the ‘SWITCH’ study, the proportions
of patients on alternative TNFi and rituximab who achieved DAS28 low disease activity or remission at
24 weeks were similar, whereas the proportion of patients who achieved low disease activity or remission
on abatacept was lower. Furthermore, among patients on alternative TNFi, the proportion achieving low
disease activity or remission continued to increase to week 48, whereas among those on abatacept and
rituximab this proportion fell between 24 and 48 weeks.
Functional and quality-of-life patient-reported outcome measures remain important indicators of patient
well-being. Overall, a general improvement in HAQ-DI, RAQoL and the Patient Global Assessment of
General Health was apparent over time, with no notable differences between treatment groups. There was
a marked initial improvement in the Patient Global Assessment of Pain and Patient Global Assessment of
Arthritis at 12 weeks across all three treatment groups. Small improvements in the HADS anxiety and
depression scores over the 48-week period were observed in patients treated with alternative TNFi or
abatacept, whereas no notable improvement was apparent in those receiving rituximab.
The safety profile was similar for all three treatments. Ten SAEs were reported in nine patients, of which
three events in three patients were considered to be related to trial medications. There were no SUSARs
reported. Two patients died, in both cases following the development of a SAE (one each in the rituximab
and abatacept groups). Ten patients experienced toxicity resulting in a permanent cessation of treatment
(four patients on alternative TNFi, two on abatacept and four on rituximab).
The most common protocol deviations related to receiving steroid treatment within 6 weeks of an
end-point assessment, not being compliant with treatment to 24 weeks and receiving additional
contraindicated treatment, all of which were likely to have contributed to a less conservative estimate of
the mean treatment effect relative to the ITT patient population.
Strengths and weaknesses
The principal strength of the ‘SWITCH’ study design was its emphasis on evaluation of a more defined and
refined patient population, in keeping with the overall ambitions of the medical community for a more
precise, tailored approach to medicine. This in itself, however, posed its own challenges, such as in
recruitment. To date, almost all TNFi failure studies (RCTs and observationa studiesl) have included any
cause of failure (inefficacy and toxicity/intolerance), limiting the strength in application of the data on an
individual patient level and also the potential mechanistic insights that can be drawn from clinical studies
(‘reverse translation’). The SWITCH study permitted the enrolment of only patients in whom TNFi had been
found to be ineffective; although this is the predominant reason for failure, it will have limited the eligible
patient pool. In addition, evaluating only patients on concomitant MTX (to recognise MTX synergy with
bDMARD) will have limited the available recruitment pool further. In hindsight, accepting a less precise
approach by including all patients (any cause of TNFi failure and TNFi with/without MTX combination) with
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sensitivity analysis adjusting for MTX combination would have been more pragmatic and reduced some of
the challenges in recruitment.
Nevertheless, the scientific design and rigorous conduct of this, albeit small, trial means that the SWITCH
study will contribute to the evidence base for future research in RA, including in meta-analyses, and,
hopefully, encourage future study design to address the factors such as those included in our exploratory
subgroup analysis.
The obvious major weakness was the early termination, which resulted in a small number of patients
recruited into the study. This naturally led to uncertainty in providing definitive conclusions. Despite this,
the study identifies some indicators of response, which, although not definitive, provide support for, in
particular, alternative TNFi rather than rituximab as a second-line bDMARD therapy in the management
of RA. Furthermore, although an exploratory outcome, further diminished with the small sample size,
the absence of a response to rituximab in the seronegative population is consistent with the published
meta-analyses in efficacy trials.84 These results, thus, further support that the hypothesis that an alternative
bDMARD to rituximab may be preferable if a patient is seronegative. Moreover, if secondary non-response
has resulted from a first TNFi, then it may also be more appropriate to consider a second TNFi.
It is important to emphasise, however, that no single treatment (or sequence) is appropriate for all patients
and no single study will be able to address this completely. Although these and other complementary data
may not provide definitive evidence on tailoring therapy, they do provide initial evidence to support a
clinical judgement and increase the chance of treatment success on which subsequent studies can build.
This approach to stratification of treatment would represent an advance to the current status of generally
prescribing rituximab to all patients, thereby dismissing the potential benefits of switching to alternative
therapies in patients who fail TNFi.
A further limitation of the design was the open-label nature of the study. Although blinding patients and
treating clinicians to the allocated intervention would have reduced the risk and impact of any assessment
bias, it would have been impractical to implement: each of the seven distinct bDMARDs in the SWITCH
study involved a different route of delivery and dosing regimen, thus requiring multiple dummy infusions
(necessitating additional inpatient attendance) and injections to maintain the blind. Such a treatment
schedule was given careful consideration by our PPI advisor, and it was concluded that it would have
imposed considerable burden on patients and was unethical, potentially either reducing recruitment
further or increasing the rate of attrition throughout the study. However, the fact that all patients received
an active therapy may have attenuated any bias introduced by the lack of blinding.
When the SWITCH study was designed, it included all three classes of bDMARD available for evaluation as
second-line therapies when taken in combination with MTX, thereby reflecting the full range of therapies
available. After the trial design and initiation, tocilizumab was approved as a first-line bDMARD and,
hence, represented an additional option for the TNFi-inadequate response RA patient cohort. In addition,
NICE has also approved the use of tocilizumab as a monotherapy, broadening the available therapies when
given as monotherapy (without concomitant MTX).
The trial design allowed a pragmatic approach with clinician choice of the monoclonal antibody if the
patient previously received etanercept. Moreover, a fourth monoclonal antibody, golimumab, was
introduced into the alternative TNFi arm during the recruitment phase, thereby allowing further clinician
choice across all available TNFis and ensuring further generalisability of the trial results to clinical practice.
Although this pragmatic design may have introduced some heterogeneity into the results, it reflected
current practice in the NHS and ensured that the EULAR guidance, recommending discussion between
patient and treating clinician in the choice of bDMARD, was adhered to; this was considered important in
order to maximise recruitment.
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Recruitment
It is important to provide information on recruitment strategies in the SWITCH study in order to inform
future trials. We would refer the reader to the more exhaustive case study (Maya H Buch, Leeds Institute of
Rheumatic and Musculoskeletal Medicine, University of Leeds and National Institute for Health Research
(NIHR) Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds, UK,
2015) that systematically dissected each stage of the SWITCH study, from time of grant submission to
active recruitment period. Some of the points and strategies to overcome the challenges faced in the
SWITCH study are summarised below.
Despite attempts by the investigators to elicit reliable pre-trial recruitment estimates from centres, the
numbers of eligible patients proposed were optimistic. In addition, the prolonged grant application and
contracting processes resulted in a loss of momentum and the presence of competing studies that usurped
the SWITCH study in some centres. Furthermore, centres reported research staff shortages and had to rely
on clinical nurse specialist services to identify patients. Despite this, we recruited significantly more study
sites than originally planned to address recruitment challenges. A clinical research fellow was appointed to
support centres and to advise on co-ordination of research and clinical teams, but the heterogeneity in
service provision meant that this had limited success. They were, however, effective in navigating the
clinical challenges of patient recruitment and provided specific clinical guidance that aided recruitment.
Other strategies for recruitment included clinic posters, leaflets, patient websites, e-bulletins and social
media via the National Rheumatoid Arthritis Society. Fortnightly news flashes, monthly teleconferences and
training days were also initiated to support centres.
As rituximab was the only NICE-approved treatment option in this context, a number of CCGs would not
fund the experimental arms, so that centres were expected to underwrite the cost of these drugs (which
was not a realistic option), although NICE provided clarification that its guidance applied to routine
practice only and these treatments should be funded if part of a well-designed RCT. Such guidance was
not mandated, meaning that CCGs could deviate from this and restrict participation by some centres, and
many attempts to establish a dialogue with CCGs proved lengthy and unsuccessful. Discussions with
pharmaceutical companies resulted in supplies of abatacept but not before additional delays attributable to
negotiations and contract preparation.
The NHS routinely uses home health-care companies to deliver medication to patients’ homes. These
companies raised concerns regarding their regulatory authority to deliver trial IMPs only following activation
of the initial three centres, which resulted in extended discussions, risk assessments and revisions to the
protocol, during which recruitment was halted for 9 months at the beginning of the recruitment period.
Ultimately, as a result of discussions initiated with the NIHR Clinical Research Network (CRN) Coordinating
Centre to overcome these obstacles, the CRN used the SWITCH trial as a case study to highlight the
challenges in trial set-up, including areas for improvement in the CRN, feasibility and centre-specific
approvals process and the insufficient resources (Maya H Buch, Leeds Institute of Rheumatic and
Musculoskeletal Medicine, University of Leeds and NIHR Leeds Musculoskeletal Biomedical Research Unit,
Leeds Teaching Hospitals NHS Trust, Leeds, UK, 2015).
The recruitment estimates may have been moderated had we repeated the recruitment survey once the
study had been set up, and this is something that we would recommend as routine prior to study
activation. Earlier engagement with the Medicines and Healthcare products Regulatory Agency, NIHR CRN
and NICE may also have improved the trial status, although their influence on the NHS landscape and
commissioning groups remains debatable. Clinician experience suggests that CCG approach to NICE
guidance and TAs can be variable. To be able to deliver a fully ‘independent’ study to the diverse portfolio
of studies, involvement of pharmaceutical partners was deliberately not considered at the start. Following
the experience with the SWITCH study, however, this remains a naive aspiration, and, certainly,
approaching industry to support IMP provision from the outset in future clinical trials of an IMP is vital to
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militate against CCG lack of support and to prevent delays. Finally, given the complexity of the governance
and practical requirements of a clinical trial of an IMP and lengthy approvals process, it is important that
the set-up period for such trials is not underestimated and that any estimates of patient recruitment are
based on robust local audits rather than clinician judgement.
Health economic evaluation
Principal findings
The trial-based cost-effectiveness analysis indicated that the current NICE guidance to switch to rituximab
after initial TNFi failure was not the most cost-effective use of NHS resources. Instead, switching to
alternative TNFi drug following an initial failure was the most cost-effective treatment option. Switching
to alternative TNFi was more costly, but provided more QALYs than rituximab over a 48-month period.
Moreover, switching to abatacept was not cost-effective compared with switching to alternative TNFi, as
the associated costs were much higher and the QALY gain was small.
All three trial arms showed an increase in mean EQ-5D score over the 12-month trial period, with an initial
increase from baseline to 12 weeks that was more or less maintained to 48 weeks. The small (non-significant)
differences in QALYs resulting from these treatments could relate to the benefits being measured only over
the trial period of 48 weeks, meaning that longer-term benefits could not be considered. In the primary
analysis costs from a health and social services perspective and a wider social perspective were highest for the
abatacept group and lowest for the rituximab group, but only slightly lower than the costs for the alternative
TNFi group. These costs-effectiveness results were driven by the (statistically significant) difference in costs
between abatacept and the other treatment groups. These results may change in longer follow-up if the
side-effect profiles of the treatments are different when the drugs are used for prolonged periods, or
effectiveness persists for different durations.
Base-case cost-effectiveness results were not sensitive to assumptions in a small number of deterministic
sensitivity analyses. In line with the NICE reference case that indicates that costs to patients may be
included in cost-effectiveness evaluations, results from a secondary analysis including the costs incurred by
patients remained consistent, indicating that switching to alternative TNFi is cost-effective but switching to
abatacept is not. However, these results should be treated with caution because of the small sample size,
for which estimation of asymmetrical cost distributions is particularly difficult.
An estimate of the value of perfect information suggested that further research, in order that robust
economic decisions are made, is worth in the order of £129M. This suggests that the early termination of
the study by the funders may have imposed extremely large costs (either financial or in terms of health
forgone) on the NHS, through allowing a high degree of decision uncertainty to persist. It is acknowledged,
however, that, even had the trial achieved its expected sample size, it is unlikely to have addressed
all uncertainty.
Strengths and weaknesses of the economic analysis
The main strength of this analysis lies in the randomised controlled design of the study, which enabled the
collection of high-quality data over the 48-week time horizon of the trial that were subsequently used in
this analysis.
The small sample size achieved led to greater uncertainty in the conclusions drawn from the analyses and
limited the scope of the analyses that could be performed. Only complete cases were used for the primary
analysis. This meant that an even smaller sample was used for the primary analysis and the results must be
treated with caution because of the potential for bias and the high likelihood of overestimation of the level
of precision in the estimates of cost-effectiveness. The value of perfect information estimate indicates that
further research is likely to be of value. Given the relatively short duration of follow-up, consideration of
longer-term outcomes would be beneficial as part of any future research.
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Meaning of the study
The costs associated with TNFi drugs and abatacept are relatively high because of the larger number of
treatments that are given weekly or fortnightly (see Table 1), compared with the costs of rituximab, which is
given in weeks 1 and 2 with a potential repeat at 6 months. However, when all health economic data were
taken into account, to give the full costs incurred of the treatments over 48 weeks from a health and social
services perspective, the difference in overall costs between the TNFis used in this trial and rituximab is
quite small. The overall costs associated with abatacept are much higher. With only a small, non-significant,
difference in the change in EQ-5D scores between trial arms, it is these differences in costs that drive the
results and show that the use of alternative TNFi following an initial TNFi failure could be viable as a
cost-effective treatment option alongside the currently approved treatment, rituximab.
Unanswered questions and further research
Although the analysis conducted here provides useful insights into the costs and effects of the treatment
options in the trial period of 48 weeks, further research is required to provide evidence on the cost-effectiveness
for alternative TNFi over a longer time horizon beyond 48 weeks. This could involve the development of an
economic model that would also allow an extension to the value of information analysis conducted here to
include the expected value of partial perfect information. This would provide a clearer idea of the areas around
which further research should be conducted. Additional research would also be beneficial using a larger sample
size to reduce the uncertainty in the conclusions drawn from the analysis and to ensure that a representative
sample of the patient group is captured.
The existing evidence base has been limited to numerous small trials, whereas the ambition of the SWITCH
randomised trial was to deliver a large-scale definitive trial that would have represented a paradigm shift in
the RA community, delivering the largest RA pragmatic trial undertaken in the UK. Early termination of the
SWITCH trial limits the conclusions that may be drawn and is therefore considered a lost opportunity to
obtain definitive evidence on cost-effectiveness of either treatment option. However, the data presented
may be used in meta-analysis in future research.
Comparison with other studies
The only studies comparable with the SWITCH trial are the preliminary reports of the French study [Rotation
of anti-TNF Or Change of class of biologic (ROC)] by Gottenberg et al.145 and the Dutch study by Manders
et al.87 Although the ROC study is an instructive randomised trial that reached its primary outcome (non-TNFi
bDMARD significantly superior to alternative TNFi), the multiple treatment options included within the
non-TNFi randomised group limit the extent to which these data can inform the optimal targeted agent.
The study by Manders et al.87 found no significant difference between alternative TNFi, abatacept and
rituximab, but further details on whether or not these treatments are equivalent are needed. Moreover,
the study reported that, of the three treatments, rituximab was the most cost-effective and that treating
patients with alternative TNFi was more cost-effective than treating patients with abatacept. However,
similar to the SWITCH trial, this study is limited in what conclusions can be made because of the low
number of patients recruited.
A requirement for non-inferiority trials is the assumption of assay sensitivity (constancy assumption), that is,
establishing that the active control arm, rituximab, would be superior to placebo in the setting of the
SWITCH trial.146 One previous study, the REFLEX trial,49 established the efficacy of rituximab compared with
placebo in patients receiving MTX who had failed more than one treatment with a TNFi. The SWITCH trial
was similar in a number of respects. The intervention was substantially the same over the 24-week period
during which the primary end point was to be assessed; the primary and key secondary end points of the
DAS28 reduction and ACR20 response were assessed at week 24, which was the key assessment time point
in the REFLEX study. Moreover, the enrolled population had a similar age range and disease duration.
Notable differences include the REFLEX study requiring a minimum level of disease activity in order for a
patient to be enrolled, the difference in blinding (which had a much simpler requirement in the REFLEX
DISCUSSION
NIHR Journals Library www.journalslibrary.nihr.ac.uk
70
study’s two-arm placebo-controlled study) and that patients were eligible if they had failed treatment with
more than one TNFi and had demonstrated intolerance to prior TNFi therapy. The reduction in disease activity
for rituximab in the SWITCH trial was sufficiently similar to that reported in the REFLEX study, supporting the
conclusion that the SWITCH trial fulfilled the assay sensitivity requirement for a non-inferiority trial.
Implications for health care and future research
The clinical question of whether or not alternative bDMARDs to rituximab are comparable in efficacy and
safety outcomes in patients with RA who had not responded adequately to an initial TNFi bDMARD and
MTX treatment remains unresolved. The lack of evidence, which is based on a single treatment (rituximab)
being appropriate for all patients, limits guidance options.
In addition, NICE acknowledges this and has explicitly stated the need for comparative studies to inform future
guidance.25 In response to this unmet need, the scale and ambition of the SWITCH study was impressive,
planned as one of the largest RA trials. It was, thus, particularly unfortunate that the trial was prematurely
stopped. This has again made contribution to a meta-analysis the best outcome of this trial, although this also
means the loss of a more definitive UK NHS-relevant answer; this is particularly disheartening when substantial
investment into the study had already been made. Had the SWITCH trial been permitted to recruit to target,
definitive evidence on whether or not either of the interventions were non-inferior to rituximab may have
been provided, which may have opened up further treatment options for patients.
The ‘SWITCH’ study design also aimed to serve as a driver to the RA community to develop novel trial
designs into our clinical trial repertoire, such that we can begin to address some of the challenges that
currently impede delivery of the promise of personalised medicine in RA.147 Incorporating stratification
based on RF/ACPA seropositivity status and primary/secondary non-response to an initial TNFi would have
allowed an exploratory analysis to determine if there was any evidence of a differential treatment response
in these subgroups of patients, an aspect which no other RCT to date has attempted to do.
Finally, more seamless and integrated data capture is vital to support successful delivery of, in particular,
large-scale definitive studies. Health informatics and electronic health records linking the needs of NHS
with the NIHR and clinical research environment represents a core area for development to effectively
embed research in the NHS.
The ‘SWITCH’ study provided several learning points for the academic community that will inform future
initiatives. Many of the challenges illustrated deficiencies in the NHS organisational approach and
infrastructure that are needed if it is to successfully deliver NIHR research, detailed by way of a case study
initiated by the NIHR CRN (Maya H Buch, Leeds Institute of Rheumatic and Musculoskeletal Medicine,
University of Leeds and NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals
NHS Trust, Leeds, UK, 2015).
Trial activity in the clinical area of RA is in its relative infancy compared with other high-prevalence clinical
areas, such as cancer and cardiovascular disease. The SWITCH trial began to harness the academic and
clinical community’s commitment to trial activity and established a RCT research network, setting up a
total of 35 centres: a massive achievement in itself that was truly representative of the wider rheumatology
community. Continuing and ultimately delivering on the SWITCH trial, therefore, would have not just
answered the trial question but also would have represented a substantial achievement for the RA
community. The SWITCH study was therefore considered as an early investment for future (independent)
RA trials that would allow the rheumatology community to build up its experience incrementally and, with
this progression of trial design and better integration of research in the NHS, trial efficiency and landscape
would have evolved. We hope future considerations take account of the SWITCH trial experience using the
case study to support the rheumatology community in delivering on its ambition to improve the lives of
people with RA (and other musculoskeletal conditions).
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Appendix 1 Participant information sheet and
consent forms
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Appendix 2 Participant health social care
expenditure
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Appendix 3 Study closure patient information
sheet
Delete this, then print first 
page  
of Information Sheet and 
Consent Form 
 on Trust/Hospital headed 
paper 
 
SWITCH: Clinical Trial for Patients with Rheumatoid Arthritis who haven’t 
benefited from an initial TNF-blocking drug. 
 
Dear SWITCH Study Participant, 
Many thanks for your participation to date in the SWITCH study, a clinical trial 
comparing three types of drugs in the treatment of rheumatoid arthritis.  We are 
writing to you today to update you on some recent developments in the study, 
explain why they have happened and explain how you will be affected. 
At the end of 2014 the SWITCH study’s funders (the National Institute for Health 
Research (NIHR) Health Technology Assessment (HTA) programme) came to a 
decision to withdraw their future funding for the study. The reason they made this 
difficult decision was simply because they could not justify the additional timeframe, 
and therefore resource, that would be needed to recruit all the participants to 
complete the study. It is important to highlight, that the decision was in no way made 
due to any concerns about the safety of the study; the study is still safe for all current 
participants to continue with. The decision was purely due to the difficulties in 
justifying additional finances needed to support finding enough participants including 
within an acceptable timeframe. 
 
Unfortunately this means there will be some changes for those people taking part in 
the study.  
 
The way you will be affected depends on whether you are still receiving treatment as 
part of the study: 
 
Participants who are still receiving their study treatment 
o Treatment:  
If you are still in the first 48 weeks of your treatment (the interventional 
phase), and you are still receiving the drug you were allocated at the time you 
joined the study then you will continue with your  treatment as normal until 
week 48. As mentioned above, there are no safety concerns about the 
treatments and it is completely safe to carry on taking part in the study.  
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After week 48, you will continue to be treated according to your hospital’s 
local policy. This is the same as was described in the original Participant 
Information Sheet you were given when you joined the study. 
 
 
 
o Visits:  
You will still be asked to come to visits at your hospital every 12 weeks until 
you reach week 48 of your study treatment so we can continue to collect 
information about the study from you. It is still important that we collect as 
much information as possible about the people taking part and therefore it is 
important that you carry on taking your treatment and coming to the visits. 
 
However, previously we would have asked you to carry on coming to clinical 
study visits after your study treatment had finished to continue collecting 
information about you for the SWITCH study. Instead, your doctor will decide 
how often you need to come to hospital visits. There will be no more 
information collected about you at these visits specifically for the SWITCH 
study.  
 
Also, if for any reason you stop taking your study treatment before week 48, 
then you will no longer be required to provide information for the SWITCH 
study after 24 weeks (this is the time to undertake the primary study analysis); 
once again, your doctor will decide how often you need to come to hospital 
visits and what information needs collecting.  
 
Participants who have finished their study treatment 
o If you have already finished 48 weeks of study treatment then your next visit 
will be your last visit and we will not be asking you to come back for any more 
visits to collect information about you for the study. Instead, your doctor will 
decide how often you need to come to hospital visits and there will be no 
study information collected about you at these visits.  
 
Please note: Regardless of whether or not you are still receiving your study 
treatment, you will still receive NHS care for the treatment of your Rheumatoid 
Arthritis; there will be no reduction in the standard of NHS care you will receive.  
 
X-rays and bone densitometry scans 
In addition, study participants at some hospitals were having x-rays of their hands 
and feet and bone densitometry scans of their back and legs (your research team will 
be able to discuss with you whether this applies to you as these parts of the study 
were optional and hospital sites had the choice to undertake them or not).  Although 
the study will still use the information from the scans performed so far, no further 
scans will be performed for the study from this date forward. 
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• What will happen to the results of the research study? 
Unfortunately, as there have been fewer participants recruited onto the study than we 
had planned we will not be able to draw significant conclusions as we intended. 
However the data is still important and useful: we will be able to look for potential 
patterns of how well the treatments work which will inform further research in this 
area. The Health Technologies Assessment programme will publish any outcomes 
from the study on their website.  If you would like to obtain a copy of the published 
results, please ask your doctor.  We may also be able to combine the results with 
those from other studies, in order to strengthen our findings.  If your information is 
used in combination with other studies, your personal details will not be used to 
identify you. 
 
We are very keen that you continue your participation in the study and allow us to 
collect information about you at your next visit and until the end of your study 
treatment (where relevant). However, if for any reason you should wish to withdraw 
from the study then please contact your doctor to discuss this. 
If you have any questions about anything in this letter, please talk to your doctor at: 
 
<<Enter PI, nurse name>> 
<<contact details for site>> 
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SWITCH: Clinical Trial for Patients with Rheumatoid Arthritis who haven’t 
benefited from an initial TNF-blocking drug. 
 
 
Participant ID:  Initials:  
Date of Birth:  NHS/Hospital Number:  
EudraCT Number: 2010-023880-17 Principal Investigator: 
 
 
IMPORTANT INFORMATION ABOUT THE FUTURE OF THE SWITCH CLINICAL 
TRIAL 
 
We would like to thank you for your participation in the SWITCH trial and taking the 
time to read this letter.  
 
We would be grateful if you could acknowledge receipt of the letter below. 
 
 
I confirm that I have read and understand the information sheet 
above and have had the opportunity to ask questions. 
  
I agree to a copy of this acknowledgement form being sent to the 
CTRU. 
  
Participant: 
Signature  
 
Name (block capitals) .  
 
Date .  
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Appendix 4 SWITCH study closure patient
information Article for National Rheumatoid Arthritis
Society web page and other relevant electronic
forums
You may remember that last year we published details of a new clinical trial, called SWITCH, on ourwebsite and Facebook page, amongst other areas. This trial was designed to compare three types of
drugs in the treatment of RA (abatacept, rituximab and TNF inhibitors).
We are sorry to say this trial will not be able to accept any new participants after all. The study recruited
122 of the 477 participants it was looking to recruit, but unfortunately the study’s funders (the NIHR HTA
programme) have had to withdraw their future funding for the study. The reason they made this difficult
decision was simply because they could not justify the additional time frame and, therefore, the resource,
that would be needed to recruit all the participants to complete the study.
The study organisers are very keen to stress to all the trial participants and anyone else taking the drugs
being used in the study that the decision was in no way due to any concerns about the safety of the study;
the study is still safe for all current participants to continue with. The decision was purely due to the
difficulties in justifying additional finances needed to support finding enough participants including within
an acceptable time frame. Unfortunately, without the full numbers of participants entered into the trial,
the study team will be unable to reach the significant conclusions they have intended. However, they still
hope to be able to look for potential patterns of how well the treatments work which will inform further
research in this area, and possibly combine the results with those from other studies, in order to
strengthen any findings.
All participants who were still being seen by the research teams will have been contacted to discuss their
future treatment. However, if you were previously involved in the trial and have any further questions
please contact the research team who were looking after you whilst you were on the study and they will
be happy to answer any queries you might have.
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Appendix 5 Schedule of events for each
treatment
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TABLE 33 Schedule of events for rituximab
Event
Study phase
Screening Baseline Interventional Observational
Study week 0
(≤ – 4 weeks)
Study
week 0
Study
week 2a
(+5 days)
Study
week 12a
Study
week 24a
Study
week 26a
(+5 days)
Study
week 36a
Study
week 48a
Study
week 60a
Study
week 72a
Study
week 84a
Study
week 96a
Assessment/procedure
Study treatment: rituximab ✗ ✗ ✗ ✗
Informed consent and
registration
✗
Inclusion/exclusion ✗
Randomisation ✗
Demographic data ✗
Medical and recent surgical
history
✗
Pregnancy test (urine) ✗
Chest radiographyb and
12-lead ECG
✗
Hepatitis B and C screening ✗
TB screeningb ✗
Urinalysis ✗
Immunoglobulins ✗
Serological test (RF, ACPA,
ANA test and anti-dsDNA
antibodies)
✗ ✗
Haematology test (FBC);
blood chemistry (U&E, LFT);
and CRP and ESR
✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗
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Event
Study phase
Screening Baseline Interventional Observational
Study week 0
(≤ – 4 weeks)
Study
week 0
Study
week 2a
(+5 days)
Study
week 12a
Study
week 24a
Study
week 26a
(+5 days)
Study
week 36a
Study
week 48a
Study
week 60a
Study
week 72a
Study
week 84a
Study
week 96a
Glucose and lipid profile ✗ ✗ ✗
Unplanned surgery details ✗ ✗ ✗ ✗
Concomitant medication ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗
Physical examination and
vital signs
✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗
28-joint count (TJC and SJC) ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗
Patient Assessment of
General Health VAS
✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗
Patient Global Assessment of
Arthritis VAS
✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗
Patient Global Assessment of
Pain VAS
✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗
Physician Global Assessment
of Disease Activity VAS
✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗
Morning stiffness (minutes) ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗
HAQ-DI ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗
RAQoL ✗ ✗ ✗ ✗ ✗
HADS ✗ ✗ ✗ ✗ ✗
EQ-5D ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗
Health Utilities Index ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗
Health, social care use and
expenditure
✗ ✗ ✗ ✗
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TABLE 33 Schedule of events for rituximab (continued )
Event
Study phase
Screening Baseline Interventional Observational
Study week 0
(≤ – 4 weeks)
Study
week 0
Study
week 2a
(+5 days)
Study
week 12a
Study
week 24a
Study
week 26a
(+5 days)
Study
week 36a
Study
week 48a
Study
week 60a
Study
week 72a
Study
week 84a
Study
week 96a
Inpatient/outpatient hospital
form
✗ ✗ ✗ ✗
Dorsal–posterior radiography
of hands and feetc
✗ ✗
Bone densitometry scanc ✗ ✗
Optional biobank samples ✗ ✗d ✗ ✗ ✗ ✗
AEs Monitor during trial treatment
ANA, anti-nuclear antibody; dsDNA, double-stranded deoxyribonucleic acid; FBC, full blood count; LFT, liver function test; U&E, urea and electrolytes.
a When a time delay between randomisation and the first dose of protocol treatment occurs, this was accounted for when arranging the clinical assessment visits during the interventional
(weeks 12, 24, 36 and 48) and the observational (weeks 60, 72, 84 and 96) phases of the study, that is, the week 12 visit should be scheduled 12 weeks after the participant’s first
dose of protocol treatment. So, for example, if a participant’s first treatment was delayed by 4 weeks, then all subsequent clinical assessment visits were scheduled from the date of
randomisation +4 weeks to ensure that all participants received equal drug exposure despite treatment delays.
b Assessments need be repeated only if they have not been performed in the 24 weeks prior to screening.
c These procedures are to be performed at sites with specialist facilities only. Assessments undertaken up to 6 months prior to baseline or 6 weeks after the baseline visit are permissible.
d Only 5 ml of serum to be collected at week 2.
A
PPEN
D
IX
5
N
IH
R
Journals
Library
w
w
w
.journalslibrary.nihr.ac.uk
116
TABLE 34 Schedule of events for infliximab
Event
Study phase
Screening Baseline Interventional Observational
Study week 0
(≤ –4 weeks)
Study
week 0
Study
week 2a
(±2 days)
Study
week 6a
(±2 days)
Study
week 12a
Study
week 14a
(±1 week)
Study
week 22a
(±1 week)
Study
week 24a
Study
week 30a
(±1 week)
Study
week 36a
Study
week 38a
(±1 week)
Study
week 46a
(±1 week)
Study
week 48a
Study
week 60a
Study
week 72a
Study
week 84a
Study
week 96a
Assessment/
procedure
Study treatment:
infliximab
✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗
Informed
consent and
registration
✗
Inclusion/
exclusion
✗
Randomisation ✗
Demographic
data
✗
Medical and
recent surgical
history
✗
Pregnancy test
(urine)
✗
Chest
radiographyb and
12-lead ECG
✗
Hepatitis B and C
screening
✗
TB screeningb ✗
Urinalysis ✗
Immunoglobulins ✗
Serological test
(RF, ACPA,
ANA test and
anti-dsDNA
antibodies)
✗ ✗
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TABLE 34 Schedule of events for infliximab (continued )
Event
Study phase
Screening Baseline Interventional Observational
Study week 0
(≤ –4 weeks)
Study
week 0
Study
week 2a
(±2 days)
Study
week 6a
(±2 days)
Study
week 12a
Study
week 14a
(±1 week)
Study
week 22a
(±1 week)
Study
week 24a
Study
week 30a
(±1 week)
Study
week 36a
Study
week 38a
(±1 week)
Study
week 46a
(±1 week)
Study
week 48a
Study
week 60a
Study
week 72a
Study
week 84a
Study
week 96a
Haematology
test (FBC); blood
chemistry (U&E,
LFT); and CRP
and ESR
✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗
Glucose and lipid
profile
✗ ✗ ✗
Unplanned
surgery details
✗ ✗ ✗ ✗
Concomitant
medication
✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗
Physical
examination and
vital signs
✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗
28-joint count
(TJC and SJC)
✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗
Patient
Assessment of
General Health
VAS
✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗
Patient Global
Assessment of
Arthritis VAS
✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗
Patient Global
Assessment of
Pain VAS
✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗
Physician Global
Assessment of
Disease Activity
VAS
✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗
Morning stiffness
(minutes)
✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗
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Event
Study phase
Screening Baseline Interventional Observational
Study week 0
(≤ –4 weeks)
Study
week 0
Study
week 2a
(±2 days)
Study
week 6a
(±2 days)
Study
week 12a
Study
week 14a
(±1 week)
Study
week 22a
(±1 week)
Study
week 24a
Study
week 30a
(±1 week)
Study
week 36a
Study
week 38a
(±1 week)
Study
week 46a
(±1 week)
Study
week 48a
Study
week 60a
Study
week 72a
Study
week 84a
Study
week 96a
HAQ-DI ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗
RAQoL ✗ ✗ ✗ ✗ ✗
HADS ✗ ✗ ✗ ✗ ✗
EQ-5D ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗
Health Utilities
Index
✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗
Health, social
care use and
expenditure
✗ ✗ ✗ ✗
Inpatient/
outpatient
hospital form
✗ ✗ ✗ ✗
Dorsal–posterior
radiography of
hands and feetc
✗ ✗
Bone
densitometry
scanc
✗ ✗
Optional biobank
samples
✗ ✗
d
✗ ✗ ✗ ✗
AEs Monitor during trial treatment
ANA, anti-nuclear antibody; dsDNA, double-stranded deoxyribonucleic acid; FBC, full blood count; LFT, liver function test; U&E, urea and electrolytes.
a When a time delay between randomisation and the first dose of protocol treatment occurs, this was accounted for when arranging the clinical assessment visits during the interventional
(weeks 12, 24, 36 and 48) and the observational (weeks 60, 72, 84 and 96) phases of the study, that is, the week 12 visit should be scheduled 12 weeks after the participant’s first
dose of protocol treatment. So, for example, if a participant’s first treatment was delayed by 4 weeks, then all subsequent clinical assessment visits were scheduled from the date of
randomisation +4 weeks to ensure that all participants receive equal drug exposure despite treatment delays.
b These procedures are to be performed at sites with specialist facilities only. Assessments undertaken up to 6 months prior to baseline or 6 weeks after the baseline visit are permissible.
c Only 5 ml of serum to be collected at week 2.
d Assessments need be repeated only if they have not been performed in the 24 weeks prior to screening.
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TABLE 35 Schedule of events for subcutaneous treatments
Event
Study phase
Screening Baseline Interventional Observational
Study week 0
(≤ – 4 weeks)
Study
week 0
Study
week 2a
Study
week 4
safety
visita
Study
week 12a
Study
week 24a
Study
week 36a
Study
week 48a
Study
week 60a
Study
week 72a
Study
week 84a
Study
week 96a
Assessment/procedure
Study treatment: subcutaneous
IMP
✗4
Informed consent and
registration
✗
Inclusion/exclusion ✗
Randomisation ✗
Demographic data ✗
Medical and recent surgical
history
✗
Pregnancy test (urine) ✗
Chest radiographyb and 12-lead
ECG
✗
Hepatitis B and C screening ✗
TB screeningb ✗
Urinalysis ✗
Immunoglobulins ✗
Serological test (RF, ACPA, ANA
test and anti-dsDNA antibodies)
✗ ✗
Haematology test (FBC); blood
chemistry (U&E, LFT); and CRP
and ESR
✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗
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Event
Study phase
Screening Baseline Interventional Observational
Study week 0
(≤ – 4 weeks)
Study
week 0
Study
week 2a
Study
week 4
safety
visita
Study
week 12a
Study
week 24a
Study
week 36a
Study
week 48a
Study
week 60a
Study
week 72a
Study
week 84a
Study
week 96a
Glucose and lipid profile ✗ ✗ ✗
Unplanned surgery details ✗ ✗ ✗ ✗
Concomitant medication ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗
Physical examination and vital
signs
✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗
28-joint count (TJC and SJC) ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗
Patient Assessment of General
Health VAS
✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗
Patient Global Assessment of
Arthritis VAS
✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗
Patient Global Assessment of
Pain VAS
✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗
Physician Global Assessment of
Disease Activity VAS
✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗
Morning stiffness (minutes) ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗
HAQ-DI ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗
RAQoL ✗ ✗ ✗ ✗ ✗
HADS ✗ ✗ ✗ ✗ ✗
EQ-5D ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗
Health Utilities Index ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗
Health, social care use and
expenditure
✗ ✗ ✗ ✗
continued
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TABLE 35 Schedule of events for subcutaneous treatments (continued )
Event
Study phase
Screening Baseline Interventional Observational
Study week 0
(≤ – 4 weeks)
Study
week 0
Study
week 2a
Study
week 4
safety
visita
Study
week 12a
Study
week 24a
Study
week 36a
Study
week 48a
Study
week 60a
Study
week 72a
Study
week 84a
Study
week 96a
Inpatient/outpatient hospital
form
✗ ✗ ✗ ✗
Dorsal–posterior radiography of
hands and feetc
✗ ✗
Bone densitometry scanc ✗ ✗
Optional biobank samples ✗ ✗d ✗ ✗ ✗ ✗
AEs Monitor during trial treatment
ANA, anti-nuclear antibody; dsDNA, double-stranded deoxyribonucleic acid; FBC, full blood count; LFT, liver function test; U&E, urea and electrolytes.
a When a time delay between randomisation and the first dose of protocol treatment occurs, this was accounted for when arranging the clinical assessment visits during the interventional
(weeks 12, 24, 36 and 48) and the observational (weeks 60, 72, 84 and 96) phases of the study, that is, the week 12 visit should be scheduled 12 weeks after the participant’s first
dose of protocol treatment. So, for example, if a participant’s first treatment was delayed by 4 weeks, then all subsequent clinical assessment visits were scheduled from the date of
randomisation +4 weeks to ensure that all participants receive equal drug exposure despite treatment delays.
b These procedures are to be performed at sites with specialist facilities only. Assessments undertaken up to 6 months prior to baseline or 6 weeks after the baseline visit are permissible.
c Only 5 ml of serum to be collected at week 2.
d Assessments need be repeated only if they have not been performed in the 24 weeks prior to screening.
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Appendix 6 Disease activity response categories
BOX 1 Derivation of the DAS28
The DAS28 used for the primary end-point analysis is a composite measure of four items:
1. TJC: (range 0–28)
2. SJC: (range 0–28)
3. ESR: (range 0–99)
4. Patient-completed VAS of Global Assessment of Arthritis, to answer the question ‘Considering all of
the ways your arthritis has affected you, mark on the line below how you feel your arthritis is today’
(VAS: range ‘very well’ = 0mm – ‘very poor’ = 100 mm)
With these four items, the DAS28 is calculated in the following manner:
DAS28 = (0:56 ×
ﬃﬃﬃﬃﬃﬃﬃ
TJC
p
) + (0:28 ×
ﬃﬃﬃﬃﬃﬃﬃ
SJC
p
) + (0:7 × logeESR) + (0:014 × VAS(mm)), (11)
where loge is the natural logarithm function, and
ﬃﬃ
x
p
is the square root function.
TABLE 36 DAS28 response categories
Response category DAS28 values
High > 5.1
Moderate > 3.2 but ≤ 5.1
Low > 2.6 but ≤ 3.2
Remission ≤ 2.6
TABLE 37 EULAR28 response criteria based on the Disease Activity Score
DAS28 values
DAS28 improvement since baseline
> 1.2 ≤ 1.2 and ≥ 0.6 < 0.6
≤ 3.2 Good response
> 3.2 but ≤ 5.1 Moderate response Moderate response
> 5.1 No response
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TABLE 39 Simplified Disease Activity Index disease activity states
Disease activity SDAI values
High disease activity < 26
Moderate disease activity > 11 but ≤ 26
Low disease activity > 3.3 but ≤ 11
Remission ≥ 0 but ≤ 3.3
TABLE 38 Clinical Disease Activity Index disease activity states
Disease activity CDAI values
High disease activity < 22
Moderate disease activity > 10 but ≤ 22
Low disease activity > 2.8 but ≤ 10
Remission ≥ 0 but ≤ 2.8
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Appendix 7 Statistical analysis plan
 
 
Clinical Trials Research Unit 
(CTRU) 
University of Leeds 
 
Statistical Analysis Plan 
 
SWITCH 
 
 
Version 1.0 
4th November 2015 
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Glossary 
ABT Abatacept. One of the study drugs in the SWITCH study. 
ACPA Anti-Citrullinated Peptide Antibody – the assay that detects 
presence of anti-CCP 
ACR American College of Rheumatology 
ADA Adalimumab. One of the allowable monoclonal antibody treatments 
under the SWITCH study 
Anti-CCP Anti-Cyclic Citrullinated Peptide. 
Anti-TNF See TNFi 
Arthritis Research 
UK AIA CSG 
Arthritis Research United Kingdom AIA Clinical Studies Group. 
An arthritis-related special interest group. 
BSR British Society for Rheumatology 
CC Complete Case (analysis). A patient with complete data for all 
ﬁelds required in the analysis. 
CDAI Clinical Disease Activity Index 
CONSORT Consolidated Standards of Reporting Trials. Refers to either the 
patient ﬂow diagram, recommended by such guidance, or the 
guidance itself. See references (1,2) and Appendix A 
CRF Case Report Form 
CRP C-Reactive Protein. A measure of inﬂammation. 
CTRU Clinical Trials Research Unit, Leeds Institute of Clinical Trials 
Research, University of Leeds 
CTZ Certoliuzumab pegol. One of the allowable monoclonal antibody 
treatments under the SWITCH study 
DAS28 Disease Activity Score with 28 joint counts. A composite outcome 
measure for patients with Rheumatoid Arthritis. (See Section 2.3 
for deﬁnition) 
DCF Data Clariﬁcation Form 
DMA Data Management Assistant 
DMARD Disease-modifying Anti-Rheumatic Drug 
DMEC Data Monitoring and Ethics Committee 
EQ5D EuroQol 5-dimensions questionnaire. 
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ESR Erythrocyte Sedimentation Rate. A measure of inﬂammation. 
ETN Etanercept. One of the possible alternative TNFi options in the 
SWITCH study. 
EULAR European League Against Rheumatism 
GCP Good Clinical Practice 
GOL Golimumab. One of the allowable monoclonal antibody treatments 
under the SWITCH study 
HADS Hospital Anxiety and Depression Scale. A Quality of Life 
questionnaire. 
HAQ-DI Health Assessment Questionnaire – Disability Index. A Quality of 
Life questionnaire. 
HTA Health Technology Assessment. The funding stream for the 
SWITCH study. 
IB Investigator Brochure 
ICC Intra-class correlation coefﬁcient 
IFX Inﬂiximab. One of the allowable monoclonal antibody treatments 
under the SWITCH study 
ITT Intention to Treat 
IV Intravenous 
LDA Low Disease Activity 
MAB Monoclonal Antibody. One of the possible alternative TNFi options 
in the SWITCH study 
MAR Missing At Random. The assumption that if a data item is missing, 
the “missingness” is not related to its underlying unobserved value 
once we account for the observed values of other variables in the 
imputation model. 
MTX Methotrexate. A required concomitant medication for patients in 
SWITCH. 
NHS National Health Service 
NICE National Institute for Health and Clinical Excellence 
NSAID Non-steroidal anti-inﬂammatory drug 
NYHA New York Heart Association 
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QoL Quality of Life 
RA Rheumatoid Arthritis 
RAQoL Rheumatoid Arthritis Quality of Life. A Quality of Life 
Questionnaire 
REFLEX Rituximab for Rheumatoid Arthritis Refractory to 
Anti–Tumor Necrosis Factor Therapy. 2006 Phase III randomised 
controlled trial assessing the beneﬁt of rituximab vs placebo in 
patients receiving methotrexate who failed their initial TNFi 
therapy. See reference (3). 
RF Rheumatoid Factor 
RTX Rituximab – One of the study drugs in the SWITCH study 
SAS Statistical Analysis Software. Cary NC, USA 
SDAI Simpliﬁed Disease Activity Index 
SJC Swollen Joint Count. The number of joints out of 28 that are 
swollen. 
SmPC Summary of Product Characteristics 
SUSAR Suspected Unexpected Serious Adverse Reaction 
SWITCH The present study. For protocol paper, see reference (4)  
TB Tuberculosis 
TC Trial Co-ordinator 
TJC Tender Joint Count. The number of joints out of 28 that are tender. 
TMG Trial Management Group 
TNF (alpha) Tumor Necrosis Factor (alpha). A biomarker indicative of 
inﬂammation. 
TNFi Tumor Necrosis Factor (alpha) Inhibitor. An agent that acts to 
reduce levels of this biomarker. 
TSC Trial Steering Committee 
VAS Visual Analogue Scale. A means of assessing a patient-reported 
outcome. 
WCBP Woman of Child Bearing Potential 
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Box 1: Primary Endpoint: DAS28 
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1. Introduction 
 
1.1 Background 
Rheumatoid arthritis (RA) is one of the most common autoimmune diseases; a chronic, systemic, 
inﬂammatory arthritis, affecting over 600,000 people in the UK (5) and is the largest cause of 
treatable disability in the Western world (6,7). Patients suffer considerable pain, stiffness and 
swelling and if not adequately controlled, sustain various degrees of joint destruction, deformity, 
and signiﬁcant functional decline. RA can occur at any age, but the peak time of onset is in the 
fourth and ﬁfth decades of life, a time which coincides with i) highest earning potential for those in 
work, and ii) may also represent a signiﬁcant transition phase in roles within the family -including 
dealing with adolescents moving toward independence at one end of the spectrum and likely 
increased dependence of elderly parents at the other end (8).  
Given its high prevalence in the working population, the impact of RA represents a major individual 
and societal economic burden (9). The signiﬁcant direct costs of hospitalisation, joint replacement 
surgery, drugs and social care are matched with equivalent indirect ﬁnancial impact, through loss of 
employment. Expedient implementation of disease-modifying anti-rheumatic drug (DMARD) 
therapy is the cornerstone of management of RA. Nevertheless, it has become clear that poor 
response (even if initially effective) remains a feature with most DMARDs over time. In addition, a 
high incidence of toxicity has been observed with these drugs (10). Such obstacles to therapy 
combined with data suggesting limited alteration in long-term outcome even in those showing 
response has argued for more optimal therapy (11).  
This unmet clinical need fuelled research into RA which led to signiﬁcant advances in our 
understanding of RA by the 1990s; excess pro-inﬂammatory cytokines, in particular, TNF-alpha 
was shown to be critical in driving RA pathogenesis (12). Following in vitro and in vivo work, the 
most compelling evidence for a key role for TNF-alpha stemmed from studies where marked 
clinical beneﬁt was observed in patients with RA treated with chimeric anti-TNF-alpha monoclonal 
antibodies (13).  
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1.1.1 TNF-Inhibitors  
Cochrane reviews provide clear evidence that three currently licensed TNFi drugs (etanercept, 
inﬂiximab and adalimumab) produce better outcomes in RA compared with placebo or treatment 
with conventional DMARDs (14). All these are in the same class of drug i.e. TNFi but differ in 
several respects, such as molecule type, target, binding afﬁnity to TNFi, mechanism or action and 
method of administration.  
Despite the extensive beneﬁts of TNF-directed biologic therapies, a signiﬁcant proportion of RA 
patients fail to achieve sufﬁcient response (15). Two broad approaches can be employed to manage 
initial TNFi non-response; switching to an alternative TNFi therapy or use of another mechanism 
agent. Of the latter, rituximab, a B-cell depleting therapy and abatacept, another agent that targets 
T-cell co-stimulation are licensed, with rituximab also approved by National Institute of Health and 
Clinical Excellence (NICE) for the treatment of RA. 
Tocilizumab, an interleukin-6 receptor monoclonal antibody, has also been recently licensed and 
approved by NICE following TNFi failure.  
 
1.1.2 Switching between TNF-Inhibitors  
Current NICE guidance does not permit switching to an alternative TNFi as a second-line biologic 
therapy choice. Several early phase, uncontrolled studies and an initial small randomised study 
suggested beneﬁt in switching between TNFi agents (16-26). The rationale and argument for 
switching between different anti-TNF drugs was recently strengthened by a large, randomised 
industry-led efﬁcacy study comparing Golimumab to Placebo in a Phase II study of 461 patients 
previously having failed or intolerant to 1 or more TNF-inhibitors (27). A key beneﬁt of the TNFi is  
their suitability in both seropositive and seronegative disease (to rheumatoid factor (RF) +/- anti- 
citrullinated peptide antibody (ACPA)). This contrasts with the inﬂuence of antibody status and 
response rates in patients treated with rituximab due to its distinct target and rationale for use 
(rituximab depletes B-cells that produce antibodies; see below). It is important therefore not to 
prematurely discount an alternative TNFi drug as an effective therapeutic option, particularly in the 
context of such resistant and aggressive disease cohorts. 
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1.1.3 Alternative Biologic Therapies 
Recently introduced alternative targeted biological therapies provide another option in the setting of 
TNFi failure. These include rituximab and abatacept. Industry-led efﬁcacy studies have 
demonstrated beneﬁts of both these therapies after TNFi failure (3, 28) although only rituximab is 
NICE-approved (and neither abatacept nor a TNF-antagonist has been compared to rituximab). 
Certain patients however will not be appropriate for rituximab (and may even lead to unpredictable 
responses/toxicity (29)) or will fail to respond (up to a third of patients). Furthermore, seronegative 
antibody status (seen in up to 25-30% of patients in this cohort) is associated with poorer response 
although this has not been formally tested (3, 30, 31). Abatacept’s mechanism, like the TNFi 
therapies is associated with use in both seropositive and seronegative RA. 
A recently published Swiss observational study (32) comprised 116 patients that had failed at least 
one TNFi agent that were either switched to an alternative TNFi therapy or to one cycle of 
rituximab with suggestion of rituximab a more favourable treatment option. Aside from including 
small numbers, this retrospective study had several other design limitations with outcome taken 
from differing time-points and inclusion of all types of initial TNFi failure; in addition it was 
neither controlled nor randomised to treatment type. We recently reported an interim observational 
analysis of patients switched to either an alternative TNFi or rituximab following failure of 
one/more TNFi therapies; this suggested equivalent clinical responses (33). Similar conclusions 
were drawn from another Swiss study (34). Notably, meta-analyses have failed to demonstrate 
superiority of one therapy over another (35), with European recommendations also conﬁrming all as 
appropriate options (36).  
Despite the beneﬁts of recent advances in the management of RA, it is also apparent that no 
universally effective treatment exists. It remains unclear how best to utilise the alternative 
biological therapies described above following initial TNFi failure. The present approach is 
unsatisfactory, with clinicians treating patients in the absence of sufﬁciently strong data. The 
current reality, of 2nd-line biologic treatment restricted to a single option (rituximab) seriously 
impedes effective management. This is particularly pertinent to TNFi failure patients that have 
seronegative RA (up to 25-30% patients) for whom no NICE-approved options exist despite several 
more appropriate licensed therapies available and indeed other pathologies or disease characteristics 
that would argue for an alternative line of management. This poses a signiﬁcant problem to the 
NHS and is in conﬂict with the patient agenda. Despite several treatment options now available, no 
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good quality head-to-head comparisons investigating the efﬁcacy of sequential biologic treatments 
have been conducted to date.  
Figure 1: Brief trial design. 
 
1.2 Design 
1.2.1 Current Trial Design 
SWITCH is a UK multi-centre, Phase IV 3-arm parallel group, randomised controlled trial. A total 
of 477 patients with Rheumatoid Arthritis, receiving Methotrexate and having failed to respond to 
initial TNFi therapy will be randomised to receive one of rituximab, abatacept, or alternative TNFi. 
Randomisation will be achieved using minimisation including a random element that will allocate 
patients on a 1:1:1 basis to the three treatment strategies. If a patient is allocated to the alternative 
TNFi arm, then the patient will receive either etanercept (if patient failed to respond to monoclonal 
antibody) or a monoclonal antibody (if the patient failed to respond to etanercept). (See Figure 1) 
The trial is open-label, since it would be unreasonable to administer multiple dummy injections and 
In the re-design, 477 patients would be allocated on a 1:1:1 ratio to either rituximab (RTX), 
abatacept (ABT), or alternative TNFi (SWITCH). Within the alternative TNFi arm, a patient 
previously failing to respond to a monoclonal antibody will receive etanercept (ETN) and a 
patient failing to respond to etanercept will receive a monoclonal antibody (MAB) at the 
discretion of the treating clinician. Possible Monoclonal antibodies will include certolizumab 
(CTZ), golimumab (GOL), inﬂiximab (IFX) or adalimumab (ADA). Following early trial 
closure, only 122 patients were randomised. 
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infusions as a means to keep the patient blinded to their true allocation. The primary endpoint is 
absolute reduction in DAS28 over a period of 24 weeks. 
 
1.2.2 Early closure of trial 
In November 2014, the HTA requested that the trial halt all further recruitment, and proceed with 
ﬁnishing follow-up for all randomised patients to a minimum of 48 weeks, and begin ﬁnal analysis.  
The randomisation service closed to further recruitment with 122 patients randomised between 14th 
August 2012 and 18th December 2014. 
 
1.3 Study aims and objectives 
The study aims and objectives listed here are as provided in the protocol. Following the early 
closure of the study, the focus of the analysis will be on estimating the treatment effect of 
either experimental arm compared to rituximab in terms of disease activity; it is considered 
unlikely that a conclusion of non-inferiority (or superiority) will be reached. 
 
1.3.1 Primary objective 
To establish whether an alternative-mechanism-TNF-inhibitor (TNFi) or abatacept are non-inferior 
to rituximab in terms of disease response at 6 months (24 weeks) post randomisation. 
 
1.3.2 Secondary objectives 
• To compare alternative-mechanism-TNFi and abatacept to rituximab in terms of disease 
response over a 12 month period (48 weeks). 
• To compare alternative-mechanism-TNFi and abatacept to rituximab in terms of quality of 
life, toxicity and safety over a 12 month period (48 weeks). 
• To undertake an evaluation of the cost-effectiveness/health economics of switching patients 
to an alternative-mechanism TNFi, abatacept or rituximab. 
• To compare structural and bone density outcomes for abatacept and alternative-mechanism 
TNFi to rituximab over a 12 month period (48 weeks), in terms of bone densitometry score. 
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1.3.3 Exploratory Objectives: 
• To determine the optimal sequence of treatments by assessing whether the response to the 
second treatment in RA patients is affected by which of the initial TNFi groups the patients 
failed (anti-TNF monoclonal or TNF receptor fusion protein).  
• To evaluate whether the response to the second treatment (alternative mechanism TNFi, 
abatacept or rituximab) is affected by whether the patient was a primary (no initial response)  
or secondary (loss of an initial response) response failure to their initial TNF-blocking 
therapy.  
• To ascertain whether seropositive and seronegative (to rheumatoid factor +/-anti-cyclic-
citrullinated peptide antibody) RA patients behave differently in their response and disease 
outcome measures to the three treatment arms, particularly with respect to rituximab 
 
1.4 Sample size and expected accrual 
1.4.1 Current Trial Design 
A total of 477 participants were to be recruited.  
Each experimental trial arm (alternative mechanism TNFi, abatacept) will be compared to rituximab 
for non-inferiority in terms of change in DAS28 at 6 months. In the following justiﬁcation, no 
adjustment for multiplicity of the comparisons of each experimental trial arm to rituximab has been 
made. Each of the comparisons can be interpreted independently; the comparison between abatacept 
and rituximab will provide no information on the comparison between alternative mechanism anti-
TNF and rituximab. Multiple comparison procedures are therefore not required when testing two 
independent hypotheses (37, 38).  
A total of 429 evaluable participants are required to have 80% power for demonstrating non-
inferiority of either abatacept or alternative mechanism TNFi to rituximab at the 5% signiﬁcance 
level. A total of 143 evaluable participants in each treatment group will ensure that the lower limit 
of the two-sided 95% conﬁdence interval for the true difference in DAS28 (abatacept/alternative 
mechanism TNFi – rituximab) lies above -0.6 units, assuming no difference between treatment 
groups and a standard deviation between participants of 1.8 units (REFLEX trial (3)). Allowing for 
a loss to follow-up of 10%, a total of 477 participants will be recruited.  
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The proposed non-inferiority margin of -0.6 units in the change in DAS28 at 6 months corresponds 
to the maximum difference in DAS28 score that is considered to be of no clinical relevance and is 
the threshold for the clinical distinction of ‘inferiority’ (corresponds to the maximum change in 
DAS28 in participants with low or moderate disease activity that is classiﬁed as “no response” by 
the EULAR criteria). DAS28 score of 0.6 units is also the reported measurement error (39).  
For the secondary outcomes analysis to compare quality of life, toxicity and safety at 6 months 
between treatment arms our sample size of 143 evaluable participants per group would enable us to 
detect a standardised effect size of 0.33 (small to medium by the deﬁnition of Cohen (40)), with 
80% power and a 2-sided 5% signiﬁcance level. 
 
1.4.2 Prior Trial Design 
Prior to implementation of Protocol V6.0, the target recruitment was 870 patients. This would allow 
the trial to conclude that either arm were non-inferior to rituximab in terms of the proportions of 
patients achieving a DAS28 reduction of 1.2 or more without toxicity, and also detect a signiﬁcant 
interaction effect between seropositivity status and treatment effect. For details as to the 
assumptions and original choice of non-inferiority margin, refer to the SWITCH protocol paper (4). 
 
1.4.3 Planned Recruitment Rate 
In order to recruit 477 participants the target recruitment rate was 0.5 to 0.75 patients per month per 
centre over a maximum of 40 sites across the UK, over a maximum of 53 months. 
 
1.4.4 Final Recruitment 
The SWITCH trial closed to further recruitment in December 2014 with 122 patients randomised. 
 
1.5 Randomisation 
Randomisation to one of the three study arms was performed centrally using the CTRU automated 
24-hour telephone randomisation system. Authorisation codes, provided by the CTRU, were 
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required to access the randomisation system. These activities were performed by a member of the 
SWITCH research team. 
Patients who gave written informed consent were ﬁrst registered, and given a unique study ID 
number. Following completion of eligibility screening, patients who fulﬁlled the eligibility criteria 
were randomised to one of the three study arms.  
Randomisations were achieved using minimisation incorporating a random element, via a computer 
program, that allocated patients in a 1:1:1 ratio between Alternative TNFi: Abatacept: Rituximab 
after taking account of the following factors, details of which will be required for randomisation: 
• Randomising site 
• Disease Duration (0 – 4 years, 5 or more years)  
• Rheumatoid Factor / Anti-CCP status (Either seropositive, both seronegative) 
• Pattern of TNFi non-response (Primary, Secondary) 
After a randomisation is made to Alternative TNFi arm, the patient will be allocated to receive 
either Etanercept (if the previous TNFi failure was to a monoclonal antibody) or a monoclonal 
antibody (if the previous TNFi failure was to Etanercept). The treating clinician will choose the 
appropriate monoclonal antibody at his / her discretion. 
In statistical analysis, underlined values will be taken as the reference category levels (estimating 
the effect of being eg Secondary Non-responder compared to Primary Non-Responder). 
Randomising Centre will not be ﬁtted as a ﬁxed effect in the analysis, so no reference category is 
required. See section 5.1.9, for how the random centre effect will be ﬁtted. 
 
1.6 Eligibility 
Patients were required to satisfy the following criteria. Eligibility waivers to the inclusion / 
exclusion criteria were NOT permitted. 
 
1.6.1 Inclusion Criteria 
1. Male and female subjects aged ≥18 years at the time of signing the Informed Consent Form. 
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2. Patients with a diagnosis of rheumatoid arthritis as per the ACR/EULAR 2010 classiﬁcation 
criteria conﬁrmed at least 24 weeks prior to the screening visit. 
3. Patients who have failed conventional DMARD therapy as per NICE/BSR Guidelines (41) i.e. 
failure of at least 2 DMARDS including MTX. 
4. Patients with persistent RA disease activity despite having been treated with a current initial 
TNFi agent for at least 12 weeks. Active RA deﬁned as*: 
• Primary non-response: failing to improve DAS28 by > 1.2 or failing to achieve DAS28 ≤ 
3.2 within the ﬁrst 12 to 24 weeks of starting the initial TNFi. 
This may include patients that have shown a reduction in DAS28 of > 1.2 but still 
demonstrate unacceptably high disease activity in the physician’s judgement with evidence 
of an overall DAS28 of ≥ 3.2 
OR 
• Secondary non-response: deﬁned as inefﬁcacy to ﬁrst TNFi (having demonstrated prior 
satisfactory response) as per clinician judgement; with intolerance not the reason for 
cessation of ﬁrst TNFi. 
*These criteria are consistent with BSR guidelines (41). 
5. MTX dose stable for 4 weeks prior to the screening visit and to be continued for the duration of 
the study. 
6. Patients on NSAIDs and / or corticosteroids (oral prednisolone not exceeding 10mg daily) who 
have been on an unchanged regimen for at least 4 weeks prior to the screening visit and are 
expected to remain on a stable dose until the baseline assessments have been completed. 
7. Provided written informed consent prior to any trial-speciﬁc procedures. 
 
1.6.2 Exclusion Criteria 
1.6.2.1 General 
1. Major surgery (including joint surgery) within 8 weeks prior to the screening visit or planned 
major surgery within 52 weeks following randomization. 
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1.6.2.2 Study Specific 
2. Patients with inﬂammatory joint disease of different origin, mixed connective tissue disease, 
Reiter’s syndrome, psoriatic arthritis, systemic lupus erythematosus, or any arthritis with onset prior 
to 16 years of age. 
3. Patients receiving doses of prednisolone > 10mg/day within the 4 weeks prior to the screening 
visit. 
4. Patients receiving intra-articular or intra-muscular steroid injections within 4 weeks prior to the 
screening visit. 
 
1.6.2.3 Excluded Previous or Concomitant Therapy: 
5. Patients who have previously received more than 1 TNFi drug OR any other biological therapy 
for the treatment of RA. 
6. Patients unable or unwilling to stop treatment with a prohibited DMARD (i.e synthetic DMARD 
aside from MTX e.g. oral or injectable gold, chloroquine, hydroxychloroquine, cyclosporine, 
azathioprine, leﬂunomide, sulphasalazine) prior to the start of protocol treatment. 
7. Treatment with any investigational drug in the last 12 weeks prior the start of protocol treatment. 
 
1.6.2.4 Exclusions for general safety 
These criteria should be considered in the context of BSR guidance (41). 
8. Patients with other co-morbidity including acute, severe infections, uncontrolled diabetes, 
uncontrolled hypertension, unstable ischaemic heart disease, moderate/severe heart failure (Class 
III/IV of the New York Heart Association (NYHA) functional classiﬁcation system (42)), active 
bowel disease, active peptic ulcer disease, recent stroke (within 12 weeks before the screening 
visit), or any other condition which, in the opinion of the investigator, would put the patient at risk 
to participate in the study or would make implementation of the protocol difﬁcult. 
9. Patients with any major episode of infection requiring hospitalisation or treatment with IV 
antibiotics within 12 weeks of start of treatment protocol or oral antibiotics within 4 weeks of start 
of protocol treatment. 
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10. Patients at signiﬁcant risk of infection, which in the opinion of the investigator would put the 
patient at risk to participate in the study (e.g. leg ulceration, indwelling urinary catheter, septic joint 
within 52 weeks (or ever if prosthetic joint still in situ)). 
11. Patients with known active current or history of recurrent bacterial, viral, fungal, mycobacterial 
or other infections including herpes zoster (for tuberculosis and Hepatitis B and C see below), but 
excluding fungal infections of nail beds as per clinical judgment. 
12. Patients with untreated active current or latent tuberculosis (TB). Patients should have been 
screened for latent TB (as per BSR guidelines) within 24 weeks prior to the screening visit and, if 
positive, treated following local practice guidelines prior to the start of protocol treatment. 
13. Patients with active current hepatitis B and/or C infection. Patients should have been screened 
for hepatitis B and C within 24 weeks prior to the screening visit and if positive, excluded from the 
study. 
14. Primary or secondary immunodeﬁciency (history of or currently active) unless related to 
primary disease under investigation. 
15. Pregnancy, lactation or women of child-bearing potential (WCBP) unwilling to use an effective 
birth control measure whilst receiving treatment and after the last dose of protocol treatment as 
indicated in the relevant SmPC/IB. 
16. Men whose partners are of child-bearing potential but who are unwilling to use an effective 
birth control measure whilst receiving treatment and after the last dose of protocol treatment as 
indicated in the relevant SmPC/IB. 
 
1.6.2.5 Laboratory value exclusions 
17. Patients with known signiﬁcantly impaired bone marrow function as for example signiﬁcant 
anaemia, leukopaenia, neutropaenia or thrombocytopaenia as shown by the following laboratory 
values at the time of the screening visit: 
• Haemoglobin < 8.5 g/dl 
• Platelet count < 100 x 109 / L 
• White blood cell count < 2.0 x 109 / L 
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• Neutrophil count < 1 x 109 / L 
18. Patients with known severe hypoproteinaemia at the time of the screening visit, e.g. in nephrotic 
syndrome or impaired renal function, as shown by: 
• Serum Creatinine > 150 μmol / L 
 
1.7 Planned analyses 
No interim analyses will be undertaken prior to ﬁnal analysis. One pre-speciﬁed interim analysis 
would have been conducted when 50% of patients had passed week 24, designed to allow for early 
stopping of an arm for demonstrating inferiority of either abatacept or alternative TNFi. With the 
closure of the trial before 25% of the expected patient numbers being recruited, the interim analysis 
is now obsolete. 
The DMEC, in the light of the interim reports and of any advice or evidence requested, will if 
necessary report to the Trial Steering Committee (TSC) if there are concerns regarding the safety of 
the trial treatment. 
 
2. Endpoints 
The study endpoints are listed below. For deﬁnitions of endpoints (including references, where 
applicable) please see the endpoint deﬁnition sections 2.3 and 2.4.1 – 2.4.13. 
 
2.1 Primary endpoint 
The primary endpoint is the absolute change in DAS28 score (Disease Activity Score with 28 joint 
counts) between Baseline and Week 24.  
 
2.2 Secondary endpoints 
• DAS28 Score measured at Baseline, Week 12, Week 24, Week 36, Week 48. 
• DAS28 “Response” at Week 12, Week 24, Week 36, Week 48.  
• DAS28 Low Disease Activity at Baseline, Week 12, Week 24, Week 36, Week 48. 
• DAS28 Remission at Baseline, Week 12, Week 24, Week 36, Week 48. 
• EULAR Response Scores at Week 12, Week 24, Week 36, Week 48.  
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• EULAR / ACR Remission at Baseline, Week 12, Week 24, Week 36, Week 48. 
• ACR Response Scores at Week 12, Week 24, Week 36, Week 48. 
• CDAI Score at Baseline, Week 12, Week 24, Week 36, Week 48.  
• SDAI Score at Baseline, Week 12, Week 24, Week 36, Week 48. 
 
Quality of Life Endpoints 
• RAQoL at Baseline, Week 12, Week 24, Week 36 and Week 48. 
• HAQ-DI (also evaluated at weeks 60, 72, 84 and 96) 
• HADS at Baseline, Week 12, Week 24, Week 36 and Week 48. 
• Pain Visual Analogue Scale (also evaluated at weeks 60, 72, 84 and 96) 
• General Health Visual Analogue Scale (also evaluated at weeks 60, 72, 84 and 96) 
• Global Assessment of Arthritis Visual Analogue Scale (also evaluated at weeks 60, 72, 84 
and 96) 
 
Safety Endpoints (over 52 weeks) 
• Toxicity 
• Adverse Events 
 
Economic Evaluation Endpoints 
• EuroQol 5-dimensions (EQ-5DTM) (also evaluated at weeks 60, 72, 84 and 96) 
• Health Utilities Index (also evaluated at weeks 60, 72, 84 and 96) 
• Health and Social Care Use & Expenditure due to Rheumatoid Arthritis  
• Incremental Cost Effectiveness 
 
Imaging Endpoints 
• Bone densitometry scan scores (T-scores unilateral neck of femur and lumbar spine- 
evaluated at baseline and week 48) 
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2.3 Primary endpoint definition 
The DAS28 score to be used for the primary endpoint analysis is a composite measure of four 
items: 
• Tender Joint Count (TJC: Range 0-28) 
• Swollen Joint Count (SJC: Range 0-28) 
• Erythrocyte Sedimentation Rate (ESR: Range 0-99) 
• Patient-completed Visual Analogue Scale of Global Assessment of Arthritis, to answer the 
question “Considering all of the ways your arthritis has affected you, mark on the line below 
how you feel your arthritis is today” (VAS: Range “Very Well” = 0mm – “Very Poor” = 
100mm) 
 
With these four items, the DAS28 score is calculated in the following manner: (43,44)  
 
 
Where LOGe is the natural logarithm function, and  is the square root function. 
Although other possible formulae exist for the DAS28 taking into account C-Reactive Protein 
(CRP) instead of ESR, or excluding ESR or CRP altogether, this is the deﬁnition of DAS28 that 
shall apply to the Primary Endpoint. 
The Primary Endpoint is interpreted such that greater values indicate more active disease, and lower 
values indicate less active disease. Clinically relevant thresholds include Low Disease Activity 
(LDA) and Remission, both of which are deﬁned in Section 2.4.2-2.4.3. EULAR disease response 
criteria consider the change from baseline as well as the present state, and are deﬁned in Section 
2.4.4. 
For the Primary Endpoint Analysis, the absolute change from baseline in DAS28 shall be 
computed, by subtracting the follow-up value from the baseline value (see section 5.1.3). For this 
variable, positive values shall indicate worsening disease activity, and negative values shall indicate 
improving disease activity. Imputation of Missing Data items for the primary endpoint analysis is 
covered under section 2.6.1. 
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DAS28 can be categorised according to the value at a particular point in time as below: 
Box 2 :DAS28 categories 
High 5.1 < DAS28 
Moderate 3.2 < DAS28 <= 5.1 
Low 2.6 < DAS28 <= 3.2 
Remission DAS28 <= 2.6 
 
Values in bold relate to key secondary endpoints at sections 2.4.2 and 2.4.3. 
If any of the four components of DAS28 are missing, then the DAS28 value will be missing. See 
section 2.6 for how missing data will be imputed. 
 
2.4 Secondary endpoint definitions 
 
2.4.1 DAS28 “Response” 
A patient will be deemed to have achieved a “Response” to treatment in terms of DAS28 (see 
section 2.3) if they achieve a reduction in DAS28 from baseline of 1.2 units or more. If the patient 
does has not achieved the required DAS28 reduction since baseline, the patient will be deemed to 
be a non-responder. If either the baseline or current values of DAS28 are not complete, then DAS28 
“Response” will be missing. See section 2.6.1 for how missing data will be imputed. 
 
2.4.2 DAS28 Low Disease Activity 
A patient will be deemed to be in the state of Low Disease Activity (LDA) if at the assessment visit, 
their DAS28 score is in the interval (2.6, 3.2] (see section 2.3).  
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2.4.3 DAS28 Remission 
A patient will be deemed to be in the state of Remission – both in terms of DAS28 (see section 2.3) 
and in terms of EULAR response – if at the assessment visit, their DAS28 score is 2.6 units or 
lower. 
 
2.4.4 EULAR Response Criteria 
European League Against Rheumatism (EULAR) Response criteria are determined according to the 
level of disease activity at the assessment, and by how much the DAS28 (see section 2.3) has 
improved since baseline. The diagram Box 3 illustrates how a patient is classiﬁed according to their 
Disease Activity and the improvement in disease activity. 
A patient will be classed as having achieved No Response if: 
• The DAS28 has reduced by less than 0.6 units (or has increased) since baseline, OR 
• The DAS28 has reduced by between 0.6 and 1.2 units, and current DAS28 score is greater 
than 5.1 units.  
A patient will be classed as having achieved Moderate Response if:  
• The DAS28 has reduced by between 0.6 and 1.2 units, and current DAS28 score is 5.1 units 
or lower, OR 
• The DAS28 has reduced by more than 1.2 units, and current DAS28 score is greater than 3.2 
units. 
A patient will be classed as having achieved Good Response if: 
• The DAS28 has reduced by more than 1.2 units AND the current DAS28 score is 3.2 units 
or lower.  
 
If the current DAS28 value, or the baseline value of DAS28 are not known, then the EULAR 
response level will be missing. See section 2.6 for how missing data will be imputed. 
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Box 3: EULAR response categories 
Current DAS28 at 
endpoint 
DAS28 IMPROVEMENT SINCE BASELINE 
>1.2 <= 1.2 and ≥ 0.6 < 0.6 
DAS28 <= 3.2 GOOD Response   
3.2 < DAS28 <= 5.1 MODERATE Response  
DAS28 > 5.1   NO Response 
 
 
2.4.5 ACR Response Criteria (ACR20 / ACR50 / ACR70) 
The American College of Rheumatology (ACR) Response criteria are composite measures 
developed for rheumatoid arthritis. There are three criteria that can be achieved, referred to as 
ACR20, ACR50 and ACR70. To achieve an ACR20, participants must demonstrate a relative 
improvement (reduction) from baseline of at least 20% (or 50%/70% for ACR50/ACR70 
respectively) in both tender and swollen joint counts and also a relative 20% (or 50%/70%) 
improvement in 3 out of 5 following criteria (45): 
• Patient global health assessment of disease activity (measured by a Visual Analogue Scale 
(VAS)) 
• Physician global assessment of disease activity (Measured by a VAS) 
• Patient assessment of pain (Measured by VAS) 
• Patient assessment of physical function (Measured by HAQ-DI© questionnaire) 
• Results of laboratory test for inﬂammatory marker (Either erythrocyte sedimentation rate 
(ESR) or C-Reactive Protein (CRP)) 
 
2.4.6 ACR/EULAR Boolean remission rates (46)  
Boolean remission is deﬁned as swollen joint count (SJC), tender joint count (TJC), VAS patient 
global assessment (VAS) and CRP all ≤1. 
 
APPENDIX 7
NIHR Journals Library www.journalslibrary.nihr.ac.uk
146
  
2.4.7 SDAI (Simplified Disease Activity Index) score (44, 47)  
The components of SDAI are the number of tender joints (28 joint count), the number of swollen 
joints (28 joint count), the patient global disease activity (10cm VAS), the physician global disease 
assessment (10cm VAS) and CRP (mg/dl). Since the SWITCH study records Visual Analogue 
Scales in mm in a range of 0-100mm, the VAS scores will ﬁrst be scaled by dividing by 10. (10 
being the conversion factor between centimetres and millimetres) Similarly, the SWITCH study 
records CRP in mg/L, so this will ﬁrst be converted by dividing by 10. The SDAI is deﬁned as: 
 
 
Box 4: SDAI disease activity states 
High Disease Activity 26 < SDAI 
Moderate Disease Activity 11 < SDAI <= 26 
Low Disease Activity 3.3 < SDAI <= 11 
Remission 0 <= SDAI <= 3.3 
 
2.4.8 CDAI (Clinical Disease Activity Index) score (44, 48)  
The components of the CDAI are: the number of tender joints (28 joint count), the number of 
swollen joints (28 joint count), a Patient global assessment of arthritis (10 cm VAS) and physician 
global assessment of arthritis (10 cm VAS). These are added to provide an assessment of disease 
activity on a scale of 0-76. Since the SWITCH study records Visual Analogue Scale scores in mm 
in a range of 0-100mm, the scores will ﬁrst be scaled by dividing by 10. The CDAI is deﬁned as: 
 
Box 5: CDAI disease activity states 
High Disease Activity 22 < CDAI 
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Moderate Disease Activity 10 < CDAI <= 22 
Low Disease Activity 2.8 < CDAI <= 10 
Remission 0 <= CDAI <= 2.8 
 
2.4.9 RAQoL (Rheumatoid Arthritis Quality of Life questionnaire) (49)  
The RAQoL in a questionnaire that comprises 30 yes/no questions to which the patient responds. 
Each “Yes” scores 1 point. A fully-completed questionnaire is scored by summing the values 
gained for each question and takes a value in the range 0-30. Guidance is provided to deal with 
cases where a questionnaire is not fully-completed. 
A summary of the scoring methodology is given in Appendix C. 
 
2.4.10 HADS (Hospital Anxiety and Depression Scale) 
The HADS is a questionnaire that comprises 16 questions, each of which is answered by the patient 
and has 4 possible responses. The questions are scored to take values in the range of 0-3. Half of the 
question scores are then summed to produce an overall Anxiety scale, with the other half being 
summed to produce an overall Depression scale. 
A summary of the scoring methodology for the HADS is given in Appendix E. 
 
2.4.11 HAQ-DI (Health Assessment Questionnaire – Disability Index) 
The HAQ-DI is a questionnaire that comprises 24 questions, each of which is answered by the 
patient and has 4 possible responses. Questions relate to how much difﬁculty is experienced in 
undertaking certain activities, and whether any help or modiﬁed devices are required in order to 
complete them. The overall score is obtained from the average of 8 possible domains, each of which 
can take a value in the range of 0-3. 
The HAQ-DI is a component of the ACR Response score. The HAQ-DI will need to be scored for 
all participants at all timepoints in order to compute the ACR response scores. A summary of the 
HAQ-DI scoring methodology is given in Appendix D. 
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2.4.12 Economic Evaluation Endpoints 
The EQ-5D, Health Utilities Index, Health and Social Care Use and Expenditure due to Rheumatoid 
Arthritis and the Incremental Cost Effectiveness are endpoints of interest to the Health Economics 
Analysis. A separate plan will be written for such analysis, and the endpoints discussed in that 
document.  
 
2.4.13 Toxicity 
Toxicity is deﬁned as the occurrence of an adverse event (including a serious adverse event, serious 
adverse reaction, adverse reaction, or SUSAR) that leads to permanent cessation of treatment. 
 
2.5 Missing data 
Data management will focus on the consenting process, participant eligibility, safety, dates and 
assessment results that feed into the primary and key secondary endpoints. Attempts will be made to 
retrieve missing data on these areas via a thorough data cleaning process. Every effort will be made 
to obtain key data items, as speciﬁed in the key data items document, all key data will be 100% 
checked for quality and completeness by either the Data Management Assistant or Data Manager. 
See Data Monitoring, Section 4.1 for further details.  
The levels of missing data and reasons for missingness will be investigated for the consenting 
process, participant eligibility, safety, dates and assessment results. The quantity of missing data 
will be monitored by treatment group, and a summary of the number of patients with missing 
primary endpoint data and the quantity of missing data by treatment group and centre will be 
reported.  
 
2.6 Imputation of missing data 
Imputation of missing data under a model-based framework is limited by the expected number of 
observations at each timepoint. In order to account for both the longitudinal nature of the study, and 
the composite endpoints, it would be preferable to impute missing DAS28 and ACR Response 
components at all timepoints from baseline to week 48, and perform all imputations separately by 
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arm. However, since SWITCH did not recruit sufﬁcient patients, such an imputation approach 
would require more observed patients at the ﬁnal timepoint in each arm than were actually 
recruited. Accordingly, in order to satisfactorily impute data for the primary and key secondary 
endpoint analyses, DAS28 components will be imputed in a different framework to ACR Response 
components. 
The decision to perform two separate approaches for the endpoints was taken to comply with three 
principles: 
1. It is preferable to impute missing data separately within each treatment arm, rather than 
ﬁtting a linear treatment covariate as a predictor. The former approach allows for the 
possibility of differential treatment modiﬁcation effects for different components at different 
timepoints, while the latter approach does not.  
2. The imputation model should, at a minimum reﬂect the analysis model. Accordingly, point 
(1) is important for the key secondary analysis of DAS28 values over time. 
3. It is preferable to impute components separately, and then re-derive the composite endpoint 
than to directly impute the missing composite value. The latter approach ignores any known 
values that might contribute to the composite endpoint value. 
 
The method of multiple imputation by chained equations (fully conditional speciﬁcation) will be 
used to impute missing data for DAS28 components and ACR Response (50). 
In each imputation, the missing value will be imputed in a model that includes the minimisation 
factors (excluding centre, owing to the large number of small centres) and the other components 
that make up the composite endpoint. The number of imputed datasets will be determined at 
analysis time, in the following manner: 
1. In each model, the analysis dataset will be split into 3 parts, one for each treatment arm. 
2. The percentage of missing values for each component at all timepoints will be determined in 
each arm. 
3. The largest percentage of missing component-timepoint variables will be used to determine 
the number of imputations for that model.  
4. The relevant percentage will be rounded up to the nearest whole percentage point, and one 
imputed dataset will be created for each percentage point of missingness indicated. 
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Thus, if the worst-completed variables in the three arms saw missingness as shown in Table 36: 
Table 1: Example extent of missingness 
Worst-completed 
components 
TNFi 
missingness 
Abatacept 
missingness 
Rituximab 
missingness 
TJC @48weeks 20.5% 0.6% 29.8% 
SJC @48weeks 20.4% 15.8% 29.5% 
ESR @48weeks 30.1% 15.7% 1.0% 
 
Then 31 fully-imputed datasets will be created, regardless of the missingness of this value in other 
arms (50).  
Since the some of the components are unlikely to be normally distributed – even after 
transformation - and may even be discrete values (in the case of the joint counts), predictive mean 
matching will be used to impute the missing value following the imputation (one observation from 
the 3 closest values to the predicted value will be chosen). In balancing the risk of biased 
imputations (due to choosing from too many neighbouring observations) and unstable results 
(choosing from too few) we bear in mind that the imputations will effectively be performed in 
subsamples of 40-41 patients, rather than 122. Since small sample sizes bring a risk of sparse 
observed data points in the vicinity of the predicted mean value, we choose to sample from the 3 
nearest observations, to reduce the chance of the selected observation being far from the predicted 
mean value (51). 
The longitudinal nature of the DAS28 (and ACR response) data over 48 weeks poses challenges for 
missing data imputation. In order to allow for correlation between visits to be accounted for, the 
data will be restructured into a “ﬂat-ﬁle” format. For DAS28, a patient will have 20 components to  
be imputed, rather than 4 at 5 timepoints (to week 48). For ACR Response, a patient will have 24 
components to be imputed, rather than 8 at 3 timepoints (to week 24).  
Once the missing data items have been multiply imputed, the DAS28 or ACR Response will be 
derived and the analysis performed on each multiply-imputed dataset. The resulting parameter 
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estimates will be combined using Rubin’s Rules for Multiple Imputation. The resulting parameter 
estimates will form the primary endpoint analysis (50, 52). 
Patterns of missing data will be explored between the treatment arms, and potential relations to 
baseline characteristics and timing of missing data will be explored. 
 
2.6.1 Primary Endpoint Analysis Imputation – DAS28 
For the primary endpoint analysis of DAS28 reduction at 24 weeks and the key secondary endpoint 
analysis of DAS28 over a 48 week period, the components of the DAS28 (Tender and Swollen Joint 
Counts, ESR and Patient global assessment of arthritis) will be imputed if they are missing at any 
timepoint from baseline up to Week 48.  
 
2.6.2 Secondary Endpoint analysis Imputation – ACR Response 
For the key secondary endpoint analysis (ACR20 Response at 24 weeks), the components of the 
ACR Response criteria (Tender and Swollen Joint Counts, ESR, CRP, Physician global assessment 
of arthritis, Patient Pain assessment and Patient global assessment of arthritis) will be imputed if 
they are missing at any timepoint from baseline up to Week 24. 
 
2.6.3 Imputation models 
For each Imputation “effort”, Multiple Imputation will be performed separately for each of the three 
treatment groups in isolation, rather than for the whole dataset incorporating a treatment group term. 
Missing values will be imputed in time order, starting with baseline values, then those at week 12, 
week 24, week 36 and ﬁnally week 48 in that order (for imputing ACR Response, imputations will 
cease after Week 24 values have been imputed). Within each visit timepoint, the missing values will 
be imputed in order from those with least missing data to those with most missing data.  
To impute missing values for the (up to) 8 partially missing values at each timepoint, the multiple 
imputation procedure shall be invoked once, to impute all missing values required for that endpoint. 
Although we acknowledge that including additional variables in the imputation model can result in 
better imputed values and may make the Missing at Random assumption more plausible, we 
recognise that the expected small size of the dataset means that it would be infeasible to extend our 
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imputation models beyond that required for analysis. At the very least, we expect that our 
imputation models will match the analysis models.  
 
2.6.4 Sensitivity Analyses 
We will investigate the sensitivity of the conclusions to the Missing At Random Assumption by 
carrying out alternative methods of imputing missing DAS28 components, or scores: 
A complete-case analysis (CC) will be performed, in which all participants missing at least one 
DAS28 component at Baseline or Week 24 will be completely excluded from the analysis. Such an 
analysis is not compatible with the Intention-to-Treat Analysis, and assumes that data is missing 
completely at random (MCAR). Differential non-completion may therefore result in biased 
treatment effect estimates.  
 
3. Populations 
3.1 Intention-to-treat population 
An intention-to-treat analysis will be the primary method for analysing and summarising the trial 
data. The intention-to-treat population is deﬁned as all randomised patients, regardless of if they are 
ineligible, withdrawn, don’t comply with the protocol, are lost to follow-up or don’t receive any 
study treatment. Only patients who have withdrawn their consent for their data to be used in the 
study (ie they have requested that their data be destroyed) or for whom written informed consent 
has not been received, will not be included in this population. These patients will be analysed and 
summarised according to the treatment they were randomised to receive. 
 
3.2 Per protocol population 
In the per-protocol population, patients will be analysed according to the treatment received. The 
per-protocol population will exclude patients whose trial conduct constitutes a major protocol 
violation (see Appendix B). A list of such violations will be discussed and agreed by the Chief 
Investigator prior to analysis.  
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For non-inferiority analysis of the Primary Endpoint, a null hypothesis of inferiority rejected in the 
ITT analysis population must also be rejected in the Per-Protocol analysis population for the 
conclusion of non-inferiority to be held. 
 
3.3 Safety population 
In the safety population, all participants will be included and safety data will be analysed according 
to the actual treatment received. If the patient is withdrawn from the study prior to receiving ﬁrst 
dose of IMP, or the patient does not receive any IMP prior to completing the study, then the patient 
will be placed in a “Not received IMP” group, separate to the other possible treatment arms. 
 
3.4 Quality of life populations 
A separate quality of life population will be formed for the analysis of each questionnaire. (RAQoL, 
HAQ-DI, HADS) Each population will comprise all patients who return an analysable baseline 
questionnaire, regardless of subsequent questionnaire completion. 
 
3.5 Complete Case (CC) Analysis Population 
The CC analysis population will include all participants with all DAS28 components recorded at 
baseline and Week 24. Any patient missing any component at either visit will be excluded from this 
analysis population. 
 
 
4. Data Handling 
Data will be monitored for quality and completeness by the CTRU in the following areas; 
consenting process, participant eligibility, safety, date consistency and assessment results. Missing 
data in these areas will be chased until it is received, conﬁrmed as not available or the trial is at 
analysis. Any problems with data collection will be discussed at internal project team meetings and, 
if appropriate, external project team meetings. All efforts will be made to ensure that as much of the 
data is present as possible and that reasons are obtained when data is unobtainable. 
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The CTRU/Sponsor will reserve the right to intermittently conduct source data veriﬁcation 
exercises on a sample of patients, which will be carried out by staff from the CTRU/Sponsor. 
Source data veriﬁcation will involve direct access to patient notes at the participating hospital sites 
and the on-going central collection of copies of consent forms and other relevant investigation 
reports. A Trial Monitoring Plan has been developed which details the standard data and process 
monitoring performed for this trial being conducted by the CTRU. 
An independent data monitoring and ethics committee (DMEC) reviewed the safety and ethics of 
the trial as described in Section 1.7. The DMEC, in the light of the interim reports and of any advice 
or evidence they wish to request, (including the extent to which treating clinicians / investigators are 
complying with the protocol) were able to - if necessary - report to the Trial Steering Committee 
(TSC) if there were concerns regarding the safety of the trial treatment. 
The following were also to be examined continuously during the course of the trial: 
• Consent 
• Recruitment 
• Randomisation 
• Data quality/completeness (priority will be given to the key data items used to analyse the 
primary endpoint) 
• Compliance with the protocol(e.g. eligibility, contraindicated medications) 
• SAEs/SUSARs/Deaths/Pregnancies 
• Withdrawals from the trial / losses to follow-up 
 
4.2 Data validation 
Data management will focus on the data associated with the consenting process, participant 
eligibility, safety, date consistency and assessment outcomes and this section refers to the cleaning 
of these items. The Data Management Assistant (DMA)/ Data Manager (DM) will carry out initial 
validation of the forms in accordance with the trial-speciﬁc Data Management Work Instructions. 
This will ensure that data is complete, consistent, and up-to-date. The Data Clariﬁcation Form 
(DCF) will be sent to sites to highlight missing data items and queries associated with data on 
CRFS that appears to have inaccurate/ inconsistent data recorded. Reasons should be obtained when 
data is unobtainable. 
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The database will validate most data in line with validation rules and highlight any issues that need 
further investigation i.e. with the site. Manual checks on all entered data will be performed prior to 
the validations being implemented. Data items collected relating to the safety and rights of 
individual patients are to be highlighted via priority validations and dealt with as a data 
management priority. Periodic batch validation will also be carried out to detect any data queries 
that may be missed if case record forms (CRFs) are entered in an order that does not allow real time 
validation checks to work. 
A key data items list drawn up by the Trial Statistician that will include all data items that are 
required for the analysis of the primary endpoint. All key data items will be checked manually for 
completeness and accuracy by the DMA/TC, in addition to any automatic checks raised on the 
database. Data automatically generated through the 24-hour randomisation system will be checked 
by the Trial Statistician. 
The Trial Statistician will also perform checks to identify any missing or inconsistent data and liaise 
with the Data Manager to resolve any queries. 
The data will be validated and checked using SAS in the following steps: 
• The data will be read into permanent SAS data sets.  
• A random sample of 5 patients from each SAS dataset were checked against the data as seen 
on the database to ensure that the data transfer has been successful, until such time as the 
download process was accepted to be working. The names and contents of the variables can 
be found on the annotated ﬁnal database speciﬁcation reports in the Statistician’s Trial File.  
 
Data checks will include:- 
• Eligibility checks 
• Sequential dates 
• Checks for unusual and outlying data 
• Inconsistency in data between forms  
• Checks for missing data (are there variables which are systematically missing/do speciﬁc 
variables have a large amount of missing data, particularly key outcome data) 
• Other checks as deemed appropriate 
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Any inconsistent data will be noted and an e-mail sent to the data manager responsible for the study. 
A copy of this e-mail will be kept in the statistician’s trial ﬁle. All queries will be resolved and the 
outcome documented. 
 
5. Data Analysis 
5.1 General Principles 
Unless otherwise stated, the Alternative TNFi arm shall be summarised as a single “Alternative 
TNFi” arm for summarising. Within this arm, listings will report either etanercept or the particular 
monoclonal antibody allocated (or received). The two comparisons of interest are between 
rituximab and Alternative TNFi, and between rituximab and abatacept. 
All percentages will be calculated using the total number of patients within the speciﬁed analysis 
population as the denominator (i.e. including all patients with missing data for that variable), 
percentages will be reported to 1 decimal place. All statistical tests will be 2-sided and performed at 
the 5% signiﬁcance level. All analyses will be carried out using SAS. Where all participants are 
included in categorical summaries, but percentages do not exactly sum to 100% due to rounding, a 
footnote will be included to the effect that percentages do not sum to 100% due to rounding. 
5.1.1 Summary Statistics 
Where “summary statistics” are requested of continuous-scale data, the number of non-missing 
items, the means, standard deviations, medians, upper and lower quartiles and minima and maxima 
will be summarised to one more decimal place than the data are collected. Values that are below the 
limit of detection and therefore non-quantiﬁable will be summarised using the limit of 
quantiﬁcation value. For listings, if required, the non-quantiﬁable value would be reported as an 
inequality and the limit of quantiﬁcation value used would also be reported. For categorical values, 
the number of values will be reported, along with the percentage of the whole population 
represented. Percentages will be reported to 1 decimal place. 
Exploratory analyses will use informal hypothesis testing.  All analyses will be carried out using 
SAS 9.4 unless otherwise stated. 
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Figure 2: Summary of interpretation of non-inferiority conclusions, as described in the CONSORT 
statement extension for non-inferiority studies (2). 
 
5.1.2 Non-inferiority Analyses 
The primary endpoint analysis of the SWITCH study is to be performed on a non-inferiority basis. 
The treatment effect will be estimated as described, and a 2-sided 95% conﬁdence interval for the 
effect will be formed. If the lower bound of this conﬁdence interval is above the pre-speciﬁed non-
inferiority margin, then the treatment will be deemed to be non-inferior to rituximab. 
The pre-speciﬁed non-inferiority margin for the primary endpoint is 0.6units of DAS28. If the 2-
sided 95% conﬁdence interval for the treatment effect is wholly below -0.6 units, then the 
conclusion of inferiority will be reached. If said conﬁdence interval lies wholly above the margin, 
then the conclusion of non-inferiority will be reached.  
 
Non-inferiority will be assessed in both the ITT population, and in the Per-protocol population. A 
conclusion of non-inferiority must be conﬁrmed in both populations for the study to reach the 
overall conclusion that an experimental arm is not inferior to rituximab. If a 2-sided 95% 
conﬁdence interval lies wholly above the null value of 0 for the intention to treat population, then it 
will be possible for the trial to conclude that an experimental arm is superior to rituximab. Figure 2 
-d: non-inferiority margin 
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above illustrates the interpretation of the results, with regard to the upper and lower conﬁdence 
limits. 
 
5.1.3 Absolute changes from baseline 
The absolute change from baseline will be computed as the value at follow-up minus the value at 
baseline. If either value is missing, then the absolute change from baseline will be missing. A brief 
interpretation of positive or negative change values will be provided. 
For example: if a patient’s swollen joint counts (SJC) are 10 at baseline, and 12 at follow-up, this 
will be a change of 2. If the SJCs are 12 at baseline and 10 at follow-up this will be a change of -2. 
 
5.1.4 Relative changes from baseline 
Relative changes from baseline are deﬁned as the absolute change divided by the baseline value. If 
the absolute change is missing, then the relative change will also be missing. A brief interpretation 
of positive or negative change values will be provided.  
For example: if a patient’s RAQoL Scores are 8 at baseline, and 16 at follow-up, this will be a 
relative change of 1.0. If the RAQoL scores are 16 at baseline and 8 at follow-up this will be a 
relative change of -0.5. 
Where a baseline value of 0 is recorded, a relative change from baseline will not be derived. 
However, in deriving the ACR Response categories, we will bear in mind that, for a baseline value 
of 0, there is no possible reduction that can yield either 20, 50 or 70% reduction. If a patient with a 
zero baseline component value records an increase (ie positive absolute change or deterioration) in 
this value, then we will impute this as a non-response for the relevant ACR component response 
criterion. However, if the absolute change at follow-up is zero, resulting in an undeﬁned division of 
0/0, then this patient’s component response will be left as a missing value.  
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5.1.5 Percentage change 
Within this document and the subsequent results, the phrase “Percentage Change” will be 
understood to be a relative change, as deﬁned in Section 5.1.4. Accordingly, relative change values 
will be multiplied by 100 in order to express the relative changes as percentage changes.  
Where a variable is to be measured on a scale of 0-100%, and the absolute change from baseline in 
this variable is required, then the unit of difference will be expressed as “percentage points” or 
“%age points”, in order to differentiate from the phrase “Percentage Change”, which is deﬁned as 
the relative changes. 
Thus, if a variable takes a baseline value of 50% and a follow-up value of 25%, this will be 
described as a 50% reduction (since the value has reduced by a half) or a reduction of 25%age 
points. Likewise, a variable with a baseline value of 20% and follow-up value of 100% will be 
described as an increase of 80 percentage points, but a 400% increase (since the follow-up value is 
four times greater than that at baseline). 
 
5.1.6 Confidence Intervals for proportions 
Conﬁdence intervals for a single proportion shall be calculated using Exact Clopper-Pearson 
intervals. (Method 5 of (53)) Conﬁdence intervals for an absolute difference between independent 
proportions shall be calculated using Exact intervals. (Method 8 of (54)) 
This will not apply to proportions estimated via logistic regression methods: ﬁtted values for odds 
and 95% conﬁdence intervals will be estimated, and these will then be back-transformed to the [0,1] 
probability scale.  
This will also not apply when combining multiple-imputed datasets using Rubin’s Rules. Instead, 
simple Wald-type conﬁdence intervals will be used. 
 
5.1.7 Randomisation errors 
When handling the minimisation factors, patient data will be categorised as described for analysis. 
Where the data entered on the telephone randomisation system differs from any true values derived 
from baseline data, the corrected values resulting from the data cleaning process will be used for the 
primary analysis. Subgroup analyses will also use the corrected values. In addition to being the 
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principled approach, this will allow us to accommodate the change to the randomisation system 
where the balancing factor “RF status” was amended to “RF and ACPA status”. 
 
5.1.8 Non-mutually exclusive selections 
In summaries (for example of prior medical conditions, concomitant medication usage) where a 
single patient may reasonably have multiple responses selected, summaries will by default report 
only the values for each individual response level. No attempt will be made to enumerate a full list 
of all observed combinations unless speciﬁcally requested. Only particular pre-speciﬁed 
combinations of interest will be speciﬁed where appropriate. It will be assumed that a footnote to 
the effect of “These categories are not mutually exclusive” or “Patients may have multiple items 
selected” will be sufﬁcient explanation for sums of percentages exceeding 100. 
 
5.1.9 Multivariable modelling 
Multivariable analyses will not be “built” following any model-ﬁtting “strategy”. Instead, all 
variables speciﬁed for inclusion will be added to the model, and the signiﬁcance of each factor will 
be reported. Where one categorical variable has more than one “factor level” then the signiﬁcance 
of overall effect of including all factor levels will be tested, rather than those for each individual 
factor level. For all factor levels, suitable point and interval estimates of effect size will be 
presented. 
Since we have two treatment comparisons of interest, our analysis will ﬁt a single multivariable 
regression model, including the 3-level treatment variable. Then treatment contrasts will be formed, 
so as to compare the treatment effect of abatacept to rituximab, and to compare Alternative TNFi to 
rituximab.  
Centre effects will be handled in accordance with Section 5.1.11. 
 
5.1.10 Reference levels for categorical fixed effects 
Where categorical variables are to be adjusted for in analyses, these shall use a pre-speciﬁed 
reference level. If the value is not pre-speciﬁed, then the modal value (ie the most frequently-
DOI: 10.3310/hta22340 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 34
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Brown et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
161
  
occurring) will be used. For the 3 minimisation factors that will be ﬁxed effects, a pre-speciﬁed 
value will be used for the reference category (underlined in section S1.5).  
For the treatment comparisons of interest, the reference category for the treatment effect will be 
rituximab. 
 
5.1.11 Centre Effects 
At the close of recruitment, 28 sites had randomised 122 patients. The median (and inter-quartile 
range) of by-centre recruitment was 3 patients (1-5), while 10 centres recruited between 1 and 2 
patients in total. Owing to the large number of randomising centres with small numbers of patients, 
we will not attempt to ﬁt a ﬁxed effect for centre since a model ﬁt is unlikely to converge: centre 
will be ﬁtted as a random effect in the ﬁrst instance. If an attempt to ﬁt centre as a random effect 
fails to converge, then the centre will not be adjusted for in the analysis: centres will not be 
combined in any way so as to create a smaller number of larger pseudo-centres in order to allow the 
model ﬁtting to converge and so randomising centre will be excluded from regression models. 
Where a decision is made to exclude a random centre effect from regression modelling, we will 
consider summaries that may support such a decision, including the intra-class correlation 
coefﬁcient. (ICC) 
 
5.1.12 Simulation and re-sampling methods 
If any analysis requires the use of simulation and / or re-sampling methods, the initial “seed” value 
for the random number generation will be 20151902. The same seed will be used at the start of 
every such analysis. 
 
5.1.13 Longitudinal Analyses 
Analyses that model the effect of treatment over a period of time will be primarily be modelled as a 
random coefﬁcients analysis as the primary analysis method, wherein the “time” effect will be 
directly  calculated as the number of weeks since randomisation. A subsequent analysis for 
graphical purposes will use an alternative covariance-pattern model, in which the “time” effect is 
treated as a sequence of discrete timepoints, corresponding to the clinical assessment schedule. In 
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all such analyses, the baseline value will be ﬁtted as a ﬁxed effects covariate, rather than the ﬁrst 
measurement at time t=0. 
 
5.1.14 Visual Analogue Scales 
Visual Analogue Scale (VAS) scores are measured on a scale of 0-100mm, and are usually only 
considered valid when scales of 100mm are used. Where sites have locally reproduced CRFs, rather 
than relying on professionally-printed CRF booklets, these scales will typically not be 100mm long. 
Rather than consider these scales to be missing data, we will rescale the VAS scores by dividing the 
position of the response by the measured line length, and multiplying the result by 100mm. 
 Table 2 below illustrates the outcome of this rescaling: 
Table 2: Rescaling of Visual Analogue Scales 
Line length Position of response (from 
leftmost extremity of scale 
Rescaled value 
96mm 78mm 100 * 78 / 96 = 81.25mm 
102mm 90mm 100 * 90 / 102 = 88.2…mm 
94mm (No mark) Missing 
 
 
5.2 Analysis 
5.2.1 Baseline Characteristics 
Summary statistics of baseline characteristics and pre-randomisation screening results will be 
presented by treatment arm and overall. Responses provided to questions during randomisation will 
be summarised. Where these differ from correct values provided on CRF, or derived values, these 
discrepancies will be listed. 
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5.2.2 Primary Endpoint Analysis 
Primary Analysis 
The observed DAS28 values at baseline, at week 24, and the absolute changes from baseline will be 
summarised by the three treatment arms. (Summary statistics are speciﬁed in S5.1.1) 
 
The treatment effect of each experimental arm compared to rituximab will be estimated by means of 
a linear regression model, modelling the absolute change from baseline at Week 24 as a function of 
the experimental arm, the duration of arthritis category, the category of non-response and for the 
Rheumatoid Factor / Anti CCP seropositivity status. These variables will be included as ﬁxed 
effects, and shall be categorised as described in Section 1.5 and Section 5.1.10. In the ﬁrst instance, 
an attempt will be made to ﬁt the randomising centre as a random effect, since most of the 
randomising centres are most likely too small for a ﬁxed effect for centre to be successfully ﬁtted. If  
this model does not converge, then centre will not be included in the regression model. As 
mentioned in Section 5.1.11, we will not combine small centres in any way to create a small number 
of larger pseudo-centres so as to improve the ﬁt of the regression model. 
As mentioned in Section 5.1.9, we will form treatment contrasts for the 3-level treatment group 
variable to compare the treatment effects of Abatacept vs Rituximab and the treatment effects of 
Alternative TNFi vs rituximab. 
After ﬁtting the model in each of the multiple-imputed datasets, and the resulting parameter 
estimates combined, the parameter estimate for each ﬁxed effect will be presented along with its 
95% conﬁdence interval and the 2-sided P-Value under the hypothesis that the true parameter 
estimate is equal to zero. 
The adequacy of the linear regression model for the primary analysis will be assessed by examining 
the following: 
• Distribution of standardised residuals by predicted values; 
• Adequacy of Normal distribution for residuals; 
• Examining values of leverage to identify inﬂuential points; 
• Correlation between residual values and order of enrolment. 
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Exploratory Analyses 
There are 3 a-priori subgroup analyses planned. These are detailed in Section S5.3.1-S5.3.3. Within 
each treatment arm, patients will be subdivided as speciﬁed, and summary statistics reported within 
each subgroup. 
 
5.2.2.1 Sensitivity Analyses 
Complete Case Analysis 
As detailed in Section 2.6.1, the primary endpoint will be analysed on a complete-case analysis 
basis: any participant missing at least one DAS28 component value at baseline or Week 24 will be 
excluded from the analysis. 
 
5.2.3 Key Secondary Endpoint Analysis 
Owing to the reduced level of recruitment and shortened trial timelines, a reduced amount of 
analysis will be conducted with respect to secondary endpoints. 
 
5.2.3.1 DAS28 “Response” (reduction of 1.2 units or more) at 12, 24, 36, 48 weeks 
The proportions of patients achieving this endpoint by arm at each timepoint will be summarised by 
treatment arm. (Summary statistics are speciﬁed in S5.1.1) After imputing missing values, the 
achievement of DAS28 “Response” will be analysed using a repeated measures random coefﬁcients  
mixed effects logistic regression model, adjusting for the three minimisation factors (excluding 
centre) and baseline values of DAS28 (all modelled as ﬁxed effects) and patient and patient by time 
effects (modelled as random effects) as well as time, randomised group and time by group 
interaction as ﬁxed effects. Baseline values will be treated as a ﬁxed effects covariate. It is not 
meaningful to include the baseline value as the ﬁrst measurement at time t=0, since the DAS28 
Response is based on change since baseline. 
For graphical purposes, the mixed modelling analysis will also be performed using a covariance-
pattern-type analysis, treating each visit as a sequence of discrete measurements, rather than a 
particular number of weeks. 
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5.2.3.2 DAS28 Score at 12, 24, 36, 48 weeks 
Summary statistics of the DAS28 score will be presented at each timepoint by treatment arm. 
(Summary statistics are speciﬁed in S5.1.1) The DAS28 score will be analysed on a longitudinal 
analysis over the ﬁve visits from baseline to week 48. The values for the DAS28 components will 
be imputed as described, and the overall DAS28 score derived at each visit. Then, the values will be  
analysed using a random coefﬁcients mixed effects linear regression model, adjusting for the three 
minimisation factors (excluding centre) and baseline value of DAS28 (all modelled as ﬁxed effects) 
and patient and patient by time effects (modelled as random effects) as well as time, randomised 
group and time by group interaction as ﬁxed effects. The baseline value will be treated as a ﬁxed 
effect covariate, rather than the ﬁrst measurement at time t=0. If attempts to ﬁt a random effect for 
centre were not successful for the primary endpoint, then no attempt will be made to ﬁt a random 
centre effect for this analysis. 
For graphical purposes, the mixed modelling will be repeated as a covariance pattern-type analysis, 
treating the visits as separate discrete timepoints, rather than a number of weeks. Again, the baseline 
value will be treated as a ﬁxed effects covariate, rather than the ﬁrst measurement at time t=0.  
 
5.2.3.3 ACR20 Response at Week 24 
The proportions of participants achieving 20% reduction from baseline at week 24 in each of the 
ACR criteria will be summarised. (Summary statistics are speciﬁed in S5.1.1) 
The binary variable ACR20 response at Week 24 will be analysed using a binary logistic regression 
model, adjusting for the 3 minimisation factors (excluding centre) all as ﬁxed effects. If attempts to 
ﬁt a random effect for centre were not successful for the primary endpoint, then no attempt will be 
made to ﬁt a random centre effect for this analysis. If an attempt is made to ﬁt a random centre 
effect in this analysis, and this is unsuccessful, the centre effect will not be included in the analysis. 
(See S5.1.11) 
Once the model is ﬁtted in each of the multiple-imputed datasets, and the resulting parameter 
estimates combined, the combined estimate of the odds ratio will be presented, along with its 95% 
conﬁdence interval, and the 2-sided P-Value under the hypothesis that the Odds Ratio is 1. 
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5.2.4 Additional Secondary Endpoint Analyses 
5.2.4.1 HAQ-DI 
After scoring the HAQ-DI for all patients at all timepoints, summary statistics of the HAQ-DI at 
each timepoint will be presented by treatment arm and overall. (Summary statistics are speciﬁed in 
S5.1.1) 
 
There will be no formal statistical analysis of this endpoint at any timepoint, as per the protocol 
Early Trial Termination Plan. 
 
5.2.4.2 EULAR Response Scores 
The frequency and proportions of participants achieving each level of EULAR response (no, 
moderate, good) at each timepoint (weeks 12, 24, 36, 48) participants will now be summarised by 
treatment arm and overall. (Summary statistics are speciﬁed in S5.1.1) 
There will be no formal statistical analysis of this endpoint at any timepoint, as per the protocol 
Early Trial Termination Plan. 
 
5.2.4.3 DAS28 Low Disease Activity and Remission states. 
The frequency and proportions of participants achieving DAS28 Low Disease Activity and / or 
DAS28 Remission at each timepoint will be summarised by treatment arm and overall. (Summary 
statistics are speciﬁed in S5.1.1) 
There will be no formal statistical analysis of this endpoint at any timepoint, as per the protocol 
Early Trial Termination Plan. 
 
5.2.4.4 EULAR / ACR Remission 
The frequency and proportions of participants achieving the EULAR / ACR Remission criteria at 
each timepoint will be summarised by treatment arm and overall. (Summary statistics are speciﬁed 
in S5.1.1) 
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5.2.4.5 ACR20, ACR50, ACR70 at Week 12, Week 24, Week 36 and Week 48 
ACR20 at 24 weeks is already covered under 5.2.3.3. For all other response criteria at all other 
timepoints, the frequency and proportions of patients who achieve the particular response level at 
each timepoint will be summarised by treatment group and overall. (Summary statistics are 
speciﬁed in S5.1.1) 
 
With the exception of the analysis planned for the ACR20 at Week 24, (as described in S5.2.3.3) 
there will be no formal statistical analysis of this endpoint at any timepoint, as per the protocol 
Early Trial Termination Plan. 
 
5.2.4.6 Simplified Disease Activity Score 
Summary statistics of the SDAI score at all timepoints will be presented by treatment arm and 
overall. The frequency and proportions of participants in each category of SDAI score will be 
summarised by treatment arm and overall. (Summary statistics are speciﬁed in S5.1.1) 
There will be no formal statistical analysis of this endpoint at any timepoint, as per the protocol 
Early Trial Termination Plan. 
 
5.2.4.7 Clinical Disease Activity Score 
Summary statistics of the CDAI score at all timepoints will be presented by treatment arm and 
overall. The frequency and proportions of participants in each category of CDAI score at each 
timepoint will be summarised by treatment arm and overall. (Summary statistics are speciﬁed in 
S5.1.1) 
There will be no formal statistical analysis of this endpoint at any timepoint, as per the protocol 
Early Trial Termination Plan. 
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5.2.4.8 RAQoL 
It is recommended by the developers of the RAQoL that the score is treated only on an ordinal 
scale, and that summaries of the values are restricted to non-parametric statistics such as median, 
quartiles, minima and maxima.  
Once scored, values of RAQoL will be summarised using non-parametric percentile-based 
summary statistics in each treatment group at each timepoint.  
There will be no formal statistical analysis of this endpoint at any timepoint, as per the protocol 
Early Trial Termination Plan. 
 
5.2.4.9 HADS 
The HADS will be scored at each timepoint for all participants, providing the Anxiety and 
Depression scales. Summary statistics of both the Anxiety and Depression scores will be presented 
by treatment arm and overall at each timepoint. (Summary statistics are speciﬁed in S5.1.1) 
There will be no formal statistical analysis of this endpoint at any timepoint, as per the protocol 
Early Trial Termination Plan. 
 
5.2.4.10 Toxicity 
The number of participants experiencing an adverse event leading to the permanent cessation of 
treatment will be summarised by arm. Within each arm, the timepoint at which treatment was 
permanently ceased will be summarised. Summaries will be presented based on both the ITT and 
Safety analysis populations. (Summary statistics are speciﬁed in S5.1.1) 
 
5.2.4.11 Safety – AEs / SAEs / SARs / SUSARs / Deaths / Pregnancies 
Summaries of Safety Data will be performed on the Safety population. (See section 3.3) 
Numbers of Adverse Events, Serious Adverse Events, Serious Adverse Reactions, Suspected 
Unexpected Serious Adverse Reactions, Deaths and Pregnancies will be summarised by each arm, 
with numbers of participants experiencing at least one such event. Line listings of SAEs, SARs and 
SUSARs will be presented. Line listings of reported deaths and Pregnancies will be presented. For 
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Adverse Events, summaries of the suspected causalities, intensities and outcome / subsequent 
cessation of treatment will be provided. 
 
5.2.4.12 Bone Densitometry 
Summary statistics of t-scores and z-scores for spine and neck of femur will be presented at 
Baseline and at Week 48. (Summary statistics are speciﬁed in S5.1.1) 
 
5.3 Subgroup Analyses 
There are three a priori subgroup analyses planned, to investigate the possibility of a treatment 
modiﬁcation effect on the primary endpoint. Any additional subgroup analyses will be deemed to 
be exploratory, and shall be described as such. Considering the small size of the study, with around 
40 patients expected in each of the three arms, it is highly unlikely that any subgroup analyses will 
have sufﬁcient power to make deﬁnitive conclusions as to any treatment modifying effect. No 
formal statistical analysis of subgroups will be performed. Owing to the reduced level of ﬁnal 
recruitment, the amount of statistical analysis has been reduced to summary statistics. (Summary 
statistics are speciﬁed in S5.1.1) 
 
5.3.1 Modification effect of initial TNFi failure on treatment effect 
Summary statistics of change in DAS28 at 24 Weeks will be presented by treatment arm and 
overall. Within each treatment arm, the summaries will be presented by initial TNFi type. 
 
5.3.2 Modification effect of response failure type on treatment effect 
Summary statistics of change in DAS28 at 24 Weeks will be presented by treatment arm and 
overall. Within each treatment arm, the summaries will be presented by primary or secondary non-
responder status. 
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5.3.3 Modification effect of Rheumatoid Factor (RF) / anti-cyclic-citrullinated peptide 
antibody (ACPA) seropositivity status on treatment effect 
Summary statistics of change in DAS28 at 24 Weeks will be presented by treatment arm and 
overall. Within each treatment arm, the summaries will be presented in two categories:  being either 
RF / ACPA seropositive or being both RF / ACPA seronegative. 
 
5.4 Additional Patient Summaries and Analyses 
Patient flow 
In line with the CONSORT guidelines for reporting randomised controlled trials (1) – including its 
extension to non-inferiority studies (2) – a ﬂow diagram shall illustrate the ﬂow of patients through 
the study, including the strategies to which they were assigned, the test strategies actually received 
and the subsequent management of the patients through to end of follow-up. The ﬂow diagram will 
include the numbers of patients contributing to each analysis population. 
The reasons for patients not being randomised in the study will be summarised. The dates on which 
the ﬁrst and ﬁnal patients were randomised will be reported, along with the date of ﬁnal follow-up 
for the last patient. 
 
Withdrawals and loss to follow-up 
The number of patient and PI withdrawals/loss to follow-up and reasons for these withdrawals will 
be summarised.  
 
Protocol violators/deviations 
Protocol violations/deviations will be summarised overall, by treatment group and centre, including 
violations of eligibility criteria on entry into the trial, deviations from the treatment and assessment 
schedule. 
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5.5 Serious breaches of GCP 
All serious and potential breaches of GCP that have occurred throughout the trial will be 
summarised by the Trial Co-ordinator and presented in the ﬁnal report. 
 
6. Reporting and Dissemination of the Results 
The trial has been registered with ClinicalTrials.gov (NCT01295151) 
6.1 Authorship and acknowledgement 
The success of the study depends upon the collaboration of all participants. For this reason, credit 
for the main results will be given to all those who have collaborated in the study, through 
authorship and by contribution. Uniform requirements for authorship for manuscripts submitted to 
medical journals will guide authorship decisions. These state that authorship credit should be based 
only on substantial contribution to: 
• conception and design, or acquisition of data, or analysis and interpretation of data 
• drafting the article or revising it critically for important intellectual content 
• ﬁnal approval of the version to be published 
• and that all these conditions must be met (www.icmje.org). 
 
Main trial-related publication: The Chief Investigator, as having conceived the study, overseeing the 
study (unless any future change) with overall responsibility and being central in drafting the article 
and interpretation of data shall be ﬁrst author on the main trial-related publication. Co-Applicants 
and senior CTRU staff that also satisfy the above requirements will be named as co-authors in any 
publication, which will be discussed amongst the Trial Management Group (TMG) members. In 
addition, all collaborators will be listed as contributors for the main study publication, giving details  
of their roles in planning, conducting and reporting the study. 
 
Additional trial-related publication(s): Whilst the exact composition of the main publication 
remains to be determined, there may be opportunities to publish additional reports associated with 
the trial. The nature of authorship will be discussed for such reports individually with the TMG but 
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may take the form of a different lead (ﬁrst) author with the Chief Investigator as senior author for 
example. 
 
The SWITCH team should be acknowledged in all publications, as should NIHR HTA (as detailed 
in Section 6.4 below). Other key individuals will be included as authors or contributors as 
appropriate and at the discretion of the TMG. The Trial Steering Committee (TSC) will resolve any 
disputes relating to authorship.  
 
The Chairs and Independent members of the TSC and Data Monitoring and Ethics Committee 
(DMEC) will be acknowledged, but will not qualify for full authorship, in order to maintain their 
independence. Bristol-Myers Squibb shall also be acknowledged for providing drug.  
Relevant NIHR Clinical Research Networks’ (e.g. CCRN) support should be acknowledged 
appropriately in trial publications. 
 
6.2 Data release 
To maintain the scientiﬁc integrity of the study, data will not be released prior to the ﬁrst 
publication of the results of the primary endpoint analysis, either for study publication or oral 
presentation purposes, without the permission of the DMEC and the TSC. The TSC will agree a 
publication plan and must be consulted prior to release or publication of any study data.  
Individual collaborators must not publish data concerning their participants, which is directly 
relevant to the questions posed in the study until the main results of the study have been published. 
Local collaborators may not have access to study data until after publication of the main study 
results. 
 
6.3 Processes for the drafting, review and submission of abstracts and manuscripts 
The Chief Investigator as ﬁrst author of abstracts is responsible for circulating these to the other 
members of the TMG and the Sponsor for review at least 15 days prior to the deadline for 
submission.  
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The agreed ﬁrst author of manuscripts is responsible for ensuring: 
• timely circulation of all drafts to all co-authors during manuscript development and prior to 
submission 
• timely (and appropriate) circulation of reviewers’ comments to all co-authors 
• incorporation of comments into subsequent drafts 
• communication with the TSC (i.e. ensuring submission is in line with TSC publication plan, 
and ensuring TSC receive the ﬁnal draft prior to submission) 
 
The Chief Investigator as ﬁrst author is responsible for submission of the publication and must keep  
the TMG and all authors informed of the abstract’s or manuscript’s status. The TSC will be kept 
informed of rejections and publications as these occur. On publication, the ﬁrst author should send 
copies of the abstract or manuscript to the TSC, the TMG, the Sponsor and to all co-authors, and 
ensure communication with NIHR HTA programme as outlined below.  
 
6.4 Funder’s Requirements  
All materials to be submitted for publication (written, audio/visual and electronic) will be prepared 
and submitted to the NIHR Co-ordinating Centre for HTA (NCCHTA) in accordance with the 
NIHR HTA programme‘s requirements at the time a publication is drafted. This applies to all 
publications regardless of whether or not the primary results have been published. 
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Appendix A: CONSORT Checklist for Non-inferiority Randomised Trials (Non-inferiority requirements in italics) 
Section/Topic 
Item 
No Checklist item 
Reported on 
page No 
Title and abstract 
 1a Identiﬁcation as a randomised trial in the title. Identification as a noninferiority randomized trial in the title  
1b Structured summary of trial design, methods, results, and conclusions (for speciﬁc guidance see CONSORT for abstracts)  
Introduction 
Background and 
objectives 
2a Scientiﬁc background and explanation of rationale. Rationale for using a noninferiority design  
2b Speciﬁc objectives or hypotheses. Hypotheses concerning noninferiority, specifying the noninferiority margin with the rationale for its 
choice 
 
Methods 
Trial design 3a Description of trial design (such as parallel, factorial) including allocation ratio  
3b Important changes to methods after trial commencement (such as eligibility criteria), with reasons  
Participants 4a Eligibility criteria for participants. Whether participants in the noninferiority trial are similar to those in any trial(s) that established efficacy 
of the reference treatment. 
 
4b Settings and locations where the data were collected  
Interventions 5 The interventions for each group with sufﬁcient details to allow replication, including how and when they were actually administered. 
Whether the reference treatment in the noninferiority trial is identical (or very similar) to that in any trial(s) that established efficacy 
 
Outcomes 6a Completely deﬁned pre-speciﬁed primary and secondary outcome measures, including how and when they were assessed. Specify the 
noninferiority outcome(s) and whether hypotheses for main and secondary outcome(s) are noninferiority or superiority. Whether the 
outcomes in the noninferiority trial are identical (or very similar) to those in any trial(s) that established efficacy of the reference 
treatment. 
 
6b Any changes to trial outcomes after the trial commenced, with reasons  
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Sample size 7a How sample size was determined. Whether the sample size was calculated using a noninferiority criterion and, if so, what the 
noninferiority margin was. 
 
7b When applicable, explanation of any interim analyses and stopping guidelines. To which outcome(s) they apply and whether related to a 
noninferiority hypothesis 
 
Randomisation:    
Sequence generation 8a Method used to generate the random allocation sequence  
8b Type of randomisation; details of any restriction (such as blocking and block size)  
Allocation 
concealment 
mechanism 
9 Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken 
to conceal the sequence until interventions were assigned 
 
Implementation 10 Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions  
Blinding 11a If done, who was blinded after assignment to interventions (for example, participants, care providers, those assessing outcomes) and 
how 
 
11b If relevant, description of the similarity of interventions  
Statistical methods 12a Statistical methods used to compare groups for primary and secondary outcomes. Whether a 1- or 2-sided confidence interval approach 
was used 
 
12b Methods for additional analyses, such as subgroup analyses and adjusted analyses  
Results 
Participant ﬂow (a 
diagram is strongly 
recommended) 
13a For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analysed for the 
primary outcome 
 
13b For each group, losses and exclusions after randomisation, together with reasons  
Recruitment 14a Dates deﬁning the periods of recruitment and follow-up  
14b Why the trial ended or was stopped  
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Baseline data 15 A table showing baseline demographic and clinical characteristics for each group  
Numbers analysed 16 For each group, number of participants (denominator) included in each analysis and whether the analysis was by original assigned 
groups 
 
Outcomes and 
estimation 
17a For each primary and secondary outcome, results for each group, and the estimated effect size and its precision (such as 95% 
conﬁdence interval). For the outcome(s) for which noninferiority was hypothesized, a figure showing confidence intervals and the 
noninferiority margin may be useful. 
 
17b For binary outcomes, presentation of both absolute and relative effect sizes is recommended  
Ancillary analyses 18 Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing pre-speciﬁed from 
exploratory 
 
Harms 19 All important harms or unintended effects in each group (for speciﬁc guidance see CONSORT for harms)  
Discussion 
Limitations 20 Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses  
Generalisability 21 Generalisability (external validity, applicability) of the trial ﬁndings  
Interpretation 22 Interpretation consistent with results, balancing beneﬁts and harms, and considering other relevant evidence. Interpret results in relation 
to the noninferiority hypothesis. If a superiority conclusion is drawn for outcome(s) for which noninferiority was hypothesized, provide 
justification for switching 
 
Other information  
Registration 23 Registration number and name of trial registry  
Protocol 24 Where the full trial protocol can be accessed, if available  
Funding 25 Sources of funding and other support (such as supply of drugs), role of funders  
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Appendix B – Protocol Deviators to be excluded from the Per-Protocol Analysis 
• 
• 
• 
• 
• 
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Inclusion Criteria 
2. Patients with a diagnosis of rheumatoid arthritis as per the ACR/EULAR 2010 classiﬁcation criteria conﬁrmed at least 24 weeks 
prior to the screening visit. 
3. Patients who have failed conventional DMARD therapy as per NICE/BSR Guidelines(41) i.e. failure of at least 2 DMARDS 
including MTX. 
4. Patients with persistent RA disease activity despite having been treated with a current initial TNFi agent for at least 12 weeks. 
Active RA deﬁned as: 
• Primary non-response: failing to improve DAS28 by > 1.2 or failing to achieve DAS28 ≤ 3.2 within the ﬁrst 12 
to 24 weeks of starting the initial TNFi. 
This may include patients that have shown a reduction in DAS28 of > 1.2 but still demonstrate unacceptably 
high disease activity in the physician’s judgement with evidence of an overall DAS28 of ≥ 3.2 
OR 
• Secondary non-response: deﬁned as inefﬁcacy to ﬁrst TNFi (having demonstrated prior satisfactory response) 
as per clinician judgement; with intolerance not the reason for cessation of ﬁrst TNFi. 
5. MTX dose stable for 4 weeks prior to the screening visit and to be continued for the duration of the study. 
6. Patients on NSAIDs and / or corticosteroids (oral prednisolone not exceeding 10mg daily) who have been on an unchanged 
regimen for at least 4 weeks prior to the screening visit and are expected to remain on a stable dose until the baseline assessments 
have been completed. 
 
Exclusion Criteria 
2. Patients with inﬂammatory joint disease of different origin, mixed connective tissue disease, Reiter’s syndrome, psoriatic 
arthritis, systemic lupus erythematosus, or any arthritis with onset prior to 16 years of age. 
3. Patients receiving doses of prednisolone > 10mg/day within the 4 weeks prior to the screening visit. 
4. Patients receiving intra-articular or intra-muscular steroid injections within 4 weeks prior to the screening visit. 
5. Patients who have previously received more than 1 TNFi drug OR any other biological therapy for the treatment of RA. 
6. Patients unable or unwilling to stop treatment with a prohibited DMARD (i.e synthetic DMARD aside from MTX e.g. oral or 
injectable gold, chloroquine, hydroxychloroquine, cyclosporine, azathioprine, leﬂunomide, sulphasalazine) prior to the start of 
protocol treatment. 
7. Treatment with any investigational drug in the last 12 weeks prior the start of protocol treatment. 
Appendix C – Outline of scoring methodology for the RAQoL (Rheumatoid Arthritis 
Quality of Life Questionnaire) 
The 30 questions of the RAQoL are scored to provide an overall single summary score. Each 
question is scored using a simple binary score: each “Yes” response scores 1 point, each “No” 
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scores 0 points. The points from each question are then summed to produce the overall 
RAQoL, as a score out of 30 points.  
 
If a patient fails to respond to between 1 and 6 questions, then the score can still be computed 
as a score out of 30 by rescaling the total scored by the number of completed responses. 
 
 
Where S is the sum of all points from the completed questions, and m is the number of 
missing items. 
 
For example, if 26 questions are completed, and these scored a total of 19 / 26, the RAQoL 
score is 19 * (30/26) = 21.923 / 30. 
 
It is recommended by the developers of the RAQoL that the score is treated only on an ordinal 
scale, and that summaries of the values are restricted to non-parametric statistics such as 
median, quartiles, minima and maxima. 
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Appendix D – Outline of scoring methodology for the HAQ-DI (Health Assessment 
Questionnaire – Disability Index) 
The questions of the HAQ-DI are scored within 8 domains of activity which are then combined 
to provide an overall single summary score on a scale of 0-3. The score for each of the eight 
domains are derived from asking the respondent to report the level of difficulty experienced 
when undertaking certain activities, and whether any aids, devices or other help is required to 
complete these activities. The eight domains of activity are listed in column A of the table 
below. 
 
(A) Domain (B) Questio
n Count 
(C) Matching Aid / Device(s) 
Dressing and 
Grooming 
2 Devices used for dressing;  
Arising 2 Special or built-up chair 
Eating 3 Built-up or special utensils 
Walking 2 Cane; Walker; Crutches; Wheelchair 
Hygiene 3 Raised toilet seat; bathtub seat; bathtub 
bar; Long handled appliances in bathroom 
Reach 2 Long-handled appliances for reach 
Gripping and Opening 3 Jar opener (for jars previously opened) 
Chores and 
Housework 
3 - 
 
Each question in each domain is scored between 0 and 3, with 0 corresponding to the least 
level of difficulty experienced (None at all) and 3 to the greatest level of difficulty experienced 
(Unable to do). Then, of the 2 or 3 questions in each domain (see column B for how many 
questions apply) the highest value is taken as the overall score for each domain. For example, 
if in the hygiene domain a patient has three responses scored 1, 1 and 3, then the overall 
score for the hygiene is 3, being the maximum value reported. 
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Once the score for each domain is determined, the score is then increased to account for any 
need to use aids and devices or help from others. If any of the matching aids or devices 
(Column C) are selected for that domain, or help is reportedly needed to undertake activities in 
this domain, then a domain score of 0 or 1 is increased to 2 (if the domain score is already a 2 
or a 3, then this has no impact). 
 
Finally, the overall score is determined by taking the average of all non-missing domain 
scores. If fewer than 6 domains have complete scores, then the HAQ score is missing. 
Appendix E – Outline of scoring methodology for the HADS (Hospital Anxiety and 
Depression Scale) 
The 14 questions of the HADS are grouped within 2 domains, which are scored and 
summarised separately. Question responses are scored with a value of 0-3, with 0 
representing least level of anxiety or depression, and 3 representing the greatest level of 
anxiety or depression. After each question is scored (some questions require “reverse scoring”, 
to account for responses being presented in different orders) the responses are summed within 
each domain to create the anxiety scale score and the depression scale score. 
 
Anxiety Scale Depression Scale 
Question Lowest Level Question Lowest Level 
Tense or “Wound Up” 0 = Not at all Enjoy things 0 = Definitely as much 
Frightened feeling 0 = Not at all See funny side of things 0 = As much as always 
Worrying thoughts 0 = Very little Feel cheerful 0 = Most of the time 
At ease and Relaxed 0 = Definitely Slowed Down 0 = Not at all 
Butterflies in stomach 0 = Not at all Lost interest in 
appearance 
0 = Just as much care 
as ever 
Feel restless 0 = Not at all Look forward to things 0 = As much as ever 
Sudden panic 0 = Not at all Enjoy good book etc 0 = Often 
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Approval of Analysis Plan 
APPENDIX 7
NIHR Journals Library www.journalslibrary.nihr.ac.uk
188
  
DOI: 10.3310/hta22340 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 34
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Brown et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
189
  
∗
∗ If the analysis plan is amended, note the new version number. If a deviation is made from the analysis plan within the analysis, leave blank.  
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Appendix 8 Key protocol amendments
Version of patient
information sheet
containing amendment
Additional
document created Description of the protocol amendment
4.0 N/A Amendment from intravenous formulation of abatacept to
subcutaneous formulation following agreement from manufacturers of
abatacept to provide trial supplies. This also required changes to other
documentation to:
1. include a further vendor responsible for packaging and labelling of
the abatacept trial supplies
2. amend wording on the labels for subcutaneous abatacept
N/A Abatacept
participant letter
Approval was obtained for a letter to provide to participants that
explained a discrepancy between the expiry date given on the internal
and external packaging of abatacept
4.0 N/A Inclusion of the option for subcutaneous IMPs to be sourced and
delivered to participants’ homes by third-party home health-care
providers as per local hospital practice
5.0 N/A Clarification included that when local practice indicates the use of a
home health-care provider for the delivery of subcutaneous IMPs, the
trial procedures will map onto the established standard care practices
in place at each individual site in terms of services and record-keeping
and retention requirements
6.0 N/A Addition of golimumab to the alternative-mechanism TNFi arm
following feedback from sites that the use of golimumab was
becoming more commonplace and, therefore, the ability to use this
may expand the field of potential patients/increase pragmatism of
study would reflect standard practice more closely
6.0 N/A Modification of the primary end point from a dichotomous end point
(whether or not the patient achieved a reduction of > 1.2 units in the
DAS28 with no toxicity) to a continuous end point (change in the
DAS28)
N/A Patient advert,
version 1.0
Designed to advertise the trial directly to patients, with the intention
that sites display the patient advert in patient waiting rooms, etc. In
addition, information contained within the advert was intended to be
used via various means, for example patient websites, e-bulletins and
social media for the purpose of advertising the trial to the wider RA
community
N/A Patient information
summary sheet,
version 1.0
A participant information summary sheet was created to summarise
and complement the main PIS/ICD before the patient reads the main
PIS/ICD following feedback from patient and public involvement
representatives that the current PIS/ICD was lengthy and a
supplementary summary sheet would be beneficial
7.0 N/A Corrections of errors noted in the research ethics committee form and
the patient information sheet relating to the amount of radiation that
patients would be exposed to as part of the imaging aspects of the
study
N/A N/A Research and development form amended to enable the use of
participant identification centres, as a number of investigators
suggested that they had clinics at other sites where eligible patients
may be seen and who they would be able to refer to their main site in
order to screen for participation
PIS/ICD, participant information sheet and informed consent document.
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Appendix 9 Screening and withdrawals
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TABLE 40 Summary of patients considered for inclusion in SWITCH, with status up to randomisation, including reasons for non-registration
Centre name and number
Patient was
ineligible
(n= 417)
Patient was
eligible but did
not consent
(n= 90)
Clinician
preferred
particular
treatment
(n= 12)
Clinician wishes to
continue current
treatment, despite
non-response
(n= 5)
Did not
attend
(n= 2)
No reason
given for non-
registration
(n= 3)
Considered,
registered,
but not
randomised
(n= 27)
Randomised
(n= 122)
Total
(n= 678)
Chapel Allerton Hospital, Leeds;
N00482
7 5 – – – – 8 32 52
Cannock Chase Hospital; N00473 29 5 – – – – 2 8 44
Manchester Royal Infirmary; N00080 28 6 – – – – 3 6 43
Airedale General Hospital; N00074 2 4 – – 1 – 2 6 15
Derriford Hospital, Plymouth; N00118 5 – – – – – 2 6 13
King George Hospital, Ilford; N00165 6 – – – – – 1 6 13
Queen Elizabeth Hospital, Gateshead;
N00071
2 4 – – – – – 6 12
Royal National Hospital for Rheumatic
Diseases, Bath; N02220
15 7 1 – – – 1 5 29
Birmingham City Hospital; N00346 24 6 – – – – – 5 35
Hull Royal Infirmary; N00078 13 – – – – – 1 4 18
Royal Hallamshire Hospital, Sheffield;
N00093
20 9 – – – – – 4 33
Leicester Royal Infirmary; N00031 17 5 – – – 2 – 4 28
Queen’s Hospital, Burton upon Trent;
N00178
16 6 1 – – – – 4 27
University Hospital, North Durham;
N00170
5 1 1 – – – 1 3 11
Poole Hospital; N00108 53 2 – – – 1 – 3 59
Northampton General Hospital;
N00038
2 – – – – – – 3 5
New Cross Hospital, Wolverhampton;
N00034
– – – – – – – 3 3
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Centre name and number
Patient was
ineligible
(n= 417)
Patient was
eligible but did
not consent
(n= 90)
Clinician
preferred
particular
treatment
(n= 12)
Clinician wishes to
continue current
treatment, despite
non-response
(n= 5)
Did not
attend
(n= 2)
No reason
given for non-
registration
(n= 3)
Considered,
registered,
but not
randomised
(n= 27)
Randomised
(n= 122)
Total
(n= 678)
Salford Royal Infirmary; N00400 – – – – – – – 3 3
Broadgreen Hospital, Liverpool;
N00589
3 – – – – – – 2 5
Royal Victoria Infirmary, Newcastle;
N00072
31 8 4 – – – 2 1 46
Nuffield Orthopaedic Centre, Oxford;
N00282
71 1 3 5 – – 1 1 82
Royal Derby Hospital; N00168 34 5 1 – – – – 1 41
Queen Alexandra Hospital,
Portsmouth; N00110
11 3 – – – – – 1 15
Guy’s Hospital, London; N00241 4 2 – – – – – 1 7
Darlington Memorial Hospital;
N00068
– 3 – – – – – 1 4
Harrogate District Hospital; N00076 – – – – – – – 1 1
Bristol Royal Infirmary; N00117 – – – – – – – 1 1
Musgrove Park Hospital, Taunton;
N00306
– – – – – – – 1 1
Royal London Hospital (Ex Mile End);
N01705
2 2 – – – – 1 – 5
St Peter’s Hospital, Ashford; N00052 2 – 1 – – – 1 – 4
Raigmore Hospital, Inverness; N00355 – 2 – – – – 1 – 3
Southend Hospital; N00049 14 2 – – 1 – – – 17
Wythenshawe Hospital, Manchester;
N00172
1 2 – – – – – – 3
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TABLE 41 Summary of reasons for ineligibility leading to patients not being approached for consent for the
SWITCH trial
Reason for ineligibility Total (n= 417), n (%)
Has not experienced RS disease activity on an initial TNFi agent 95 (22.8)
Has not been on a stable dose of MTX for 28 days prior to screening 92 (22.1)
Has received more than one TNFi drug OR any other biological therapy 72 (17.3)
Has not failed conventional DMARD therapy (including MTX) 32 (7.7)
Has another comorbidity 23 (5.5)
Has not had a diagnosis of RA 14 (3.4)
Has inflammatory joint disease of different origin 9 (2.2)
Is pregnant, lactating or a woman of child-bearing potential 8 (1.9)
Has scheduled or anticipated surgery 7 (1.7)
Has received intra-articular or intramuscular steroid injections 7 (1.7)
No reason provided 7 (1.7)
Is under 18 years of age 5 (1.2)
Is unable to provide written informed consent prior to trial 4 (1.0)
Is unable or unwilling to stop treatment with a prohibited DMARD 4 (1.0)
Has untreated active current or latent TB 4 (1.0)
Is known to have active current or history of recurrent infections. 3 (0.7)
Has received doses of prednisolone > 10mg/day 2 (0.5)
Has had treatment with any investigational drug in the last 90 days before study drug admin. 2 (0.5)
Has significantly impaired bone marrow function. 2 (0.5)
Is currently on NSAIDs and/or corticosteroids but not an unchanged regimen 1 (0.2)
Unable/unwilling to stop etanercept ≥ 4 weeks or infliximab/adalimumab/certolizumab
≥ 8 weeks prior to study drug administration
1 (0.2)
Has had a major episode of infection 1 (0.2)
Is at significant risk of infection 1 (0.2)
Has severe hypoproteinaemia 1 (0.2)
Other 20 (4.8)
TABLE 42 Summary of reasons for non-consent leading to patients not being approached for consent for the
SWITCH trial
Reason for non-consent Total (n= 90), n (%)
Does not want to be involved in the research 32 (35.6)
Refused without any reason 19 (21.1)
Patient preference for or against one or more treatments 10 (11.1)
Took/taken part in competing study 9 (10.0)
Language difficulties 4 (4.4)
Feels poorly or unwell 3 (3.3)
Patient refused to be randomised 3 (3.3)
Considered study schedule compliance to be burdensome 2 (2.2)
Patient did not respond 2 (2.2)
Other reason 6 (6.7)
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TABLE 43 Summary of reasons given for ineligibility among the 19 patients who were registered but found to be
ineligible following pre-randomisation tests
Reason for ineligibility Total, n
Persistent RA disease activity 6
Stable dose of MTX 4
Stable regimen of NSAIDs 2
Had or anticipated major surgery 2
Untreated active current TB 2
Steroid injections within 28 days before screening 2
Prior regimens 2
Participant failed conventional DMARD therapy 1
Major episode of infection 1
Significant risk of infection 1
Recurrent bacterial, viral, fungal or mycobacterial infections 1
Significantly impaired bone marrow function 1
Other comorbidities 1
TABLE 44 Summary of characteristics of patients who were considered for participation in the SWITCH trial
Patient characteristic
Considered, but not
registered (N= 529)
Consented and registered,
but not randomised (N= 27)
Randomised
(N= 122)
Total
(N= 678)
Age (years)
Mean (SD) 56.9 (13.67) 56.9 (14.15) 56.6 (12.21) 56.9 (13.41)
Range 2.0–86.0 30.4–81.1 24.4–81.6 2.0–86.0
Missing 36 0 0 36
Sex, n (%)
Male 103 (19.5) 5 (18.5) 21 (17.2) 129 (19.0)
Female 418 (79.0) 22 (81.5) 101 (82.8) 541 (79.8)
Not known 8 (1.5) – – 8 (1.2)
RF status, n (%)
RF seropositive 250 (47.3) 17 (63.0) 82 (67.2) 349 (51.5)
RF seronegative 69 (13.0) 5 (18.5) 38 (31.1) 112 (16.5)
Not known 210 (39.7) 5 (18.5) 2 (1.6) 217 (32.0)
ACPA status, n (%)
Positive 154 (29.1) 16 (59.3) 76 (62.3) 246 (36.3)
Negative 58 (11.0) 4 (14.8) 35 (28.7) 97 (14.3)
Not known 317 (59.9) 7 (25.9) 11 (9.0) 335 (49.4)
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TABLE 45 Listing of patient and clinician withdrawals
Centre
Patient
number
Randomised
treatment
Date of
randomisation
Date of
withdrawal
request
Withdrawn
from further
trial treatment
Follow-up
as per trial
schedule
Collection of
further data
from notes Withdrawal reason
00080 00023 Monoclonal
antibody
14 August 2013 11 November 2013 Yes No No Lack of efficacy
00118 00060 Etanercept 2 January 2014 12 May 2015 Yes No Yes Flares of arthritis and poor response from trial
drugs. Patient agrees to switch to a new
biologic
00038 00126 Etanercept 10 September 2014 21 May 2015 N/A No Yes Because of ill health she has missed a lot of
time at work and cannot take any more time
off to attend research appointments
00118 00068 Abatacept 12 February 2014 12 May 2015 Yes No Yes Poor response from the randomised medication
and worsening arthritis and frequent flares
00118 00109 Abatacept 18 July 2014 12 May 2015 Yes No Yes Poor response from trial drugs. Flare of arthritis
and unwilling to continue in trial. Participant
switching to rituximab
00118 00109 Abatacept 18 July 2014 14 April 2015 Yes No No Participant was requesting to switch biologic
because of reduced efficacy and because of a
house move. No longer wanted appointments
00178 00134 Abatacept 9 October 2014 12 December 2014 No – – Owing to chest infection principal investigator
wishes to withdraw patient from the study
00117 00145 Abatacept 17 November 2014 14 August 2015 Yes Yes – Would like to get pregnant
00482 00007 Rituximab 11 December 2012 23 August 2013 Yes No No Patient does not want further treatment or any
follow-up appointments, declined at every
level. The patient declined any further
treatment from the rheumatology department
in general
00080 00017 Rituximab 13 June 2013 17 June 2014 Yes No No No reason given
00093 00135 Rituximab 7 October 2014 19 March 2015 Yes No Yes Participant’s choice
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Appendix 10 Per protocol population
summary tables
TABLE 46 Summary of reasons for exclusion from the PP population
Reason for exclusion
Treatment arm, n (%)
Total (N= 122),
n (%)
Alternative TNFi
(N= 41)
Abatacept
(N= 41)
Rituximab
(N= 40)
Excluded from the PP population 28 (68.3) 27 (65.9) 26 (65.0) 81 (66.4)
Unacceptable eligibility violation 1 (2.4) – 1 (2.5) 2 (1.6)
Week 24 assessment did not occur within 30 weeks of baseline
Failed because week 24 visit did not occur 4 (9.8) 3 (7.3) – 7 (5.7)
Failed because week 24 was > 30 weeks from
baseline
5 (12.2) 2 (4.9) 7 (17.5) 14 (11.5)
Received additional contraindicated treatment 10 (24.4) 9 (22.0) 4 (10.0) 23 (18.9)
Protocol treatment interrupted for > 28 days – 3 (7.3) – 3 (2.5)
Participant was under- or overdosed – – – –
Received steroid treatment within 6 weeks of an
end-point assessment
10 (24.4) 13 (31.7) 12 (30.0) 35 (28.7)
Not compliant with MTX up to week 24 5 (12.2) 3 (7.3) 4 (10.0) 12 (9.8)
Not compliant with treatment up to week 24 10 (24.4) 12 (29.3) 5 (12.5) 27 (22.1)
Patient N00080/00069 was ineligible because of comorbidity, but this criterion was not grounds for exclusion from the
PP population. A patient’s conduct can violate the protocol in multiple ways, but can be excluded only once. Hence, the
number of reasons for exclusion may exceed the number of patients excluded.
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TABLE 47 Minimisation factors: PP population
Minimisation factor
Treatment arm, n (%)
Total (N= 41),
n (%)
Alternative TNFi
(N= 13)
Abatacept
(N= 14)
Rituximab
(N= 14)
Centre name and number
Chapel Allerton Hospital, Leeds; N00482 3 (23.1) 2 (14.3) 5 (35.7) 10 (24.4)
King George Hospital, Ilford; N00165 2 (15.4) 2 (14.3) 1 (7.1) 5 (12.2)
Royal Hallamshire Hospital, Sheffield; N00093 2 (15.4) 1 (7.1) – 3 (7.3)
Derriford Hospital, Plymouth; N00118 1 (7.7) 1 (7.1) 1 (7.1) 3 (7.3)
Airedale General Hospital; N00074 1 (7.7) 1 (7.1) – 2 (4.9)
Hull Royal Infirmary; N00078 – 1 (7.1) 1 (7.1) 2 (4.9)
Poole Hospital; N00108 1 (7.7) – 1 (7.1) 2 (4.9)
University Hospital, North Durham; N00170 – – 2 (14.3) 2 (4.9)
Broadgreen Hospital, Liverpool; N00589 1 (7.7) 1 (7.1) – 2 (4.9)
New Cross Hospital, Wolverhampton; N00034 – 1 (7.1) – 1 (2.4)
Darlington Memorial Hospital; N00068 – 1 (7.1) – 1 (2.4)
Queen Elizabeth Hospital, Gateshead; N00071 1 (7.7) – – 1 (2.4)
Manchester Royal Infirmary; N00080 – – 1 (7.1) 1 (2.4)
Queen Alexandra Hospital, Portsmouth; N00110 – – 1 (7.1) 1 (2.4)
Bristol Royal Infirmary; N00117 – 1 (7.1) – 1 (2.4)
Queen’s Hospital, Burton upon Trent; N00178 1 (7.7) – – 1 (2.4)
Musgrove Park Hospital, Taunton; N00306 – 1 (7.1) – 1 (2.4)
Salford Royal Infirmary; N00400 – – 1 (7.1) 1 (2.4)
Cannock Chase Hospital; N00473 – 1 (7.1) – 1 (2.4)
Disease duration
< 5 years 3 (23.1) 4 (28.6) 4 (28.6) 11 (26.8)
≥ 5 years 10 (76.9) 10 (71.4) 10 (71.4) 30 (73.2)
RA/ACPA seropositivity
RF seropositive and/or anti-CCP seropositive 12 (92.3) 9 (64.3) 12 (85.7) 33 (80.5)
Both RF seronegative and anti-CCP seronegative 1 (7.7) 5 (35.7) 2 (14.3) 8 (19.5)
Non-response category
Primary 4 (30.8) 6 (42.9) 8 (57.1) 18 (43.9)
Secondary 9 (69.2) 8 (57.1) 6 (42.9) 23 (56.1)
CCP, cyclic citrullinated peptide.
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TABLE 48 Demographic information: PP population
Patient characteristic
Treatment arm
Total (N= 41)
Alternative TNFi
(N= 13)
Abatacept
(N= 14)
Rituximab
(N= 14)
Participant sex, n (%)
Male 4 (30.8) 1 (7.1) 6 (42.9) 11 (26.8)
Female 9 (69.2) 13 (92.9) 8 (57.1) 30 (73.2)
Derived patient age (years)
Mean (SD) 55.3 (9.40) 53.4 (15.00) 58.1 (11.82) 55.6 (12.21)
Range 40.8–67.0 28.8–76.2 41.0–81.1 28.8–81.1
Missing 0 0 0 0
Body mass index (kg/m2)
Mean (SD) 29.8 (5.45) 29.9 (6.23) 30.9 (5.34) 30.2 (5.54)
Median (IQR) 28.3 (27.4–34.1) 27.9 (24.6–36.8) 29.0 (26.4–33.5) 29.0 (25.3–34.9)
Missing 0 2 1 3
Smoking status, n (%)
Non-smoking (never smoked) 3 (23.1) 6 (42.9) 7 (50.0) 16 (39.0)
Past smoker 5 (38.5) 4 (28.6) 6 (42.9) 15 (36.6)
Current smoker 5 (38.5) 4 (28.6) 1 (7.1) 10 (24.4)
Prior comorbidities, n (%)
Asthma 3 (23.1) – 1 (7.1) 4 (9.8)
Bowel disease – – 1 (7.1) 1 (2.4)
Cancer – – 1 (7.1) 1 (2.4)
Depression 3 (23.1) 2 (14.3) – 5 (12.2)
Diabetes – 1 (7.1) 3 (21.4) 4 (9.8)
Hypercholesterolaemia – 4 (28.6) 4 (28.6) 8 (19.5)
Hypertension 4 (30.8) 7 (50.0) 5 (35.7) 16 (39.0)
Ischaemic heart disease 1 (7.7) – 2 (14.3) 3 (7.3)
Myocardial infarction – – 2 (14.3) 2 (4.9)
Osteoarthritis 4 (30.8) 3 (21.4) 5 (35.7) 12 (29.3)
Peptic ulcer disease – 1 (7.1) 1 (7.1) 2 (4.9)
Peripheral vascular disease – – 1 (7.1) 1 (2.4)
Stroke – – 1 (7.1) 1 (2.4)
Thyroid dysfunction 3 (23.1) 3 (21.4) – 6 (14.6)
IQR, interquartile range.
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TABLE 49 Disease and treatment history: PP population
Disease activity/treatment history
Treatment arm
Total (N= 41)
Alternative TNFi
(N= 13)
Abatacept
(N= 14)
Rituximab
(N= 14)
Disease duration (years)
Median (IQR) 9.3 (5.7–17.5) 6.5 (4.4–10.6) 8.1 (4.0–15.3) 8.0 (4.4–14.3)
Range 2.2–35.2 1.1–20.4 1.3–33.7 1.1–35.2
Missing 0 0 0 0
TJC (/28)
Mean (SD) 13.2 (5.55) 17.5 (7.98) 21.1 (6.96) 17.4 (7.51)
Missing 0 0 0 0
SJC (/28)
Mean (SD) 8.3 (5.38) 9.4 (6.16) 12.3 (8.13) 10.0 (6.73)
Missing 0 0 0 0
Does the participant experience early-morning stiffness?, n (%)
Yes 12 (92.3) 14 (100.0) 14 (100.0) 40 (97.6)
No 1 (7.7) – – 1 (2.4)
ESR (mm/hour)
Median (IQR) 14.0 (8.0–22.0) 23.5 (12.0–34.0) 26.5 (15.0–42.0) 21.0 (11.0–32.0)
Missing 0 0 0 0
CRP level (mg/l)
Median (IQR) 5.0 (3.8–10.1) 8.5 (5.0–19.0) 6.5 (6.0–21.0) 6.0 (4.5–16.5)
Range 1.0–66.0 1.0–58.2 2.1–78.0 1.0–78.0
Type of TNFi failed (derived), n (%)
Monoclonal antibody 10 (76.9) 7 (50.0) 8 (57.1) 25 (61.0)
Etanercept 3 (23.1) 7 (50.0) 6 (42.9) 16 (39.0)
Previous TNFi agent, n (%)
Adalimumab 2 (15.4) 3 (21.4) 4 (28.6) 9 (22.0)
CZP 6 (46.2) 3 (21.4) – 9 (22.0)
Etanercept 3 (23.1) 7 (50.0) 6 (42.9) 16 (39.0)
Golimumab 1 (7.7) – 1 (7.1) 2 (4.9)
Infliximab 1 (7.7) 1 (7.1) 3 (21.4) 5 (12.2)
IQR, interquartile range.
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TABLE 51 Baseline patient-reported outcomes: PP population
Patient-reported
outcome
Treatment arm
Total (n= 41)Alternative TNFi (n= 13) Abatacept (n= 14) Rituximab (n= 14)
Patient Global Assessment of Arthritis VAS (mm)
Median (IQR) 68.0 (49.0–76.0) 69.5 (64.0–81.0) 74.0 (48.0–88.0) 72.0 (56.5–81.5)
Missing 0 0 1 1
Patient Assessment of General Health VAS (mm)
Median (IQR) 58.0 (47.0–74.0) 61.5 (51.0–67.0) 67.0 (29.0–72.0) 61.0 (47.5–71.0)
Missing 0 0 1 1
Patient Global Assessment of Pain VAS (mm)
Median (IQR) 66.0 (51.0–78.0) 73.0 (64.0–79.0) 78.0 (61.0–95.0) 73.0 (58.5–86.0)
Missing 0 0 1 1
HAQ-DI score
Median (IQR) 1.9 (1.8–2.1) 1.8 (1.6–2.0) 2.0 (1.4–2.5) 1.9 (1.6–2.1)
Missing 0 0 1 1
RAQoL score
Median (IQR) 22.0 (20.0–24.0) 21.5 (14.0–28.0) 21.0 (15.0–24.0) 21.6 (15.5–25.5)
Missing 0 0 1 1
continued
TABLE 50 Baseline disease activity: PP population
Disease activity
Treatment arm
Total (n= 41)Alternative TNFi (n= 13) Abatacept (n= 14) Rituximab (n= 14)
DAS28 (baseline)
Mean (SD) 5.3 (0.73) 6.2 (0.85) 6.6 (1.22) 6.0 (1.09)
Missing 0 0 1 1
CDAI
Mean (SD) 32.8 (12.80) 41.0 (12.97) 47.0 (13.43) 40.3 (14.02)
Missing 0 1 1 2
SDAI
Mean (SD) 32.8 (13.22) 42.6 (13.17) 48.8 (14.27) 41.6 (14.76)
Missing 1 1 1 3
Physician Global Assessment of Disease Activity (mm)
Median (IQR) 60.0 (45.0–70.0) 66.0 (57.3–81.0) 65.0 (62.0–84.3) 63.5 (53.5–79.0)
Missing 0 1 0 1
IQR, interquartile range.
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TABLE 51 Baseline patient-reported outcomes: PP population (continued )
Patient-reported
outcome
Treatment arm
Total (n= 41)Alternative TNFi (n= 13) Abatacept (n= 14) Rituximab (n= 14)
HADS score
Median (IQR) 13.0 (8.0–19.0) 16.0 (9.0–22.0) 11.0 (8.0–16.0) 13.0 (8.0–20.0)
Missing 0 0 1 1
HADS anxiety score
Median (IQR) 6.0 (4.0–11.0) 8.5 (6.0–12.0) 5.0 (4.0–10.0) 6.5 (4.0–11.5)
Missing 0 0 1 1
HADS depression score
Median (IQR) 6.0 (4.0–8.0) 7.5 (4.0–9.0) 6.0 (3.0–10.0) 6.0 (3.5–9.0)
Missing 0 0 1 1
IQR, interquartile range.
TABLE 52 The DAS28 and corresponding improvement in DAS28 over 48 weeks: PP population
Visit
Treatment arm
Total (n= 41)Alternative TNFi (n= 13) Abatacept (n= 14) Rituximab (n= 14)
DAS28
Baseline
Mean (SD) 5.3 (0.73) 6.2 (0.85) 6.6 (1.22) 6.0 (1.09)
Missing 0 0 1 1
12 weeks
Mean (SD) 4.2 (0.97) 4.7 (1.20) 4.8 (1.27) 4.6 (1.16)
Missing 1 1 1 3
24 weeks
Mean (SD) 3.9 (0.99) 4.6 (1.51) 4.4 (1.78) 4.3 (1.46)
Missing 0 1 1 2
36 weeks
Mean (SD) 3.7 (0.99) 4.8 (1.44) 5.1 (1.36) 4.5 (1.40)
Missing 0 1 1 2
48 weeks
Mean (SD) 3.8 (1.16) 4.5 (0.84) 5.0 (1.44) 4.5 (1.27)
Missing 3 3 1 7
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TABLE 52 The DAS28 and corresponding improvement in DAS28 over 48 weeks: PP population (continued )
Visit
Treatment arm
Total (n= 41)Alternative TNFi (n= 13) Abatacept (n= 14) Rituximab (n= 14)
DAS28 improvement
12 weeks
Mean (SD) 1.0 (1.18) 1.5 (0.91) 1.5 (0.97) 1.4 (1.02)
Missing 1 1 2 4
24 weeks
Mean (SD) 1.4 (1.08) 1.6 (1.37) 2.2 (1.75) 1.7 (1.42)
Missing 0 1 2 3
36 weeks
Mean (SD) 1.6 (1.26) 1.5 (1.33) 1.5 (1.17) 1.5 (1.22)
Missing 0 1 1 2
48 weeks
Mean (SD) 1.6 (1.58) 1.8 (0.83) 1.4 (1.40) 1.6 (1.27)
Missing 3 3 2 8
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Appendix 11 Supplementary baseline data
Baseline characteristic
Treatment arm, n (%)
Total
(N= 122),
n (%)
Alternative TNFi
(N= 41)
Abatacept
(N= 41)
Rituximab
(N= 40)
Centre name and number
Chapel Allerton Hospital, Leeds; N00482 10 (24.4) 11 (26.8) 11 (27.5) 32 (26.2)
Cannock Chase Hospital; N00473 2 (4.9) 2 (4.9) 4 (10.0) 8 (6.6)
Queen Elizabeth Hospital, Gateshead; N00071 2 (4.9) 1 (2.4) 3 (7.5) 6 (4.9)
Airedale General Hospital; N00074 2 (4.9) 3 (7.3) 1 (2.5) 6 (4.9)
Manchester Royal Infirmary; N00080 2 (4.9) – 4 (10.0) 6 (4.9)
Derriford Hospital, Plymouth; N00118 2 (4.9) 3 (7.3) 1 (2.5) 6 (4.9)
King George Hospital, Ilford; N00165 2 (4.9) 2 (4.9) 2 (5.0) 6 (4.9)
Birmingham City Hospital; N00346 2 (4.9) 2 (4.9) 1 (2.5) 5 (4.1)
Royal National Hospital for Rheumatic Diseases,
Bath; N02220
1 (2.4) 3 (7.3) 1 (2.5) 5 (4.1)
Leicester Royal Infirmary; N00031 1 (2.4) 2 (4.9) 1 (2.5) 4 (3.3)
Hull Royal Infirmary; N00078 1 (2.4) 1 (2.4) 2 (5.0) 4 (3.3)
Royal Hallamshire Hospital, Sheffield; N00093 2 (4.9) 1 (2.4) 1 (2.5) 4 (3.3)
Queen’s Hospital, Burton upon Trent; N00178 2 (4.9) 2 (4.9) – 4 (3.3)
New Cross Hospital, Wolverhampton; N00034 1 (2.4) 1 (2.4) 1 (2.5) 3 (2.5)
Northampton General Hospital; N00038 3 (7.3) – – 3 (2.5)
Poole Hospital; N00108 2 (4.9) – 1 (2.5) 3 (2.5)
University Hospital, North Durham; N00170 – 1 (2.4) 2 (5.0) 3 (2.5)
Salford Royal Infirmary; N00400 1 (2.4) 1 (2.4) 1 (2.5) 3 (2.5)
Broadgreen Hospital, Liverpool; N00589 1 (2.4) 1 (2.4) – 2 (1.6)
Darlington Memorial Hospital; N00068 – 1 (2.4) – 1 (0.8)
Royal Victoria Infirmary, Newcastle upon Tyne; N00072 1 (2.4) – – 1 (0.8)
Harrogate District Hospital; N00076 – – 1 (2.5) 1 (0.8)
Queen Alexandra Hospital, Portsmouth; N00110 – – 1 (2.5) 1 (0.8)
Bristol Royal Infirmary; N00117 – 1 (2.4) – 1 (0.8)
Royal Derby Hospital; N00168 – 1 (2.4) – 1 (0.8)
Guy’s Hospital, London; N00241 1 (2.4) – – 1 (0.8)
Nuffield Orthopaedic Centre, Oxford; N00282 – – 1 (2.5) 1 (0.8)
Musgrove Park Hospital, Taunton; N00306 – 1 (2.4) – 1 (0.8)
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Baseline characteristic
Treatment arm, n (%)
Total
(N= 122),
n (%)
Alternative TNFi
(N= 41)
Abatacept
(N= 41)
Rituximab
(N= 40)
Previous DMARDs
Azathioprine
Previously used, and stopped 4 (9.8) 3 (7.3) – 7 (5.7)
Not used 36 (87.8) 38 (92.7) 39 (97.5) 113 (92.6)
Not known 1 (2.4) – 1 (2.5) 2 (1.6)
Chloroquine
Previously used, cessation unknown 1 (2.4) – – 1 (0.8)
Not used 39 (95.1) 41 (100.0) 39 (97.5) 119 (97.5)
Not known 1 (2.4) – 1 (2.5) 2 (1.6)
Ciclosporin
Previously used, and stopped 1 (2.4) 2 (4.9) 2 (5.0) 5 (4.1)
Not used 39 (95.1) 39 (95.1) 37 (92.5) 115 (94.3)
Not known 1 (2.4) – 1 (2.5) 2 (1.6)
Hydroxychloroquine
Previously used, and stopped 33 (80.5) 23 (56.1) 24 (60.0) 80 (65.6)
Previously used, but unwilling to stop 1 (2.4) – – 1 (0.8)
Previously used, cessation unknown – 1 (2.4) 2 (5.0) 3 (2.5)
Not used 7 (17.1) 17 (41.5) 13 (32.5) 37 (30.3)
Not known – – 1 (2.5) 1 (0.8)
Leflunomide
Previously used, and stopped 11 (26.8) 4 (9.8) 11 (27.5) 26 (21.3)
Not used 29 (70.7) 37 (90.2) 28 (70.0) 94 (77.0)
Not known 1 (2.4) – 1 (2.5) 2 (1.6)
Oral/injectable gold
Previously used, and stopped 2 (4.9) 2 (4.9) 2 (5.0) 6 (4.9)
Not used 38 (92.7) 39 (95.1) 37 (92.5) 114 (93.4)
Not known 1 (2.4) – 1 (2.5) 2 (1.6)
Sulfasalazine
Previously used, and stopped 23 (56.1) 32 (78.0) 34 (85.0) 89 (73.0)
Previously used, but unwilling to stop 1 (2.4) – – 1 (0.8)
Previously used, cessation unknown – 1 (2.4) – 1 (0.8)
Not used 16 (39.0) 8 (19.5) 6 (15.0) 30 (24.6)
Not known 1 (2.4) – – 1 (0.8)
Penicillamine
Previously used, and stopped – 2 (4.9) 1 (2.5) 3 (2.5)
Not used 41 (100.0) 39 (95.1) 39 (97.5) 119 (97.5)
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Baseline characteristic
Treatment arm, n (%)
Total
(N= 122),
n (%)
Alternative TNFi
(N= 41)
Abatacept
(N= 41)
Rituximab
(N= 40)
Unknown DMARD
Previously used, and stopped 1 (2.4) – 1 (2.5) 2 (1.6)
Not used 40 (97.6) 41 (100.0) 39 (97.5) 120 (98.4)
Received steroids within 4 weeks of screening visit
None 32 (78.0) 33 (80.5) 33 (82.5) 98 (80.3)
Oral prednisolone 8 (19.5) 8 (19.5) 6 (15.0) 22 (18.0)
Intramuscular methylprednisolone – – 1 (2.5) 1 (0.8)
Intramuscular triamcinolone 1 (2.4) – – 1 (0.8)
NSAIDs 4 weeks prior to screen
Yes 24 (58.5) 14 (34.1) 22 (55.0) 60 (49.2)
No 16 (39.0) 27 (65.9) 18 (45.0) 61 (50.0)
Missing 1 (2.4) – – 1 (0.8)
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Appendix 12 Secondary outcomes
TABLE 53 Summaries of the reduction in the DAS28 at week 24 for each of the exploratory subgroups:
complete-case population
Exploratory subgroup
Treatment arm
TotalAlternative TNFi Abatacept Rituximab
RF/ACPA status
RF and ACPA seronegative n= 5 n= 10 n = 7 n= 22
Mean (SD) 1.8 (1.63) 1.2 (2.05) –0.2 (1.76) 1.0 (1.91)
Median (IQR) 1.0 (0.9 to 2.7) 1.3 (–0.1 to 2.5) 0.3 (–1.2 to 0.9) 1.0 (0.2 to 1.5)
Missing, n 1 2 3 6
RF or ACPA seropositive n= 36 n= 31 n = 33 n= 100
Mean (SD) 1.4 (1.25) 1.2 (1.65) 1.5 (1.90) 1.4 (1.59)
Median (IQR) 1.6 (0.5 to 2.1) 1.2 (0.1 to 2.2) 1.4 (0.5 to 2.5) 1.4 (0.4 to 2.2)
Missing, n 4 5 5 14
Initial alternative TNFi failed
Monoclonal antibody n= 25 n= 23 n = 22 n= 70
Mean (SD) 1.3 (1.25) 0.9 (1.58) 1.1 (1.96) 1.1 (1.57)
Median (IQR) 1.4 (0.4 to 1.9) 0.7 (–0.4 to 1.7) 1.3 (0.4 to 1.9) 1.2 (0.3 to 1.9)
Missing, n 2 4 5 11
Etanercept n= 16 n= 18 n = 18 n= 52
Mean (SD) 1.6 (1.36) 1.6 (1.85) 1.5 (1.97) 1.6 (1.72)
Median (IQR) 1.7 (0.9 to 2.2) 1.6 (0.4 to 2.6) 1.5 (–0.2 to 2.4) 1.6 (0.4 to 2.4)
Missing, n 3 3 3 9
Initial non-responder status
Primary non-response n= 15 n= 15 n = 15 n= 45
Mean (SD) 1.2 (1.51) 1.7 (2.14) 1.7 (1.78) 1.5 (1.76)
Median (IQR) 1.1 (0.3 to 2.2) 1.4 (0.0 to 3.3) 1.5 (0.1 to 3.2) 1.4 (0.3 to 2.6)
Missing, n 1 4 3 8
Secondary non-response n= 26 n= 26 n = 25 n= 77
Mean (SD) 1.5 (1.13) 1.0 (1.48) 1.1 (2.05) 1.2 (1.57)
Median (IQR) 1.6 (0.9 to 2.1) 1.2 (–0.2 to 1.8) 0.9 (0.3 to 1.8) 1.3 (0.3 to 2.0)
Missing, n 4 3 5 12
IQR, interquartile range.
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TABLE 54 Frequency of patients achieving a DAS28 response (a reduction of 1.2 units or more from baseline) over
48 weeks: complete-case population
Visit
Treatment arm, n/N (%)
Total, n/N (%)Alternative TNFi Abatacept Rituximab
Week 12 14/34 (41.2) 19/35 (54.3) 16/34 (47.1) 49/103 (47.6)
Week 24 21/36 (58.3) 17/34 (50.0) 17/32 (53.1) 55/102 (53.9)
Week 36 18/34 (52.9) 16/31 (51.6) 15/29 (51.7) 49/94 (52.1)
Week 48 19/30 (63.3) 18/30 (60.0) 13/23 (56.5) 50/83 (60.2)
TABLE 55 Covariance matrix of the unstructured covariance (95% CI) from mixed-effects model for the DAS28 over
48 weeks
Visit
Time point
12 weeks 24 weeks 36 weeks 48 weeks
12 weeks 2.11 (1.56 to 2.66)
24 weeks 1.04 (0.63 to 1.44) 1.69 (1.23 to 2.15)
36 weeks 0.82 (0.38 to 1.25) 1.05 (0.64 to 1.47) 1.90 (1.36 to 2.44)
48 weeks 0.72 (0.38 to 1.07) 0.83 (0.49 to 1.16) 0.74 (0.39 to 1.08) 1.38 (1.00 to 1.75)
TABLE 56 Covariance matrix of the unstructured covariance (95% CI) from mixed-effects model for DAS28
response over 48 weeks
Visit
Time point
12 weeks 24 weeks 36 weeks 48 weeks
12 weeks 1.03 (0.75 to 1.30)
24 weeks 0.40 (0.18 to 0.63) 1.08 (0.79 to 1.37)
36 weeks 0.28 (0.07 to 0.50) 0.27 (0.06 to 0.47) 0.95 (0.70 to 1.21)
48 weeks 0.48 (0.26 to 0.70) 0.44 (0.21 to 0.68) 0.20 (0.00 to 0.40) 1.09 (0.80 to 1.38)
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TABLE 57 Frequency of patients achieving ACR20, ACR50 or ACR70 response at each follow-up until week 48:
complete-case population
Visit
Treatment arm, n/N (%)
Total, n/N (%)Alternative TNFi Abatacept Rituximab
ACR20
Week 12 12/37 (32.4) 16/37 (43.2) 14/37 (37.8) 42/111 (37.8)
Week 24 16/36 (44.4) 11/35 (31.4) 10/37 (27.0) 37/108 (34.3)
Week 36 16/34 (47.1) 12/32 (37.5) 11/32 (34.4) 39/98 (39.8)
Week 48 17/31 (54.8) 11/31 (35.5) 12/28 (42.9) 40/90 (44.4)
ACR50
Week 12 6/37 (16.2) 5/37 (13.5) 3/39 (7.7) 14/113 (12.4)
Week 24 8/37 (21.6) 7/36 (19.4) 3/38 (7.9) 18/111 (16.2)
Week 36 7/34 (20.6) 6/32 (18.8) 3/33 (9.1) 16/99 (16.2)
Week 48 9/31 (29.0) 6/32 (18.8) 6/29 (20.7) 21/92 (22.8)
ACR70
Week 12 1/37 (2.7) 1/39 (2.6) 0/40 (0.0) 2/116 (1.7)
Week 24 3/37 (8.1) 3/36 (8.3) 2/38 (5.3) 8/111 (7.2)
Week 36 6/34 (17.6) 4/32 (12.5) 0/34 (0.0) 10/100 (10.0)
Week 48 5/31 (16.1) 3/32 (9.4) 3/30 (10.0) 11/93 (11.8)
TABLE 58 Summary statistics of the DAS28 and reduction in the DAS28 over time
Visit
Treatment arm
Total (n= 122)
Alternative TNFi
(n= 41)
Abatacept
(n= 41)
Rituximab
(n= 40)
DAS28
Baseline
Mean score (SD) 5.9 (1.05) 6.2 (1.08) 6.2 (1.28) 6.1 (1.13)
Missing, n 1 3 5 9
12 weeks
Mean score (SD) 4.7 (1.33) 5.0 (1.34) 5.0 (1.22) 4.9 (1.29)
Missing, n 7 4 2 13
24 weeks
Mean score (SD) 4.3 (1.32) 4.9 (1.60) 4.9 (1.55) 4.7 (1.51)
Missing, n 5 4 3 12
36 weeks
Mean score (SD) 4.0 (1.35) 4.9 (1.47) 4.9 (1.25) 4.6 (1.41)
Missing, n 7 8 9 24
48 weeks
Mean score (SD) 4.1 (1.58) 4.8 (1.24) 4.8 (1.42) 4.6 (1.44)
Missing, n 11 8 13 32
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TABLE 58 Summary statistics of the DAS28 and reduction in the DAS28 over time (continued )
Visit
Treatment arm
Total (n= 122)
Alternative TNFi
(n= 41)
Abatacept
(n= 41)
Rituximab
(n= 40)
60 weeks
Mean score (SD) 3.5 (1.40) 4.1 (1.44) 4.8 (1.19) 4.1 (1.42)
Missing, n 27 26 29 82
72 weeks
Mean score (SD) 3.4 (1.71) 4.9 (1.47) 4.9 (0.93) 4.5 (1.53)
Missing, n 33 28 32 93
84 weeks
Mean score (SD) 3.3 (1.46) 3.8 (1.48) 5.1 (1.28) 4.1 (1.54)
Missing, n 35 34 34 103
96 weeks
Mean score (SD) 2.6 (1.52) 3.2 (1.34) 4.8 (2.07) 3.3 (1.73)
Missing, n 36 37 37 110
Absolute reduction in the DAS28
12 weeks
Mean reduction in score (SD) 1.1 (1.30) 1.3 (1.27) 1.1 (1.16) 1.1 (1.24)
Missing, n 7 6 6 19
24 weeks
Mean reduction in score (SD) 1.4 (1.28) 1.2 (1.72) 1.3 (1.94) 1.3 (1.64)
Missing, n 5 7 8 20
36 weeks
Mean reduction in score (SD) 1.6 (1.36) 1.2 (1.68) 1.2 (1.18) 1.3 (1.42)
Missing, n 7 10 11 28
48 weeks
Mean reduction in score (SD) 1.6 (1.64) 1.4 (1.38) 1.2 (1.49) 1.4 (1.50)
Missing, n 11 11 17 39
60 weeks
Mean reduction in score (SD) 2.1 (1.37) 2.3 (1.31) 1.3 (1.89) 2.0 (1.52)
Missing, n 27 28 30 85
72 weeks
Mean reduction in score (SD) 2.4 (1.53) 1.4 (1.28) 1.1 (2.18) 1.7 (1.63)
Missing, n 33 31 34 98
84 weeks
Mean reduction in score (SD) 2.6 (1.10) 1.3 (1.57) 2.1 (1.04) 2.1 (1.25)
Missing, n 35 37 35 107
96 weeks
Mean reduction in score (SD) 3.3 (1.18) 3.0 (–) 2.3 (1.58) 3.0 (1.16)
Missing, n 36 40 38 114
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TABLE 59 The DAS28 category over time
DAS28 category
Treatment arm, n (%)
Total (N= 122),
n (%)
Alternative TNFi
(N= 41)
Abatacept
(N= 41)
Rituximab
(N= 40)
Baseline
High disease activity (DAS28) 33 (80.5) 32 (78.0) 28 (70.0) 93 (76.2)
Moderate disease activity (DAS28) 7 (17.1) 6 (14.6) 7 (17.5) 20 (16.4)
Missing 1 (2.4) 3 (7.3) 5 (12.5) 9 (7.4)
12 weeks
High disease activity (DAS28) 11 (26.8) 16 (39.0) 18 (45.0) 45 (36.9)
Moderate disease activity (DAS28) 19 (46.3) 18 (43.9) 17 (42.5) 54 (44.3)
Low disease activity (DAS28) 3 (7.3) 2 (4.9) 2 (5.0) 7 (5.7)
Remission (DAS28) 1 (2.4) 1 (2.4) 1 (2.5) 3 (2.5)
Missing 7 (17.1) 4 (9.8) 2 (5.0) 13 (10.7)
24 weeks
High disease activity (DAS28) 9 (22.0) 15 (36.6) 20 (50.0) 44 (36.1)
Moderate disease activity (DAS28) 19 (46.3) 16 (39.0) 9 (22.5) 44 (36.1)
Low disease activity (DAS28) 4 (9.8) 3 (7.3) 4 (10.0) 11 (9.0)
Remission (DAS28) 4 (9.8) 3 (7.3) 4 (10.0) 11 (9.0)
Missing 5 (12.2) 4 (9.8) 3 (7.5) 12 (9.8)
36 weeks
High disease activity (DAS28) 7 (17.1) 17 (41.5) 15 (37.5) 39 (32.0)
Moderate disease activity (DAS28) 17 (41.5) 12 (29.3) 13 (32.5) 42 (34.4)
Low disease activity (DAS28) 5 (12.2) 2 (4.9) 1 (2.5) 8 (6.6)
Remission (DAS28) 5 (12.2) 2 (4.9) 2 (5.0) 9 (7.4)
Missing 7 (17.1) 8 (19.5) 9 (22.5) 24 (19.7)
48 weeks
High disease activity (DAS28) 8 (19.5) 14 (34.1) 14 (35.0) 36 (29.5)
Moderate disease activity (DAS28) 11 (26.8) 16 (39.0) 10 (25.0) 37 (30.3)
Low disease activity (DAS28) 6 (14.6) 1 (2.4) 1 (2.5) 8 (6.6)
Remission (DAS28) 5 (12.2) 2 (4.9) 2 (5.0) 9 (7.4)
Missing 11 (26.8) 8 (19.5) 13 (32.5) 32 (26.2)
60 weeks
High disease activity (DAS28) 1 (2.4) 5 (12.2) 4 (10.0) 10 (8.2)
Moderate disease activity (DAS28) 7 (17.1) 5 (12.2) 6 (15.0) 18 (14.8)
Low disease activity (DAS28) 2 (4.9) 1 (2.4) 1 (2.5) 4 (3.3)
Remission (DAS28) 4 (9.8) 4 (9.8) – 8 (6.6)
Missing 27 (65.9) 26 (63.4) 29 (72.5) 82 (67.2)
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TABLE 59 The DAS28 category over time (continued )
DAS28 category
Treatment arm, n (%)
Total (N= 122),
n (%)
Alternative TNFi
(N= 41)
Abatacept
(N= 41)
Rituximab
(N= 40)
72 weeks
High disease activity (DAS28) 1 (2.4) 5 (12.2) 3 (7.5) 9 (7.4)
Moderate disease activity (DAS28) 2 (4.9) 6 (14.6) 5 (12.5) 13 (10.7)
Low disease activity (DAS28) 2 (4.9) 1 (2.4) – 3 (2.5)
Remission (DAS28) 3 (7.3) 1 (2.4) – 4 (3.3)
Missing 33 (80.5) 28 (68.3) 32 (80.0) 93 (76.2)
84 weeks
High disease activity (DAS28) – 2 (4.9) 4 (10.0) 6 (4.9)
Moderate disease activity (DAS28) 3 (7.3) 3 (7.3) 1 (2.5) 7 (5.7)
Low disease activity (DAS28) 1 (2.4) – 1 (2.5) 2 (1.6)
Remission (DAS28) 2 (4.9) 2 (4.9) – 4 (3.3)
Missing 35 (85.4) 34 (82.9) 34 (85.0) 103 (84.4)
96 weeks
High disease activity (DAS28) – – 2 (5.0) 2 (1.6)
Moderate disease activity (DAS28) 1 (2.4) 3 (7.3) – 4 (3.3)
Low disease activity (DAS28) 1 (2.4) – – 1 (0.8)
Remission (DAS28) 3 (7.3) 1 (2.4) 1 (2.5) 5 (4.1)
Missing 36 (87.8) 37 (90.2) 37 (92.5) 110 (90.2)
TABLE 60 The EULAR response over time
EULAR response category
Treatment arm, n (%)
Total (N= 122),
n (%)
Alternative TNFi
(N= 41)
Abatacept
(N= 41)
Rituximab
(N= 40)
12 weeks
Good response 4 (9.8) 3 (7.3) 1 (2.5) 8 (6.6)
Moderate response 13 (31.7) 18 (43.9) 20 (50.0) 51 (41.8)
No response 17 (41.5) 14 (34.1) 13 (32.5) 44 (36.1)
Missing 7 (17.1) 6 (14.6) 6 (15.0) 19 (15.6)
24 weeks
Good response 8 (19.5) 5 (12.2) 7 (17.5) 20 (16.4)
Moderate response 18 (43.9) 15 (36.6) 13 (32.5) 46 (37.7)
No response 10 (24.4) 14 (34.1) 12 (30.0) 36 (29.5)
Missing 5 (12.2) 7 (17.1) 8 (20.0) 20 (16.4)
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TABLE 60 The EULAR response over time (continued )
EULAR response category
Treatment arm, n (%)
Total (N= 122),
n (%)
Alternative TNFi
(N= 41)
Abatacept
(N= 41)
Rituximab
(N= 40)
36 weeks
Good response 9 (22.0) 3 (7.3) 3 (7.5) 15 (12.3)
Moderate response 15 (36.6) 14 (34.1) 13 (32.5) 42 (34.4)
No response 10 (24.4) 14 (34.1) 13 (32.5) 37 (30.3)
Missing 7 (17.1) 10 (24.4) 11 (27.5) 28 (23.0)
48 weeks
Good response 11 (26.8) 2 (4.9) 2 (5.0) 15 (12.3)
Moderate response 8 (19.5) 18 (43.9) 12 (30.0) 38 (31.1)
No response 11 (26.8) 10 (24.4) 9 (22.5) 30 (24.6)
Missing 11 (26.8) 11 (26.8) 17 (42.5) 39 (32.0)
60 weeks
Good response 6 (14.6) 4 (9.8) – 10 (8.2)
Moderate response 5 (12.2) 7 (17.1) 6 (15.0) 18 (14.8)
No response 3 (7.3) 2 (4.9) 4 (10.0) 9 (7.4)
Missing 27 (65.9) 28 (68.3) 30 (75.0) 85 (69.7)
72 weeks
Good response 5 (12.2) 1 (2.4) – 6 (4.9)
Moderate response 2 (4.9) 5 (12.2) 3 (7.5) 10 (8.2)
No response 1 (2.4) 4 (9.8) 3 (7.5) 8 (6.6)
Missing 33 (80.5) 31 (75.6) 34 (85.0) 98 (80.3)
84 weeks
Good response 3 (7.3) – 1 (2.5) 4 (3.3)
Moderate response 3 (7.3) 2 (4.9) 3 (7.5) 8 (6.6)
No response – 2 (4.9) 1 (2.5) 3 (2.5)
Missing 35 (85.4) 37 (90.2) 35 (87.5) 107 (87.7)
96 weeks
Good response 4 (9.8) – 1 (2.5) 5 (4.1)
Moderate response 1 (2.4) 1 (2.4) 1 (2.5) 3 (2.5)
Missing 36 (87.8) 40 (97.6) 38 (95.0) 114 (93.4)
DOI: 10.3310/hta22340 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 34
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Brown et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
221
TABLE 61 The ACR/EULAR Boolean remission response over time
ACR/EULAR Boolean remission
Treatment arm, n (%)
Total (N= 122),
n (%)
Alternative TNFi
(N= 41)
Abatacept
(N= 41)
Rituximab
(N= 40)
Baseline
No 39 (95.1) 38 (92.7) 35 (87.5) 112 (91.8)
Missing 2 (4.9) 3 (7.3) 5 (12.5) 10 (8.2)
12 weeks
No 31 (75.6) 38 (92.7) 38 (95.0) 107 (87.7)
Missing 10 (24.4) 3 (7.3) 2 (5.0) 15 (12.3)
24 weeks
Yes 2 (4.9) 1 (2.4) – 3 (2.5)
No 32 (78.0) 36 (87.8) 36 (90.0) 104 (85.2)
Missing 7 (17.1) 4 (9.8) 4 (10.0) 15 (12.3)
36 weeks
Yes 2 (4.9) – – 2 (1.6)
No 30 (73.2) 34 (82.9) 34 (85.0) 98 (80.3)
Missing 9 (22.0) 7 (17.1) 6 (15.0) 22 (18.0)
48 weeks
Yes 1 (2.4) 1 (2.4) – 2 (1.6)
No 30 (73.2) 31 (75.6) 28 (70.0) 89 (73.0)
Missing 10 (24.4) 9 (22.0) 12 (30.0) 31 (25.4)
60 weeks
Yes 1 (2.4) 2 (4.9) – 3 (2.5)
No 12 (29.3) 13 (31.7) 11 (27.5) 36 (29.5)
Missing 28 (68.3) 26 (63.4) 29 (72.5) 83 (68.0)
72 weeks
Yes 1 (2.4) – – 1 (0.8)
No 6 (14.6) 13 (31.7) 7 (17.5) 26 (21.3)
Missing 34 (82.9) 28 (68.3) 33 (82.5) 95 (77.9)
84 weeks
Yes 1 (2.4) – – 1 (0.8)
No 5 (12.2) 7 (17.1) 4 (10.0) 16 (13.1)
Missing 35 (85.4) 34 (82.9) 36 (90.0) 105 (86.1)
96 weeks
Yes 1 (2.4) 1 (2.4) – 2 (1.6)
No 4 (9.8) 3 (7.3) 3 (7.5) 10 (8.2)
Missing 36 (87.8) 37 (90.2) 37 (92.5) 110 (90.2)
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TABLE 62 Clinical Disease Activity Index, change in CDAI over time
Visit
Treatment arm
Total (n= 122)
Alternative TNFi
(n= 41)
Abatacept
(n= 41)
Rituximab
(n= 40)
CDAI score
Baseline
Median score (IQR) 38.7 (27.8 to 46.5) 37.4 (28.3 to 47.9) 39.3 (29.3 to 51.0) 38.2 (28.8 to 48.0)
Missing, n 1 3 4 8
12 weeks
Median score (IQR) 18.5 (11.8 to 37.2) 17.8 (10.2 to 36.7) 22.0 (13.6 to 30.2) 21.2 (12.5 to 35.7)
Missing, n 6 2 2 10
24 weeks
Median score (IQR) 15.4 (9.1 to 28.5) 22.1 (8.9 to 36.4) 23.5 (12.2 to 36.1) 20.8 (9.8 to 32.4)
Missing, n 6 5 5 16
36 weeks
Median score (IQR) 14.6 (9.2 to 28.8) 24.1 (8.5 to 32.3) 20.6 (13.9 to 30.6) 18.8 (9.6 to 30.4)
Missing, n 8 8 6 22
48 weeks
Median score (IQR) 19.3 (5.4 to 25.3) 17.2 (13.5 to 25.6) 19.7 (10.8 to 30.9) 17.7 (9.9 to 28.1)
Missing, n 10 9 12 31
60 weeks
Median score (IQR) 16.9 (3.4 to 29.8) 13.1 (6.1 to 26.7) 16.1 (10.5 to 30.9) 16.1 (6.1 to 28.5)
Missing, n 27 27 29 83
72 weeks
Median score (IQR) 7.7 (4.3 to 25.7) 18.4 (14.6 to 33.5) 15.1 (12.8 to 31.2) 15.5 (9.9 to 33.5)
Missing, n 33 29 32 94
84 weeks
Median score (IQR) 7.6 (3.9 to 17.1) 11.8 (5.0 to 31.8) 28.5 (11.4 to 30.9) 12.6 (4.1 to 29.7)
Missing, n 34 33 35 102
96 weeks
Median score (IQR) 2.6 (1.2 to 14.0) 8.3 (5.4 to 15.1) 28.7 (11.4 to 33.6) 10.4 (3.0 to 24.8)
Missing, n 36 37 37 110
Change in CDAI score
12 weeks
Median change in score (IQR) –12.4
(–21.4 to –1.6)
–15.6
(–22.6 to –6.8)
–16.2
(–26.5 to –5.8)
–14.6
(–23.1 to –5.7)
Missing, n 6 5 4 15
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TABLE 62 Clinical Disease Activity Index, change in CDAI over time (continued )
Visit
Treatment arm
Total (n= 122)
Alternative TNFi
(n= 41)
Abatacept
(n= 41)
Rituximab
(n= 40)
24 weeks
Median change in score (IQR) –17.8
(–25.7 to –10.6)
–14.7
(–22.3 to 0.4)
–17.0
(–25.1 to –4.9)
–16.1
(–24.8 to –4.5)
Missing, n 6 8 8 22
36 weeks
Median change in score (IQR) –17.5
(–23.3 to –11.7)
–15.5
(–24.1 to 0.6)
–19.0
(–26.7 to –8.0)
–17.7
(–24.8 to –6.6)
Missing 8 11 8 27
48 weeks
Median change in score (IQR) –19.3
(–28.8 to –5.7)
–14.1
(–29.2 to –5.9)
–20.3
(–32.3 to –5.3)
–18.5
(–29.2 to –5.7)
Missing, n 10 12 15 37
60 weeks
Median change in score (IQR) –19.5
(–27.7 to –10.0)
–20.5
(–31.6 to –7.7)
–12.8
(–38.8 to –9.9)
–19.5
(–31.0 to –9.9)
Missing, n 27 27 29 83
72 weeks
Median change in score (IQR) –20.0
(–28.4 to –11.1)
–9.3
(–17.3 to –2.1)
–13.3
(–27.0 to –0.7)
–14.5
(–26.3 to –4.5)
Missing, n 33 30 33 96
84 weeks
Median change in score (IQR) –20.6
(–27.7 to –15.5)
–9.9
(–25.5 to 5.8)
–23.5
(–30.0 to –7.6)
–19.1
(–27.7 to –2.7)
Missing, n 34 34 35 103
96 weeks
Median change in score (IQR) –25.2
(–32.7 to –19.1)
1.2
(–16.3 to 4.1)
–12.9
(–18.5 to 1.0)
–16.3
(–25.2 to 1.0)
Missing, n 36 38 37 111
IQR, interquartile range.
Note
Negative change values indicate lower disease activity and an improvement in the patient’s condition.
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TABLE 63 Clinical Disease Activity Index response over time
CDAI category
Treatment arm, n (%)
Total (N= 122),
n (%)
Alternative TNFi
(N= 41)
Abatacept
(N= 41)
Rituximab
(N= 40)
Baseline
High disease activity 36 (87.8) 32 (78.0) 32 (80.0) 100 (82.0)
Moderate disease activity 4 (9.8) 5 (12.2) 4 (10.0) 13 (10.7)
Low disease activity – 1 (2.4) – 1 (0.8)
Missing 1 (2.4) 3 (7.3) 4 (10.0) 8 (6.6)
12 weeks
High disease activity 15 (36.6) 18 (43.9) 18 (45.0) 51 (41.8)
Moderate disease activity 16 (39.0) 12 (29.3) 14 (35.0) 42 (34.4)
Low disease activity 4 (9.8) 8 (19.5) 6 (15.0) 18 (14.8)
Remission – 1 (2.4) – 1 (0.8)
Missing 6 (14.6) 2 (4.9) 2 (5.0) 10 (8.2)
24 weeks
High disease activity 13 (31.7) 18 (43.9) 19 (47.5) 50 (41.0)
Moderate disease activity 13 (31.7) 6 (14.6) 10 (25.0) 29 (23.8)
Low disease activity 7 (17.1) 11 (26.8) 4 (10.0) 22 (18.0)
Remission 2 (4.9) 1 (2.4) 2 (5.0) 5 (4.1)
Missing 6 (14.6) 5 (12.2) 5 (12.5) 16 (13.1)
36 weeks
High disease activity 13 (31.7) 18 (43.9) 15 (37.5) 46 (37.7)
Moderate disease activity 6 (14.6) 6 (14.6) 14 (35.0) 26 (21.3)
Low disease activity 11 (26.8) 6 (14.6) 5 (12.5) 22 (18.0)
Remission 3 (7.3) 3 (7.3) – 6 (4.9)
Missing 8 (19.5) 8 (19.5) 6 (15.0) 22 (18.0)
48 weeks
High disease activity 11 (26.8) 11 (26.8) 13 (32.5) 35 (28.7)
Moderate disease activity 10 (24.4) 14 (34.1) 9 (22.5) 33 (27.0)
Low disease activity 8 (19.5) 6 (14.6) 5 (12.5) 19 (15.6)
Remission 2 (4.9) 1 (2.4) 1 (2.5) 4 (3.3)
Missing 10 (24.4) 9 (22.0) 12 (30.0) 31 (25.4)
60 weeks
High disease activity 6 (14.6) 5 (12.2) 4 (10.0) 15 (12.3)
Moderate disease activity 2 (4.9) 2 (4.9) 5 (12.5) 9 (7.4)
Low disease activity 3 (7.3) 5 (12.2) 2 (5.0) 10 (8.2)
Remission 3 (7.3) 2 (4.9) – 5 (4.1)
Missing 27 (65.9) 27 (65.9) 29 (72.5) 83 (68.0)
continued
DOI: 10.3310/hta22340 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 34
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Brown et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
225
TABLE 63 Clinical Disease Activity Index response over time (continued )
CDAI category
Treatment arm, n (%)
Total (N= 122),
n (%)
Alternative TNFi
(N= 41)
Abatacept
(N= 41)
Rituximab
(N= 40)
72 weeks
High disease activity 2 (4.9) 5 (12.2) 3 (7.5) 10 (8.2)
Moderate disease activity 2 (4.9) 5 (12.2) 4 (10.0) 11 (9.0)
Low disease activity 3 (7.3) 2 (4.9) 1 (2.5) 6 (4.9)
Remission 1 (2.4) – – 1 (0.8)
Missing 33 (80.5) 29 (70.7) 32 (80.0) 94 (77.0)
84 weeks
High disease activity 1 (2.4) 3 (7.3) 3 (7.5) 7 (5.7)
Moderate disease activity 2 (4.9) 1 (2.4) 1 (2.5) 4 (3.3)
Low disease activity 3 (7.3) 3 (7.3) – 6 (4.9)
Remission 1 (2.4) 1 (2.4) 1 (2.5) 3 (2.5)
Missing 34 (82.9) 33 (80.5) 35 (87.5) 102 (83.6)
96 weeks
High disease activity 1 (2.4) – 2 (5.0) 3 (2.5)
Moderate disease activity 1 (2.4) 1 (2.4) 1 (2.5) 3 (2.5)
Low disease activity – 3 (7.3) – 3 (2.5)
Remission 3 (7.3) – – 3 (2.5)
Missing 36 (87.8) 37 (90.2) 37 (92.5) 110 (90.2)
TABLE 64 Simplified Disease Activity Index, change in SDAI over time
Visit
Treatment arm
Total (n= 122)
Alternative TNFi
(n= 41)
Abatacept
(n= 41)
Rituximab
(n= 40)
SDAI score
Baseline
Median score (IQR) 39.8 (27.9 to 47.5) 38.0 (29.7 to 50.4) 40.6 (29.9 to 52.4) 39.8 (29.5 to 51.4)
Missing, n 2 5 5 12
12 weeks
Median score (IQR) 19.4 (12.3 to 38.6) 19.1 (12.1 to 37.5) 23.3 (15.8 to 36.1) 21.0 (13.0 to 37.5)
Missing, n 11 3 3 17
24 weeks
Median score (IQR) 15.9 (9.6 to 30.7) 23.1 (9.9 to 38.2) 23.9 (12.7 to 39.8) 21.6 (9.9 to 35.1)
Missing, n 8 5 6 19
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TABLE 64 Simplified Disease Activity Index, change in SDAI over time (continued )
Visit
Treatment arm
Total (n= 122)
Alternative TNFi
(n= 41)
Abatacept
(n= 41)
Rituximab
(n= 40)
36 weeks
Median score (IQR) 14.7 (9.5 to 29.1) 24.6 (9.5 to 35.4) 21.4 (14.4 to 31.6) 19.9 (10.2 to 31.6)
Missing, n 10 8 6 24
48 weeks
Median score (IQR) 19.8 (6.0 to 25.7) 19.2 (14.1 to 31.3) 20.3 (12.0 to 32.1) 19.4 (11.1 to 29.8)
Missing, n 10 10 12 32
60 weeks
Median score (IQR) 23.0 (4.8 to 30.3) 17.2 (6.8 to 28.7) 16.6 (11.0 to 31.8) 17.2 (8.0 to 30.3)
Missing, n 28 28 29 85
72 weeks
Median score (IQR) 11.0 (5.1 to 41.1) 21.6 (16.1 to 39.0) 19.3 (11.7 to 38.0) 18.7 (11.0 to 38.0)
Missing, n 34 29 33 96
84 weeks
Median score (IQR) 12.7 (4.4 to 19.6) 10.3 (4.1 to 37.1) 30.5 (20.5 to 36.6) 17.2 (6.3 to 31.9)
Missing, n 35 34 36 105
96 weeks
Median score (IQR) 3.1 (1.7 to 14.5) 8.8 (5.7 to 15.6) 29.2 (11.5 to 35.9) 10.6 (3.3 to 25.3)
Missing, n 36 37 37 110
Change in SDAI score
12 weeks
Median change in score (IQR) –13.6
(–21.4 to 2.7)
–14.9
(–23.1 to –8.5)
–17.2
(–27.4 to –6.0)
–15.1
(–24.3 to –5.3)
Missing, n 12 8 6 26
24 weeks
Median change in score (IQR) –18.2
(–26.7 to –9.3)
–14.9
(–22.5 to –0.5)
–18.2
(–27.3 to –5.2)
–16.6
(–25.7 to –5.0)
Missing, n 9 10 9 28
36 weeks
Median change in score (IQR) –19.9
(–24.7 to –11.8)
–15.0
(–23.5 to 0.6)
–19.7
(–28.0 to –8.7)
–18.2
(–25.5 to –6.7)
Missing, n 11 12 9 32
48 weeks
Median change in score (IQR) –20.1
(–27.2 to –7.9)
–13.7
(–31.2 to –6.3)
–20.1
(–34.0 to –5.3)
–19.7
(–30.5 to –5.6)
Missing, n 11 15 15 41
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TABLE 64 Simplified Disease Activity Index, change in SDAI over time (continued )
Visit
Treatment arm
Total (n= 122)
Alternative TNFi
(n= 41)
Abatacept
(n= 41)
Rituximab
(n= 40)
60 weeks
Median change in score (IQR) –21.6
(–29.5 to –8.6)
–23.2
(–38.7 to –14.2)
–12.9
(–38.3 to –9.9)
–21.9
(–32.1 to –10.4)
Missing, n 29 30 29 88
72 weeks
Median change in score (IQR) –20.8
(–31.6 to –9.1)
–10.7
(–19.5 to –2.2)
–16.7
(–26.8 to –2.5)
–13.3
(–26.8 to –2.5)
Missing, n 34 31 34 99
84 weeks
Median change in score (IQR) –21.7
(–28.8 to –15.0)
–1.3
(–25.4 to 5.8)
–16.9
(–32.9 to –3.9)
–20.7
(–28.8 to –1.3)
Missing, n 35 36 36 107
96 weeks
Median change in score (IQR) –25.3
(–33.8 to –20.3)
–8.1
(–19.8 to 3.6)
–13.8
(–25.5 to 1.0)
–20.1
(–25.5 to –11.0)
Missing, n 36 39 37 112
IQR, interquartile range.
Note
Negative change values indicate lower disease activity and an improvement in the patient’s condition.
TABLE 65 Simplified Disease Activity Index response over time
SDAI category
Treatment arm, n (%)
Total (N= 122),
n (%)
Alternative TNFi
(N= 41)
Abatacept
(N= 41)
Rituximab
(N= 40)
Baseline
High disease activity 34 (82.9) 30 (73.2) 31 (77.5) 95 (77.9)
Moderate disease activity 5 (12.2) 5 (12.2) 4 (10.0) 14 (11.5)
Low disease activity – 1 (2.4) – 1 (0.8)
Missing 2 (4.9) 5 (12.2) 5 (12.5) 12 (9.8)
12 weeks
High disease activity 12 (29.3) 16 (39.0) 14 (35.0) 42 (34.4)
Moderate disease activity 14 (34.1) 16 (39.0) 17 (42.5) 47 (38.5)
Low disease activity 4 (9.8) 5 (12.2) 6 (15.0) 15 (12.3)
Remission – 1 (2.4) – 1 (0.8)
Missing 11 (26.8) 3 (7.3) 3 (7.5) 17 (13.9)
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TABLE 65 Simplified Disease Activity Index response over time (continued )
SDAI category
Treatment arm, n (%)
Total (N= 122),
n (%)
Alternative TNFi
(N= 41)
Abatacept
(N= 41)
Rituximab
(N= 40)
24 weeks
High disease activity 11 (26.8) 17 (41.5) 13 (32.5) 41 (33.6)
Moderate disease activity 13 (31.7) 7 (17.1) 15 (37.5) 35 (28.7)
Low disease activity 7 (17.1) 11 (26.8) 4 (10.0) 22 (18.0)
Remission 2 (4.9) 1 (2.4) 2 (5.0) 5 (4.1)
Missing 8 (19.5) 5 (12.2) 6 (15.0) 19 (15.6)
36 weeks
High disease activity 11 (26.8) 15 (36.6) 13 (32.5) 39 (32.0)
Moderate disease activity 8 (19.5) 9 (22.0) 16 (40.0) 33 (27.0)
Low disease activity 9 (22.0) 7 (17.1) 5 (12.5) 21 (17.2)
Remission 3 (7.3) 2 (4.9) – 5 (4.1)
Missing 10 (24.4) 8 (19.5) 6 (15.0) 24 (19.7)
48 weeks
High disease activity 7 (17.1) 8 (19.5) 10 (25.0) 25 (20.5)
Moderate disease activity 13 (31.7) 18 (43.9) 12 (30.0) 43 (35.2)
Low disease activity 9 (22.0) 4 (9.8) 5 (12.5) 18 (14.8)
Remission 2 (4.9) 1 (2.4) 1 (2.5) 4 (3.3)
Missing 10 (24.4) 10 (24.4) 12 (30.0) 32 (26.2)
60 weeks
High disease activity 5 (12.2) 5 (12.2) 3 (7.5) 13 (10.7)
Moderate disease activity 3 (7.3) 3 (7.3) 5 (12.5) 11 (9.0)
Low disease activity 3 (7.3) 3 (7.3) 3 (7.5) 9 (7.4)
Remission 2 (4.9) 2 (4.9) – 4 (3.3)
Missing 28 (68.3) 28 (68.3) 29 (72.5) 85 (69.7)
72 weeks
High disease activity 2 (4.9) 5 (12.2) 2 (5.0) 9 (7.4)
Moderate disease activity 1 (2.4) 5 (12.2) 4 (10.0) 10 (8.2)
Low disease activity 3 (7.3) 2 (4.9) 1 (2.5) 6 (4.9)
Remission 1 (2.4) – – 1 (0.8)
Missing 34 (82.9) 29 (70.7) 33 (82.5) 96 (78.7)
84 weeks
High disease activity 1 (2.4) 3 (7.3) 3 (7.5) 7 (5.7)
Moderate disease activity 2 (4.9) – 1 (2.5) 3 (2.5)
Low disease activity 2 (4.9) 3 (7.3) – 5 (4.1)
Remission 1 (2.4) 1 (2.4) – 2 (1.6)
Missing 35 (85.4) 34 (82.9) 36 (90.0) 105 (86.1)
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TABLE 65 Simplified Disease Activity Index response over time (continued )
SDAI category
Treatment arm, n (%)
Total (N= 122),
n (%)
Alternative TNFi
(N= 41)
Abatacept
(N= 41)
Rituximab
(N= 40)
96 weeks
High disease activity 1 (2.4) – 2 (5.0) 3 (2.5)
Moderate disease activity 1 (2.4) 1 (2.4) 1 (2.5) 3 (2.5)
Low disease activity – 3 (7.3) – 3 (2.5)
Remission 3 (7.3) – – 3 (2.5)
Missing 36 (87.8) 37 (90.2) 37 (92.5) 110 (90.2)
TABLE 66 The HAQ-DI, RAQoL and HADS scores over time
Visit
Treatment arm
Total (n= 122)
Alternative TNFi
(n= 41)
Abatacept
(n= 41)
Rituximab
(n= 40)
HAQ-DI score
Baseline
Median score (IQR) 1.9 (1.4–2.1) 1.9 (1.6–2.3) 1.9 (1.4–2.3) 1.9 (1.5–2.1)
Missing, n 1 1 1 3
12 weeks
Median score (IQR) 1.8 (1.1–2.1) 1.7 (1.3–2.1) 1.8 (1.1–2.1) 1.8 (1.1–2.1)
Missing, n 4 2 0 6
24 weeks
Median score (IQR) 1.6 (1.1–2.0) 1.8 (1.0–2.1) 1.7 (1.0–2.0) 1.6 (1.0–2.1)
Missing, n 5 4 2 11
36 weeks
Median score (IQR) 1.6 (1.1–1.9) 1.7 (1.3–2.3) 1.5 (1.0–2.1) 1.6 (1.1–2.0)
Missing, n 7 7 6 20
48 weeks
Median score (IQR) 1.5 (1.1–1.9) 1.6 (1.0–2.1) 1.7 (1.1–2.1) 1.6 (1.1–2.0)
Missing, n 11 7 10 28
60 weeks
Median score (IQR) 1.6 (1.0–2.0) 1.8 (1.3–2.4) 1.6 (1.0–2.0) 1.6 (1.1–2.1)
Missing, n 27 24 30 81
72 weeks
Median score (IQR) 1.3 (0.5–1.9) 1.6 (1.5–2.4) 1.4 (0.8–1.7) 1.6 (0.9–1.9)
Missing, n 33 28 32 93
84 weeks
Median score (IQR) 1.8 (0.8–2.0) 1.4 (1.1–1.6) 1.5 (0.8–2.4) 1.4 (0.9–1.9)
Missing, n 34 32 34 100
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TABLE 66 The HAQ-DI, RAQoL and HADS scores over time (continued )
Visit
Treatment arm
Total (n= 122)
Alternative TNFi
(n= 41)
Abatacept
(n= 41)
Rituximab
(n= 40)
96 weeks
Median score (IQR) 1.0 (0.4–2.0) 1.1 (0.8–1.1) 1.4 (0.4–2.5) 1.1 (0.4–1.7)
Missing, n 36 37 37 110
RAQoL score
Baseline
Median score (IQR) 21.6 (15.0–24.5) 22.0 (14.0–25.5) 22.0 (15.0–25.0) 22.0 (15.0–25.0)
Missing, n 1 1 2 4
12 weeks
Median score (IQR) 19.0 (11.5–24.0) 17.0 (11.8–23.0) 19.0 (12.0–26.0) 18.5 (12.0–24.0)
Missing, n 5 2 1 8
24 weeks
Median score (IQR) 18.0 (9.0–24.0) 20.5 (8.9–26.0) 20.0 (13.0–25.0) 19.0 (9.0–25.0)
Missing, n 6 7 2 15
36 weeks
Median score (IQR) 17.3 (8.0–22.0) 16.8 (10.3–25.0) 18.0 (13.0–22.0) 17.5 (10.0–23.0)
Missing, n 7 7 7 21
48 weeks
Median score (IQR) 19.0 (9.0–23.0) 17.5 (11.4–24.0) 19.5 (12.0–25.0) 18.4 (11.0–23.0)
Missing, n 11 7 10 28
HADS total score
Baseline
Median total score (IQR) 13.5 (8.0–20.0) 17.0 (10.0–22.0) 14.0 (11.0–19.0) 15.0 (10.0–21.0)
Missing, n 1 1 3 5
12 weeks
Median total score (IQR) 12.0 (9.0–18.0) 13.0 (9.0–22.0) 13.5 (11.0–20.5) 13.0 (9.0–20.0)
Missing, n 4 3 0 7
24 weeks
Median total score (IQR) 12.5 (6.0–18.5) 13.0 (8.0–17.0) 15.0 (10.0–20.0) 14.0 (8.0–19.0)
Missing, n 5 5 3 13
36 weeks
Median total score (IQR) 9.5 (5.0–17.0) 13.0 (7.0–18.0) 13.0 (11.0–18.0) 13.0 (7.0–18.0)
Missing 7 8 6 21
48 weeks
Median total score (IQR) 12.5 (4.0–19.0) 12.0 (7.0–16.0) 13.0 (10.0–20.0) 13.0 (7.0–19.0)
Missing, n 11 8 10 29
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TABLE 66 The HAQ-DI, RAQoL and HADS scores over time (continued )
Visit
Treatment arm
Total (n= 122)
Alternative TNFi
(n= 41)
Abatacept
(n= 41)
Rituximab
(n= 40)
HADS anxiety score
Baseline
Median anxiety score (IQR) 7.0 (4.0–10.5) 9.0 (6.0–12.0) 8.0 (6.0–11.0) 8.0 (5.0–11.0)
Missing, n 1 1 3 5
12 weeks
Median anxiety score (IQR) 6.0 (4.0–9.0) 7.0 (5.0–10.0) 8.0 (6.0–12.0) 7.0 (5.0–11.0)
Missing, n 4 3 0 7
24 weeks
Median anxiety score (IQR) 6.0 (3.0–9.5) 6.0 (4.0–9.5) 8.0 (6.0–11.0) 7.0 (4.0–10.0)
Missing, n 5 5 3 13
36 weeks
Median anxiety score (IQR) 6.0 (3.0–10.0) 6.0 (4.0–11.0) 8.0 (6.0–10.0) 7.0 (3.0–10.0)
Missing, n 7 8 6 21
48 weeks
Median anxiety score (IQR) 6.0 (3.0–11.0) 7.0 (4.0–10.0) 8.0 (5.0–12.0) 7.0 (4.0–10.0)
Missing, n 11 8 10 29
HADS depression score
Baseline
Median depression score (IQR) 6.5 (4.0–9.0) 7.0 (4.0–10.0) 6.0 (4.0–9.0) 6.0 (4.0–9.0)
Missing, n 1 1 3 5
12 weeks
Median depression score (IQR) 6.0 (3.0–8.0) 7.0 (4.0–9.0) 6.0 (4.0–9.0) 6.0 (4.0–9.0)
Missing, n 4 3 0 7
24 weeks
Median depression score (IQR) 6.0 (2.0–9.5) 6.0 (2.5–9.0) 6.0 (3.0–9.0) 6.0 (3.0–9.0)
Missing, n 5 5 3 13
36 weeks
Median depression score (IQR) 4.0 (2.0–8.0) 5.0 (4.0–8.0) 5.5 (4.0–8.0) 5.0 (3.0–8.0)
Missing, n 7 8 6 21
48 weeks
Median depression score (IQR) 4.5 (2.0–9.0) 5.0 (3.0–7.0) 5.5 (4.0–9.0) 5.0 (3.0–9.0)
Missing, n 11 8 10 29
IQR, interquartile range.
Note
Higher scores correspond to a higher extent of disability in the HAQ-DI, lower quality of life in the RAQoL and higher level
of anxiety and depression in the HADS.
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TABLE 67 Patient global assessment of pain, arthritis and general health over time
Visit
Treatment arm
Total (n= 122)
Alternative TNFi
(n= 41)
Abatacept
(n= 41)
Rituximab
(n= 40)
Patient Global Assessment of Pain VAS
Baseline
Median, mm (IQR) 70.5 (59.0–82.5) 69.5 (57.5–79.0) 77.0 (55.0–85.0) 71.0 (58.0–81.0)
Missing, n 1 1 3 5
12 weeks
Median, mm (IQR) 47.5 (27.0–64.0) 42.0 (22.0–63.0) 50.0 (39.0–79.0) 47.5 (30.0–70.0)
Missing, n 5 2 1 8
24 weeks
Median, mm (IQR) 47.0 (30.5–67.0) 54.0 (23.0–68.0) 61.0 (42.0–74.0) 51.0 (28.0–70.0)
Missing, n 5 4 3 12
36 weeks
Median, mm (IQR) 40.0 (21.0–60.0) 38.0 (19.0–72.0) 56.0 (41.0–63.0) 48.5 (24.0–63.0)
Missing, n 7 7 6 20
48 weeks
Median, mm (IQR) 49.0 (22.0–66.0) 51.5 (19.0–72.0) 57.0 (34.0–67.0) 51.0 (22.0–68.0)
Missing, n 10 7 10 27
60 weeks
Median, mm (IQR) 64.0 (32.0–71.0) 48.5 (15.5–63.5) 47.0 (27.0–83.0) 58.0 (27.0–71.0)
Missing, n 27 25 29 81
72 weeks
Median, mm (IQR) 42.0 (12.5–53.0) 56.0 (31.0–87.0) 52.0 (24.0–85.0) 45.0 (26.0–62.5)
Missing, n 33 28 33 94
84 weeks
Median, mm (IQR) 57.0 (16.0–71.0) 41.0 (14.0–66.0) 67.0 (29.0–85.0) 57.0 (16.0–71.0)
Missing, n 34 32 34 100
96 weeks
Median, mm (IQR) 30.0 (7.0–36.0) 30.5 (3.0–60.0) 36.0 (31.0–89.0) 33.5 (7.0–53.0)
Missing, n 36 37 37 110
Patient Global Assessment of Arthritis VAS
Baseline
Median, mm (IQR) 70.5 (62.0–83.0) 67.5 (52.0–79.5) 74.0 (53.0–85.0) 71.0 (56.0–83.0)
Missing, n 1 1 3 5
12 weeks
Median, mm (IQR) 51.5 (32.0–71.0) 43.0 (27.0–60.0) 49.0 (42.0–78.0) 48.0 (30.0–69.0)
Missing, n 5 2 1 8
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TABLE 67 Patient global assessment of pain, arthritis and general health over time (continued )
Visit
Treatment arm
Total (n= 122)
Alternative TNFi
(n= 41)
Abatacept
(n= 41)
Rituximab
(n= 40)
24 weeks
Median, mm (IQR) 45.5 (26.5–68.0) 48.0 (20.0–66.0) 52.0 (39.0–70.0) 48.0 (31.0–69.0)
Missing, n 5 4 3 12
36 weeks
Median, mm (IQR) 41.5 (21.0–60.0) 49.0 (27.1–71.0) 51.5 (39.0–62.0) 49.0 (28.0–66.0)
Missing, n 7 7 6 20
48 weeks
Median, mm (IQR) 47.0 (22.0–69.0) 55.5 (25.0–68.0) 55.0 (35.0–70.0) 53.0 (26.0–69.0)
Missing, n 10 7 10 27
60 weeks
Median, mm (IQR) 60.0 (21.0–69.0) 44.0 (21.0–71.5) 66.0 (27.0–77.0) 54.0 (24.0–70.0)
Missing, n 27 25 29 81
72 weeks
Median, mm (IQR) 40.0 (18.0–54.5) 48.0 (38.0–77.0) 56.5 (19.5–64.5) 47.0 (29.0–65.0)
Missing, n 33 28 32 93
84 weeks
Median, mm (IQR) 51.0 (18.0–64.0) 56.0 (24.0–63.0) 53.0 (24.0–85.0) 53.5 (24.0–72.0)
Missing, n 34 32 34 100
96 weeks
Median, mm (IQR) 25.0 (11.0–35.0) 32.5 (6.0–57.5) 43.0 (24.0–81.0) 30.0 (10.5–54.5)
Missing, n 36 37 37 110
Patient Global Health Assessment of General Health
Baseline
Median, mm (IQR) 56.5 (45.5–72.0) 62.0 (47.8–68.5) 61.0 (46.0–74.0) 59.0 (47.0–70.0)
Missing, n 1 1 3 5
12 weeks
Median, mm (IQR) 46.5 (25.5–64.5) 46.0 (23.0–60.0) 53.0 (34.0–70.0) 50.0 (28.0–64.0)
Missing, n 5 2 1 8
24 weeks
Median, mm (IQR) 46.0 (32.5–63.0) 48.0 (24.0–68.0) 42.0 (27.0–65.0) 47.0 (27.0–64.0)
Missing, n 5 4 3 12
36 weeks
Median, mm (IQR) 38.5 (19.0–55.0) 55.0 (30.0–70.0) 49.0 (40.0–58.0) 48.0 (29.0–60.0)
Missing 7 7 7 21
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TABLE 67 Patient global assessment of pain, arthritis and general health over time (continued )
Visit
Treatment arm
Total (n= 122)
Alternative TNFi
(n= 41)
Abatacept
(n= 41)
Rituximab
(n= 40)
48 weeks
Median, mm (IQR) 48.0 (26.0–63.0) 49.0 (27.0–67.0) 52.0 (31.0–64.0) 50.0 (28.0–63.0)
Missing, n 11 7 10 28
60 weeks
Median, mm (IQR) 54.5 (24.0–61.0) 43.0 (22.0–55.0) 46.0 (24.0–65.0) 47.5 (24.0–61.0)
Missing, n 27 24 29 80
72 weeks
Median, mm (IQR) 43.5 (21.5–56.0) 50.0 (33.0–75.0) 50.0 (25.0–72.0) 48.5 (27.5–69.5)
Missing, n 33 28 33 94
84 weeks
Median, mm (IQR) 46.0 (18.0–60.0) 46.0 (31.0–55.0) 74.5 (66.0–82.0) 49.5 (31.0–71.0)
Missing, n 34 32 34 100
96 weeks
Median, mm (IQR) 24.0 (20.0–37.0) 20.5 (10.0–31.0) 43.0 (20.0–89.0) 22.5 (20.0–42.0)
Missing, n 36 37 37 110
IQR, interquartile range.
Note
Higher scores correspond to worse pain, poor disease activity and poor general health.
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TABLE 68 Bone densitometry at baseline and 48 weeks
Bone densitometry parameter
Treatment arm
Total (n= 55)
Alternative TNFi
(n= 17)
Abatacept
(n= 20)
Rituximab
(n= 18)
Baseline
Bone densitometry scan been performed, n (%)
Yes 11 (64.7) 12 (60.0) 10 (55.6) 33 (60.0)
No 6 (35.3) 8 (40.0) 8 (44.4) 22 (40.0)
Neck of femur densitometry
Median t-score (IQR) –0.8 (–1.6 to –0.2) –0.5 (–0.8 to 0.2) –1.0 (–1.3 to 0.3) –0.7 (–1.3 to 0.1)
Missing, n 6 9 8 23
Neck of femur densitometry
Median z-score (IQR) –0.6 (–0.8 to 0.4) 0.4 (0.0 to 1.1) 0.4 (–0.7 to 0.7) 0.4 (–0.7 to 0.8)
Missing, n 7 9 8 24
Spine densitometry
Median t-score (IQR) –0.2 (–1.9 to 1.2) 0.4 (–0.8 to 1.1) –1.3 (–1.8 to 0.5) –0.3 (–1.3 to 1.1)
Missing, n 6 9 8 23
Spine densitometry
Median z-score (IQR) 0.2 (–0.4 to 1.2) 1.6 (0.6 to 2.7) 0.3 (–0.2 to 1.5) 0.6 (–0.1 to 2.1)
Missing, n 7 9 8 24
Week 48
Bone densitometry scan been performed, n (%)
Yes 6 (35.3) 5 (25.0) 3 (16.7) 14 (25.5)
No 11 (64.7) 15 (75.0) 15 (83.3) 41 (74.5)
Neck of femur densitometry
Median t-score (IQR) –0.8 (–2.1 to 0.4) –0.7 (–0.8 to –0.7) –0.3 (–2.0 to 1.5) –0.7 (–1.1 to –0.3)
Missing, n 11 15 15 41
Neck of femur densitometry
Median z-score (IQR) –0.7 (–1.6 to –0.7) 0.7 (0.0 to 0.9) 0.1 (–1.2 to 0.6) –0.1 (–0.7 to 0.6)
Missing, n 12 15 15 42
Spine densitometry
Median t-score (IQR) –1.2 (–1.9 to –0.1) 0.5 (–2.2 to 2.4) –0.9 (–2.2 to –0.3) –0.9 (–1.9 to –0.1)
Missing, n 11 16 15 42
Spine densitometry
Median z-score (IQR) –0.7 (–1.2 to 0.0) 1.8 (0.5 to 4.1) 0.0 (–1.3 to 0.7) 0.0 (–1.0 to 0.7)
Missing, n 11 16 15 42
IQR, interquartile range.
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Appendix 13 Data missingness
TABLE 69 Summary of component-level missingness for DAS28 and ACR response at all time points to week 48
Component (visit)
Treatment arm
Alternative TNFi Abatacept Rituximab
n % n % n %
CRP level
Baseline 1 2.4 2 4.9 1 2.5
12 weeks 9 22.0 3 7.3 1 2.5
24 weeks 6 14.6 3 7.3 1 2.5
36 weeks 9 22.0 7 17.1 5 12.5
48 weeks 10 24.4 8 19.5 9 22.5
ESR
Baseline 0 0.0 2 4.9 2 5.0
12 weeks 5 12.2 4 9.8 1 2.5
24 weeks 4 9.8 3 7.3 1 2.5
36 weeks 7 17.1 8 19.5 8 20.0
48 weeks 11 26.8 7 17.1 10 25.0
HAQ-DI
Baseline 1 2.4 1 2.4 1 2.5
12 weeks 4 9.8 2 4.9 0 0.0
24 weeks 5 12.2 4 9.8 2 5.0
36 weeks 7 17.1 7 17.1 6 15.0
48 weeks 11 26.8 7 17.1 10 25.0
Patient Global Assessment of Arthritis VAS
Baseline 1 2.4 1 2.4 3 7.5
12 weeks 5 12.2 2 4.9 1 2.5
24 weeks 5 12.2 4 9.8 3 7.5
36 weeks 7 17.1 7 17.1 6 15.0
48 weeks 10 24.4 7 17.1 10 25.0
Patient Global Assessment of Pain VAS
Baseline 1 2.4 1 2.4 3 7.5
12 weeks 5 12.2 2 4.9 1 2.5
24 weeks 5 12.2 4 9.8 3 7.5
36 weeks 7 17.1 7 17.1 6 15.0
48 weeks 10 24.4 7 17.1 10 25.0
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TABLE 69 Summary of component-level missingness for DAS28 and ACR response at all time points to
week 48 (continued )
Component (visit)
Treatment arm
Alternative TNFi Abatacept Rituximab
n % n % n %
Physician Global Assessment of Disease Activity VAS
Baseline 0 0.0 2 4.9 1 2.5
12 weeks 5 12.2 2 4.9 1 2.5
24 weeks 5 12.2 4 9.8 3 7.5
36 weeks 8 19.5 8 19.5 5 12.5
48 weeks 10 24.4 8 19.5 10 25.0
SJC
Baseline 0 0.0 0 0.0 1 2.5
12 weeks 4 9.8 2 4.9 0 0.0
24 weeks 4 9.8 3 7.3 1 2.5
36 weeks 7 17.1 7 17.1 5 12.5
48 weeks 10 24.4 8 19.5 10 25.0
TJC
Baseline 0 0.0 0 0.0 1 2.5
12 weeks 4 9.8 2 4.9 0 0.0
24 weeks 4 9.8 3 7.3 1 2.5
36 weeks 7 17.1 7 17.1 5 12.5
48 weeks 10 24.4 8 19.5 10 25.0
Note
Frequency of patients with at least one component missing over the follow-up duration and the summary statistics of the
numbers of missing components for each patient.
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TABLE 70 Summary of patient-level missingness for DAS28 components to week 48 and ACR response components
to week 24 and 48
Patient-level missingness
Treatment arm
Total (n= 122)
Alternative TNFi
(n= 41) Abatacept (n= 41) Rituximab (n= 40)
Missing DAS28 components (up to week 48 per patient)
Mean, n (SD) 2.6 (4.94) 2.1 (3.78) 2.0 (2.98) 2.2 (3.97)
Median, n (IQR) 0.0 (0.0–4.0) 0.0 (0.0–4.0) 0.0 (0.0–3.5) 0.0 (0.0–4.0)
Range 0.0–17.0 0.0–16.0 0.0–12.0 0.0–17.0
Missing, n 0 0 0 0
All DAS28 components completed over 48 weeks, n (%)
All completed 26 (63.4) 24 (58.5) 21 (52.5) 71 (58.2)
One or more incomplete 15 (36.6) 17 (41.5) 19 (47.5) 51 (41.8)
Missing ACR response components (up to week 48 per patient)
Mean, n (SD) 5.5 (9.85) 4.2 (7.53) 4.0 (6.00) 4.6 (7.93)
Median, n (IQR) 1.0 (0.0–8.0) 1.0 (0.0–8.0) 1.0 (0.0–8.0) 1.0 (0.0–8.0)
Range 0.0–35.0 0.0–32.0 0.0–23.0 0.0–35.0
Missing, n 0 0 0 0
All ACR response components completed over 48 weeks, n (%)
All completed 19 (46.3) 19 (46.3) 19 (47.5) 57 (46.7)
One or more incomplete 22 (53.7) 22 (53.7) 21 (52.5) 65 (53.3)
Missing ACR response components (up to week 24 per patient)
Mean, n (SD) 2.0 (4.85) 1.4 (3.66) 0.8 (1.74) 1.4 (3.66)
Median, n (IQR) 0.0 (0.0–1.0) 0.0 (0.0–1.0) 0.0 (0.0–1.0) 0.0 (0.0–1.0)
Range 0.0–19.0 0.0–16.0 0.0–7.0 0.0–19.0
Missing, n 0 0 0 0
All ACR response components completed over 24 weeks, n (%)
All completed 27 (65.9) 29 (70.7) 29 (72.5) 85 (69.7)
One or more incomplete 14 (34.1) 12 (29.3) 11 (27.5) 37 (30.3)
IQR, interquartile range.
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Appendix 14 Safety line listings
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TABLE 71 Line listing of all serious ARs
Treatment
Randomised
Medical
Dictionary for
Regulatory
Activities’
System
Organ Class SAE code
SAE in
medical
terms SAE description
Age
(years) Sex
Seriousness
criteria Causality
Suspected
to be
related to Expectedness
Date of
registration
Randomisation
date
Date event
became
serious
Alternative
TNFi
Hepatobiliary
disorders
N00072/
00024/001
Autoimmune
Hepatitis
Persistently raised/rising
liver enzyme levels
despite cessation of MTX
co-therapy
34 Female 3 Trial
medications
Infliximab Expected 7 August
2013
4 September
2013
27 April
2014
Abatacept Skin and
subcutaneous
tissue disorders
N00400/
00074/001
Angiooedema Participant woke up
feeling unwell after first
injection of abatacept,
husband confirmed she
had signs of angiooedema
(swollen tongue, swollen
face) and swollen hands.
No rash, pruritus, no other
symptoms/signs reported.
It is unclear if breathing
was somehow
compromised but if
affirmative likely not to be
severe, as patient took
co-codamol and went to
bed again. The principal
investigator has informed
patient of the potential
seriousness of symptoms
and strongly advised to
seek medical attention if
happens again
43 Female 6 Trial
medications
Abatacept Expected 4 March
2014
4 March 2014 10 April
2014
Abatacept Infections and
infestations
N02220/
00077/001
Pneumonia Pneumonia leading to
sepsis. Stroke – left
middle cerebral artery
81 Female 1–3 Trial
medications,
998 to 999
(COPD, smoking
history)
Abatacept Expected 12 March
2014
31 March 2014 10 October
2014
COPD, chronic obstructive pulmonary disorder.
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TABLE 72 Line listing of all serious ARs
Treatment
Randomised
Medical Dictionary for
Regulatory Activities’ System
Organ Class SAE code
SAE in
medical
terms
Recovery
date
Duration
(days) Outcome
First ever trial
medication Product form
First trial
dose
Date most
recent dose
Most recent
dosing
schedule
Most recent
route
Alternative
TNFi
Hepatobiliary disorders N00072/
00024/001
Autoimmune
hepatitis
30 September
2014
157 Recovered
with sequelae
Infliximab Intravenous 10 September
2013
10 February
2014
261mg Intravenous
Abatacept Skin and subcutaneous tissue
disorders
N00400/
00074/001
Angiooedema 11 April 2014 2 Recovered Abatacept Subcutaneous
injection
9 April 2014 8 July 2014 125mg,
weekly
Subcutaneous
Abatacept Infections and infestations N02220/
00077/001
Pneumonia Death Abatacept Subcutaneous
injection
31 March
2014
TABLE 73 Line listing of all SAEs (not related to IMP)
Treatment
Randomised
Medical
Dictionary for
Regulatory
Activities’
System Organ
Class SAE code
SAE in
medical
terms SAE description Age Sex
Seriousness
criteria Causality
Date of
registration
Randomisation
date
Date event
became
serious
Recovery
date
Abatacept N00168/
00146/001
Chest
pain/epigastric
pain
Constant epigastric/chest pain for past
2 weeks. Increasingly worse. Prior
admission to King’s Mill Hospital and
discharged with no diagnosis. Today
(5 February 2015) seen in the accident
and emergency department at Royal
Derby Hospital and admitted for
surgical assessment. Patient was
admitted to hospital for a third
occasion on 22 February 2015 for the
same medical condition. 24 hours
stay. Nothing abnormal detected.
Investigations continue
36 Female 3 10 November
2014
11 November
2014
25 January
2015
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TABLE 73 Line listing of all SAEs (not related to IMP) (continued )
Treatment
Randomised
Medical
Dictionary for
Regulatory
Activities’
System Organ
Class SAE code
SAE in
medical
terms SAE description Age Sex
Seriousness
criteria Causality
Date of
registration
Randomisation
date
Date event
became
serious
Recovery
date
Abatacept Infections and
infestations
N00178/
00134/001
Chest
Infection
Persistent cough, chest Infection 81 Female 3 999 (contact
with family
with viral chest
infection)
24 September
2014
9 October 2014 11 December
2014
29 December
2014
Rituximab Neoplasms
benign, malignant
and unspecified
(including cysts
and polyps)
N00071/
00037/001
Malignant
melanoma
Presented to the accident and
emergency department with
fungating and partially necrotic mass
posteromedial knee. Magnetic
resonance imaging highly suggestive
of sarcoma. Referred to Freeman
Hospital. Biopsies confirm melanoma
with positive groin nodes. Referred for
surgery
66 Male 1–3 999 [Humira
(previous
medication)]
4 October
2013
14 October 13 27 February
14
Rituximab Musculoskeletal
and connective
tissue disorders
N00473/
00045/001
Flare of RA Admitted via the accident and
emergency department with ‘flare of
RA’ suspected to have underlying
chest infection. CRP level > 100.
Secondary to left basal pneumonia.
Signs/symptoms= generalised joint
pain. Admitted 24 January 2014.
Discharged 29 January 2014
58 Male 3 998
(pneumonia)
5 November
2013
13 November
2013
24 January
2014
29 January
14
Rituximab Respiratory,
thoracic and
mediastinal
disorders
N00473/
00045/002
Left basal
pneumonia
Flu-like symptoms, pyrexia, pleuritic
chest pain and productive cough.
Admitted 24 January 2014.
Discharged 29 January 2014
58 Male 3 999
(community
acquired)
5 November
2013
13 November
2013
24 January
2014
10 February
2014
Rituximab Musculoskeletal
and connective
tissue disorders
N00473/
00114/001
Collapse and
broken coccyx
As a result of collapse in the
bathroom the patient sustained a
broken coccyx
75 Female 3 998 (suspected
neurological
condition)
25 July 2014 7 August 2014 22 January
2015
27 January
2015
Rituximab Gastrointestinal
disorders
N00482/
00008/001
Abdominal
pain
Vomiting and two episodes of
diarrhoea
53 Female 3 999 (scarring
from
hysterectomy)
8 January
2013
22 January 2013 7 May 2013 8 May 2013
A
PPEN
D
IX
14
N
IH
R
Journals
Library
w
w
w
.journalslibrary.nihr.ac.uk
244
TABLE 74 Line listing of all SAEs (not related to IMP)
Treatment
Randomised
Medical Dictionary for
Regulatory Activities’
System Organ Class SAE code
SAE in
medical terms
Duration
(days) Outcome
First ever trial
medication
Product
form
First trial
dose
Date most
recent dose
Most recent
dosing
schedule
Most recent
route
Abatacept N00168/
00146/001
Chest
pain/epigastric
pain
Condition still
present and
unchanged
Abatacept Subcutaneous
injection
14 November
2014
4 February
2015
125mg
weekly
Subcutaneous
Abatacept Infections and infestations N00178/
00134/001
Chest infection 19 Recovered Abatacept Subcutaneous
injection
9 October
2014
27 November
2014
125mg
weekly
Subcutaneous
Rituximab Neoplasms benign, malignant
and unspecified (including
cysts and polyps)
N00071/
00037/001
Malignant
melanoma
Death Rituximab Intravenous 23 October
2013
6 November
2013
1 g Intravenous
Rituximab Musculoskeletal and
connective tissue disorders
N00473/
00045/001
Flare of RA 6 Recovered a . . .
Rituximab Respiratory, thoracic and
mediastinal disorders
N00473/
00045/002
Left basal
pneumonia
18 Recovered a . . .
Rituximab Musculoskeletal and
connective tissue disorders
N00473/
00114/001
Collapse and
broken coccyx
6 Recovered
with sequelae
Rituximab Intravenous 4 September
2014
24 September
2014
1 g Intravenous
Rituximab Gastrointestinal disorders N00482/
00008/001
Abdominal pain 2 Recovered Rituximab Intravenous 24 January
2013
7 February
2013
1 g Intravenous
a Patient 00045 had not received first infusion by the time of SAE onset because of a prolonged delay to the start of treatment. Hence, no treatment had been received.
D
O
I:10.3310/hta22340
H
EA
LTH
TECH
N
O
LO
G
Y
A
SSESSM
EN
T
2018
VO
L.22
N
O
.34
©
Q
ueen
’s
Printer
and
C
ontroller
of
H
M
SO
2018.
This
w
ork
w
as
produced
by
Brow
n
et
al.
under
the
term
s
of
a
com
m
issioning
contract
issued
by
the
Secretary
of
State
for
H
ealth
and
SocialC
are.
This
issue
m
ay
be
freely
reproduced
for
the
purposes
of
private
research
and
study
and
extracts
(or
indeed,
the
fullreport)
m
ay
be
included
in
professional
journals
provided
that
suitable
acknow
ledgem
ent
is
m
ade
and
the
reproduction
is
not
associated
w
ith
any
form
of
advertising.
A
pplications
for
com
m
ercialreproduction
should
be
addressed
to:
N
IH
R
Journals
Library,
N
ationalInstitute
for
H
ealth
Research,
Evaluation,
Trials
and
Studies
C
oordinating
C
entre,
A
lpha
H
ouse,
U
niversity
of
Southam
pton
Science
Park,
Southam
pton
SO
16
7N
S,
U
K
.
245
TABLE 75 Line listing of non-SAEs
Treatment
randomised
Centre name and
number
Patient
number
First
reported AE description
New or
pre-existing
event? Intensity Causality Expectedness
(For infections)
Requested
treatment with
antibiotics?
SAE or
SUSAR?
Stopping of
treatment
Adalimumab Northampton
General Hospital;
N00038
00119 Week 12 URTI (sore throat,
runny nose)
New Moderate Unrelated Unexpected No No No
Adalimumab Northampton
General Hospital;
N00038
00119 Week 12 Non-cardiac chest pain New Moderate Unrelated Unexpected N/A No No
Adalimumab Manchester Royal
Infirmary; N00080
00023 Week 12 Worsening RA New Moderate Probably Unexpected N/A No Permanent
Adalimumab Cannock Chase
Hospital; N00473
00028 Week 48 Nausea Pre-existing Mild Unrelated Unexpected No No No
Adalimumab Chapel Allerton
Hospital, Leeds;
N00482
00032 Week 12 LRTI, lower respirating
chest infection
New Moderate Possibly Expected Yes No Temporary
Adalimumab Chapel Allerton
Hospital, Leeds;
N00482
00032 Week 12 Exacerbation of COPD New Moderate Possibly Expected No No Temporary
Adalimumab Chapel Allerton
Hospital, Leeds;
N00482
00032 Week 24 Benign cyst on right
breast
New Mild Unlikely Unexpected No No No
Adalimumab Chapel Allerton
Hospital, Leeds;
N00482
00032 Week 24 Cold symptoms New Mild Probably Expected Yes No Temporary
Adalimumab Chapel Allerton
Hospital, Leeds;
N00482
00032 Week 36 Infective exacerbation
of COPD
Pre-existing Moderate Unrelated Unexpected Yes No Temporary
Adalimumab Chapel Allerton
Hospital, Leeds;
N00482
00032 Week 48 Exacerbation of COPD Pre-existing Severe Possibly Expected Yes No Temporary
Adalimumab Broadgreen
Hospital, Liverpool;
N00589
00110 Week 12 Rash – maculopapular
grade 1
New Moderate Possibly Unexpected N/A No No
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Treatment
randomised
Centre name and
number
Patient
number
First
reported AE description
New or
pre-existing
event? Intensity Causality Expectedness
(For infections)
Requested
treatment with
antibiotics?
SAE or
SUSAR?
Stopping of
treatment
CZP Birmingham City
Hospital; N00346
00086 Week 12 Vomiting New Moderate Unlikely Unexpected No No Temporary
Golimumab Airedale General
Hospital; N00074
00088 Week 36 Chest infection New Moderate Probably Expected Yes No Temporary
Golimumab Airedale General
Hospital; N00074
00088 Week 48 Fatigue New Mild Unrelated Unexpected N/A No No
Golimumab Airedale General
Hospital; N00074
00088 Week 48 Mouth ulcers New Moderate Unrelated Unexpected N/A No No
Golimumab Airedale General
Hospital; N00074
00088 Week 48 Poor sleep New Mild Unrelated Unexpected N/A No No
Golimumab Derriford Hospital,
Plymouth; N00118
00133 Week 24 Abnormal liver blood
test
New Moderate Possibly Unexpected No No No
Golimumab Derriford Hospital,
Plymouth; N00118
00133 Week 24 One episode of heart
rate rise to 146 b.p.m+
feeling faint
New Mild Possibly Unexpected No No No
Golimumab Derriford Hospital,
Plymouth; N00118
00133 Week 36 Nasal sores crusts New Moderate Possibly Unexpected Yes No Temporary
Golimumab Derriford Hospital,
Plymouth; N00118
00133 Week 36 Reduced liver function
blood results stopped
MTX temporarily
New Moderate Almost
certainly
Unexpected N/A No Temporary
Golimumab Derriford Hospital,
Plymouth; N00118
00133 Week 48 Chest infection New Mild Possibly Unexpected No No No
Golimumab Derriford Hospital,
Plymouth; N00118
00133 Week 48 Sore throat and
earache
New Mild Unlikely Unexpected No No No
Golimumab Derriford Hospital,
Plymouth; N00118
00133 Week 48 Nasal crusts/ulcers New Mild Probably Unexpected No No No
Golimumab Derriford Hospital,
Plymouth; N00118
00133 Week 48 Styes both eyes New Mild Unlikely Unexpected No No No
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TABLE 75 Line listing of non-SAEs (continued )
Treatment
randomised
Centre name and
number
Patient
number
First
reported AE description
New or
pre-existing
event? Intensity Causality Expectedness
(For infections)
Requested
treatment with
antibiotics?
SAE or
SUSAR?
Stopping of
treatment
Infliximab Royal Victoria
Infirmary,
Newcastle; N00072
00024 Week 12 Sore throat New Mild Possibly Expected No No No
Infliximab Royal Victoria
Infirmary,
Newcastle; N00072
00024 Week 24 Elevated ALT levels in
blood samples taken
on 10 February 2014
New Moderate Possibly Expected N/A No Permanent
Etanercept Leicester Royal
Infirmary; N00031
00094 Week 24 Viral infection New Moderate Possibly Unexpected Yes No Temporary
Etanercept Leicester Royal
Infirmary; N00031
00094 Week 24 Haemoglobin
decreased
New Mild Unlikely Unexpected No No No
Etanercept Leicester Royal
Infirmary; N00031
00094 Week 24 Abdominal pain New Mild Unlikely Unexpected No No No
Etanercept Leicester Royal
Infirmary; N00031
00094 Week 24 ↑left wrist pain Pre-existing Mild Unlikely Expected No No No
Etanercept Northampton
General Hospital;
N00038
00112 Week 24 Chest infection New Moderate Possibly Unexpected Yes No Temporary
Etanercept Queen Elizabeth
Hospital,
Gateshead; N00071
00096 Week 12 Reaction around
injection site
New Moderate Almost
certainly
Expected No No Permanent
Etanercept Airedale General
Hospital; N00074
00147 Week 12 Nausea New Moderate Unrelated Expected N/A No Temporary
Etanercept Derriford Hospital,
Plymouth; N00118
00060 Week 12 Nausea New Moderate Probably Expected N/A No No
Etanercept Derriford Hospital,
Plymouth; N00118
00060 Week 36 Pain in both feet New Moderate Unlikely Unexpected N/A No No
Etanercept Derriford Hospital,
Plymouth; N00118
00060 Week 36 Pimples on neck New Mild Unlikely Unexpected N/A No No
Etanercept King George
Hospital, Ilford;
N00165
00046 Week 12 UTI requiring oral
antibiotics
New Moderate Possibly Expected Yes No Temporary
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Treatment
randomised
Centre name and
number
Patient
number
First
reported AE description
New or
pre-existing
event? Intensity Causality Expectedness
(For infections)
Requested
treatment with
antibiotics?
SAE or
SUSAR?
Stopping of
treatment
Etanercept King George
Hospital, Ilford;
N00165
00046 Week 12 Erythematous lesion at
Enbrel injection site
New Moderate Almost
certainly
Expected N/A No Temporary
Etanercept King George
Hospital, Ilford;
N00165
00046 Week 24 Pain with swelling in
the tummy area where
injection was given
New Mild Almost
certainly
Expected N/A No No
Etanercept King George
Hospital, Ilford;
N00165
00057 Week 12 UTI New Moderate Possibly Expected Yes No Temporary
Etanercept King George
Hospital, Ilford;
N00165
00057 Week 12 Twisted (right) knee New Mild Unrelated Unexpected N/A No No
Etanercept King George
Hospital, Ilford;
N00165
00057 Week 24 Upper molar
extraction abscess
New Moderate Possibly Unexpected Yes No Temporary
Etanercept Queen’s Hospital,
Burton upon Trent;
N00178
00073 Week 12 Itching erythema New Mild Almost
certainly
Expected No No No
Etanercept Queen’s Hospital,
Burton upon Trent;
N00178
00073 Week 48 Right haemorrhagic
branch retinal vein
occlusion (retinal
vascular disorder
CTCAE description)
New Moderate Unrelated Unexpected No No No
Etanercept Queen’s Hospital,
Burton upon Trent;
N00178
00121 Week 12 Tonsillitis New Moderate Unrelated Expected Yes No Temporary
Etanercept Queen’s Hospital,
Burton upon Trent;
N00178
00121 Week 12 Injection site reaction New Moderate Almost
certainly
Expected No No No
Etanercept Queen’s Hospital,
Burton upon Trent;
N00178
00121 Week 12 Subconjunctival
haemorrhage
New Mild Unrelated Expected No No No
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TABLE 75 Line listing of non-SAEs (continued )
Treatment
randomised
Centre name and
number
Patient
number
First
reported AE description
New or
pre-existing
event? Intensity Causality Expectedness
(For infections)
Requested
treatment with
antibiotics?
SAE or
SUSAR?
Stopping of
treatment
Etanercept Guy’s Hospital,
London; N00241
00064 Week 12 Migraine New Moderate Unrelated Expected N/A No No
Etanercept Guy’s Hospital,
London; N00241
00064 Week 24 Migraine Pre-existing Mild Unrelated Expected No No No
Etanercept Guy’s Hospital,
London; N00241
00064 Week 36 Migraine Pre-existing Moderate Unrelated Expected N/A No No
Etanercept Guy’s Hospital,
London; N00241
00064 Week 48 Right flank abdominal
pain
New Mild Unrelated Unexpected N/A No No
Etanercept Salford Royal
Infirmary; N00400
00084 Week 12 URTI New Mild Unrelated Unexpected No No No
Etanercept Salford Royal
Infirmary; N00400
00084 Week 24 Mouth ulcers New Moderate Unlikely Unexpected No No No
Etanercept Salford Royal
Infirmary; N00400
00084 Week 24 Toothache New Moderate Unlikely Unexpected No No No
Etanercept Salford Royal
Infirmary; N00400
00084 Week 36 Rash left hand New Moderate Unlikely Unexpected N/A No No
Etanercept Salford Royal
Infirmary; N00400
00084 Week 48 Hay fever New Mild Unrelated Unexpected N/A No No
Etanercept Cannock Chase
Hospital; N00473
00041 Week 12 Injection site reaction New Moderate Almost
certainly
Unexpected N/A No No
Etanercept Cannock Chase
Hospital; N00473
00041 Week 24 Sickness New Mild Unlikely Unexpected No No No
Etanercept Cannock Chase
Hospital; N00473
00041 Week 24 Diarrhoea New Mild Unlikely Unexpected No No No
Etanercept Cannock Chase
Hospital; N00473
00041 Week 24 Throat infection New Mild Unlikely Unexpected Yes No Temporary
Etanercept Cannock Chase
Hospital; N00473
00041 Week 24 Eye infection New Mild Unlikely Unexpected Yes No No
Etanercept Cannock Chase
Hospital; N00473
00041 Week 36 Vaginal thrush New Mild Unlikely Unexpected No No No
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Treatment
randomised
Centre name and
number
Patient
number
First
reported AE description
New or
pre-existing
event? Intensity Causality Expectedness
(For infections)
Requested
treatment with
antibiotics?
SAE or
SUSAR?
Stopping of
treatment
Etanercept Cannock Chase
Hospital; N00473
00041 Week 36 Sinusitis New Mild Unlikely Unexpected Yes No No
Etanercept Cannock Chase
Hospital; N00473
00041 Week 48 Sinusitis Pre-existing Mild Unlikely Unexpected No No No
Etanercept Chapel Allerton
Hospital, Leeds;
N00482
00001 Week 12 (Left) lower backache New Mild Unrelated Unexpected N/A No No
Etanercept Chapel Allerton
Hospital, Leeds;
N00482
00004 Week 12 Injection site reaction New Mild Almost
certainly
Expected No No No
Etanercept Chapel Allerton
Hospital, Leeds;
N00482
00004 Week 48 Facial rash and chest
rash, non-blanching
New Moderate Possibly Expected No No No
Etanercept Chapel Allerton
Hospital, Leeds;
N00482
00018 Week 12 Bruising New Mild Possibly Unexpected N/A No No
Etanercept Chapel Allerton
Hospital, Leeds;
N00482
00018 Week 12 Chest infection New Moderate Unlikely Unexpected Yes No Temporary
Etanercept Chapel Allerton
Hospital, Leeds;
N00482
00018 Week 12 Nausea New Mild Possibly Unexpected N/A No No
Etanercept Chapel Allerton
Hospital, Leeds;
N00482
00018 Week 24 Sickness with (nausea)
etanercept
New Moderate Almost
certainly
Expected N/A No Permanent
Etanercept Chapel Allerton
Hospital, Leeds;
N00482
00018 Week 24 Bruising New Mild Possibly Unexpected N/A No Permanent
Etanercept Chapel Allerton
Hospital, Leeds;
N00482
00018 Week 24 Chest infection New Moderate Probably Expected Yes No No
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TABLE 75 Line listing of non-SAEs (continued )
Treatment
randomised
Centre name and
number
Patient
number
First
reported AE description
New or
pre-existing
event? Intensity Causality Expectedness
(For infections)
Requested
treatment with
antibiotics?
SAE or
SUSAR?
Stopping of
treatment
Etanercept Chapel Allerton
Hospital, Leeds;
N00482
00018 Week 48 Cut (right) shin New Mild Unrelated Unexpected N/A No No
Etanercept Chapel Allerton
Hospital, Leeds;
N00482
00059 Week 48 Cold New Mild Probably Expected No No No
Etanercept Chapel Allerton
Hospital, Leeds;
N00482
00065 Week 48 Cellulitis New Moderate Probably Unexpected Yes No Temporary
Etanercept Chapel Allerton
Hospital, Leeds;
N00482
00070 Week 48 Diarrhoea New Mild Missing Unexpected No No No
Etanercept Chapel Allerton
Hospital, Leeds;
N00482
00070 Week 48 Cold New Mild Missing Expected No No No
Etanercept Chapel Allerton
Hospital, Leeds;
N00482
00070 Week 48 Fall New Moderate Missing Unexpected No No No
Etanercept Chapel Allerton
Hospital, Leeds;
N00482
00070 Week 48 Tooth infection New Moderate Missing Expected Yes No No
Etanercept Royal National
Hospital for
Rheumatic Diseases,
Bath; N02220
00044 Week 12 Swelling of ankles in
the evening
New Mild Possibly Unexpected N/A No No
Etanercept Royal National
Hospital for
Rheumatic Diseases,
Bath; N02220
00044 Week 12 Blocked nose
(on SmPC)
New Mild Probably Unexpected N/A No No
Etanercept Royal National
Hospital for
Rheumatic Diseases,
Bath; N02220
00044 Week 12 Right shoulder/neck
pain
New Mild Unrelated Unexpected N/A No No
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Treatment
randomised
Centre name and
number
Patient
number
First
reported AE description
New or
pre-existing
event? Intensity Causality Expectedness
(For infections)
Requested
treatment with
antibiotics?
SAE or
SUSAR?
Stopping of
treatment
Abatacept Leicester Royal
Infirmary; N00031
00087 Week 24 Mouth ulcer Pre-existing Moderate Possibly Unexpected No No No
Abatacept Leicester Royal
Infirmary; N00031
00087 Week 36 Nose bleeds Pre-existing Mild Unrelated Unexpected N/A No No
Abatacept Leicester Royal
Infirmary; N00031
00087 Week 36 Dizziness Pre-existing Mild Unrelated Unexpected N/A No No
Abatacept Leicester Royal
Infirmary; N00031
00087 Week 36 Swollen ankles Pre-existing Moderate Unrelated Expected N/A No No
Abatacept Leicester Royal
Infirmary; N00031
00087 Week 36 Slurring Pre-existing Mild Unrelated Unexpected N/A No No
Abatacept Leicester Royal
Infirmary; N00031
00087 Week 36 Sore mouth Pre-existing Mild Unrelated Unexpected N/A No No
Abatacept Darlington
Memorial Hospital;
N00068
00097 Week 12 Feeling generally a bit
low and lethargic
New Mild Unlikely Expected No No No
Abatacept Darlington
Memorial Hospital;
N00068
00097 Week 12 Cool hands and feet New Mild Possibly Expected No No No
Abatacept Darlington
Memorial Hospital;
N00068
00097 Week 12 ↓ haemoglobin levels New Moderate Unlikely Unexpected No No No
Abatacept Darlington
Memorial Hospital;
N00068
00097 Week 24 Flare of RA New Moderate Possibly Unexpected N/A No No
Abatacept Queen Elizabeth
Hospital,
Gateshead; N00071
00034 Week 12 Infected leg ulcer New Moderate Possibly Unexpected Yes No Temporary
Abatacept Queen Elizabeth
Hospital,
Gateshead; N00071
00034 Week 12 Ear infection New Moderate Possibly Unexpected Yes No Temporary
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TABLE 75 Line listing of non-SAEs (continued )
Treatment
randomised
Centre name and
number
Patient
number
First
reported AE description
New or
pre-existing
event? Intensity Causality Expectedness
(For infections)
Requested
treatment with
antibiotics?
SAE or
SUSAR?
Stopping of
treatment
Abatacept Queen Elizabeth
Hospital,
Gateshead; N00071
00034 Week 12 Flu-like symptoms New Mild Unlikely Unexpected No No Temporary
Abatacept Queen Elizabeth
Hospital,
Gateshead; N00071
00034 Week 48 Short of breath?
Attributable to MTX
New Moderate Possibly Unexpected – No Temporary
Abatacept Airedale General
Hospital; N00074
00033 Week 12 URTI New Moderate Probably Expected No No No
Abatacept Airedale General
Hospital; N00074
00078 Week 12 UTI New Moderate Unlikely Expected Yes No No
Abatacept Airedale General
Hospital; N00074
00078 Week 24 Middle ear infection New Moderate Unlikely Expected Yes No Temporary
Abatacept Airedale General
Hospital; N00074
00078 Week 36 Back pain New Moderate Unrelated Unexpected N/A No No
Abatacept Airedale General
Hospital; N00074
00078 Week 36 (Ingrowing toe nail)
inflamed big toe
New Mild Unrelated Unexpected No No No
Abatacept Airedale General
Hospital; N00074
00078 Week 48 UTI Pre-existing Moderate Unlikely Expected Yes No Temporary
Abatacept Bristol Royal
Infirmary; N00117
00145 Week 24 Campylobacter
gastroenteritis
New Moderate Possibly Unexpected Yes No No
Abatacept Derriford Hospital,
Plymouth; N00118
00040 Week 12 Chest infection New Moderate Possibly Unexpected Yes No Temporary
Abatacept Derriford Hospital,
Plymouth; N00118
00040 Week 12 Urinary infection New Moderate Possibly Expected Yes No Temporary
Abatacept Derriford Hospital,
Plymouth; N00118
00040 Week 24 Tiredness New Mild Possibly Expected No No No
Abatacept Derriford Hospital,
Plymouth; N00118
00040 Week 48 Urinary infection New Moderate Possibly Unexpected Yes No No
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Treatment
randomised
Centre name and
number
Patient
number
First
reported AE description
New or
pre-existing
event? Intensity Causality Expectedness
(For infections)
Requested
treatment with
antibiotics?
SAE or
SUSAR?
Stopping of
treatment
Abatacept Derriford Hospital,
Plymouth; N00118
00068 Week 12 Infected left big toe New Moderate Possibly Unexpected Yes No No
Abatacept Derriford Hospital,
Plymouth; N00118
00068 Week 48 Patient has a cold and
feeling unwell. Treated
with amoxicillin
21 January 2015 to
1 week out of 52
and oxytetracycline
4 February 2015 to 1/52
New Moderate Unlikely Unexpected Yes Yes Temporary
Abatacept King George
Hospital, Ilford;
N00165
00051 Week 12 Elevated ALP (145 IU/l –
range 30 to 130 IU/l)
New Mild Possibly Unexpected N/A No No
Abatacept King George
Hospital, Ilford;
N00165
00052 Week 12 (Right) axilla infection
of hair follicles
New Moderate Possibly Unexpected Yes No Temporary
Abatacept King George
Hospital, Ilford;
N00165
00052 Week 24 Gastroenteritis New Mild Unlikely Unexpected No No Temporary
Abatacept Royal Derby
Hospital; N00168
00146 Week 12 Chest pain New Severe Unrelated Unexpected N/A Yes Temporary
Abatacept Royal Derby
Hospital; N00168
00146 Week 24 Upper abdominal pain Pre-existing Moderate Unrelated Unexpected N/A Yes Temporary
Abatacept University Hospital,
North Durham;
N00170
00071 Week 12 UTI New Moderate Possibly Unexpected Yes No Temporary
Abatacept University Hospital,
North Durham;
N00170
00071 Week 12 Mouth ulcers New Mild Possibly Unexpected N/A No No
Abatacept University Hospital,
North Durham;
N00170
00071 Week 12 Sore throat New Mild Possibly Unexpected N/A No No
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TABLE 75 Line listing of non-SAEs (continued )
Treatment
randomised
Centre name and
number
Patient
number
First
reported AE description
New or
pre-existing
event? Intensity Causality Expectedness
(For infections)
Requested
treatment with
antibiotics?
SAE or
SUSAR?
Stopping of
treatment
Abatacept University Hospital,
North Durham;
N00170
00071 Week 12 Abscess tooth, tooth
out
New Moderate Possibly Unexpected Yes No Temporary
Abatacept Musgrove Park
Hospital, Taunton;
N00306
00089 Week 36 Right wrist swollen
and painful 120-mg
Depo injection given
New Moderate Missing Expected No No No
Abatacept Birmingham City
Hospital; N00346
00061 Week 12 Upper respiratory
indigestion
New Moderate Possibly Unexpected No No Temporary
Abatacept Birmingham City
Hospital; N00346
00061 Week 24 Upper respiratory
injection
Pre-existing Moderate Possibly Unexpected No No No
Abatacept Birmingham City
Hospital; N00346
00061 Week 24 Occasional wheeze New Moderate Possibly Unexpected No No No
Abatacept Birmingham City
Hospital; N00346
00079 Week 24 UTI New Moderate Unlikely Unexpected Yes No No
Abatacept Birmingham City
Hospital; N00346
00079 Week 48 Nausea New Mild Unrelated Unexpected N/A No No
Abatacept Salford Royal
Infirmary; N00400
00074 Week 12 Bruising New Mild Possibly Unexpected N/A No No
Abatacept Salford Royal
Infirmary; N00400
00074 Week 12 Angiooedema face,
tongue, hands
New Moderate Possibly Unexpected N/A Yes No
Abatacept Salford Royal
Infirmary; N00400
00074 Week 12 Angiooedema right
cheek
New Moderate Possibly Unexpected N/A Yes No
Abatacept Salford Royal
Infirmary; N00400
00074 Week 24 Mouth ulcers New Mild Possibly Unexpected No No No
Abatacept Salford Royal
Infirmary; N00400
00074 Week 24 Sickness/nausea New Moderate Unrelated Unexpected N/A No No
Abatacept Salford Royal
Infirmary; N00400
00074 Week 24 Hypertension New Moderate Unrelated Unexpected N/A No No
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Treatment
randomised
Centre name and
number
Patient
number
First
reported AE description
New or
pre-existing
event? Intensity Causality Expectedness
(For infections)
Requested
treatment with
antibiotics?
SAE or
SUSAR?
Stopping of
treatment
Abatacept Salford Royal
Infirmary; N00400
00074 Week 24 Neck pain New Moderate Unrelated Unexpected N/A No No
Abatacept Salford Royal
Infirmary; N00400
00074 Week 36 Flare of RA (left wrist
and left hip)
– Missing Missing Missing – Missing Missing
Abatacept Salford Royal
Infirmary; N00400
00074 Week 48 Pain in hip Pre-existing Moderate Unrelated Expected No No No
Abatacept Cannock Chase
Hospital; N00473
00106 Week 36 Mouth ulcers New Mild Possibly Unexpected No No No
Abatacept Cannock Chase
Hospital; N00473
00106 Week 36 Chest (URTI) infection New Moderate Possibly Unexpected Yes No No
Abatacept Cannock Chase
Hospital; N00473
00106 Week 36 Cellulitis New Moderate Possibly Unexpected Yes No No
Abatacept Chapel Allerton
Hospital, Leeds;
N00482
00002 Week 12 (Right) tooth abscess New Moderate Possibly Expected Yes No Temporary
Abatacept Chapel Allerton
Hospital, Leeds;
N00482
00002 Week 12 Chest infection New Moderate Possibly Expected Yes No Temporary
Abatacept Chapel Allerton
Hospital, Leeds;
N00482
00006 Week 36 UTI New Moderate Unlikely Expected Yes No Temporary
Abatacept Chapel Allerton
Hospital, Leeds;
N00482
00009 Week 48 Flu illness with URTI New Moderate Unrelated Expected Yes No Temporary
Abatacept Chapel Allerton
Hospital, Leeds;
N00482
00014 Week 24 Chest infection New Moderate Possibly Expected Yes No Temporary
Abatacept Chapel Allerton
Hospital, Leeds;
N00482
00016 Week 12 Back pain after getting
up from chair
New Severe Unrelated Unexpected N/A No No
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TABLE 75 Line listing of non-SAEs (continued )
Treatment
randomised
Centre name and
number
Patient
number
First
reported AE description
New or
pre-existing
event? Intensity Causality Expectedness
(For infections)
Requested
treatment with
antibiotics?
SAE or
SUSAR?
Stopping of
treatment
Abatacept Chapel Allerton
Hospital, Leeds;
N00482
00016 Week 12 Nausea and change in
smell
New Mild Unrelated Unexpected N/A No No
Abatacept Chapel Allerton
Hospital, Leeds;
N00482
00021 Week 24 Foot ulcer right MTP 1 New Moderate Possibly Expected Yes No Temporary
Abatacept Chapel Allerton
Hospital, Leeds;
N00482
00026 Week 12 Mild hair loss New Mild Possibly Expected N/A No No
Abatacept Chapel Allerton
Hospital, Leeds;
N00482
00026 Week 24 Swelling and lumps on
both sides of the neck
New Mild Unlikely Unexpected N/A No No
Abatacept Chapel Allerton
Hospital, Leeds;
N00482
00026 Week 48 Chest infection New Moderate Possibly Expected Yes No No
Abatacept Chapel Allerton
Hospital, Leeds;
N00482
00038 Week 36 Sinusitis New Moderate Possibly Expected Yes No Temporary
Abatacept Chapel Allerton
Hospital, Leeds;
N00482
00038 Week 36 Laryngitis New Moderate Possibly Expected Yes No Temporary
Abatacept Chapel Allerton
Hospital, Leeds;
N00482
00102 Week 36 Cold New Mild Probably Expected No No No
Abatacept Chapel Allerton
Hospital, Leeds;
N00482
00103 Week 36 Cold New Mild Probably Expected No No No
Abatacept Chapel Allerton
Hospital, Leeds;
N00482
00137 Week 12 URTI New Moderate Probably Expected Yes No No
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Treatment
randomised
Centre name and
number
Patient
number
First
reported AE description
New or
pre-existing
event? Intensity Causality Expectedness
(For infections)
Requested
treatment with
antibiotics?
SAE or
SUSAR?
Stopping of
treatment
Abatacept Chapel Allerton
Hospital, Leeds;
N00482
00137 Week 36 Tooth abscess New Moderate Probably Expected Yes No Temporary
Abatacept Chapel Allerton
Hospital, Leeds;
N00482
00137 Week 48 Hair loss Pre-existing Moderate Probably Expected N/A No Permanent
Abatacept Broadgreen
Hospital, Liverpool;
N00589
00130 Week 12 Laryngeal
inflammation
New Mild Unlikely Unexpected N/A No No
Abatacept Royal National
Hospital for
Rheumatic Diseases,
Bath N02220
00077 Week 12 Chest infection New Moderate Possibly Expected Yes No Temporary
Abatacept Royal National
Hospital for
Rheumatic Diseases,
Bath N02220
00077 Week 12 Chest infection New Moderate Possibly Expected Yes No Temporary
Abatacept Royal National
Hospital for
Rheumatic Diseases,
Bath N02220
00077 Week 12 Infected dog scratch New Moderate Unrelated Unexpected Yes No Temporary
Abatacept Royal National
Hospital for
Rheumatic Diseases,
Bath N02220
00123 Week 36 UTI low backache.
No fever, dysuria,
frequency
New Moderate Possibly Unexpected Yes No No
Abatacept Royal National
Hospital for
Rheumatic Diseases,
Bath N02220
00123 Week 36 UTI low backache
no fever, dysuria,
frequency
New Moderate Possibly Unexpected Yes No No
Abatacept Royal National
Hospital for
Rheumatic Diseases,
Bath N02220
00125 Week 12 Severe flare –
widespread pain and
stiffness, bed/
chairbound, assessed
by out-of-hours GP
New Severe Unrelated Unexpected N/A No No
continued
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TABLE 75 Line listing of non-SAEs (continued )
Treatment
randomised
Centre name and
number
Patient
number
First
reported AE description
New or
pre-existing
event? Intensity Causality Expectedness
(For infections)
Requested
treatment with
antibiotics?
SAE or
SUSAR?
Stopping of
treatment
Rituximab New Cross Hospital,
Wolverhampton;
N00034
00142 Week 36 Rash – forearms and
trunk
New Mild Possibly Unexpected No No No
Rituximab Queen Elizabeth
Hospital,
Gateshead; N00071
00031 Week 24 Vomited (once) New Mild Possibly Unexpected N/A No No
Rituximab Queen Elizabeth
Hospital,
Gateshead; N00071
00037 Week 24 Metastatic melanoma New Life-
threatening
Unrelated Unexpected N/A Yes Permanent
Rituximab Queen Elizabeth
Hospital,
Gateshead; N00071
00066 Week 12 Rash New Moderate Possibly Unexpected No No No
Rituximab Airedale General
Hospital; N00074
00058 Week 12 White cells 3.4 × 109/l
(below normal limit)
New Mild Unrelated Expected No No Temporary
Rituximab Airedale General
Hospital; N00074
00058 Week 12 Neutrophils 1.74 × 109/l
(below normal limit)
New Mild Unrelated Expected No No Temporary
Rituximab Airedale General
Hospital; N00074
00058 Week 24 White cell count
(3.1 × 109/l, 3.3 × 109/l,
3.3 × 109/l)
New Mild Unrelated Expected No No Temporary
Rituximab Airedale General
Hospital; N00074
00058 Week 24 Low neutrophils
(1.45×109/l, 1.45×109/l,
1.62 × 109/l)
New Mild Unrelated Expected No No Temporary
Rituximab Airedale General
Hospital; N00074
00058 Week 36 Cystitis New Moderate Unrelated Expected Yes No No
Rituximab Airedale General
Hospital; N00074
00058 Week 36 Raised ALT (5S g/l) Pre-existing Mild Unrelated Expected N/A No Temporary
Rituximab Airedale General
Hospital; N00074
00058 Week 48 Around 15 November
2014 croaky voice
New Moderate Possibly Expected No No No
Rituximab Airedale General
Hospital; N00074
00058 Week 48 Around 15 November
2014 (ongoing) blocked
nose (took paracetamol
on the weekend when
she felt worse)
New Moderate Possibly Expected No No No
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Treatment
randomised
Centre name and
number
Patient
number
First
reported AE description
New or
pre-existing
event? Intensity Causality Expectedness
(For infections)
Requested
treatment with
antibiotics?
SAE or
SUSAR?
Stopping of
treatment
Rituximab Hull Royal Infirmary;
N00078
00149 Week 12 Ruptured sebaceous
cyst
New Mild Unrelated Unexpected N/A No No
Rituximab Hull Royal Infirmary;
N00078
00149 Week 24 Urine infection New Mild Unrelated Unexpected Yes No No
Rituximab Manchester Royal
Infirmary; N00080
00013 Week 12 Chest infection New Moderate Possibly Expected Yes No No
Rituximab Manchester Royal
Infirmary; N00080
00013 Week 48 Neutropenia New Moderate Unrelated Unexpected N/A No Temporary
Rituximab Manchester Royal
Infirmary; N00080
00017 Week 12 Widespread soft tissue
tenderness
New Mild Possibly Unexpected N/A No No
Rituximab Manchester Royal
Infirmary; N00080
00017 Week 12 No sleep for past
2 days
New Mild Unlikely Unexpected N/A No No
Rituximab Manchester Royal
Infirmary; N00080
00017 Week 36 Longstanding wind in
stomach
Pre-existing Mild Unrelated Unexpected N/A No No
Rituximab Manchester Royal
Infirmary; N00080
00056 Week 24 Low white cell count New Moderate Almost
certainly
Unexpected N/A No Permanent
Rituximab Manchester Royal
Infirmary; N00080
00056 Week 24 Mouth ulcer New Moderate Almost
certainly
Unexpected N/A No No
Rituximab Manchester Royal
Infirmary; N00080
00092 Week 12 Increased fatigue New Mild Possibly Unexpected N/A No No
Rituximab Manchester Royal
Infirmary; N00080
00092 Week 12 Slight breathlessness
at night
New Mild Possibly Unexpected N/A No No
Rituximab Manchester Royal
Infirmary; N00080
00092 Week 36 Left hand injury New Moderate Unrelated Unexpected N/A No No
Rituximab Poole Hospital;
N00108
00075 Week 12 Rash to upper arms New Mild Unlikely Unexpected N/A No No
Rituximab Poole Hospital;
N00108
00075 Week 36 Submitted Yellow
Card for severe skin
reaction
New Moderate Probably Unexpected No No Permanent
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TABLE 75 Line listing of non-SAEs (continued )
Treatment
randomised
Centre name and
number
Patient
number
First
reported AE description
New or
pre-existing
event? Intensity Causality Expectedness
(For infections)
Requested
treatment with
antibiotics?
SAE or
SUSAR?
Stopping of
treatment
Rituximab Queen Alexandra
Hospital,
Portsmouth;
N00110
00148 Week 12 Infusion reaction on
first rituximab infusion
27 November 2014.
Treated with
intravenous
hydrocortisone
infusion stopped then
restarted: no further
infusion reactions
New Moderate Unlikely Unexpected No No No
Rituximab Queen Alexandra
Hospital,
Portsmouth;
N00110
00148 Week 48 Patient reports hair
loss – MTX dose
reduced to 10mg
weekly
New Mild Unrelated Expected N/A No No
Rituximab Derriford Hospital,
Plymouth; N00118
00025 Week 24 Abscess on mouth
mucosa
New Moderate Possibly Unexpected Yes No No
Rituximab Derriford Hospital,
Plymouth; N00118
00025 Week 48 Lower back pain Pre-existing Moderate Unlikely Unexpected N/A No No
Rituximab King George
Hospital, Ilford;
N00165
00030 Week 12 Suspected UTI New Moderate Unlikely Unexpected Yes No No
Rituximab King George
Hospital, Ilford;
N00165
00030 Week 24 Chest infection Pre-existing Moderate Probably Expected Yes No Temporary
Rituximab King George
Hospital, Ilford;
N00165
00030 Week 24 Chest infection Pre-existing Moderate Probably Expected Yes No Temporary
Rituximab King George
Hospital, Ilford;
N00165
00030 Week 24 Exacerbation of
asthma
New Moderate Unlikely Unexpected N/A No No
Rituximab King George
Hospital, Ilford;
N00165
00030 Week 24 Shingles New Moderate Probably Expected Yes No No
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Treatment
randomised
Centre name and
number
Patient
number
First
reported AE description
New or
pre-existing
event? Intensity Causality Expectedness
(For infections)
Requested
treatment with
antibiotics?
SAE or
SUSAR?
Stopping of
treatment
Rituximab King George
Hospital, Ilford;
N00165
00030 Week 36 (Right) sided suspected
pleurisy
New Severe Unlikely Unexpected Yes No Temporary
Rituximab University Hospital,
North Durham;
N00170
00083 Week 12 ALT raised New Moderate Unlikely Unexpected N/A No No
Rituximab University Hospital,
North Durham;
N00170
00083 Week 24 Eye infection treated
with antibiotic eye
ointment by GP
New Mild Possibly Unexpected Yes No No
Rituximab University Hospital,
North Durham;
N00170
00083 Week 36 Flare New Moderate Unrelated Unexpected N/A No No
Rituximab University Hospital,
North Durham;
N00170
00083 Week 48 (Light) knee swollen
(inner) painful
New Moderate Unlikely Unexpected N/A No No
Rituximab University Hospital,
North Durham;
N00170
00107 Week 12 22 October 2014
shortness of breath
New Moderate Unlikely Unexpected Yes No No
Rituximab University Hospital,
North Durham;
N00170
00107 Week 24 Chest infection New Moderate Possibly Unexpected Yes No No
Rituximab University Hospital,
North Durham;
N00170
00107 Week 24 Vertigo New Moderate Possibly Unexpected N/A No No
Rituximab Nuffield
Orthopaedic Centre,
Oxford; N00282
00104 Week 12 Neutropenia,
0.69 × 109/l
New Moderate Possibly Expected No No Temporary
Rituximab Nuffield
Orthopaedic Centre,
Oxford; N00282
00104 Week 24 URTI New Moderate Possibly Expected No No No
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TABLE 75 Line listing of non-SAEs (continued )
Treatment
randomised
Centre name and
number
Patient
number
First
reported AE description
New or
pre-existing
event? Intensity Causality Expectedness
(For infections)
Requested
treatment with
antibiotics?
SAE or
SUSAR?
Stopping of
treatment
Rituximab Nuffield
Orthopaedic Centre,
Oxford; N00282
00104 Week 24 Burn on hand New Mild Unrelated Unexpected No No No
Rituximab Nuffield
Orthopaedic Centre,
Oxford; N00282
00104 Week 24 Headaches New Mild Probably Expected No No No
Rituximab Nuffield
Orthopaedic Centre,
Oxford; N00282
00104 Week 24 Temporomandibular
pain
New Mild Unrelated Expected No No No
Rituximab Nuffield
Orthopaedic Centre,
Oxford; N00282
00104 Week 36 Carditis, 9 February
2015, co-amoxiclav
New Moderate Unrelated Expected Yes No No
Rituximab Nuffield
Orthopaedic Centre,
Oxford; N00282
00104 Week 36 Viral infection,
2–3 weeks
New Mild Possibly Expected No No No
Rituximab Birmingham City
Hospital; N00346
00132 Week 12 Rash skin New Moderate Probably Expected N/A No No
Rituximab Salford Royal
Infirmary; N00400
00113 Week 36 Gastritis New Moderate Unrelated Expected No No No
Rituximab Cannock Chase
Hospital; N00473
00036 Week 12 Worsening depression
(following
bereavement)
New Moderate Unrelated Unexpected N/A No No
Rituximab Cannock Chase
Hospital; N00473
00036 Week 24 Leg cramps at night New Mild Unlikely Unexpected N/A No No
Rituximab Cannock Chase
Hospital; N00473
00036 Week 36 Upper back pain New Moderate Unrelated Unexpected N/A No No
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Treatment
randomised
Centre name and
number
Patient
number
First
reported AE description
New or
pre-existing
event? Intensity Causality Expectedness
(For infections)
Requested
treatment with
antibiotics?
SAE or
SUSAR?
Stopping of
treatment
Rituximab Cannock Chase
Hospital; N00473
00036 Week 36 Unstable hypertension New Mild Unrelated Unexpected N/A No No
Rituximab Cannock Chase
Hospital; N00473
00036 Week 36 Elevated lipids Pre-existing Mild Unrelated Unexpected N/A No No
Rituximab Cannock Chase
Hospital; N00473
00045 Week 48 Mouth ulcers New Mild Unlikely Unexpected N/A No No
Rituximab Cannock Chase
Hospital; N00473
00045 Week 48 Chest infection New Mild Unlikely Expected No No No
Rituximab Cannock Chase
Hospital; N00473
00098 Week 12 Diabetic peripheral
neuropathy
(longstanding)
New Mild Unrelated Unexpected N/A No No
Rituximab Cannock Chase
Hospital; N00473
00098 Week 24 Left trochanteric
bursitis
New Moderate Unrelated Unexpected N/A No No
Rituximab Cannock Chase
Hospital; N00473
00098 Week 36 Hair thinning New Mild Unlikely Unexpected N/A No No
Rituximab Cannock Chase
Hospital; N00473
00098 Week 36 Intermittent numbness
of upper limbs
New Mild Unlikely Unexpected N/A No No
Rituximab Cannock Chase
Hospital; N00473
00114 Week 12 UTI New Mild Possibly Expected Yes No No
Rituximab Cannock Chase
Hospital; N00473
00114 Week 12 Tremor, right hand New Mild Unrelated Unexpected N/A No No
Rituximab Cannock Chase
Hospital; N00473
00114 Week 24 Cough New Moderate Unlikely Unexpected No No No
Rituximab Cannock Chase
Hospital; N00473
00114 Week 24 UTI New Moderate Unlikely Unexpected Yes No No
Rituximab Cannock Chase
Hospital; N00473
00114 Week 36 Cough New Moderate Unlikely Unexpected No No Permanent
Rituximab Cannock Chase
Hospital; N00473
00114 Week 36 Sterile pyuria New Moderate Unlikely Unexpected No No Permanent
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TABLE 75 Line listing of non-SAEs (continued )
Treatment
randomised
Centre name and
number
Patient
number
First
reported AE description
New or
pre-existing
event? Intensity Causality Expectedness
(For infections)
Requested
treatment with
antibiotics?
SAE or
SUSAR?
Stopping of
treatment
Rituximab Cannock Chase
Hospital; N00473
00114 Week 36 Oral thrush New Moderate Unlikely Unexpected N/A No Permanent
Rituximab Cannock Chase
Hospital; N00473
00114 Week 36 Flare of RA New Moderate Unlikely Unexpected N/A No Permanent
Rituximab Chapel Allerton
Hospital, Leeds;
N00482
00003 Week 24 Skin rash (left wrist) New Mild Possibly Unexpected N/A No No
Rituximab Chapel Allerton
Hospital, Leeds;
N00482
00003 Week 24 Lower respiratory
chest infection
New Mild Possibly Unexpected Yes No No
Rituximab Chapel Allerton
Hospital, Leeds;
N00482
00003 Week 48 (Left) ear deafness?
Eustachian tube
dysfunction
New Moderate Unlikely Unexpected N/A No No
Rituximab Chapel Allerton
Hospital, Leeds;
N00482
00003 Week 48 Cough and dry
1 month out of 12
New Moderate Possibly Unexpected N/A No No
Rituximab Chapel Allerton
Hospital, Leeds;
N00482
00007 Week 12 Lower respiratory
chest infection
(January 2013)
New Moderate Possibly Unexpected Yes No No
Rituximab Chapel Allerton
Hospital, Leeds;
N00482
00007 Week 12 Lower respiratory
chest infection
(7 March 2013)
New Moderate Possibly Unexpected Yes No Temporary
Rituximab Chapel Allerton
Hospital, Leeds;
N00482
00007 Week 24 Chest infection New Mild Possibly Unexpected Yes No No
Rituximab Chapel Allerton
Hospital, Leeds;
N00482
00008 Week 24 Acute abdominal pain
over previous
hysterectomy scar
New Severe Unlikely Unexpected N/A Yes No
Rituximab Chapel Allerton
Hospital, Leeds;
N00482
00015 Week 24 (Right) groin pain New Mild Unrelated Expected N/A No No
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Treatment
randomised
Centre name and
number
Patient
number
First
reported AE description
New or
pre-existing
event? Intensity Causality Expectedness
(For infections)
Requested
treatment with
antibiotics?
SAE or
SUSAR?
Stopping of
treatment
Rituximab Chapel Allerton
Hospital, Leeds;
N00482
00019 Week 12 Urticarial rash with
faster infusion
rituximab
New Moderate Almost
certainly
Expected N/A No No
Rituximab Chapel Allerton
Hospital, Leeds;
N00482
00019 Week 24 Headaches twice with
MTX
Pre-existing Mild Possibly Expected N/A No No
Rituximab Chapel Allerton
Hospital, Leeds;
N00482
00019 Week 36 Tooth infection New Moderate Probably Expected Yes No Temporary
Rituximab Chapel Allerton
Hospital, Leeds;
N00482
00047 Week 48 Sinusitis New Moderate Probably Expected Yes No Temporary
Rituximab Chapel Allerton
Hospital, Leeds;
N00482
00055 Week 48 Chest infection New Moderate Probably Expected Yes No No
Rituximab Chapel Allerton
Hospital, Leeds;
N00482
00080 Week 36 Chest infection New Moderate Possibly Expected Yes No No
Rituximab Chapel Allerton
Hospital, Leeds;
N00482
00082 Week 36 Blepharitis (left eye) New Moderate Unlikely Unexpected N/A No No
Rituximab Chapel Allerton
Hospital, Leeds;
N00482
00101 Week 36 UTI (cystitis) New Moderate Probably Expected Yes No Temporary
Rituximab Chapel Allerton
Hospital, Leeds;
N00482
00101 Week 48 Wound infection New Moderate Possibly Expected Yes No Temporary
ALP, alkaline phosphatase; ALT, alanine aminotransferase; b.p.m., beats per minutes; COPD, chronic obstructive pulmonary disease; CTCAE, Common Terminology Criteria for Adverse
Events; LRTI, lower respiratory tract infection; MTP 1, first metatarsophalangeal joint; URTI, upper respiratory tract infection; UTI, urinary tract infection.
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Appendix 15 Supplementary health
economics tables
TABLE 76 Resource use: unit costs
Type of service Cost (£)
Unit of
measure Notes Source
Community-based health and social services
GP, surgery visit 44.00 Per visit GP, per patient contact lasting
11.7 minutes including direct care
staff costs
PSSRU Unit Costs of Health and
Social Care 2015, p. 177127
GP, surgery
telephone
27.00 Per
telephone
call
GP, per telephone consultation
lasting 7.1 minutes
PSSRU Unit Costs of Health and
Social Care 2015, p. 177127
GP, home visit 90.00 Per home
visit
(Per patient contact lasting
11.7 minutes + average 12-minute
travel time) × £3.80/minute cost of
patient
PSSRU Unit Costs of Health and
Social Care 2015, p. 177127
District nurse face to
face
37.26 Per visit District nurse, adult, face to face NHS Reference Costs 2014 to
2015128
District nurse
telephone/e-mail
16.53 District nurse, adult non-face to
face
NHS Reference Costs 2014 to
2015128
Social worker face to
face
79.00 Per visit Assuming 1-hour appointment PSSRU Unit Costs of Health and
Social Care 2015, p. 188127
Social worker
telephone/e-mail
9.34 Assuming telephone consultation
lasting 7.1 minutes, based on cost
per hour
PSSRU Unit Costs of Health and
Social Care 2015, p. 188127
Physiotherapist face
to face
52.00 Per
appointment
Community physiotherapist mean
cost for one-to-one contact
NHS Reference Costs 2014 to
2015128
Physiotherapist
telephone/e-mail
35.00 Physiotherapy non-admitted
non-face-to-face follow-up,
consultant led
NHS Reference Costs 2014 to
2015128
Occupational
therapist face to face
44.00 Per
appointment
NHS community occupational
therapist
PSSRU Unit Costs of Health and
Social Care 2015, p. 191127
Occupational
therapist telephone/
e-mail
9.00 Occupational therapy consultant-
led non-admitted non-face-to-face
follow-up (first cost = £17.00)
NHS Reference Costs 2014 to
2015128
Podiatrist face to
face
39.63 Per
appointment
NHS Reference Costs 2014 to
2015128
Podiatrist telephone/
e-mail
18.00 Podiatry non-admitted non-face-to-
face follow-up (first cost= £30.00)
NHS Reference Costs 2014 to
2015128
Counsellor face to
face
50.79 Per
appointment
Assuming 1-hour appointment PSSRU Unit Costs of Health and
Social Care 2014, p. 51148 and
EPPI-Centre Cost Converter to
2015 price, URL: http://eppi.ioe.
ac.uk/costconversion/Default.aspx
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TABLE 76 Resource use: unit costs (continued )
Type of service Cost (£)
Unit of
measure Notes Source
Counsellor
telephone/e-mail
6.01 Assuming telephone consultation
lasting 7.1 minutes, based on cost
per hour
PSSRU Unit Costs of Health and
Social Care 2014, p. 51148 and
EPPI-Centre Cost Converter to
2015 price, URL: http://eppi.ioe.
ac.uk/costconversion/Default.aspx
Psychiatrist or
psychologist face to
face
61.96 Per visit Clinical psychologist per hour PSSRU Unit Costs of Health and
Social Care 2014, p. 183148 and
EPPI-Centre Cost Converter to
2015 price, URL: http://eppi.ioe.
ac.uk/costconversion/Default.aspx
Psychiatrist or
psychologist
telephone/e-mail
34.00 Clinical psychology non-admitted
non-face-to-face follow-up (first
cost = £31.00)
NHS Reference Costs 2014 to
2015128
Home help or care
workers face to face
24.00 Per session Face-to-face 1-hour weekday
session
PSSRU Unit Costs of Health and
Social Care 2015, p. 192127
Home help or care
workers telephone/
e-mail
2.84 Assuming telephone consultation
lasting 7.1 minutes, based on cost
per hour
PSSRU Unit Costs of Health and
Social Care 2015, p. 192127
Practice nurse 12.14 Per 15.5-
minute
consultation
Based on £47 per hour PSSRU Unit Costs of Health and
Social Care 2015, p. 174127
Specialist nurse
telephone
7.69 Assuming telephone consultation
lasting 7.1 minutes, based on £65
per hour
PSSRU Unit Costs of Health and
Social Care 2015, p. 172127
Hydrotherapy pool 27.00 Physiotherapy non-admitted,
non-face to face, non-consultant
led
NHS Reference Costs 2014 to
2015128
Hospital-based or residential care services
Hospital inpatient
stay
303.00 Per day General ward, non-elective
inpatients – excess bed-days
NHS Reference Costs 2014 to
2015128
Hospital day centre 160.00 Per visit Inpatient specialist palliative care,
same day
NHS Reference Costs 2014 to
2015128
Hospital outpatient
clinic
112.00 Per visit Weighted average of all
outpatient attendances
PSSRU Unit Costs of Health and
Social Care 2015, p. 107127
Hospital accident
and emergency
department
132.00 Per visit Emergency medicine NHS Reference Costs 2014 to
2015128
Nursing home 88.71 Per day Assume cost for 1 day and night
equals the reported private sector
nursing home cost per week/7
PSSRU Unit Costs of Health and
Social Care 2015, p. 37127
Residential home 72.00 Per day Assume cost for 1 day and night
equals the reported private sector
residential home cost per week/7
PSSRU Unit Costs of Health and
Social Care 2015, p. 38127
Inpatient procedures
Oral surgery (dental
clearance)
154.00 Oral surgery, extraction of
multiple teeth aged ≥ 19 years
NHS Reference Costs 2014 to
2015128
Excision of cystic
swelling
2054.30 Minor foot procedures for
non-trauma, inpatient elective
NHS Reference Costs 2014 to
2015128
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TABLE 76 Resource use: unit costs (continued )
Type of service Cost (£)
Unit of
measure Notes Source
Rheumatology visits
Day-case
rheumatology
421.00 Day case inflammatory, spine,
joint or connective tissue
disorders, with CC score 0–2
DH’s NHS Reference Costs 2014
to 2015 (HD23J)128
Outpatient
rheumatology, first
attendance
162.00 Non-admitted face to face, first DH’s NHS Reference Costs 2014
to 2015 (WF01B)128
Outpatient
rheumatology,
follow-up attendance
91.00 Non-admitted face to face
follow-up
DH’s NHS Reference Costs 2014
to 2015 (WF01A)128
Staff nurse 36.00 Cost per hour PSSRU’s Unit Costs of Health
and Social Care 2015127
Nurse specialist 45.00 Cost per hour PSSRU’s Unit Costs of Health
and Social Care 2015127
CC score, case mix classification score; DH, Department of Health.
TABLE 77 Trial medication costs
Medication Dose
Cost per
dose
Unit
cost (£) Description Source
Rituximab First cycle: 1 g as an intravenous
infusion at days 0 (week 0) and
15 (week 2; + 5 days)
Second cycle: 1 g as an intravenous
infusion at 2-week interval
£1746.30 873.15 10mg/ml of a 50-ml
vial concentrate for
intravenous infusion
BNF130
Abatacept 125 mg by subcutaneous injection at
week 0 and once weekly thereafter
for a minimum of 24 weeks
£302.40 302.40 125-mg prefilled pen or
prefilled syringe
BNF130
Infliximab 3mg/kg per intravenous infusion to
be administered at weeks 0, 2 and 6
then 8-weekly thereafter for minimum
24 weeks
419.62 100-mg vial BNF130
Etanercept 50 mg by subcutaneous injection
weekly for minimum 24 weeks
£178.75 178.75 50-mg prefilled pen or
prefilled syringe
BNF130
Adalimumab 40mg by subcutaneous injection
every 2 weeks for a minimum of
24 weeks
£352.14 352.14 40-mg prefilled pen or
prefilled syringe
BNF130
CZP 400mg by subcutaneous injection at
weeks 0, 2 and 4, then 200mg every
2 weeks thereafter for a minimum of
24 weeks
400-mg dose,
£715.00;
200-mg dose,
£357.50
357.50 200-mg prefilled syringe BNF130
Golimumab 50mg of self-administered
subcutaneous injection monthly, same
date each month
£762.97 762.97 50-mg prefilled pen or
prefilled syringe
BNF130
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TABLE 78 Trial drug administration costs
Treatment
Hours of nurse
supervision for
intravenous drug
administration
per treatment
Intravenous
equipment
required per
treatmenta
Educational visit,
outpatient,
rheumatology
(first attendance)
Safety check: visit
staff nurse (week 4)
Administration
cost (£)
Etanercept – – 1 1 198
Adalimumab – – 1 1 198
CZP – – 1 1 198
Abatacept – – 1 1 198
Golimumab – – 1 1 198
Infliximab 2 1 – – 98.66
Rituximab 7 1 – – 278.66
a Cost of intravenous equipment was taken from relevant literature149 and inflated to the current year prices (pounds
sterling) using an online inflator.131
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TABLE 79 Average resource use per patient in each trial arma,b
Resource
Time point
12 weeks 24 weeks 36 weeks 48 weeks
Treatment arm
Rituximab
(n= 29)
Abatacept
(n= 26)
TNFi
(n= 25)
Rituximab
(n= 29)
Abatacept
(n= 26)
TNFi
(n= 25)
Rituximab
(n= 29)
Abatacept
(n= 26)
TNFi
(n= 25)
Rituximab
(n= 29)
Abatacept
(n= 26)
TNFi
(n= 25)
Community Health and Social Services
GP surgery visit
Face to face
Mean (SD) 1.48 (1.70) 1.23 (2.1) 1 (1.26) 2.1 (2.78) 1.46 (1.56) 1.32 (1.44) 2.52 (4.47) 1.81 (1.39) 2.2 (2.87) 3 (3.74) 1.69 (1.83) 1.8 (1.76)
Minimum 0 0 0 0 0 0 0 0 0 0 0 0
Maximum 6 10 3 10 6 4 20 5 12 12 6 6
Telephone/e-mail
Mean (SD) 0.86 (1.73) 0.12 (0.33) 0.44 (1.26) 0.31 (0.93) 0.15 (0.46) 0.48 (1.05) 0.45 (1.15) 0.77 (0.27) 0.32 (0.9) 0.72 (2.37) 0.23 (1.18) 0.2 (0.58)
Minimum 0 0 0 0 0 0 0 0 0 0 0 0
Maximum 6 1 5 4 2 4 5 1 3 12 6 2
GP home visit
Face to face
Mean (SD) 0 0 0 0.14 (0.52) 0 0 0.1 (0.56) 0.08 (0.39) 0 0 0 0.04 (0.2)
Minimum 0 0 0 0 0 0 0 0 0 0 0 0
Maximum 0 0 0 2 0 0 3 2 0 0 0 1
District nurse
Face to face
Mean (SD) 0.14 (0.58) 0.27 (0.83) 0.44 (1.04) 0.14 (0.58) 0.23 (0.82) 0.32 (0.9) 0.21 (0.77) 0.19 (0.69) 0.04 (0.2) 0.24 (1.12) 0.12 (0.59) 0.48 (1.23)
Minimum 0 0 0 0 0 0 0 0 0 0 0 0
Maximum 3 3 3 3 3 3 3 3 1 6 3 5
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TABLE 79 Average resource use per patient in each trial arma,b (continued )
Resource
Time point
12 weeks 24 weeks 36 weeks 48 weeks
Treatment arm
Rituximab
(n= 29)
Abatacept
(n= 26)
TNFi
(n= 25)
Rituximab
(n= 29)
Abatacept
(n= 26)
TNFi
(n= 25)
Rituximab
(n= 29)
Abatacept
(n= 26)
TNFi
(n= 25)
Rituximab
(n= 29)
Abatacept
(n= 26)
TNFi
(n= 25)
Telephone/e-mail
Mean (SD) 0 0.15 (0.78) 0 0 0 0 0 0 0 0.03 (0.19) 0.12 (0.59) 0.08 (0.4)
Minimum 0 0 0 0 0 0 0 0 0 0 0 0
Maximum 0 4 0 0 0 0 0 0 0 1 3 2
Social worker
Face to face
Mean (SD) 0 0 0 0.03 (0.19) 0 0 0 0 0 0.07 (0.26) 0 0
Minimum 0 0 0 0 0 0 0 0 0 0 0 0
Maximum 0 0 0 1 0 0 0 0 0 1 0 0
Telephone/e-mail
Mean (SD) 0.03 (0.19) 0 0 0 0 0 0 0 0 0.03 (0.19) 0 0
Minimum 0 0 0 0 0 0 0 0 0 0 0 0
Maximum 1 0 0 0 0 0 0 0 0 1 0 0
Physiotherapist
Face to face
Mean (SD) 0.38 (0.19) 0.54 (1.9) 0 0.52 (2.05) 0 0.6 (1.94) 0.76 (2.85) 1.81 (7.91) 0.64 (1.87) 1.48 (3.3) 0.54 (1.82) 0.12 (0.44)
Minimum 0 0 0 0 0 0 0 0 0 0 0 0
Maximum 8 7 0 10 0 7 12 40 7 12 8 2
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Resource
Time point
12 weeks 24 weeks 36 weeks 48 weeks
Treatment arm
Rituximab
(n= 29)
Abatacept
(n= 26)
TNFi
(n= 25)
Rituximab
(n= 29)
Abatacept
(n= 26)
TNFi
(n= 25)
Rituximab
(n= 29)
Abatacept
(n= 26)
TNFi
(n= 25)
Rituximab
(n= 29)
Abatacept
(n= 26)
TNFi
(n= 25)
Telephone/e-mail
Mean (SD) 0 0 0 0 0 0 0.07 (0.37) 0 0 0.34 (1.86) 0.04 (0.2) 0
Minimum 0 0 0 0 0 0 0 0 0 0 0 0
Maximum 0 0 0 0 0 0 2 0 0 10 1 0
Occupational therapist
Face to face
Mean (SD) 0 0.15 (0.54) 0 0.1 (0.41) 0.08 (0.39) 0.04 (0.2) 0.1 (0.41) 0 0.2 (1) 0.21 (0.68) 0.31 (0.62) 0.08 (0.4)
Minimum 0 0 0 0 0 0 0 0 0 0 0 0
Maximum 0 2 0 2 2 1 2 0 5 3 2 2
Telephone/e-mail
Mean (SD) 0 0 0 0 0 0 0 0 0 0.07 (0.37) 0.04 (0.2) 0
Minimum 0 0 0 0 0 0 0 0 0 0 0 0
Maximum 0 0 0 0 0 0 0 0 0 2 1 0
Podiatrist
Face to face
Mean (SD) 0.31 (0.76) 0.27 (0.83) 0.24 (0.72) 0.31 (0.76) 0.35 (1.02) 0.48 (0.96) 0.69 (1.83) 0.62 (1.3) 0.92 (2.56) 0.93 (1.98) 0.88 (1.86) 0.32 (1.22)
Minimum 0 0 0 0 0 0 0 0 0 0 0 0
Maximum 3 3 3 3 4 3 9 4 12 8 6 6
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TABLE 79 Average resource use per patient in each trial arma,b (continued )
Resource
Time point
12 weeks 24 weeks 36 weeks 48 weeks
Treatment arm
Rituximab
(n= 29)
Abatacept
(n= 26)
TNFi
(n= 25)
Rituximab
(n= 29)
Abatacept
(n= 26)
TNFi
(n= 25)
Rituximab
(n= 29)
Abatacept
(n= 26)
TNFi
(n= 25)
Rituximab
(n= 29)
Abatacept
(n= 26)
TNFi
(n= 25)
Telephone/e-mail
Mean (SD) 0.07 (0.37) 0 0 0 0 0 0 0 0 0.21 (1.11) 0 0
Minimum 0 0 0 0 0 0 0 0 0 0 0 0
Maximum 2 0 0 0 0 0 0 0 0 6 0 0
Counsellor
Face to face
Mean (SD) 0 0 0 0.1 (0.56) 0 0.16 (0.8) 0.1 (0.56) 0 0.08 (0.4) 0.1 (0.56) 0 0
Minimum 0 0 0 0 0 0 0 0 0 0 0 0
Maximum 0 0 0 3 0 4 3 0 2 3 0 0
Telephone/e-mail
Mean (SD) 0 0 0 0 0 0 0 0 0.16 (0.8) 0 0 0
Minimum 0 0 0 0 0 0 0 0 0 0 0 0
Maximum 0 0 0 0 0 0 0 0 4 0 0 0
Psychologistc
Face to face
Mean (SD) 0 0 0 0 0 0 0.03 (0.19) 0 0 0.1 (0.56) 0 0
Minimum 0 0 0 0 0 0 0 0 0 0 0 0
Maximum 0 0 0 0 0 0 1 0 0 3 0 0
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Resource
Time point
12 weeks 24 weeks 36 weeks 48 weeks
Treatment arm
Rituximab
(n= 29)
Abatacept
(n= 26)
TNFi
(n= 25)
Rituximab
(n= 29)
Abatacept
(n= 26)
TNFi
(n= 25)
Rituximab
(n= 29)
Abatacept
(n= 26)
TNFi
(n= 25)
Rituximab
(n= 29)
Abatacept
(n= 26)
TNFi
(n= 25)
Home helpc
Face to face
Mean (SD) 0.83 (3.09) 0.46 (2.35) 0 0.83 (3.09) 0 0.48 (2.4) 0.83 (3.09) 0 0 1.24 (3.72) 0 0
Minimum 0 0 0 0 0 0 0 0 0 0 0 0
Maximum 12 12 0 12 0 12 12 0 0 12 0 0
Hospital or residential care service
Hospital inpatient stay
Mean (SD) 0 0 0 0.21 (0.94) 0 0 0.59 (1.66) 0 0 0 0 0.08 (0.28)
Minimum 0 0 0 0 0 0 0 0 0 0 0 0
Maximum 0 0 0 5 0 0 6 0 0 0 0 1
Hospital outpatient clinic
Mean (SD) 0.59 (1.02) 1.12 (1.24) 1.44 (2.75) 0.86 (1.03) 0.88 (1.03) 1.36 (0.95) 1.1 (1.11) 1.27 (1.04) 0.88 (0.97) 0.93 (1) 0.88 (0.95) 1.08 (1.04)
Minimum 0 0 0 0 0 0 0 0 0 0 0 0
Maximum 4 5 14 3 3 3 4 3 2 2 2 3
Hospital day centre
Mean (SD) 0.45 (1.02) 0 0.12 (0.6) 0.17 (0.66) 0.23 (0.82) 0.12 (0.6) 0.48 (1.12) 0.31 (0.97) 0.4 (1.32) 0.66 (1.37) 0.54 (1.73) 0.56 (1.32)
Minimum 0 0 0 0 0 0 0 0 0 0 0 0
Maximum 3 0 3 3 3 3 4 4 6 5 8 4
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TABLE 79 Average resource use per patient in each trial arma,b (continued )
Resource
Time point
12 weeks 24 weeks 36 weeks 48 weeks
Treatment arm
Rituximab
(n= 29)
Abatacept
(n= 26)
TNFi
(n= 25)
Rituximab
(n= 29)
Abatacept
(n= 26)
TNFi
(n= 25)
Rituximab
(n= 29)
Abatacept
(n= 26)
TNFi
(n= 25)
Rituximab
(n= 29)
Abatacept
(n= 26)
TNFi
(n= 25)
Hospital accident and emergency department
Mean (SD) 0 0.08 (0.39) 0.12 (0.6) 0.17 (0.54) 0.08 (0.39) 0.08 (0.4) 0.14 (0.58) 0.04 (0.2) 0 0.03 (0.19) 0 0.2 (0.58)
Minimum 0 0 0 0 0 0 0 0 0 0 0 0
Maximum 0 2 3 2 2 2 3 1 0 1 0 2
a For consistency in sample sizes, only the resource use of patients with no missing cost data is reported in this table.
b The table reports only the use of main services and, as there were no reported nursing home or residential home visits, these are excluded from the table.
c There were no reported household help or psychologist contacts by telephone or e-mail.
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TABLE 80 Average health-care costs (£) by trial arma
Health-care
cost
Cost
Time point
Total costs12 weeks 24 weeks 36 weeks 48 weeks
Treatment arm Treatment arm Treatment arm Treatment arm Treatment arm
Rituximab
(n= 29)
Abatacept
(n= 26)
TNFi
(n= 25)
Rituximab
(n= 29)
Abatacept
(n= 26)
TNFi
(n= 25)
Rituximab
(n= 29)
Abatacept
(n= 26)
TNFi
(n= 25)
Rituximab
(n= 29)
Abatacept
(n= 26)
TNFi
(n= 25)
Rituximab
(n= 29)
Abatacept
(n= 26)
TNFi
(n= 25)
Total community health and social services costs
Mean (SD) 148.36
(189.81)
126.36
(163.97)
81.79
(97.53)
190.07
(248.13)
95.56
(92.58)
154.59
(213.56)
240.88
(351.98)
214.09
(415.49)
191.57
(258.95)
347.86
(567.01)
165.19
(209.73)
129.85
(155.14)
927.17
(1238.6)
601.2
(553.7)
557.8
(513.42)
Minimum 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Maximum 818.89 651.78 267 916 358.3 890.20 1297.63 2168 1003.56 2649.79 829.78 570.15 5291.57 2388 1818.23
Total hospital and residential care service costs
Mean (SD) 175.48
(242.04)
188.12
(241.07)
267.04
(399.20)
254.35
(524.83)
222.49
(332.29)
199.04
(166.25)
454.93
(555.61)
230.42
(225.73)
192.92
(312.42)
227.93
(521.64)
221.58
(290.24)
298.78
(273.42)
1112.71
(1137.51)
862.61
(788.43)
957.78
(678.42)
Minimum 0 0 0 0 0 0 0 0 0 0 0 0 0 0 224
Maximum 999 972 1846 2802.21 1230 704 1901 743 1209 1024 1280 864 5039.21 3322 2523
Trial medication costs (inclusive of drug administration cost)
Mean (SD) 3980.09
(376.03)
3966.37
(542.51)
2302.18
(377.75)
418.96
(1255.21)
2721.6
(1443.94)
1662.59
(864.53)
1675.83
(2029.94)
2535.51
(1611.71)
1625.14
(865.73)
578.56
(1443.18)
2361.05
(1710.67)
1349.28
(1003.26)
6633.49
(3197.01)
11584.52
(4733.65)
6939.19
(2679.69)
Minimum 2024.96 1407.6 902.28 0 0 0 0 0 0 0 0 0 2024.96 1407.6 902.28
Maximum 4049.92 4129.2 3415.5 4049.92 3628.8 2288.91 4049.92 3628.8 2288.91 4049.92 3628.8 2288.91 16199.68 15015.6 9353.64
Other medication costs
MTX
Mean (SD) 9.93 (2.1) 8.03 (1.65) 10.18
(2.52)
7.7 (1.49) 7.66 (1.8) 8.64
(1.39)
7.53 (2.38) 7.66 (1.36) 8.16
(1.83)
8.35 (1.57) 7.87 (2.02) 8.16
(1.55)
32.36
(5.27)
30.92
(3.42)
35.14
(3.09)
Minimum 2.4 2.4 7.2 4.8 2.4 4.8 2.4 4.8 4.8 7.2 2.4 4.8 14.4 21.6 31.2
Maximum 14.4 9.6 19.2 12 12 9.6 12 12 12 12 9.6 9.6 38.4 33.6 45.6
Other concomitant medication
b
Mean (SD) – – – – – – – – – – – – 396.78
(1830.36)
519.51
(1168.58)
807.93
(1909.68)
Minimum – – – – – – – – – – – – 0 0 0
Maximum – – – – – – – – – – – – 9907.84 3590.59 7014.68
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TABLE 80 Average health-care costs (£) by trial arma (continued )
Health-care
cost
Cost
Time point
Total costs12 weeks 24 weeks 36 weeks 48 weeks
Treatment arm Treatment arm Treatment arm Treatment arm Treatment arm
Rituximab
(n= 29)
Abatacept
(n= 26)
TNFi
(n= 25)
Rituximab
(n= 29)
Abatacept
(n= 26)
TNFi
(n= 25)
Rituximab
(n= 29)
Abatacept
(n= 26)
TNFi
(n= 25)
Rituximab
(n= 29)
Abatacept
(n= 26)
TNFi
(n= 25)
Rituximab
(n= 29)
Abatacept
(n= 26)
TNFi
(n= 25)
Total NHS costs
c
Mean (SD) 4313.87
(378.37)
4288.88
(604.15)
2661.18
(565.53)
871.08
(1339.2)
3047.32
(1310.12
2024.87
(939.16)
2379.18
(1897.29)
2987.68
(1628.37)
2017.8
(823.93)
1141.6
(1532.23)
2755.38
(1649.07)
1786.07
(909.02)
9102.51
(3375.77)
13598.77
(4092.09)
9297.84
(2007.36)
Minimum 2967.85 1766 999.88 7.2 2.4 137.23 7.2 248.8 7.2 7.2 231.2 9.6 4716.78 2690.88 1462.19
Maximum 5122.32 5198.8 4201 4466.12 4840 3268.8 4994.52 6028 3268 5410.78 4611.99 2857.06 18064.16 17661.2 12573.96
Total societal costs
Mean (SD) 183.74
(361.21)
118.88
(265.37)
356.33
(1276.82)
246.76
(479.87)
65.63
(103.15)
310.14
(824.62)
211.71
(817.26)
136.05
(342.1)
176.93
(430.94)
447.95
(1676.83)
72.27
(105.59)
103.68
(171.63)
1081.66
(2020.47)
387.79
(655.19)
947.07
(2521.82)
Minimum 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Maximum 1553.85 960 6428.5 1936.5 337.5 4102.5 4415 1592 2120 9015 440 600 9028.5 2552 12676
Total all
c
Mean (SD) 4497.61
(565.02)
4407.76
(693.58)
3017.51
(1421.18)
1148.69
(1479.19)
3215.29
(1209.9)
2335
(1051.97)
2590.89
(2225.42)
3123.73
(1806.39)
2194.72
(873.79)
1589.55
(2149.22)
2827.65
(1674.5)
18889.75
(915.7)
10184.17
(3509.55)
13986.55
(4382.28)
10244.91
(3298.72)
Minimum 3058.45 1766 999.88 23.4 574.36 167.23 7.2 251 7.2 23.7 253.38 9.6 4874.25 2692.23 1462.19
Maximum 5963.07 5748.8 9211.1 5160.12 5147.48 4522.1 9073.41 7620 3659 9208.6 4794.68 3114.81 18292.16 20213.2 21882.63
a Only the resource use of patients with no missing cost data is reported in this table.
b As concomitant medications were recorded separately from the clinical assessments at the time points, only total costs are available.
c The totals presented for the time points do not include costs of concomitant medications. Costs of concomitant medications are included in the total for all time points.
A
PPEN
D
IX
15
N
IH
R
Journals
Library
w
w
w
.journalslibrary.nihr.ac.uk
280

Part of the NIHR Journals Library 
www.journalslibrary.nihr.ac.uk
Published by the NIHR Journals Library
This report presents independent research funded by the 
National Institute for Health Research (NIHR). The views 
expressed are those of the author(s) and not necessarily 
those of the NHS, the NIHR or the Department of Health
EME
HS&DR
HTA
PGfAR
PHR
